Advanced search
Publication Cover
Drug Metabolism Reviews Volume 34, 2002 - Issue 1-2
Submit an article Journal homepage
5,570
Views
624
CrossRef citations to date
0
Altmetric
Research Article

Summary of information on human CYP enzymes: human P450 metabolism data

Slobodan Rendic Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovacica 1, Zagreb, HR 10000, Croatia
Pages 83-448 | Published online: 15 Apr 2002

REFERENCES

  • Guengerich F.P. Cytochrome P450: Advances and Prospects. FASEB J. 1992; 6: 667–668, (a)
  • Guengerich F.P. Human Cytochrome P450 Enzymes. Life Sci. 1992; 50: 1471–1478, (b)
  • Coon M.J., Ding X., Pernecky S.J., Vaz A.D.N. Cytochromes P450: Progress and Predictions. FASEB J. 1992; 6: 669–673, (c)
  • Gonzales F.J., Lee Y.H. Constitutive Expression of Hepatic Cytochrome P450 Genes. FASEB J. 1996; 10: 1112–11127, (d)
  • Rendic S., Di Carlo F. Human Cytochrome P450 Enzymes: a Status Report Summarizing Their Reactions, Substrates, Inducers and Inhibitors (Engl.). Drug Metab. Rev. 1997; 29: 413–580, (e)
  • Lewis D.F.V., Lake B.G. Molecular Modeling of CYP1A Subfamily Members Based on an Alignment with CYP102: Rationalization of CYP1A Substrate Specificity in Terms of Active Site Amino Acid Residues. Xenobiotica 1996; 26: 723–753
  • Guengerich F.P. Human Cytochrome P450 Enzymes. Cytochrome P450—Structure, Mechanism and Biochemistry, P.R. Ortiz de Montellano. 2nd Ed, Plenum Press, New York 1995; 473–535
  • Kronbach T. Hepatic Microsomes and Drug-Metabolising Enzymes. Pharmacokinetics, Regulatory–Industrial–Academic Perspectives, P.G. Welling, F.L.S. Tse. 2nd Ed, Marcel Dekker, New York 1995; 236–253
  • Spatzeneger M., Jaeger W. Hepatic P450 in Drug Metabolism. Drug Metab. Rev. 1995; 27: 397–417, (a)
  • Slaughter R., Edwards D.J. Recent Advances: the Cytochrome P450 Enzymes. Pharmacokinetics 1995; 29: 619–624, (b)
  • Smith D.A., Jones B.C. Speculations on the Structure–Activity Relationship (SSAR) of Cytochrome P450 Enzymes. Biochem. Pharmacol. 1992; 44: 2089–2098
  • Beaune P.H. Les Cytochromes P450 Humains. Therapie 1993; 48: 521–526
  • Graham-Lorence S., Peterson J.A. P450s: Structural Similarities and Functional Differences. FASEB J. 1996; 10: 206–214
  • Guengerich F.P. Characterization of Human Cytochrome P450 Enzymes. FASEB J. 1992; 6: 745–748, (a)
  • Guengerich F.P. Catalytic Selectivity of Human Cytochrome P450 Enzymes: Relevance to Drug Metabolism and Toxicity. Toxicol. Lett. 1994; 70: 133–138, (b)
  • Smith D.A. Design of Drugs Through a Consideration of Drug Metabolism and Pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 1994; 19: 193–1939
  • Caldwell J. Cytochrome P450, In Vitro Drug Metabolism Studies in Drug Development and Registration. Pharm. Forum 1995; 4: 5–9
  • Park B.K., Pirmohamed M., Kitteringham N.R. The Role of Cytochrome P450 Enzymes in Hepatic and Extrahepatic Human Drug Toxicity. Pharmacol. Ther. 1995; 68: 385–424
  • Yang C.S., Brady J.F., Hong J.-Y. Dietary Effects on Cytochromes P450, Xenobiotic Metabolism, and Toxicity. FASEB J. 1992; 6: 737–744
  • Paine A.J. Heterogeneity of Cytochrome P450 and Its Toxicological Significance. Hum. Exp. Toxicol. 1995; 14: 1–7
  • Halpert J.R., Guengerich F.P., Bend J.R., Correia M.A. Selective Inhibitors of Cytochromes P450. Toxicol. Appl. Pharmacol. 1994; 125: 163–175, (a)
  • Yin H., Racha J., Li S.Y., Olejnik N., Satoh H., Moore D. Automated High Throughput Human CYP Isoform Activity Assay Using SPE-LC/MS Method: Application in CYP Inhibition Evaluation. Xenobiotica 2000; 30: 141–154, (b)
  • Newton D.J., Wang R.W., Lu A.Y. Cytochrome P450 Inhibitors, Evaluation of Specificities in the In Vitro Metabolism of Therapeutic Agents by Human Liver Microsomes. Drug Metab. Dispos. 1995; 23: 154–158, (c)
  • Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.F., Guengerich F.P., Inui Y. Characterization of Microsomal Cytochrome P450 Enzymes Involved in the Oxidation of Xenobiotic Chemicals in Human Fetal Liver and Adult Lungs. Drug Metab. Dispos. 1996; 24: 515–522
  • Schmider J., Greenblatt D.J., von Moltke L.L., Harmatz J.S., Duan S.X., Karsov D., Shader R.I. Characterization of Six In Vitro Reactions Mediated by Human Cytochrome P450 Directed Antibodies. Pharmacology 1996; 52: 125–134, (a)
  • Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsu M. Specificity of Substrate and Inhibitor Probes for Cytochrome P450s: Evaluation of In Vitro Metabolism Using cDNA-Expressed Human P450s and Human Liver Microsomes. Xenobiotica 1996; 26: 681–693, (b)
  • Koymans L., Donne-Op den Kelder G.M., Koppele Te J.M., Veremeulen N.P.E. Cytochromes P450: Their Active Site Structure and Mechanism of Oxidation. Drug Metab. Rev. 1993; 25: 325–387
  • Guengerich F.P. Bioactivation and Detoxication of Toxic and Carcinogenic Chemicals. Drug Metab. Dispos. 1993; 21: 1–6, (a)
  • Miranda C.L., Reed R.L., Guengerich F.P., Buhler D.R. Role Of Cytochrome P450IIIA4 in the Metabolism of the Pyrrolizidine Alkaloid Senecionine in Human Liver. Carcinogenesis 1991; 12: 515–519, (b)
  • Parkinson A. An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials. Toxicol. Pathol. 1996; 24: 45–57
  • Weaver R.J., Dickins M., Burke M.D. Hydroxylation of The Antimalarial Drug 58C80 by CYP2C9 in Human Liver Microsomes: Comparison with Mephenytoin and Tolbutamide Hydroxylations. Biochem. Pharmacol. 1995; 49: 997–1004, (a)
  • Weaver R.J., Dickins M., Burke M.D. Cytochrome P450 2C9 Is Responsible for Hydroxylation of the Naphthoquinone Antimalarial Drug 58C80 in Human Liver. Biochem. Pharmacol. 1993; 46: 1183–1197, (b)
  • Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., Korzekwa K. Steroid Hormone Hydroxylase Specificities of Eleven cDNA-Expressed Human Cytochrome P450s. Arch. Biochem. Biophys. 1991; 290: 160–166
  • Gibaldi M. Pharmacogenetics: Part I. Ann. Pharmacother. 1992; 26: 121–126, (a)
  • Rannung A., Alexandrie A.-K., Persson I., Ingelman-Sundberg M. Genetic Polymorphism of Cytochromes P4501A1, 1A2, 2D6, and 2E1: Regulation and Toxicological Significance. JOEM 1995; 37: 25–36, (b)
  • Daly A.K. Molecular Basis of Polymorphic Drug Metabolism. J. Mol. Med. 1995; 73: 539–553, (c)
  • Bertilsson L., Dahl M.L. Polymorphic Drug Oxidation: Relevance to the Treatment of Psychiatric Disorders. CNS Drugs 1996; 5: 200–223, (d)
  • Gibaldi M. Drug Interactions: Part I. Ann. Pharmacother. 1992; 26: 709–713
  • Gibaldi M. Pharmacogenetics: Part II. Ann. Pharmacother. 1992; 26: 255–261
  • Spink D.C., Spink B.C., Cao J.Q., Gierthy J.F., Hayes C.L., Li Y., Sutter T.R.J. Induction of Cytochrome P450 1B1 and Catechol Estrogen Metabolism in ACHN Human Renal Adenocarcinoma Cells. Steroid Biochem. Mol. Biol. 1997; 62: 223–232
  • Guengerich F.P., Kim D.H., Iwasaki M. Role of Human Cytochrome P-450 IIE1 in the Oxidation of Many Low Molecular Weight Cancer Suspects. Chem. Res. Toxicol. 1991; 4: 168–179
  • Ahmed S. Molecular Modelling Study of Pyrrolidine-2,5-dione Based Aromatase Inhibitors and Other Known Inhibitors. Drug Des. Discov. 1996; 14: 77–89, (a)
  • Ahmed S., Davis P.J., Owen C.P. Molecular Modelling Study of the Binding of Inhibitors of Aromatase to the Cytochrome P-450 Heme. Drug Des. Discov. 1996; 14: 91–102, (b)
  • Rodrigues A.D., Kukulka M.J., Surber B.W., Thomas S.B., Uchic J.T., Rotert G.A., Michel G., Thome-Kromer B., Machinist J.M. Measurement of Liver Microsomal Cytochrome P450 (CYP2D6) Activity Using [O-Methyl-14C]Dextromethorphan. Anal. Biochem. 1994; 219: 309–320
  • Kedderis G.L., Batra R., Koop D.R. Epoxidation of Acrylonitrile by Rat and Human Cytochromes P450. Chem. Res. Toxicol. 1993; 6: 866–871
  • Delgado G., Neuhauser M.M., Bearden D.T., Danziger L.H. Quinupristin–Dalfopristin: an Overview. Pharmacotherapy 2000; 20: 1469–1485, (a)
  • Lamb H.M., Figgitt D.P., Faulds D. Quinupristin/Dalfopristin: a Review of Its Use in the Management of Serious Gram-Positive Infections. Drugs 1999; 58: 1061–1097, (b)
  • Rubinstein E., Prokocimer P., Talbot G.H. Safety and Tolerability of Quinupristin/Dalfopristin: Administration Guidelines. J. Antimicrob. Chemother. 1999; 44: 37–46, (c)
  • Imaoka S., Yamada T., Hiroi T., Hayashi K., Sakaki T., Yabusaki Y., Funae Y. Multiple Forms of Human P450 Expressed in Saccharomyces cerevisiae, Systemic Characterization and Comparison with Those in Rat. Biochem. Pharmacol. 1996; 51: 1041–1050
  • Street J.C., Lee J.S., Jarema M.A.C. Study of Coumarin Metabolism by Chinese Hamster Lung Fibroplasts Expressing a Human Cytochrome P450 Using H-1-NMR. Xenobiotica 1996; 26: 447–457
  • Neal G.E. Genetic Implications in the Metabolism and Toxicity of Mycotoxins. Toxicol. Lett. 1995; 82/83: 861–867
  • Gonzalez F.J., Gelboin H.V. Role of Human Cytochromes P450 in the Metabolic Activation of Chemical Carcinogenesis and Toxins. Drug Metab. Rev. 1994; 26: 165–183, (a)
  • Roberts-Thompson S.J., McManus M.E., Tukey R.H., Gonzales F.J., Holder G.M. Metabolism of Polycyclic Aza-aromatic Carcinogens Catalyzed by Four Expressed Human Cytochromes P450. Cancer Res. 1995; 55: 1052–1059, (b)
  • Mimura M., Baba T., Yamazaki H., Ohmori S., Inui Y., Gonzalez F.J., Guengerich F.P., Shimada T. Characterization of Cytochrome P-450 2B6 in Human Liver Microsomes. Drug Metab. Dispos. 1993; 21: 1048–1056, (c)
  • Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T., Waxman D.J. Immunochemical and Enzymatic Characterization of Human Hepatic Levels of CYP2B6. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 100, (a)
  • Ekins S., VandenBranden M., Ring B.J., Wrighton S.A. Kinetic and Inhibition Characteristics of CYP2B6. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 232, (b)
  • Lewis D.F.V., Ioannides C., Parke D.V. Molecular Modeling of Cytochrome CYP1A1: a Putative Access Channel Explains Differences in Induction Potency Between the Isomers Benzo[a]pyrene and Benzo[e]pyrene, and 2- and 4-Acetylaminofluorene. Toxicol. Lett. 1994; 71: 235–243, (a)
  • Lewis D.F.V., Moereels H., Lake B.G., Ioannides C., Parke D.V. Molecular Modeling of Enzymes and Receptors Involved in Carcinogenesis: QSARs and Compact-3D. Drug Metab. Rev. 1994; 26: 261–285, (b)
  • Wrighton S.A., VandenBranden M., Stevens J.C., Shipley L.A., Ring B.J. In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their Use in Drug Development. Drug Metab. Rev. 1993; 25: 453–484
  • Ioannides C., Parke D.V. Induction of Cytochrome P4501 as an Indicator of Potential Chemical Carcinogenesis. Drug Metab. Rev. 1993; 25: 485–501, (a)
  • Juchau M.R., Lee Q.P., Fantel A.G. Xenobiotic Biotransformation/Bioactivation in Organogenesis-Stage Conceptual Tissues. Drug Metab. Rev. 1992; 24: 195–238, (b)
  • Fijii-Kuriyama Y., Imataka H., Sogawa K., Yasumoto K.-I., Kikuchi Y. Regulation of CYP1A1 Expression. FASEB J. 1992; 6: 707–710, (a)
  • Buters J.T.M., Shou M., Hardwick J.P., Korzekwa K.R., Gonzalez F.V. Human CYP1A1: cDNA-Directed Expression Using Baculovirus, Reconstitution of Catalytic Activity and Metabolism of 7,12-Dimethylbenz[a]anthracene. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 359, (b)
  • Rost K.L., Roots I. Accelerated Caffeine Metabolism After Omeprazole Treatment Is Indicated by Urinary Metabolite Ratios: Coincidence with Plasma Clearance and Breath Test. Clin. Pharmacol. Ther. 1994; 55: 402–411
  • Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J.C., Clair P., Gervot L., Lesca P., Domergue J., Jpyeux H., Fourtainer G., Murel P. Omeprazole and Lansoprazole Are Mixed Inducers of CYP1A and 3A in Human Hepatocytes in Primary Culture. J. Pharmacol. Exp. Ther. 1994; 269: 384–392
  • Buening M.K., Chang R.L., Huang M.T., Fortner J.G., Wood A.W., Conney A.H. Activation and Inhibition of Benzo[a]pyrene and Aflatoxin B1 Metabolism in Human Liver Microsomes by Naturally Occurring Flavonoids. Cancer Res. 1981; 41: 67–72
  • Siess M.H., Leclerc J., Rat P., Suschetet M. In Vitro Modulation of Monooxygenase Activities by Natural Flavonoids in Human and Rat Liver. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 179, (a)
  • Siess M.H., Leclerc J., Canivenc-Lavier M.C., Rat P., Suschetet M. Heterogenous Effects of Natural Flavonoids on Monooxygenase Activities in Human and Rat Liver Microsomes. Toxicol. Appl. Pharmacol. 1995; 130: 73–78, (b)
  • Li Y., Wang E., Patten C., Chen L., Yang C.S. Effects of Flavonoids on Cytochrome P450-Dependent Acetaminophen Metabolism in Rats and Human Liver Microsomes. Drug Metab. Dispos. 1994; 22: 566–571, (a)
  • Obermeier M.T., White R.E., Yang C.S. Effects of Bioflavonoids on Hepatic P450 Activities. Xenobiotica 1995; 25: 575–584, (b)
  • Yun C.H., Jeong H.G., Lee H.S., Guengerich P. In Vivo and In Vitro Effects of Myristicin on Cytochrome P450 Enzymes. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 55, (c)
  • Zhou L., Erickson R.R., Ardwick J.P.H., Park S.S., Wrighton S.A., Holtzman J.L. Catalysis of the Cysteine Conjugation and Protein Binding of Acetaminophen by Microsomes from a Human Lymphoblast Line Transfected with the cDNAs of Various Forms of Human Cytochrome P450. J. Pharmacol. Exp. Ther. 1997; 28: 785–790
  • McLemore T.L., Adelberg S., Liu M.C., McMahon N.A., Yu S.J., Hubbard W.C., Czerwinski M., Wood T.G., Storeng R., Lubet R.A., Eggleston J.C., Boyd M.R., Hines R.N. Expression of CYP1A1 Gene in Patients with Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas. J. Natl Cancer Inst. 1990; 83: 1333–1339, (a)
  • Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S.L. The CYP1A1 Gene and Cancer Susceptibility. Crit. Rev. Oncol. Hematol. 1993; 14: 77–87, (b)
  • Parke D., Ioannides C. The Role of Metabolic Studies in the Safety Evaluation of New Chemicals. Acta Pharm. Jugosl. 1990; 40: 363–382
  • Yamazaki H., Mimura M., Oda Y., Gonzales F.J., El-Bayoumy K., Chae H.Y., Guengerich F.P., Shimada T. Activation of trans-1,2-Dihydro-1,2-dihydro-1,2-dihydroxy-6-aminochrysene to Genotoxic Metabolites by Rat and Human Cytochromes P450. Carcinogenesis 1994; 15: 465–470, (a)
  • Yamazaki H., Mimura M., Oda Y., Inui Y., Shiraga T., Iwasaki K., Guengerich F.P., Shimada T. Roles of Different Forms of Cytochrome P450 in the Activation of the Promutagen 6-Aminochrysene to Genotoxic Metabolites in Human Liver Microsomes. Carcinogenesis 1993; 14: 1271–1278, (b)
  • Pang S., Spink D.C. Effects of Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Estrogen Metabolism in MCF-7 and HEP G2 Cells. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 173, (a)
  • Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., Sutter T.R. 17beta-Estradiol Hydroxylation Catalyzed by Human Cytochrome P450 1B1. Proc. Natl Acad. Sci. USA 1996; 93: 9776–9781, (b)
  • Tang W.M., Wo Y.Y.P., Stewart J., Hawkins A.L., Driffin C.A., Sutter T.R., Greenlee W.F. Isolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene. J. Biol. Chem. 1996; 271: 28324–28330, (c)
  • Kress S., Reichert J., Schwarz J. Functional Analysis of the Human Cytochrome P4501A1 (CYP1A1) Gene Enhancer. Eur. J. Biochem. 1998; 258: 803–812, (d)
  • Bauer E., Guo Z., Ueng Y.F., Bell L.C., Zeldin D., Guengerich F.P. Oxidation of Benzo[a]pyrene by Recombinant Human Cytochrome P450 Enzymes. Chem. Res. Toxicol. 1995; 8: 136–142, (a)
  • Jones J.P., Shou M., Korzekwa K.R. Stereospecific Activation of the Procarcinogen Benzo[a]pyrene: a Probe for the Active Sites of the Cytochrome P450 Superfamily. Biochemistry 1995; 34: 6957–6961, (b)
  • Kadlubar F.F. Biochemical Individuality and Its Implications for Drug and Carcinogen Metabolism: Recent Insights from Acetyltransferase and Cytochrome P4501A2 Phenotyping in Humans. Drug Metab. Rev. 1994; 26: 37–46
  • Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., Miners J.O. Specificity of Substrate and Inhibitor Probes for Human Cytochromes P451A1 and 1A2. J. Pharmacol. Exp. Ther. 1993; 265: 401–407
  • Butler M.N., Iwasaki M., Guengerich F.P., Kadlubar F.K. Human Cytochrome P-450PIA (P450IA2), the Phenacetin O-deethylase, Is Primarily Responsible for the Hepatic 3-Demethylation of Caffeine and N-Oxidation of Carcinogenic Arylamines. Proc. Natl Acad. Sci. USA 1989; 86: 7696–7700, (a)
  • Bloomer J.C., Clarke S.E., Chenery R.J. Determination of P4501A2 Activity in Human Liver Microsomes Using [3-14C-Methyl]Caffeine. Xenobiotica 1995; 25: 917–927, (b)
  • Jeppesen U., Loft S., Poulsen H.E., Brosen K. A Fluvoxamine–Caffeine Interaction Study. Pharmacogenetics 1996; 6: 213–222, (c)
  • Tang W., Stearns R.A., Wang R.W., Chiu S.H., Baillie T.A. Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac. Chem. Res. Toxicol. 1999; 12: 192–199, (d)
  • Rasmussen B.B., Nielsen T.L., Brosen K. Fluvoxamine Is a Potent Inhibitor of the Metabolism of Caffeine In Vitro. Pharmacol. Toxicol. 1998; 83: 240–245, (e)
  • Tassaneeyakul W., McManus M.E., Tasseneeyakul W., Veronese M.E., Andersson T., Tukex R.H., Miners J.O. Caffeine Metabolism by Human Hepatic Cytochromes P450: Contribution of 1A2, 2E1, and 3A Isoforms. Biochem. Pharmacol. 1994; 47: 1767–1776
  • Butler M.A., Lang N.P., Yang J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., Kadlubar F.F. Determination of CYP1A2 and NAT2 Phenotypes in Human Populations by Caffeine Urinary Metabolites. Pharmacogenetics 1992; 2: 116–127, (a)
  • Fuhr U., Rost K.L., Engelhardt R., Sachs M., Liermann D., Belloc C., Beaunne P., Janezic D., Grant D., Meyer U.A., Staib A.H. Evaluation of Caffeine as a Test Drug for CYP1A2, NAT2 and CYP2E1 Phenotyping in Man by In Vivo Versus In Vitro Correlations. Pharmacogenetics 1996; 6: 159–176, (b)
  • Notarianni L.J., Oliver S.E., Dobrocky P., Benett P.N., Silverman B.W. Caffeine as a Metabolic Probe—a Comparison of the Metabolic Ratios Used to Assess CYP1A2 Activity. Br. J. Clin. Pharmacol. 1995; 39: 65–69, (a)
  • Miners J.O., Birkett D.J. The Use of Caffeine as a Metabolic Probe for Human Drug Metabolising Enzymes. Gen. Pharmacol. 1996; 27: 245–249, (b)
  • Shaw L., Lennard M.S., Tucker G.T., Bax N.D.S., Wood H.F. Irreversible Binding of Propranolol by Human Liver Microsomes—Relationship to Polymorphic Oxidation. Biochem. Pharmacol. 1987; 36: 2283–2288, (a)
  • Masubuchi Y., Hosokawa S., Horie T., Suzuki T., Ohmori S., Kitada M., Narimatsu S. Cytochrome P450 Isoenzymes Involved in Propranolol Metabolism in Human Liver-Microsomes—the Role of 2D6 as Ring-Hydroxylase and CYP1A2 as N-Deisopropylase. Drug Metab. Dispos. 1994; 22: 909–915, (b)
  • Yoshimoto K., Echizen H., Chiba K., Tani M., Ishizaki T. Identification of Human CYP Isoforms Involved in the Metabolism of Propranolol Enantiomers—Desisopropylation Is Mediated Mainly by CYP1A2. Br. J. Clin. Pharmacol. 1995; 39: 421–431, (c)
  • Ching M., Bichara N., Blake C.L., Ghabrial H., Tukey R.H., Smallwood R.A. Propranolol 4- and 5-Hydroxylation and N-Desisopropylation by Cloned Human Cytochrome P4501A1 and 1A2. Drug Metab. Dispos. 1996; 24: 692–695, (d)
  • Narimatsu S., Kobayashi N., Masubuchi Y., Horie T., Kakegawa T., Kobayashi H., Hardwick J.P., Gonzalez F.J., Shimada N., Ohmori S., Kitada M., Asaoka K., Kataoka H., Yamamoto S., Satoh T. T Species Difference in Enantioselectivity for the Oxidation of Propranolol by Cytochrome P450 2D Enzymes. Chem. Biol. Interact. 2000; 127: 73–90, (e)
  • Johnson J.A., Herring V.L., Wolfe M.S., Relling M.V. MV CYP1A2 and CYP2D6 4-Hydroxylate Propranolol and Both Reactions Exhibit Racial Differences. J. Pharmacol. Exp. Ther. 2000; 294: 1099–1105, (f)
  • Bourdi M., Timel M., Beune P.H., Pessayre D. Interactions of Dihydralazine with Cytochrome P4501A: a Possible Explanation for the Appearance of Anti-cytochrome P4501A2 Autoantibodies. Mol. Pharmacol. 1994; 45: 1287–1295
  • Buening M.K., Chang R.L., Huang M.T., Fortner J.G., Wood A.W., Conney A.H. Activation and Inhibition of Benzo[a]pyrene and Aflatoxin B1 Metabolism in Human Liver Microsomes by Naturally Occurring Flavonoids. Cancer Res. 1981; 41: 67–72
  • Kunze K.L., Trager W.F. Mechanism-Based Inhibition of Human Cytochrome P450 1A2 by Furafylline. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, USA, Nov 2–6, 1992. International Society for the Study of Xenobiotics, Bethesda, MD 1992; Vol. 2: 16, (a)
  • Clarke S.E., Ayrton A.D., Chenery R.J. Characterization of the Inhibition of P4501A2 by Furafylline. Xenobiotica 1994; 24: 517–526, (b)
  • Racha J.K., Rettie A.E., Kunze K.L. Mechanistic Studies on the Inactivation of Human Cytochrome P450 1A2 by Furafylline. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 229, (c)
  • Kunze K.L., Racha J.K., Calamia J. Novel Aspects of the Oxidation of 8-Ethyl Xanthine Analogs of Furafylline by Human P450 1A2. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 230, (d)
  • Wei X., Thummel K.E., Banks R.C., Vestal R.E. Structure-Related Inhibitory Potency of Class IB Antiarrhytmics Mexiletine, Lidocaine, and, Tocainide on In Vitro Human CYP1A2. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 151
  • Ohashi K., Sakamoto K., Sudo T., Tateishi T., Fujimura A., Shiga T., Ebihara A. Effects of Diltiazem and Cimetidine on Theophylline Oxidative Metabolism. J. Clin. Pharmacol. 1993; 33: 1233–1237, (a)
  • Knodell R.G., Browne D.G., Gwozdz G.P., Brian W.R., Guengerich F.P. Differential Inhibition of Individual Human Liver Cytochromes P450 by Cimetidine. Gastroenterology 1991; 101: 1680–1691, (b)
  • Toon S., Holt B.L., Mullins F.G.P., Kahn A. Effects of Cimetidine, Ranitidine, and Omeprazole on Tolbutamide Pharmacokinetics. J. Pharm. Pharmacol. 1995; 47: 85–88, (c)
  • Fuhr U., Anders E.M., Mahr G., Sörgel F., Staib A.H. Inhibitory Potency of Quinolone Antibacterial Agents Against Cytochrome P450IA2 Activity In Vivo and In Vitro. Antimicrob. Agents Chemother. 1992; 36: 942–948, (a)
  • Mizuki Y., Fujiwara I., Yamamoto K., Yamaguchi T., Fujii T., Miyazaki H. Essential Physicochemical Characteristics of Enoxacin on Inhibition of Theophylline Metabolism. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 140, (b)
  • Sandhu P., Guo Z., Baba T., Martin M.V., Tukey R.H., Guengerich P.F. Expression of Modified Human Cytochrome P4501A2 in Escherichia coli, Stabilization, Purification, Spectral Characterization, and Catalytic Activities of the Enzyme. Arch. Biochem. Biophys. 1994; 309: 168–177, (a)
  • Fisher C.W., Caudle D.L., Martin-Wixtrom C., Quattrochi L.C., Tukey R.H., Waterman M.R., Estabrook R. High-Level Expression of Functional Human Cytochrome P450 1A2 in Escherichia coli. FASEB J. 1992; 6: 759–764, (b)
  • Shet M.S., Fisher C.W., Estabrook R. Expression, Purification, and Enzymatic Properties of a Recombinant Fusion Protein Containing Human P4501A2 Joined to NADPH-P450 Reductase. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 362, (c)
  • Gallagher E.P., Wienkers L.C., Stapleton P.L., Kunzel K.L., Eaton D.L. Role of Human Microsomal and Human Complementary DNA-Expressed Cytochromes P4501A2 and P4503A4 in the Bioactivation of Aflatoxin B1. Cancer Res. 1994; 54: 101–108, (a)
  • Ueng Y.F., Shimada T., Yimazaki H., Guengerich F.P. Oxidation of Aflatoxin B1 by Bacterial Recombinant Human Cytochrome-P450 Enzymes. Chem. Res. 1995; 8: 218–225, (b)
  • Neal G.E., Eaton D.L., Judah D.J., Verma A. Metabolism and Toxicity of Aflatoxins M1 and B1 in Human-Derived In Vitro Systems. Toxicol. Appl. Pharmacol. 1998; 151: 152–158, (c)
  • Roberts E.A., Xie Z.W., Yang S., Lipa J. Inducibility of Enzyme Activities Associated with the Cytochrome P4501A Family, Ethoxyresorufin O-Deethylase, and Methoxyresorufin O-Demethylase in Human Hepatocyte Lines Derived from Normal Liver Tissue. Drug Metab. Dispos. 1993; 21: 56–61
  • Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome P450 Specificities of Alkoxyresorufin O-Dealkylation in Human and Rat Liver. Biochem. Pharmacol. 1994; 48: 923–936
  • Chang T.K.H., Gonzalez F.J., Waxman D.J. Evaluation of Triacetoyloleandomycin, alpha-Naphthoflavone and Diethyldithiocarbamate as Selective Chemical Probe for Inhibition of Human Cytochromes P450. Arch. Biochem. Biophys. 1994; 311: 437–442
  • Spaldin V., Madden S., Adams D.A., Edwards R.J., Davies D.S., Park B.K. Determination of Human Hepatic Cytochrome P4501A2 Activity In Vitro Use of Tacrine as an Isoenzyme-Specific Probe. Drug Metab. Dispos. 1995; 23: 929–934, (a)
  • Spaldin V., Madden S., Pool W.F., Woolf T.F., Park B.K. The Effect of Enzyme Inhibition on the Metabolism and Activation of Tacrine by Human Liver Microsomes. Br. J. Clin. Pharmacol. 1994; 38: 15–22, (b)
  • Madden S., Spaldin V., Hayes R.N., Wolf T.F., Pool W.F., Park B.K. Species Variation in the Bioactivation of Tacrine by Hepatic Microsomes. Xenobiotica 1995; 25: 103–116, (c)
  • Becquemont L., Le Bot M.A., Ciche C., Funck-Bretano C., Jaillon P., Beaune P. Use of Heterologously Expressed Human Cytochrome P450 1A2 to Predict Tacrine–Fluvoxamine Drug Interaction in Man. Pharmacogenetics 1998; 8: 101–108, (d)
  • Buening M.K., Fortner J.G., Kapas A., Conney A.H. 7,8-Benzoflavone Stimulates the Metabolic Activation of Aflatoxin B1 to Mutagens by Human Liver. Biochem. Biophys. Res. Commun. 1978; 82: 348–355
  • Yun C.H., Shimada T., Guengerich F.P. Purification and Characterization of Human Liver Microsomal Cytochrome P450 2A6. Mol. Pharmacol. 1994; 40: 679–685
  • Yamazaki H., Shimada T., Guengerich F.P. Ethnic-Related Differences in Coumarin 7-Hydroxylation Activities Catalyzed by Cytochrome P450 in Liver Microsomes of Japanese and Caucasian Populations. Xenobiotica 1996; 26: 395–403, (a)
  • Li Y., Wang E., Patten C.J., Chen L., Yang C.S. Effects of Flavonoids on Cytochrome P450-Dependent Acetaminophen Metabolism in Rats and Human Liver Microsomes. Drug Metab. Dispos. 1994; 22: 566–571, (b)
  • Cashman J.R., Yang Z.C., Yang L., Wrighton S.A. Stereo- and Regioselective N- and S-Oxygenation of Tertiary Amines and Sulfides in Adult Human Liver Microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, AZ, USA, Oct 17–21. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 34
  • Kharasch E.D., Thummel K. Cytochrome P450 Participation in Human Volatile Anesthetic Defluorination. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, USA, Nov 2–6, 1992. International Society for the Study of Xenobiotics, Bethesda, MD 1992; Vol. 2: 18, (a)
  • Kharasch E.D., Hankins D.C., Thummel K. Human Kidney Microsomal Volatile Anesthetic Metabolism: Potential Role in Nephrotoxicity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 269, (b)
  • Kharasch E.D., Hankins D.C., Thummel K.E. Human Kidney Methoxyflurane and Sevoflurane Metabolism. Intrarenal Fluoride Production as a Possible Mechanism of Methoxyflurane Nephrotoxicity. Anesthesiology 1995; 82: 689–699, (c)
  • Kharasch E.D., Thummel K.E. Identification of Cytochrome P450 2E1 as the Predominant Enzyme Catalyzing Human Liver Microsomal Defluorination of Sevoflurane, Isoflurane, and Methoxyflurane. Anesthesiology 1993; 79: 795–807, (d)
  • Eagling V.A., Howe J.L., Barry M.J., Back D.J. The Metabolism of Zidovudine by Human Liver Microsomes In Vitro: Formation of 3′-Amino-3′-deoxythimidine. Biochem. Pharmacol. 1994; 48: 267–276, (a)
  • Pan-Zhou X.R., Maurel P., Sommadossi J.P. Reduction of AZT in Human Liver Microsomes. Clin. Pharmacol. Ther. 1994; 55: 138, (b)
  • Pan-Zhou X.R., Scott E.C., Zhou X.J., Yang M.X., Lasker J.M., Sommadossi J.P. Reductive Metabolism of 3′-Azido-3′-deoxythymidine by Human Liver: Involvement of Microsomal P450, Cytochrome b5, and Their Respective Reductases. FASEB J. 1995; 9: A1487, (c)
  • Ring B.J., Binkley S.N., VandenBranden M., Catlow J., Lindsay T.J., Gillespie T., Roskos L.K., Swanson S.P., Wrighton S.A. The Use In Vitro Methodologies to Predict Potential Drug Interactions with the Antipsychotic Drug Olanzapine. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 60, (a)
  • Ring B.J., Binkley S.N., Catlow J., Lindsay T.J., Gillespie T., Roskos L.K., Cerimele B.J., Swanson S.P., Hamman M.A., Wrighton S.A. Identification of the Human P450 Responsible for In Vitro Formation of the Major Oxidative Metabolites of the Antipsychotic Drug Olanzapine. J. Pharmacol. Exp. Ther. 1996; 276: 658–666, (b)
  • Ring B.J., Binkley S.N., Vandenbranden M., Wrighton S.A. In Vitro Interaction of the Antipsychotic Agent Olanzapine with Human Cytochromes P450 CYP2C9. Br. J. Clin. Pharmacol. 1996; 41: 181–186, (c)
  • Goldstein J.A., de Morais S.M.F. Biochemistry and Molecular Biology of the Human CYP 2C Subfamily. Pharmacogenetics 1994; 4: 285–299, (a)
  • Levy R.H. Cytochrome P450 Isozymes and Antiepileptic Drug Interactions. Epilepsia 1995; 36(Suppl. 5)S8–13, (b)
  • de Morais S.M.F., Meyer U.A., Linko P., Goldstain J.A. CYP2C19 RNA Level Correlates with S-Mephenytoin 4′-Hydroxylase Activity in Human Liver. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 239, (c)
  • Sullivan T.H., Ghanayem B.I., Faletttto M.F., Goldstein J.A. Comparison of Mephenytoin 4′-Hydroxylation by Recombinant CYP2C19 and Various 2C9 Mutants Constructed by Site-Directed Mutagenesis. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 178, (d)
  • Goldstain J.A., Wilkison G.R., Nakamura K., Meyer U.A., de Morais S.M.F. Identification of the Genetic Defects Responsible for the Mephenytion 4′-Hydroxylase Polymorphism in Humans. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 2, (e)
  • Miners J.O., Birkett D.J. Cytochrome P4502C9: an Enzyme of Major Importance in Human Drug Metabolism. Br. J. Clin. Pharmacol. 1998; 45: 5238–5255, (f)
  • Heyn H., Stevens J.C., Marietta M.P. The N-Demethylation of S-Mephenytoin by Cytochromes P450 2B6 and 3A4. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 73, (a)
  • Heyn H., White R.B., Stevens J.C. Catalytic Role of Cytochrome P450 2B6 in N-Demethylation of S-Mephenytion. Drug Metab. Dispos. 1996; 24: 948–954, (b)
  • Ko J.W., Desta Z., Flockhart D.A. Human N-Demethylation of (S)-Mephenytoin by Cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos. 1998; 26: 775–778, (c)
  • Balian J.D., Sukhova N., Hewett J., Harris J.W., Woosley R.L., Flockhart D.A. Omeprazole: a Probe for the S-Mephenytion Hydroxylation. Clin. Pharmacol. Ther. 1994; 55: 169
  • Caraco Y., Tateishi T., Wood A.J.J. Interethnic Differences in Omeprazole's Inhibition of Diazepam Metabolism. Clin. Pharmacol. Ther. 1995; 58: 62–72
  • Caraco Y., Wilkinson G.R., Wood A.J.J. Differences Between White Subjects and Chinese Subjects in the In Vivo Inhibition of Cytochrome P450s 2C19, 2D6, and 3A4 by Omeprazole. Clin. Pharmacol. Ther. 1996; 60: 396–404, (a)
  • Petersen K.U. Review Article: Omeprazole and the Cytochrome P450 System. Aliment. Pharmacol. Ther. 1995; 9: 1–9, (b)
  • Andersson T., Miners J.O., Birket D.J. Diazepam Metabolism by Human Liver Microsomes Is Mediated by Both S-Mephenytion Hydroxylase and CYP3A Isoforms. Clin. Pharmacol. Ther. 1994; 55: 138, (a)
  • Ono S., Hatanaka T., Miyzawa S., Tsutsui M., Aoyama T., Gonzalez F.J., Satoh T. Human Liver Microsomal Diazepam Metabolism Using cDNA-Expressed Cytochrome P450s: Role of CYP2B6, 2C19 and 3A Subfamily. Xenobiotica 1996; 26: 1155–1166, (b)
  • Yang T.J., Shou M., Korzekwa K.R., Gonzales F.J., Gelboin H.V., Yang S.K. Role of cDNA-Expressed Human Cytochromes P450 in the Metabolism of Diazepam. Biochem. Pharmacol. 1998; 55: 889–896, (c)
  • He M., Korzekwa K.R., Kunze K.L., Jones J.P., Trager W.F. Probing the Active Site of Cytochrome P450—Metabolic and Kinetic Studies on a Series of Coumarin Anticoagulants Which Serve as Substrates/Inhibitors of P4502C9. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 49
  • Lopez-Garzia P., Ansette P.D., Mansuy D. Thiophene Derivatives as New Mechanism-Based Inhibitors of Cytochrome P450: Inactivation of Yeast Expressed Human Liver Cytochrome P450 2C9 by Tienilic Acid. Biochemistry 1994; 33: 166–175, (a)
  • Miners J.O., Rees D.L.P., Valente L., Veronese M.E., Birket D.J. Human Hepatic Cytochrome P-450 2C9 Catalyses the Rate-Limiting Pathway of Torsemide Metabolism. J. Pharmacol. Exp. Ther. 1995; 272: 1076–1081, (b)
  • Baldwin S.J., Bloomer J.C., Smith G.J., Airton A.D., Clarke S.E., Chenery R.J. Ketoconazole and Sulphaphenazole as the Respective Selective Inhibitors of P450 3A and 2C9. Xenobiotica 1995; 25: 261–270
  • Miners J.O. In Vitro Approaches for Prediction of Oxidative Drug Metabolism In Vivo. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 2, (a)
  • Tassaneeyakul W., Birkett D.J., Edvards J.W., Veronese M.E., Tassaneeyakul W., Turkey R., Miners J.O. Human Cytochrome P450 Isoform Specificity in the Regioselective Metabolism of Toluene and o-, m- and p-Xylene. J. Pharmacol. Exp. Ther. 1996; 276: 101–108, (b)
  • Nielsen K.K., Brosen K., Jeppe Hansen M.G., Gram L.F. Single Dose Kinetics of Clomipramine: Relationship to the Sparteine and S-Mephenytoin Oxidation Polymorphisms. Clin. Pharmacol. Ther. 1994; 55: 518–527, (a)
  • Nielsen K.K., Linois J.P., Beaune P., Brosen K. The Biotransformation of Clomipramine In Vitro, Identification of the Cytochrome P450s Responsible for the Sparteine Metabolic Pathways. J. Pharmacol. Exp. Ther. 1996; 278: 1659–1664, (b)
  • Bonnabry P., Leemann T., Dayer P. Biotransformation by Hepatic P450TB (CYP2C) Controls Mefenamic Elimination. Clin. Pharmacol. Ther. 1994; 55: 139–(PI66), Meeting-Abstract, (a)
  • Tracy T.S., Marra C., Wrighton S.A., Gonzalez F.J., Korzekwa K.R. Studies of Flurbiprofen 4′-Hydroxylation, Additional Evidence Suggesting the Sole Invlovement of Cytochrome P450 2C9. Biochem. Pharmacol. 1996; 52: 1305–1310, (b)
  • Tracy T.S., Rosenbluth B.W., Wrighton S.A., Gonzalez F.J., Korzekwa K.R. Role of Cytochrome P450 2C9 and an Allelic Variant in the 4′-Hydroxylation of (R)-and (S)-Flurbiprofen. Biochem. Pharmacol. 1995; 49: 1269–1275, (c)
  • Transon C., Leemann T., Dayer P. In Vitro Comparative Inhibition Profiles of Major Human Drug Metabolising Cytochrome P450 Isozymes (CYP2C9, CYP2D6, and CYP3A4) by HMG-CoA Reductase Inhibitors. Eur. J. Clin. Pharmacol. 1996; 50: 209–215
  • Parkinson A. In Vitro Approach to Studying Human P450 Enzymes. ISSX Proceedings, Sixth North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 5
  • Karam W.G., Goldstein J.A., Lasker J.M., Ghanay G.I. Human CYP2C19 Is a Major Omeprazole 5-Hydroxylase, as Demonstrated with Recombinant Cytochrome P450 Enzymes. Drug Metab. Dispos. 1996; 24: 1081–1087, (a)
  • Ibenau G.C., Ghanayern B.I., Linko P., Pedersen L.G., Goldstein J.A. Identification of Residues 99, 220, and 221 of Human Cytochrome P4502C19 as Key Determinants of Omeprazole Hydroxylase Activity. J. Biol. Chem. 1996; 271: 12496–12501, (b)
  • Andersson T., Miners J.O., Veronese M.E., Birkett D.J. Identification of Human Liver Cytochrome P450 Isoforms Mediating Secondary Omeprazole Metabolism. Br. J. Clin. Pharmacol. 1994; 37: 597–604
  • Trager W.F. Stereoselectivity as a Tool for Identifying the Enzymes Controlling the Clearance of Chiral and Prochiral Drugs In Vivo. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 30
  • Kitchen I., Tremblay J., Andrés J., Dring L.G., Idle J.R., Smith R.L., Williams R.T. Interindividual and Interspecies Variation in the Metabolism of the Hallucinogen 4-Methoxyamphetamine. Xenobiotica 1979; 9: 397–404
  • Roy S.D., Hawes E.M., McKay G., Korchinski E.D., Midha K.K. Metabolism of Methoxyphenamine in Extensive and Poor Metabolizers of Debrisoquin. Clin. Pharmacol. Ther. 1985; 38: 128–133, (a)
  • Geertsen S., Foster B.C., Wilson D.L., Cyr T.D., Casly W. Metabolism of 2-Methoxyphenamine and 2-Methoxyamphetamine in 2D6-Transfected Cells and Cell Preparations. Xenobiotica 1995; 25: 895–906, (b)
  • Coutts R.T., Bolaji O.O., Su P., Baker G.B. Metabolism of Methoxyphenamine In Vitro by a CYP2D6 Microsomal Preparation. Drug Metab. Dispos. 1994; 22: 756–760, (c)
  • Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y.Y. The Demethylenation of Methylenedioxymethamphethamine (ECSTASY) by Debrisoquine Hydroxylase (CYP2D6). Biochem. Pharmacol. 1994; 47: 1151–1156
  • Ellis S.W., Ching M.S., Watson P.F., Henderson C.J., Simzula A.P., Lennard M.S., Tucker G.T., Woods H.F. Catalytic Activities of Human Debrisoquine 4-Hydroxylase Cytochrome P450 (CYP2D6) Expressed in Yeast. Biochem. Pharmacol. 1992; 44: 617–620, (a)
  • Gillam E.M.J., Guo Z., Martin M.V., Jenkins C.M., Guengerich F.P. Expression of Cytochrome P450 2D6 in Escherichia coli, Purification, Spectral and Catalytic Characterization. Arch. Biochem. Biophys. 1995; 319: 540–550, (b)
  • Paine M.J.I., Gilham D., Roberts G.C.K., Wolf C.R. Functional High Level Expression of Cytochrome P4502D6 Using Baculoviral Expression Systems. Arch. Biochem. Biophys. 1996; 328: 143–150, (c)
  • Otton S.V., Schadel M., Cheung S.W., Kaplan H.L., Busto U.E., Sellers E.M. CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone. Clin. Pharmacol. Ther. 1993; 54: 463–472, (a)
  • Kroemer H.K., Eichelbaum M. Molecular Bases and Clinical Consequences of Genetic Cytochrome P4502D6 Polymorphism. Life Sci. 1995; 26: 2285–2298, (b)
  • Liu Z.R., Mortimer O., Smith C.A.D., Wolf C.R., Rane A. Evidence for Role of Cytochrome P450 2D6 and 3A4 in Ethylmorphine Metabolism. Br. J. Clin. Pharmacol. 1995; 39: 77–80, (c)
  • Ducharme J., Abdullah S., Fried K., Wainer I.W. Dextromethorphan as an In Vivo Probe for CYP3A4 Activity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; 240
  • Gorski J.C., Jones D.J., Wrighton S.A., Hall S.D. Characterization of Dextromethorphan N-Demethylation by Human Liver Microsomes, Contribution of P4503A (CYP3A) Subfamily. Biochem. Pharmacol. 1994; 48: 173–182, (a)
  • McIntyre C.J., Madan A., Parkinson A. Investigation of the Role of CYP2B6 in the N-Demethylation of Dextromethorphan by Human Liver Microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 231, (b)
  • Mortimer Ö., Lindström B., Laurell H., Bergman U., Rane A. Dextromethorphan: Polymorphic Serum Pattern of the O-Demethylated and Didemethylated Metabolites in Man. Br. J. Clin. Pharmacol. 1989; 27: 223–227, (a)
  • Schadel M., Wu D., Oton S.W., Kallow W., Sellers E.M. Pharmacokinetics of Dextromethorphan and Metabolites in Humans, Influence of the 2D6 Phenotype and Quinidine Inhibition. J. Clin. Psychopharmacol. 1995; 15: 263–269, (b)
  • Jaruratanasirikul S., Hortiwakul R. The Inhibitory Effect of Amiodarone and Desmethylamiodarone on Dextromethorphan O-Demethylation in Human and Rat Liver Microsomes. Clin. Pharmacol. Ther. 1994; 55: 169
  • Distlerath L.M., Guengerich F.P. Characterization of Human Liver Cytochrome P450 Involved in the Oxidation of Debrisoquine and Other Drugs by Using Antibodies Raised to the Analogous Rat Enzyme. Proc. Natl Acad. Sci. USA 1984; 81: 7348–7352
  • Zekorn C., Achtert G., Hausleiter H.J., Moon C.H., Eichelbaum M. Pharmacokinetics of N-Propylajmaline in Relation to Polymorphic Sparteine Oxidation. Klin. Wochenschr. 1985; 63: 1180–1186
  • Kharasch E.D., Thummel K., Mautz D., Bosse S. Clinical Enflurane Metabolism by Cytochrome P4502E1. Clin. Pharmacol. Ther. 1994; 55: 434–440, (a)
  • Garton K.J., Meinwald J., Thumel K.E., Kharasch E. Stereoselective Metabolism of Enflurane by Human Liver Cytochrome P450 2E1. Drug Metab. Dispos. 1996; 23: 1426–1430, (b)
  • Kharasch E.D., Armstrong A.S., Gunn K., Artru A., Cox K., Karol M.D. Clinical Sevoflurane Metabolism and Disposition, 2. The Role of Cytochrome P450 2E1 in Fluoride and Hexafluorisopropanol Formation. Anesthesiology 1995; 82: 1379–1388, (a)
  • Kharasch E.D., Hankins D.C., Cox K. Clinical Isoflurane Metabolism by Cytochrome P450 2E1. Anesthesiology 1999; 90: 766–771, (b)
  • Hase I., Imaoka S., Oda Y., Hiroi T., Nakamoto T., Asada A., Funae Y. Area Under the Plasma Concentration–Time Curve of Inorganic Fluoride Following Sevoflurane Anesthesia Correlates with CYP2E1 mRNA Level in Mononuclear Cells. Anesthesiology 2000; 92: 1661–1666, (c)
  • Kenna J.G., van Pelt F.N. The Metabolism and Toxicity of Inhaled Anaesthetic Agents. Anaesth. -Pharmacol. Rev. 1994; 2: 29–42, (a)
  • Gut J., Christen U., Frey N., Koch V., Stoffler D. Halothane Hepatitis: Molecular Mimicry Between Triflouroacetyl-Adducts to Proteins and Lipoylated Self Components. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 235, (b)
  • Kharasch E.D., Thummel K., Hankins D., Mautz D. Human Oxidative Halothane Metabolism In Vivo Is Catalyzed by P452E1. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 94, (c)
  • Eliasson E., Hume-Smith H.V., Gardber I., Kenna J.K. Cytochrome P450 2E1 and Halothane Hepatitis. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 229, (d)
  • Raucy J.L. Risk Assessment: Toxicity from Chemical Exposure Resulting from Enhanced Expression of CYP2E1. Toxicology 1995; 105: 217–224, (a)
  • Seaton M.J., Schlosser P.M., Bond J.A., Medinsky M.A.A. Benzene Metabolism by Human Liver Microsomes in Relation to Cytochrome P4502E1. Carcinogenesis 1994; 15: 1799–1806, (b)
  • Roberts B.J., Song B.J., Shoaf S.E. Induction of CYP2E1 by Ethanol Is due to Protein Stabilisation. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 175, (c)
  • Roberts B.J., Song B.J., Shoaf S.E. Induction of CYP2E1 in Liver, Kidney, Brain and Intestine During Chronic Ethanol Administration and Withdrawal: Evidence That CYP2E1 Possess a Rapid Phase Half-Life of 6 Hours or Less. Biochem. Biophys. Res. Commun. 1994; 205: 1064–1071, (d)
  • Nakagawa T., Sawada M., Gonzalez F.J., Yokoi T., Kamataki T. Stable Expression of Human CYP2E1 in Chinese Hamster Cells: High Sensitivity to N,N-Dimethylnitrosamine in Cytotoxycity Testing. Mutat. Res. 1996; 354: 181–186, (e)
  • Novak R.F., Woodcroft K.J. The Alcohol-Inducible Form of Cytochrome P450 (CYP 2E1): Role in Toxicology and Regulation of Expression. Arch. Pharm. Res. 2000; 23: 267–282, (f)
  • Nakajima T., Wang R.S. Induction of Cytochrome P450 by Toluene. Int. J. Biochem. 1994; 26: 1333–1340
  • Gorski J.C., Wrighton S.A., Jones D.R., Hall S.D. The Contribution of Cytochrome P450 3A (CYP3A) to the 6-Hydroxylation of Chlorzoxazone. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 116, (a)
  • Berthou F., Carriere V., Ratanasavanh D., Goasduff T., Morel F., Gautier J.C., Guillouzo A., Beaune P. On the Specificity of Chlorzoxazone as Drug Probe of Cytochrome P4502E1. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, Sept 26–29, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 116, (b)
  • Wynalda M.A., Wienkers L.C. In Vitro Metabolism of Chlorzoxazone Is Mediated by Human Microsomal CYP1A2 and CYP2E1. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 246, (c)
  • Dresibach A.W., Fertencz N., Hopkins N.E., Fuentes M.G., Rege A.B., George W.J., Lertora J.J.L. Urinary Excretion of 6-OH-Chlorzoxazone (CXZ-OH) as an Index of Cytochrome P4502E1 Activity. Clin. Pharmacol. Ther. 1995; 58: 498–505
  • Girre C., Lucas D., Hispard E., Menez C., Dally S., Menez J.F. Assessment of Cytochrome P4502E1 Induction in Alcoholic Patients by Chlorzoxazone Pharmacokinetics. Biochem. Pharmacol. 1994; 47: 1503–1508
  • Tassaneeyakul W., Veronese M.E., Birkett D.J., Gonzalez F.J., Miners J.O. Validation of 4-Nitrophenol as an In Vitro Substrate Probe for Human Liver CYP2E1 Using cDNA Expression and Microsomal Kinetic Techniques. Biochem. Pharmacol. 1993; 46: 1975–1981
  • Carpenter S.P., Lasker J.M., Raucy J.L. Expression, Induction, and Catalytic Activity of the Ethanol-Inducible Cytochrome P450 (CYP2E1) in Human Fetal Liver and Hepatocytes. Mol. Pharmacol. 1996; 49: 260–268, (b)
  • Chen W., Peter R.M., Thumel K.E., Nelson S.D. Baculovirus Expression and Purification of Human Cytochrome P4502E1. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 365
  • Kivistö K.T., Linder A., Friedel G., Beaune P., Belloc C., Kroemer H.K., Fritz P. Immunohistochemical Localization of Cytochrome P4502E1 in Human Pulmonary Carcinoma and Normal Bronchial Tissue. Virchows Arch. 1995; 426: 243–247
  • Herbst J., Köster U., Kerssebaum R., Dekant W. Role of P450E1 in the Metabolism of 1,1,2,2,-Tetrafluoro-1-(2,2,2-trifluoroethoxy)ethane. Xenobiotica 1994; 24: 507–516, (a)
  • Urban G., Speerschnaider P., Dekant W. Metabolism of the Chlorofluorocarbon Substitute 1,1-Dichloro-2,2,2-trifluoroethane by Rat and Human Liver Microsomes: the Role of Cytochrome P4502E1. Chem. Res. Toxicol. 1994; 7: 170–176, (b)
  • Dekant W., Assman M., Urban G. The Role of Cytochrome P4502E1 in Species-Dependent Biotransformation of 1,2-Dichloro-1,1,2-trifluoroethane in Rats and Mice. Toxicol. Appl. Pharmacol. 1995; 135: 200–207, (c)
  • Mitra A.K., Thummel K.E., Kalhorn T.F., Kharsch E.D., Unadkat J.D., Slattery J.T. Metabolism of Dapsone in Human Liver by Cytochrome P450 2E1 In Vitro and In Vivo. Clin. Pharmacol. Ther. 1995; 58: 556–566
  • Gill H.J., Tingle M.D., Park B.K. N-Hydroxylation of Dapsone by Multiple Enzymes of Cytochrome P450: Implications for Inhibition of Haematoxicity. Br. J. Clin. Pharmacol. 1995; 40: 531–538, (b)
  • Coleman M.D., Rhodes L.E., Scott A.K., Verbov J.L., Friedman P.S., Breckenridge A.M. The Use of Cimetidine to Reduce Dapsone Dependent Methaemoglobinaemia in Dermatitis Herpetiformis Patients. Br. J. Clin. Pharmacol. 1992; 34: 244–249, (c)
  • Rhodes L.E., Tingle M.D., Park B.K., Chu P., Verbov J.L., Friedman P.S. Cimetidine Improves the Therapeutic/Toxic Ratio of Dapsone in Patients on Chronic Dapsone Therapy. Br. J. Dermathol. 1995; 132: 257–262, (d)
  • Occhipinti D.J., Choi A., Deyo K., Danzinger L.H., Fischer J.H. Influence of Rifampin and Clarithromycin on Dapsone Disposition and Methemoglobin Concentrations. Clin. Pharmacol. Ther. 1995; 57: 163, (e)
  • Watkins P.B. Noninvasive Tests of CYP3A Enzymes. Pharmacogenetics 1994; 4: 171–184, (a)
  • Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., Guzelian P.S. Erythromycin Breath Test as an Assay of Glucocorticoid-Inducible Liver Cytochromes P450. J. Clin. Invest. 1989; 83: 688–697, (b)
  • Yamazaki H., Hiroki S., Urano T., Inuoe K., Shimada T. Effects of Roxithromycin, Erythtomycin and Troleandomycin on Their N-Demethylation by Rat and Human Cytochrome P450 Enzymes. Xenobiotica 1996; 26: 1143–1153, (c)
  • Mäenpää J., Pelkonen O., Cresteil T., Rane A. The Role of Cytochrome P450 3A (CYP3A) Isoform(s) in Oxidative Metabolism of Testosterone and Benzphetamine in Human Adult and Fetal Liver. J. Steroid Biochem. Mol. Biol. 1993; 44: 61–67, (a)
  • Mäenpää J., Syngelmä T., Onkakoski P.H., Lang M.A., Pelkonen O. Comparative Studies on Coumarin and Testosterone Metabolism in Mouse and Human Livers. Differential Inhibitions by the Anti-P450Coh Antibody and Metyrapone. Biochem. Pharmacol. 1991; 42: 1229–1235, (b)
  • Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of Imidazole Derivatives on Cytochrome P450 from Human Hepatocytes in Primary Culture. FASEB J. 1992; 6: 752–758
  • Waxman D.J., Attisano C., Guengerich F.P., Lapenson D.P. Human Liver Microsomal Steroid Metabolism: Identification of the Major Microsomal Steroid Hormone 6beta-Hydroxylase Cytochrome P450 Enzyme. Arch. Biochem. Biophys. 1988; 263: 424–436, (a)
  • Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The Increase in Urinary Excretion of 6beta-Hydroxycortisol as a Marker of Human Cytochrome P450IIIA Induction. Br. J. Clin. Pharmacol. 1989; 28: 373–387, (b)
  • Flaishaker J.C., Pearson L.K., Peters G.R. Phenytion Causes a Rapid Increase in 6beta-Hydroxycortisol Urinary-Excretion in Humans—a Putative Measure of CYP3A Induction. J. Pharm. Sci. 1995; 84: 292–294, (c)
  • Ucharme M.P.D., Warbasse L.H., Edwards D.J. Grapefruit Juice Affects Oral But Not IV Cyclosporine Disposition in Man. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 81, (a)
  • Edwards D.J., Bellevue F.H., Woster P.M. Identification of 6,7-Dihydroxybergamottin, a P450 Inhibitor in Grapefruit Juice. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 254, (b)
  • Edwards D.J., Bernier S.M. Naringin and Naringenin Are Not the Primary CYP3A Inhibitors of Grapefruit Juice. Life Sci. 1966; 59: 1025–1030, (c)
  • Bailey D.G., Arnold J.M.O., Tran L.T., Abktar J., Spence J.D. Marked Effects of Both Erythromycin and Grapefruit Juice on Felodipine Pharmacokinetics. Clin. Pharmacol. Ther. 1994; 55: 165–(PII-48) Meeting-Abstract, (a)
  • Bailey D.G., Arnold J.M.O., Bend J.R., , et al. Grapefruit Juice–Felodipine Interaction: Reproducibility and Characterization with the Extended Release Drug Formulation. Br. J. Clin. Pharmacol. 1995; 40: 135–140, (b)
  • Benton R.E., Honig P.K., Zamani K., Cantilena L.R., Woosley R.L. Grapefruit Juice Alters Terfenadine Pharmacokinetics Resulting in Prolongation of Repolarization on the Electrocardiogram. Clin. Pharmacol. Ther. 1996; 59: 383–388, (c)
  • LeDuc B.W., Sinclair P.R., Shuster L., Sinclair J.F., Evans J.E., Greenblatt D.J. Norcocaine and N-Hydroxynorcocaine Formation in Human Liver Microsomes: Role of Cytochrome P-450 3A4. Pharmacology 1993; 46: 294–300, (a)
  • Pellinen P., Onkakoski P.H., Stenbäck F., Niemitz M., Alhava E., Pelkonen O., Lang M.A., Pasanen M. Cocaine N-Demethylation and the Metabolism Related Hepatotoxicity Can Be Prevented by Cytochrome P450 3A Inhibitors. Eur. J. Pharmacol. 1994; 270: 35–43, (b)
  • Pellinen P., Kulmala L., Konttila J., Auriola S., Pasanen M., Juvonen R. Kinetic Characteristics of Norcocaine N-Hydroxylation in Mouse and Human Liver Microsomes: Involvement of CYP Enzymes. Arch. Toxicol. 2000; 74: 511–520, (c)
  • Pasanen M., Pellinen P., Stenback F., Juvonen R.O., Raunio H., Pelkonen O. The Role of CYP Enzymes in Cocaine-Induced Liver-Damage. Arch. Toxicol. 1995; 69: 287–290, (d)
  • Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., Wrighton S.A. Regioselective Biotransformation of Midazolam by Members of the Human Cytochrome P453A (CYP3A) Subfamily. Biochem. Pharmacol. 1994; 47: 1643–1653, (a)
  • Podoll T.D., Kunze K.L., Thummel K.E., Fisher J.M., Trager W.F. Evidence Supporting Mechanism-Based Inactivation of CYP3A by Midazolam. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 154, (b)
  • Ghosal A., Satoh H., Thomas P.E., Bush E., Moore D. Inhibition and Kinetics of Cytochrome P4503A Activity in Microsomes from Rat, Human, and cDNA-Expressed Human Cytochrome P450. Drug Metab. Dispos. 1996; 24: 940–947, (c)
  • Paine M.F., Kunze K.L., Shen D.D., Lown K.S., Watkins P.B., Thummel K.E. Hydroxylation of Midazolam as an Indicator of Human Intestinal CYP3A Activity. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 243, (a)
  • Wandel C., Böcker R., Böhrer H., Browne A., Rügheimer E., Martin E. Midazolam Is Metabolized by at Least 3 Different Cytochrome P450 Enzymes. Br. J. Anaesth. 1994; 73: 658–661, (b)
  • Thumel K.E., Kunze K.L. Design and Interpretation of Kinetic Studies in the Characterization of Cytochrome P450-Dependent Drug Metabolism. International Society for the Study of Xenobiotics, Bethesda, MD 1995, (c)
  • Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., Meier P.J., Krahenbuhl S. Interaction Between Grapefruit Juice and Midazolam in Humans. Clin. Pharmacol. Ther. 1995; 58: 20–28, (d)
  • Olkkola K.T., Backman J.T., Neuvonen P.J. Midazolam Should Be Avoided in Patients Receiving the Systemic Antimycotics Ketoconazole or Itraconazole. Clin. Pharmacol. Ther. 1994; 55: 481–485, (a)
  • Wrighton S.A., Ring B.J. Inhibition of CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine. Pharmacol. Res. 1994; 11: 921–924, (b)
  • Onig P.H., Wortham D., Hull R., Zamani K., Smith J., Cantinela L. Itraconazole Affects Single-Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics. Clin. Pharmacol. Ther. 1994; 55: 165
  • Gomez D.Y., Hebert M., Benet L.Z. The Effect of Ketoconazole on the Intestinal Metabolism and Bioavaiability of Cyclosporine. Clin. Pharmacol. Ther. 1994; 55: 209–(BIII-O-3) Meeting-Abstract, (a)
  • Gomez D.Y., Watcher V.J., Tomlanovich S.J., Hebert M.F., Benet L.Z. The Effect of Ketoconazole on the Intestinal Metabolism and Bioavaiability of Cyclosporine. Clin. Pharmacol. Ther. 1995; 58: 15–19, (b)
  • Zhang Z.Y., Kaminsky L.S. Characterization of Human Cytochromes P450 Involved in Theophylline 8-Hydroxylation. Biochem. Pharmacol. 1995; 50: 205–211
  • Olsen A.K., Stentoft K., Tainaka H., Hansen K.T. Ethinylestradiol Metabolism by cDNA-Expressed Human Cytochrome P450. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 90, (a)
  • Weber A., Jager R., Borner A., Klinger G., Vollanth R., Matthey K., Balogh A. Can Grapefruit Juice Influence Ethinylestradiol Bioavailability?. Contraception 1996; 53: 41–47, (b)
  • Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mulin J.C., Cantilena L.R. Terfenadine–Ketoconazole Interaction, Pharmacokinetic and Electrocardiographic Consequences. J. Am. Med. Assoc. 1993; 269: 1513–1518, (a)
  • von Moltke L.L., Greenblatt D.J., Duan A.X., Harmatz J.S., Shader R.I. In Vitro Prediction of the Terfenadine–Ketoconazole Pharmacokinetic Interaction. J. Clin. Pharmacol. 1994; 34: 1222–1227, (b)
  • Rodrigues A.D., Mulford D.J., Lee R.D., Surber B.W., Kukulka M.J., Thomas S.B., Shet M.S., Estabrook R.W. In Vitro Metabolism of Terfenadine by Purified Recombinant Fusion Protein Containing Cytochrome P450 3A4 and NADPH-Reductase, Comparison to Human Liver Microsomes and Precision-Cut Tissue Slices. Drug Metab. Dispos. 1995; 23: 765–775, (c)
  • Ling K.H., Leeson G.A., Burmaster S.D., Hook R.H., Reith M.K., Cheng L.K. Metabolism of Terfenadine Associated with CYP3A(4) Activity in Human Hepatic Microsomes. Drug Metab. Dispos. 1995; 23: 631–663, (d)
  • Bell-Parikh L.C., Guengerich F.P. Kinetics of Cytochrome P450 2E1-Catalyzed Oxidation of Ethanol to Acetic Acid via Acetaldehyde. J. Biol. Chem. 1999; 274: 23833–23840
  • Kerr B.M., Thummel K.T., Wurden C.J., Klain S.M., Kroetz D.L., Gonzalez F.J., Levy R.H. Human Liver Carbamazepine Metabolism, Role of Cyp3A4 and CYP2C8 in 10,11-Epoxide Formation. Biochem. Pharmacol. 1994; 47: 1969–1979
  • Yue Q.Y., Tomson T., Säwe J. Carbamazepine and Cigarette Smoking Induce Differentially the Metabolism of Codeine in Man. Pharmacogenetics 1994; 4: 193–198, (a)
  • Yue Q.Y., Sawe J. Different Effects of Inhibitors on the O- and N-Demethylation of Codeine in Human Liver Microsomes. Eur. J. Clin. Pharmacol. 1997; 52: 41–47, (b)
  • Walker D., Flinois J.P., Monkman S.C., Beloc C., Boddy A.V., Cholerton S., Daly A.K., Lind M.J., Pearson A.D.J., Beaune P.H., Idle J.R. Identification of the Major Human Hepatic Cytochrome P450 Involved in Activation and N-Dechloroethylation of Ifosfamide. Biochem. Pharmacol. 1994; 47: 1157–1163
  • Murray M., Butler A.M., Stupans I. Competitive Inhibition of Human Liver Microsomal Cytochrome P4503A-Dependent Steroid 6β-Hydroxylation Activity by Cyclophosphamide and Ifosfamide In Vitro. J. Pharmacol. Exp. Ther. 1994; 270: 645–649
  • Lee C.B., Jin H.S., Chong C.H., Yun J.S., Park D.H. Involvement of P4503A in the Metabolism of 7,8-Benzoflavone by Human Liver Microsomes. Xenobiotica 1994; 24: 1053–1062, (a)
  • Lee H.S., Jin C.B., Park J., Kim D.H. Modulation of Cytochrome P450 Activities by 7,8-Benzoflavone and Its Metabolites. Biochem. Mol. Biol. Int. 1994; 34: 483–491, (b)
  • Ring B.J., Parli C.J., George M.C., Wrighton S.A. In Vitro Metabolism of Zatosetron: Interspecies Comparison and Role of CYP 3A. Drug Metab. Dispos. 1994; 22: 352–357
  • Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. O-Demethylation of Epipodophyllotoxins Is Catalyzed by Human Cytochrome P450. Mol. Pharmacol. 1994; 45: 352–358
  • May D.G., Porter J., Wilkinson G.R., Branch R.A. Frequency Distribution of Dapsone N-Hydroxylase, a Putative Probe for P450 3A4 Activity, in a White Population. Clin. Pharmacol. Ther. 1994; 55: 492–500, (a)
  • Mitra A.K., Schoborg D.L., Michell D.B. Dapsone as a Probe for Microsomal Cytochrome P450 3A4 and 2E1 in Different Species. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 247, (b)
  • Irshaid Y., Branch R.A., Adedoyin A. Metabolic Interactions of Putative Cytochrome P4503A Substrates with Alternative Pathways of Dapsone Metabolism in Human Liver Microsomes. Drug Metab. Dispos. 1996; 24: 164–171, (c)
  • Kumar G.N., Walle T. Paclitaxel (Taxol) 6alpha-Hydroxylation: Role of CYP3A and the Effect of Other Drugs. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 181, (a)
  • Kumar G.N., Walle U.K., Walle T. Cytochrome P450 3A-Mediated Human Liver Taxol 6alpha-Hydroxylation. J. Pharmacol. Exp. Ther. 1994; 268: 1160–1165, (b)
  • Harris J.W., Rahman A., Kim B.R., Guengerich F.P., Collins J. Metabolism of Taxol by Human Hepatic Microsomes and Human Liver Slices. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, Sept 26–29, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 24, (c)
  • Harris J.W., Rahman A., Kim B.R., Guengerich F.P., Collins J. Metabolism of Taxol by Human Hepatic Microsomes and Human Liver Slices: Participation of Cytochrome P450 3A4 and an Unknown P450 Enzyme. Cancer. Res. 1994; 54: 4026–4035, (d)
  • Cresteil T., Monsarrat B., Alvinerie P., Treluyer J.M., Vieira I., Wright M. Taxol Metabolism by Human Liver Microsomes: Identification of Cytochrome P450 Isozymes Involved in Its Biotransformation. Cancer Res. 1994; 54: 386–392, (e)
  • Sonnichsen D., Shuetz E., Shuetz J., Pappo A., Relling M. Variability in Human Metabolism of Paclitaxel. J. Pharmacol. Exp. Ther. 1995; 275: 566–575, (f)
  • Monsarrat B., Chatelut E., Royer I., Alvinerie P., Dubois J., Dezeuse A., Roche H., Cros S., Wright M., Canal P. Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4. Drug Metab. Dispos. 1998; 26: 229–233, (g)
  • Palamanda J.R., Unadkat J.D. Kinetics of Cytochrome Isoforms Involved in the Metabolism of Trimethoprim in Human Microsomes. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 241
  • Kharasch E.D., Mautz D., Labroo R. In Vitro–In Vivo Correlations of Human Opoid Metabolism: the Role of Cytochrome P4503A4 in Alfentanil Pharmacokinetics. ISSX Proceedings, 6th North American ISSX Meeting, Raleigh, NC, USA, Oct 23–27, 1994. International Society for the Study of Xenobiotics, Bethesda, MD 1994; Vol. 6: 176
  • Crespi C.L., Code E.L., Penman B.W., Waxman D.J. An Activity-Based Method for Integrating Metabolism Data from cDNA-Expressed Cytochrome P450 Enzymes to the Balance of Enzymes in Human Liver Microsomes. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 420
  • Gorski J.C., Jones D.R., Hamman M.A., Wrighton S.A., Hall S.D. Biotransformation of Alprazolam by the Human Cytochrome P450 3A Subfamily. Xenobiotica 1999; 29: 931–944
  • Varhe A., Klaus M.B., Olkkola T., Neuvonen P.J. Oral Triazolam Is Potentially Hazardous to Patients Receiving Systemic Antimycotics. Clin. Pharmacol. Ther. 1994; 56: 601–607, (a)
  • von Moltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau-Bibbo M.M., Pritchardt G.A., Wright C.E., Shader R.I. Triazolam Biotransformation by Human Liver Microsomes In Vitro: Effects of Metabolic Inhibitors and Clinical Confirmation of a Predicted Interaction with Ketoconazole. J. Pharmacol. Exp. Ther. 1996; 276: 370–379, (b)
  • Varhe A., Klaus M.B., Olkkola T., Neuvonen P.J. Diltiazem Enhances the Effects of Triazolam by Inhibiting Its Metabolism. Clin. Pharmacol. Ther. 1996; 59: 369–375, (c)
  • Zang Z.I., Fasco M.J., Guengerich F.P., Kaminsky L.S. Warfarin Metabolism by Human P450 1A1 and 1A2—Noninvasive Probe. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 81, (a)
  • Kaminsky L.S., Demorais S.M.F., Faletto M.B., Dunbar D.A., Goldstain J.A. Correlation of Human Cytochrome P450 Substrate Specificities with Primary Structure: Warfarin as a Probe. Mol. Pharmacol. 1993; 43: 234–239, (b)
  • Darbyshire J.F., Iyer K.R., Grogan J., Korzekwa K.R., Trager W.F. Selectively Deuterated Warfarin: Substrate Probe for the Mechanism of Aromatic Hydroxylation Catalysed by Cytochrome P450. Drug Metab. Dispos. 1996; 24: 1038–1045, (c)
  • Kunze K.L. Prediction and Management of Metabolism-Based Drug Interactions: In Vitro–In Vivo Correlations. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 4, (d)
  • Wienkers L.C., Kunze K.L., Trager W.F. The Effect of Fluconazole on the Metabolism of the Warfarin Enantiomers by Human Liver Microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, FL, USA, Nov 2–6, 1992. International Society for the Study of Xenobiotics, Bethesda, MD 1992; Vol. 2: 20, (e)
  • Kunze K.L., Wienkers L.C., Thumel K.E., Trager W.F. Warfarin–Fluconazole I—Inhibition of the Human Cytochrome P450-Dependent Metabolism of Warfarin by Fluconazole: In Vitro Studies. Drug Metab. Dispos. 1996; 24: 414–421, (f)
  • Wienkers L.C., Wurden C.J., Storch E., Kunze K.L., Rettie A.E., Trager W.F. Formation of (R)-8-Hydroxywarfarin in Human Liver Microsomes. A New Metabolic Marker for the (S)-Mephenytoin Hydroxylase, P4502C19. Drug Metab. Dispos. 1996; 24: 610–614, (g)
  • Pearce R.E., Rodrigues D., Goldstein J.A., Parkinson A. Identification of the Human P450 Enzymes Involved in Lansoprazole Metabolism. J. Pharmacol. Exp. Ther. 1996; 277: 805–816, (a)
  • Prichard L., Curi-Pedrosa R., Bonfils C., Jacqz-Aigrain E., Domergue J., Joyeux H., Cosme J., Guengerich F.P., Maurel P. Oxidative-Metabolism of Lansoprazole by Human Liver Cytochromes P450. Mol. Pharmacol. 1995; 47: 410–418, (b)
  • Sadeque A.J.M., Korzekwa K.R., Gonzalez F.J., Rettie A.E. Identification of Human Liver P450 Enzymes Responsible for the Formation of 4-Ene Valproic Acid. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 87
  • Jang G.R., Benet L.Z. Evidence for Human Liver Microsomal Cytochrome P450 3A Mediated Metabolism Of Mefipristone (RU486). ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 92, (a)
  • Jang G.R., Wrighton S.A., Benet L.Z. Identification of CYP3A4 as the Principal Enzyme Catalyzing Mifepristone (RU 486) Oxidation in Human Liver Microsomes. Biochem. Pharmacol. 1996; 52: 753–762, (b)
  • Shepard D.R., Krecic M.E., Mays D.C., Boyd R.T., Lasker J., Raucy J., Gerber N. Metabolism of Phenytion by Human and Rat Liver Microsomes, Cytochrome P450s 2C8 and 2C9 Expressed in Cos-1 Cells, and Purified P450s 2C8 and 2C9. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, Sept 26–29, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 44, (a)
  • Shepard D.R., Krecic M.E., Chang T.-H., Collins J., Greber N. Metabolism of Phenytion by Human Cytochrome P450s 2C9 and 2C18 Expressed in Yeast. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 95, (b)
  • Krecic M.E., Shepard D.R., Chang T.-H., Collins J., Greber N. Stereoselective Metabolism of Phenytion by Hepatic Microsomes and Human 2C9 and 2C18 Expressed in Yeast. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 370, (c)
  • Spracklin D.K., Thummel K.E., Kharasch E.D. Reductive Halothane Metabolism in Humans. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 98, (a)
  • Spracklin D.K., Hankins D.C., Thummel K.E., Kharasch E.D. Human Oxidative Halothane Metabolism In Vitro Is Catalyzed by 2A6 and 2E1. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 377, (b)
  • Spracklin D.K., Kharasch E.D. Human Halothane Reduction In Vitro by Cytochrome P450 2A6 and 3A4: Identification of Low and High KM Isoforms. Drug Metab. Dispos. 1998; 26: 605–607, (c)
  • Spracklin D.K., Hankins D.C., Fisher J.M., Thummel K.E., Kharasch E.D. Cytochrome P450 2E1 Is the Principal Catalyst of Human Oxidative Halothane Metabolism In Vitro. J. Pharmacol. Exp. Ther. 1997; 281: 400–411, (d)
  • Spracklin D.K., Thummel K.E., Kharasch E.D. Human Reductive Halothane Metabolism In Vitro Is Catalyzed by Cytochrome P450 2A6 and 3A4. Drug Metab. Dispos. 1996; 24: 976–983, (e)
  • Chen W.C., Nelson S.D. Oxidation of Acetaminophen to Its Toxic Quinone Imine and non-Toxic Catechol Metbolites by Purified Human Cytochrome P450 2E1. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 210, (a)
  • Lee C.A., Thumel K.E., Korzekwa K.R., Nelson S.D., Slattery J.T. Contribution of Human P450 2E1, 1A2, and 3A4 to the Bioactivation of Acetaminophen. ISSX Proceedings, 5th North American ISSX Meeting, Bal Harbour, Florida, USA, November 2–6, 1992. International Society for the Study of Xenobiotics, Bethesda, MD 1992; 17, (b)
  • Chen W.C., Thumel K.E., Nelson S.D., Slattery J.T. Pharmacokinetic Model of the Effect of CYP2E1 Induction by Protein Stabilization on Substrate Clearance. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 329, (c)
  • Chen W.C., Peter R.M., Haining R.L., Rettie A.E., Nelson S.D. Selective Oxidation of Acetaminophen by Major Human Cytochrome P450 Isozymes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 374, (d)
  • Patten C.J., Thomas P.E., Guy R.L., Lee M., Gonzalez F.J., Guengerich F.P., Yang C.S. Cytochrome P450 Enzymes Involved in Acetaminophen Activation by Rat and Human Liver Microsomes and Their Kinetics. Chem. Res. Toxicol. 1993; 6: 511–518, (e)
  • Raucy J.L., Lasker J.M., Lieber C.S., Black A. Acetaminophen Activation by Human Liver Cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys. 1989; 271: 270–283, (f)
  • Botsch S., Gautier J.-C., Beaune P., Eichelbaum M., Kroemer H.K. Identification and Characterization of the Cytochrome P450 Enzymes Involved in N-Dealkylation of Propafenone: Molecular Base for Interaction Potential and Variable Disposition of Active Metabolites. Mol. Pharmacol. 1993; 43: 120–126, (a)
  • Hemeryck A., De Vriendt C., Belpaire F.M. Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes. J. Clin. Psychopharmacol. 2000; 20: 428–434, (b)
  • Imaoka S., Enomoto K., Oda Y., Asada A., Fujimori M., Shimada T., Fujita S., Guengerich F.P., Funae Y. Lidocaine Metabolism by Human Cytochrome P-450s Purified from Hepatic Microsomes: comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 1990; 255: 1385–1391, (a)
  • Wang J.S., Backman J.T., Taavitsainen P., Neuvonen P.J., Kivisto K.T. Involvement of CYP1A2 and CYP3A4 in Lidocaine N-Deethylation and 3-Hydroxylation in Humans. Drug Metab. Dispos. 2000; 28: 959–965, (b)
  • Berson A., Wolf C., Chachaty C., Fisch C., Fau D., Eugene D., Loeper J., Gauthier J.-C., Beaune P., Pompon D. Metabolic Activation of the Nitroaromatic Antiandrogen Flutamide by Rat and Human Cytochromes P-450, Including Forms Belonging to the 3A and 1A Subfamilies. J. Pharmacol. Exp. Ther. 1993; 265: 366–372
  • Salcedo J.A., Yasuda S.U., Murphy M.P., Woosley R.L., Flockhart D.A. Stereoselective Inhibition of CYP 2D6 by Chlorpheniramine. Clin. Pharmacol. Ther. 1995; 57: 149 (PI-59), (a)
  • Hiroi T., Ohishi N., Imaoka S., Yabusaki Y., Fukui H., Funae Y. Mepyramine, a Histamine H1 Receptor Antagonist, Inhibits the Metabolic-Activity of Rat and Human P450 2D Forms. J. Pharmacol. Exp. Ther. 1995; 272: 939–944, (b)
  • Chang T.K.H., Weber G.F., Crespi C.L., Waxman D.J. Differential Activation of Cyclophosphamide and Iphosphamide by Cytochromes P-450 2B and 3A in Human Liver Microsomes. Cancer. Res. 1993; 53: 5629–5637, (a)
  • Chang T.K.H., Goldstein J.A., Waxman D.J. Cylophosphamide 4-Hydroxylation and Ifosfamide 4-Hydroxylation Catalyzed by Recombinant Human CYP2C9 and CYP2C18 Expressed in Yeast. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 361, (b)
  • Waxman D.J. Role of Human P450 Enzymes in Anti-cancer Drug Activation: The Example of Cyclophosphamide. Metabolism in Cancer Chemotherapy, Short Course C, 7th North American ISSX Meeting, San Diego, USA, Oct 20–24, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996, (c)
  • Bohnenstengel F., Hofmann U., Eichelbaum M., Kroemer H.K. Characterization of the Cytochrome P450 Involved in Side Chain Oxidation of Cyclophosphamide in Humans. Eur. J. Clin. Pharmacol. 1996; 51: 297–301, (d)
  • Ren S., Yang J.S., Kalhorn T.F., Slattery J.T. Oxidation of Cyclophosphamide to 4-Hydroxycyclophosphamide and Deschloroethylcyclophosphamide in Human Liver Microsomes. Cancer Res. 1997; 57: 4229–4235, (e)
  • De Montelano P.R.O., Chan W.K., Tack S.E., Kaikaus R.M., Bass N.M., Peterson J.A. Mechanism-Based Probes of the Topology and Function of Fatty Acid Hydroxylases. FASEB J. 1992; 6: 695–699
  • Ha H.R., Wyss P.A., Stieger B., Meier P.J., Meyer U.A., Follath F. Amiodarone Metabolism in Human Liver Microsomes. FASEB J. 1992; 6: A1845, (a)
  • Fabre G., Julian B., Saint Aubert B., Joyeux H., Berger Y. Evidence for CYP3A-Mediated N-Deethylation of Amiodarone in Human Liver Microsomal Fractions. Drug Metab. Dispos. 1993; 21: 978–985, (b)
  • Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., Yokoi T.A. Significant Role of Human Cytochrome P450 2C8 in Amiodarone N-Deethylation: An Approach to Predict the Contribution with Relative Activity Factor. Drug Metab. Dispos. 2000; 28: 1303–1310, (c)
  • Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The Effect of Paroxetine and Other Specific 5-HT Re-Uptake Inhibitors on Cytochrome P450IID6 Activity in Human Liver Microsomes. Br. J. Clin. Pharmacol. 1991; 32: 658P–659P, (a)
  • Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The Effect of Selective Serotonin Re-Uptake Inhibitors on cytochrome P4502D6 (CYP2D6) Activity in Human Liver Microsomes. Br. J. Clin. Pharmacol. 1992; 34: 262–265, (b)
  • Wang J.-P., Unadkat J.D. Human P450 Isoforms Involved in the Formation of the Active Metabolites of (R)- and (S)-Fluoxetine. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 385, (c)
  • van Moltke L.L., Greenbalatt D.J., Court M.H., Duen S.X., Harmatz J.S., Shader R.I. Inhibition of Alprazolam and Desipramine Hydoxylation In Vitro by Paroxetine and Fluvoxamine. Clin. Pharmacol. Ther. 1995; 57: 221 (OIII-A33), (d)
  • Brosen K., Skjelbo E., Rasmussen B.B., Poulsen H.E., Loft S. Fluvoxamine Is a Potent Inhibitor of Cytochrome P4501A2. Biochem. Pharmacol. 1993; 45: 1211–1214, (f)
  • Jeppessen V., Gram L.F., Vistisen K., Loft S., Poulsen H.E., Brosen K. Dose Dependent Inhibition of CYP1A2, CYP2C19, and CYP2D6 by Citalopram, Fluoxetine, Fluvoxamine, and Paroxetine. Eur. J. Clin. Pharmacol. 1996; 51: 73–78, (g)
  • Hamelin B.A., Turgeon J., Vallee F., Belanger P.-M., Paquet F., LeBell M. The Disposition of Fluoxetine But Not Sertraline Is Altered in Poor Metabolizers of Debrisoquin. Clin. Pharmacol. Ther. 1996; 60: 512–521, (h)
  • Brosen K. Differences in interactions of SSRIs. Int. Clin. Psychopharmacol. 1998; 13: 45–47, (i)
  • Feifel N., Kucher K., Fuchs L., Jedrychowski M., Schmidt E., Antonin K.H., Bieck P.R., Gleiter C.H. Role of Cytochrome P4502D6 in the Metabolism of Brofaromine. A New Selective MAO-A Inhibitor. Eur. J. Clin. Pharmacol. 1993; 45: 265–269
  • Ferrari S., Leeman T., Dayer P. The Role of Lipophilicity in the Inhibition of Polymorphic Cytochrome P450IID6 Oxidation by Beta-Blocking Agents In Vitro. Life Sci. 1991; 48: 2259–2265
  • Kerlan V., Dreano Y., Bercovici J.P., Beaune P.H., Floch H.H., Berthou F. Nature of Cytochromes P450 Involved in the 2-/4-Hydroxylations of Estradiol in Human liver Microsomes. Biochem. Pharmacol. 1992; 44: 1745–1756
  • Skjelbo E., Brosen K. Inhibitors of Imipramine Metabolism by Human Liver Microsomes. Br. J. Clin. Pharmacol. 1992; 34: 256–261, (a)
  • Lemoine A., Gautier J.C., Azoulay D., Kiffel L., Beloc C., Guengerich F.P., Maurel R., Beaune P., Leroux J.P. Major Pathway of Imipramine Metabolism Is Catalyzed by Cytochromes P450 1A2 and P450 3A4 in Human Liver. Mol. Pharmacol. 1992; 43: 827–832, (b)
  • Bolaji O.O., Coutts R.T., Baker G.B. Metabolism of Trimipramine In Vitro by Human CYP2D6 Isoenzyme. Res. Commun. Chem. Pathol. Pharmacol. 1993; 82: 111–120, (c)
  • Su P., Coutts R.T., Baker G.B., Dansehtalab M. Analysis of Imipramine and Three Metabolites Produced by Isozyme CYP2D6 Expressed in a Human Cell Line. Xenobiotica 1993; 23: 1289–1298, (d)
  • von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of Desipramine Hydroxylation In Vitro by Serotonin-Reuptake Inhibitor Antidepressants, and by Quinidine and Ketoconazole: A Novel System to Predict Drug Interactions In Vivo. J. Pharmacol. Exp. Ther. 1994; 268: 1278–1283, (e)
  • von Moltke L.L., Harmatz J.S., Aberg G., Shader R.I. Differential Inhibition of Desipramine Hydroxylation In Vitro, by the Enantiomers of Fluoxetine. Clin. Pharmacol. Ther. 1995; 57: 205 (PIII-44), (f)
  • Albers L.J., Reist C., Helmeste D., Vu R., Tang S.W. Paroxetine Shifts Imipramine Metabolism. Psychiatry Res. 1996; 59: 189–196, (g)
  • Eichelbaum M. How Realiable Are In Vitro Approaches for the Prediction of Human In Vivo Drug Metabolism. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 3, (a)
  • Engel G., Hofman U., Heideman H., Cosme J., Eichelbaum M. Antipyrine as a Probe for Human Oxidative Drug Metabolism: Identification of the Cytochrome P450 Enzymes Catalyzing 4-Hydroxyantipyrine, 3-Hydroxyantipyrine, and 4-Norantipyrine. Clin. Pharmacol. Ther. 1996; 59: 613–623, (b)
  • Agundez J.A.G., Martinez C., Benitez J. Metabolism of Aminopyrine and Derivatives in Man: In Vivo Study of Monomorphic and Polymorphic Metabolic Pathways. Xenobiotica 1995; 25: 417–427, (a)
  • Niwa T., Sato R., Yabusaki Y., Ishibashi F., Katagiri M. Contribution of Human Hepatic Cytochrome P450s and Steroidogenic CYP17 to the N-Demethylation of Aminopyrine. Xenobiotica 1999; 29: 187–193, (b)
  • Blake B.L., Rose R.L., Mailman R.B., Levi P.E., Hodgson E. Metabolism of Thioridazine by Microsomal Monooxygenases: Relative Role of P450 and Flavin-Containing Monooxygenase. Xenobiotica 1995; 25: 377–393
  • Zhou-Pan X.-R., Seree E., Zhou X.-J., Placidi M., Maurel P., Barra Y., Rahmani R. Involvement of Human Liver Cytochrome P4503A in Vinblastine Metabolism: Drug Interactions. Cancer Res. 1993; 53: 5121–5126, (a)
  • Relling M.V. Does Interindividual Variability in Drug Metabolism Translate into Important Clinical Pharmacokinetic and Pharmacodinamic Differences. Metabolism in Cancer Chemotherapy, Short Course C, 7th North American ISSX Meeting, San Diego, USA, Oct 20–24, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996, (b)
  • Zhou X.J., Zhou-Pan X.R., Gauthier T., Placidi M., Maurel P., Rahmani R. Human Liver Microsomal Cytochrome P450 3A Isozymes Mediated Vindesine Biotransformation. Metabolic Drug Interactions. Biochem. Pharmacol. 1993; 45: 853–861, (c)
  • Yao D., Ding S., Burchell B., Wolf C.R., Friedberg T. Detoxication of Vinca Alkaloids by Human P450 CYP3A4-Mediated Metabolism: Implications for the Development of Drug Resistance. J. Pharmacol. Exp. Ther. 2000; 294: 387–395, (d)
  • Nakasa H., Komiya M., Ohmori S., Rikihisa T., Kiuchi M. Characterization of Human Liver Microsomal Cytochrome P450 Involved in the Reductive Metabolism of Zonisamide. Mol. Pharmacol. 1993; 44: 216–221
  • Vyas K.P., Kari P.H., Pitzenberger S.P., Wang R.W., Lu A.Y.H. Identification of 3′,5′-Dihydro-3′,5′-diol-delta4-lovastatin as a New Cytochrome P450 3-Acetalyzed Metabolite of Lovastatin in Rat and Human Liver Microsomes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, Arizona, USA, Oct 17–21, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 35
  • Waxman D.J., Chang T.K.H., Chen G. Interactions of Anticancer Drugs with Cytochromes P450 and Glutathione S-Transferases: Drug Activation and Drug Resistance Mechanisms. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, Arizona, USA, Oct 17–21, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 2
  • Labroo R.B., Kharasch E.D. Human Liver Microsomal Alfetanil Metabolism: GC/MS Assay and Predominant Catalytic Role of P450 3A3/4. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, Arizona, USA, Oct 17–21, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 144
  • Mitra A.K., Kalhorn T.F., Thummel K.E., Unadkat J.D., Slattery J.T. Metabolism of Arylamines by Human Liver Microsomal Cytochrome P-450s. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, Arizona, USA, Oct 17–21, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 148
  • Andersson P., Jönsson G. Metabolism of Budesonide in Human Liver Is Catalysed by Cytochrome P450 3A Isoenzymes. ISSX Proceedings, 5th North American ISSX Meeting, Tucson, Arizona, USA, Oct 17–21, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 4: 236, (a)
  • Jönsson G., Aström A., Andersson P. Budesonide Is Metabolised by Cytochrome P450 3A (CYP3A) Enzymes in Human Liver. Drug Metab. Dispos. 1995; 23: 137–142, (b)
  • Berthou F., Dreano Y., Belloc C., Kangas L., Beaune P. Involvement of Cytochrome P450 3A in the Major Metabolic Pathways of Toremifene in Human Liver Microsomes. Biochem. Pharmacol. 1994; 47: 1883–1895
  • Simon I., Berthou F., Riche C., Beaune P., Ratanasavanh D. Both Cytochromes P450 1A and 3A4 Are Involved in the N-Demethylation of Tamoxifen. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, Sept 26–29, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 44
  • Gillet G., Pichard L., Filali-Ansary A., Thenot J.-P., Maurel P. Identification of the Major Cytochromes P450 Involved in the Formation of Plasma Metabolite of Alpidem in Man. ISSX Proceedings, 5th European ISSX Meeting, Tours, France, Sept 26–29, 1993. International Society for the Study of Xenobiotics, Bethesda, MD 1993; Vol. 3: 47
  • Bauer E., Gou Z.Y., Ueng Y.F., Bell L.C., Zeldon D., Guengerich F.P. Oxidation of Benzo[a]Pyrene by Recombinant Human Cytochrome P450 Enzymes. Chem. Res. Toxicol. 1995; 8: 136–142
  • Daikh B.E., Lasker J.M., Raucy J.L., Koop D.R. Regioselective and Stereoselective Epoxidation of Arachidonic Acid by Human Cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 1994; 271: 1427–1433
  • Krynetskii E.Y., Kovaleva I.E., Luzikov V.N. Heterologous Expression of Functionally Active Human Cytochromes P450—Cytochrome P450IIIA Catalyzes Conversion of the Anabolic-Steroid Hormone Methandrostenolone. Biochemistry (Moscow) 1994; 59: 203–206
  • Deuscher R.J., Elfarra A.A. Human Liver-Microsomes Are Efficient Catalysts of 1,3-Butadiene Oxidation—Evidence for Major Roles by Cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys. 1994; 311: 342–349, (a)
  • Krause R.J., Elfarra A.A. Oxidation of Butadiene Monoxide to meso- and (+/−)-Diepoxybutane by cDNA-Expressed Human Cytochrome P450s and by Mouse, Rat, and Human Liver Microsomes: Evidence for Preferential hydration of meso-Diepoxybutane in Rat and Human Liver Microsomes. Arch. Biochem. Biophys. 1997; 337: 176–184, (b)
  • Elfarra A.A., Krause R.J., Selzer R.R. Biochemistry of 1,3-Butadiene Metabolism and Its Relevance to 1, 3-Butadiene-Induced Carcinogenicity. Toxicology 1996; 113: 23–30, (c)
  • Wienkers L.C., Steenwyk R.C., Sanders R.C., Pearson P.G. CYP3A4 and 5alpha-Reductase Mediated Clearance of Tirilazad in Human Liver. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 78, (a)
  • Wienkers L.C., Steenwik R.C., Sanders P.E., Pearson P.G. Biotransformation of Tirilazad in Human. 1. Cytochrome P4503A-Mediated Hydroxylation of Tirilazad Mesylate in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 982–990, (b)
  • Russell A.L., Herron W.J., Rush W.R., Graham D.J. The Involvment of Cytochrome P4503A (CYP3A) in the Metabolism of Ranolazine in Human Liver. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 89
  • Yokoi T., Li Y., Sasaki M., Kitamura R., Gunji M., Katsuki M., Kamataki T. Metabolic Activation of Aflatoxin B1 by Human Fetus-Specific Cytochrome P450 (CYP3A7) Expressed in Transgenic Mice. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 214, (a)
  • Li Y., Yokoi T., Katsuki M., Wang J.-S., Groopman J.D., Kamataki T. In Vivo Activation of Aflatoxin B1 in C57BL/6N Mice Carring a Human Fetus-Specific CYP3A7 Gene. Cancer Res. 1997; 57: 641–645, (b)
  • Sanwald P., David M., Dow J. Role of CYP2D6 in the Metabolism of the 5-HT3 Antagonists, Tropisetron, Ondansetron and Dolasetron. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 96, (a)
  • Sanwald P., David M., Dow J. Characterization of the Cytochrome P450 Enzymes Involved in the In Vitro Metabolism of Dolasetron—Comparison with other Indole-Containing 5-HT3 Antagonists. Drug Metab. Dispos. 1996; 24: 602–609, (b)
  • Smith B.J., Zupan L.A., Riley P. Interactions of Azimilide with Human Hepatic Microsomal Cytochromes P450 and Its Metabolism by the P450 3A Subfamily. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 97
  • Wong B.K., Bruhin P.J., Chiba M., Wang R., Lin J.H. Metabolism of Dorzolamide by Human Liver Microsomes and Liver Slices. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 140
  • Winter H.R., Unadkat J.D. Human Liver Microsomal Metabolism of Sulfadiazine to Its Toxic Hydroxylamine Metabolite. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 236, (a)
  • Cribb A.C., Spielberg S.P., Griffin G.P. N4-Hydroxylation of Sulfamethoxazole by Cytochrome P450 of the P4502C Subfamily and Reduction of Sulfamethoxazole Hydroxylamine in Human and Rat Hepatic Microsomes. Drug Metab. Dispos. 1995; 23: 406–414, (b)
  • Gill H.J., Magos J.L., Madden S., Pirmohamed M., Park K. The Effect of Fluconazole and Ketoconazole on the Metabolism of Sulphamethazole. Br. J. Clin. Pharmacol. 1996; 42: 347–353, (c)
  • Gill H.J., Tjia J.F., Kitteringham N.R., Pirmohamed M., Back D.J., Park B.K. The Effect of Genetic Polymorphisms in CYP2C9 on Sulphamethoxazole N-Hydroxylation. Pharmacogenetics 1999; 9: 43–53, (d)
  • Weaver R.J., Dickins M., Waller S.J., Chambers J.H., Morley T.J., Burke M.D. Proguanil Metabolism in Hepatic Microsomes and Isolated Hepatocytes from Animals and Man, and the Effect of Atavaquone and CYP Inhibitors. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 295
  • Frame L.T., Si Y., Zelinski W.L., Crespi C.L., Leakey J.E.A. Use of Human Lymphoblastoid Cells Expressing Human Cytochrome P450s or Human UDP-Glucuronosyltransferases for Mechanistic Studies of Human Drug Metabolism. ISSX Proceedings, 4th International ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995; Vol. 8: 372
  • Bloomer J.C., Baldwin S.J., Smith G.J., Ayrton A.D., Clarke S.E., Chenery R.J. Characterisation of the Cytochrome P450 Enzymes Involved in the In Vitro Metabolism of Granisetron. Br. J. Clin. Pharmacol. 1994; 38: 557–567
  • Von Moltke L.L., Greenblatt D.J., Granda B.W., Duan S.X., Grassi J.M., Venkatakrishnan K., Harmatz J.S., Shader R.I. Zolpidem Metabolism In Vitro: Responsible Cytochromes, Chemical Inhibitors, and In Vivo Correlations. Br. J. Clin. Pharmacol. 1999; 48: 89–97
  • Oda Y., Furuichi K., Tanaka K., Hiroi T., Imaoka S., Asada A., Fujimori M., Funae Y. Metabolism of a New Local-Anesthetic, Ropivacaine, by Human Hepatic Cytochrome-P450. Anaestesiology 1995; 82: 214–220, (a)
  • Ekstrom G., Gunnarsson U.B. Ropivacaine, a New Amide-Type Local Anesthetic Agent, Is Metabolized by Cytochromes P450 1A and 3A in Human Liver Microsomes. Drug Metab. Dispos. 1996; 24: 955–961, (b)
  • Adedoyin A., Mauro K., Frye R., Porter J., Branch R.A. Selective Modulation of Specific Metabolizing Activities by Chloroquine. Clin. Pharmacol. Ther. 1995; 57: 150 (PI-60), (a)
  • Masimirembwa C.M., Hasler J.A., Johansson I. Inhibitory Efects of Antiparasitic Drugs on Cytochrome P4502D6. Eur. J. Clin. Pharmacol. 1995; 48: 35–38, (b)
  • Adedoyin A., Frye R.F., Mauro K., Branch R.A. Chloroquine Modulation of Specific Metabolizing Enzymes Activities: Investigation with Selective Five Drug Cocktail. Br. J. Clin. Pharmacol. 1998; 46: 215–219, (c)
  • Maurel P. Use of Human Hepatocytes to Characterize the Metabolism of Drugs (Lecture). Short Course I, ISSX Meeting, Seattle, WA, USA, Aug 27–Sept 1, 1995. International Society for the Study of Xenobiotics, Bethesda, MD 1995, (a)
  • Lampen A., Christmas U., Bader A., Hackbarth I., Sewing K.-F. Drug Interactions and Interindividual Variability of Cyclosporin Metabolism. Pharmacology 1996; 52: 159–168, (b)
  • Ullrich V., Nüsing R. Thromboxane Synthase, from Isolation to Function. Stroke 1990; 21(Suppl. IV)134–138, (a)
  • Nüsing R., Lesch R., Ullrich V. Immunohistochemical Localization of Thromboxane Synthase in Human Tissue. Eicosanoids 1990; 3: 53–58, (b)
  • Nüsing R., Wernet M.P., Ullrich V. Production and Characterization of Polyclonal and Monoclonal Antibodies Against Human Thromboxan Synthase. Blood 1990; 76: 80–85, (c)
  • Tanabe T., Yokoyama C., Miyata A., Ihara H., Kosaka T., Suzuki K., Nishikawa Y., Yoshimoto T., Yamamoto S., Nüsing R., Ullrich V. Molecular Cloning and Expression of Human Thromboxane Synthase. J. Lipid Med. 1993; 6: 139–144, (d)
  • Yokoyama C., Miyata A., Suzuki K., Nishikawa Y., Yoshimoto T., Yamamoto S., Nüsing R., Ullrich V., Tanabe T. Expression of Human Thromboxane Synthase Using a Baculovirus System. FEBS Lett. 1993; 318: 91–94, (e)
  • Hecker M., Ullrich V. On the Mechanism of Prostacyclin and Thromboxane A2 Biosynthesis. J. Biol. Chem. 1989; 264: 141–150, (a)
  • Tanabe T., Ullrich V. Prostacyclin and Thromboxane synthases. J. Lipid Mediat. Cell Signal 1995; 12: 243–255, (b)
  • Ullrich V., Brugger R. Prostacyclin and Thromboxane Synthase: New Aspects of Hemethiolate Catalysis. Angew. Chem. 1994; 33: 1911–1919, (c)
  • Ullrich V., Ruf H.H. Heme Proteins in Prostaglandin Biosynthesis. Metaloporphyrins in Catalytic Oxidations, R.A. Sheldon. Marcel Dekker Inc., New York 1994; 157–1929, (d)
  • Ihara H., Yokoyama C., Miyata A., Kosaka T., Nüsing R., Ullrich V., Tanabe T. Induction of Thromboxane Synthase and Prostaglandin Endoperoxide Synthase mRNA in Human Erythroleukemia Cells by Phorbol Ester. FEBS Lett. 1992; 306: 161–164, (a)
  • Hecker M., Ullrich V. Studies on the Interaction Minoxidil with Prostacyclin Synthase In Vitro. Biochem. Pharmacol. 1988; 37: 3363–3365, (b)
  • Miyata A., Hara S., Yokoyama C., Inoue H., Ullrich V., Tanabe T. Molecular Cloning and Expression of Human Prostacyclin Synthase. Biochem. Biophys. Res. Commun. 1994; 200: 1728–1734, (c)
  • Kagawa N., Waterman M.R. Regulation of Steroidogenic Enzymes. Cytochrome P450- Structure, Mechanism and Biochemistry, P.R. Ortiz de Montellano. 2nd Ed, Plenum Press, New York 1995; 419–442
  • Hanukoglu I. Steroidogenic Enzymes: Structure, Function, and Role in Regulation of Steroid Hormone Biosynthesis. J. Steroid Biochem. Mol. Biol. 1992; 43: 779–804
  • Hartmann R.W. Selective Inhibition of Steroidogenic P450 Enzymes: Current Status and Future Perspectives. Eur. J. Pharm. Sci. 1994; 2: 15–16, (a)
  • Burke D.F., Laughton C.A., Snook C.F., Neidle S. Active Site Conformation of 17(3-Pyridyl) androsta-5,6-dien-3beta-ol, a Potent Inhibitor of the P450 Enzyme C17alpha-Hydroxylase/C17-20 Lyase. Bioorg. Med. Chem. Lett. 1995; 5: 1125–1130, (b)
  • Vanden Bossche H. Inhibitors of P450 Dependent Steroid Biosynthesis: from Research to Medical Treatment. J. Steroid Biochem. Molec. Biol. 1992; 43: 1003–1021, (a)
  • Vanden Bossche H., DeCoster R., Amery W.K. Pharmacology and Clinical Uses of Ketoconazole. Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, B.J.A. Furr, A.S.E. Wakeling. Bailliere Tindall, London 1986; 288, Chapter 15
  • Boidin M.P., Stuurman A., Erdmann W.A. Scorbic Acid Prevents Cimetidine-Induced Decrease of Serum Hydrocortisone Concentrations. Pharm. Weekbl. [Sci] 1990; 12: 151–153, (a)
  • Kenyon C.J., Fraser R., Birnie G.G., Connell J.M.C., Lever A.F. Dose Related In Vitro Effects of Ranitidine and Cimetidine on Basal and ACTH Stimulated Steroidogenesis. Gut 1986; 27: 1143–1145, (b)
  • Galbreith R.A., Michnowitz J.J. The Effect of Cimetidine on Oxidative Metabolism of Estradiol. N. Engl J. Med. 1989; 321: 269–274
  • Rodriguez L., Jick H. Risk of Gynaecomastia Associated with Cimetidine, Omeprazole, and other Antiulcer Drugs. Br. Med. J. 1994; 308: 503–506
  • White P.C., Pascoe L., Curnow K.M., Tannin G., Rösler A. Molecular Biology of 11beta-Hydroxylase and 11beta-Hydroxysteroid Dehydrogenase Enzymes. J. Steroid Biochem. Mol. Biol. 1992; 43: 827–835, (a)
  • White P.C., Curnow K.M., Pascoe L. Disorders of Steroid 11 beta-Hydroxylase Isozymes. Endocr. Rev. 1994; 15: 421–438, (b)
  • Mulatero P., Curnow K.M., Aupetit-Faisant B., Foekling M., Gomez-Sanchez C., Veglio F., Jeunemaitre X., Corvol P., Pascoe L. Recombinant CYP11B Genes Encode Enzymes That Can Catalyze Conversion of 11-Deoxycortisol to Cortisol, 18-Hydroxycortisol, and 18-Oxocortisol. J. Clin. Endocrinol. Metab. 1998; 83: 3996–4001, (c)
  • Rendic S. Metabolism of Testosterone. 10th Cologne Workshop on Dope Analysis, 7th to 12th June, Proceedings. SPORT und BUCH Strauss, Köln 1993; 27–46, (a)
  • Rendic S. Biochemistry of Drug Metabolism Studies: Metabolism of Testosterone and T/E ratio. Acta Pharm. 1994; 44: 215–227, (b)
  • Sonino N. The Use of Ketoconazole as an Inhibitor of Steroid Production. N. Engl. J. Med. 1987; 317: 812–818
  • Loose D.S., Kan P.B., Hirst M.A., Marcus R.A., Feldman D. Ketoconazole Blocks Adrenal Steroidogenesis by Inhibiting Cytochrome P-450-Dependent Enzymes. J. Clin. Invest. 1983; 71: 1495–1499
  • Weber M.M., Lang J., Abedinpour F., Zeilberger K., Adelmann B., Engelhard D. Different Inhibitory Effect of Etomidate and Ketoconazole on the Human Adrenal Steroid Biosynthesis. Clin. Invest. 1993; 71: 933–938
  • Dowie L.J., Smith J.E., MacGilchrist A.J., Fraser R., Honour J.W., Reid J.L., Kenyon C.J. In Vivo and In Vitro Studies of the Site of Inhibitory Action of Omeprazole on Adrenocortical Steroidogenesis. Eur. J. Clin. Pharmacol. 1988; 35: 625–629
  • Swinney D.C., Mak A.Y. Androgen Formation by Cytochrome-P450 Cyp17—Solvent Isotope Effect and pL Studies Suggest a Role for Protons in the Regulation of Oxene Versus Peroxide Chemistry. Biochemistry 1994; 33: 2185–2190
  • Hall P.F. Cytochrome P-450 C21scc: One Enzyme with Two Actions: Hydroxylase and Lyase. J. Steroid Biochem. Mol. Biol. 1991; 40: 527–532, (a)
  • Zanger U.M., Kagawa N., Lund J., Waterman M.R. Distinct Biochemical Mechanisms for cAMP-Dependent Transcription of CYP17 and CYP21. FASEB J. 1992; 6: 719–723, (b)
  • Hosaka M., Oshima H., Troen P. Studies of the Human Testis XIV. Properties of C17-C20 lyase. Acta Endocrinol. 1980; 94: 389–396
  • Simpson E.R., Mahendroo M.S., Means G.D., Kilgore M.W., Hinshelwood M.M., Graham-Lorence S., Amarneh B., Ito Y., Fisher C.R., Michael M.D., Mendelson C.R., Bulun S.E. Aromatase Cytochrome P450, the Enzyme Responsible for Estrogen Biosynthesis. Endocr. Rev. 1994; 15: 342–355, (a)
  • Dowsett M. Aromatase Inhibition: Basic Concepts, and Pharmacodynamics of Formestane. Ann. Oncol. 1994; 5: S3–S5, (b)
  • Toda K., Nomoto S., Shizuta S. Identification and Characterization of Transcriptional Regulatory Elements of the Human Aromatase Cytochrome P450 Gene (CYP19). J. Steroid. Biochem. Mol. Biol. 1996; 56: 151–159, (c)
  • Lephart E.D. A Review of Brain Aromatase Cytochrome P450. Brain Res. Rev. 1996; 22: 1–26, (d)
  • Lephart E.D. Molecular Aspects of Brain Aromatase Cytochrome P450. J. Steroid Biochem. Mol. Biol. 1997; 61: 375–380, (e)
  • Bicikova M., Hampl R., Hill M., Starka L. Inhibition of Steroid 17alpha-Hydroxylase and C 17,20-Lyase in the Human Testis by Epitestosterone. J. Steroid Biochem. Mol. Biol. 1993; 46: 515–518
  • Howden C.W., Kenyon C.J., Beastall G.H., Reid J.L. Inhibition by Omeprazole of Adrenocortical Response to ACTH: Clinical Studies and Experiments on Bovine Adrenal Cortex In Vitro. Clin. Sci. 1986; 70: 99–102
  • Pont A., Williams P.L., Loose D.S., Feldman D., Reitz R.E., Bochra C., Steven D.A. Ketoconazole Blocks Adrenal Steroid Synthesis. Ann. Intern. Med. 1982; 97: 370–372
  • Trzaskos J.M. Oxylanosterols as Modifiers of Cholesterol Biosynthesis. Prog. Lipid. Res. 1995; 34: 99–116
  • Bogaards J.J.P., Omen B.V., Wolf C.R., Van Bladeren P.J. Human Cytochrome P450 Enzyme Selectivities in the Oxidation of Chlorinated Benzenes. Toxicol. Appl. Pharamcol. 1995; 132: 44–52
  • Donato M.T., Castell J.V., Gómez-Lechón M.J. Effects of Model Inducers on Catochrome P450 Activities of Human Hepatocytes in Primary Culture. Drug Metab. Dispos. 1995; 23: 553–558
  • Khalil M.W., Strutt B., Vachon D., Killinger D.W. Effect of Dexamethasone and Cytochrome P450 Inhibitors on the Formation of 7alpha-Hydroxydehydroepiandrosterone by Human Adipose Stromal Cells. J. Steroid Biochem. Mol. Biol. 1994; 48: 545–552
  • Schuetz E.G., Schuetz J.D., Thompson M.T., Fisher R.A., Madariage J.R., Strom S.C. Phenotypic Variability in Induction of P-Glycoprotein mRNA by Aromatic Hydrocarbons in Primary Human Hepatocytes. Mol. Carcinog. 1995; 12: 61–65
  • Abolfathi Z., Pakdel H., Beaune P., Turgeon J. CYP1A2 is the Major Enzyme Involved in the N-Oxidation of Mexiletine (MEX) in Man. Clin. Pharmacol. Ther. 1995; 57: 221 (OIII-A33)
  • Dahl M.L., Nordin C., Bertilsson L. Enantioselective Hydroxylation of Nortryptyline in Human Liver Microsomes, Intestinal Homogenate, and Patients Treated with Nortriptyline. Ther. Drug Monit. 1991; 13: 189–194, (a)
  • Pfandl B., Morike K., Winne D., Schareck W., Breyer-Pfaff U. Stereoselective Inhibition of Nortriptyline Hydroxylation in Man by Quinidine and Ketoconazole. Xenobiotica 1992; 22: 721–730, (b)
  • Breyer-Pfaff U., Pfandl B., Nill K., Nusser E., Monney C., Jonzier-Perey M., Beatting D., Baumann P. Enantioselective Amitriptyline Metabolism in Patients Phenotypes for Two Cytochrome P450 Isoenzymes. Clin. Pharmacol. Ther. 1992; 52: 350–358, (c)
  • Coutts R.T., Bach M.V., Baker G.B. Metabolism of Amitriptyline with CYP2D6 Expressed in a Human Cell Line. Xenobiotica 1997; 25: 33–47, (d)
  • Olesen O.V., Linnet K. Metabolism of the Tricyclic Antidepressant Amitriptyline by cDNA-Expressed Human Cytochrome P450 Enzymes. Pharmacology 1997; 55: 235–243, (e)
  • Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.E., Tucker G.T. Cytochromes P450 Mediating the N-Demethylation of Amitriptyline. Br. J. Clin. Pharmacol. 1997; 43: 137–144, (f)
  • Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five Distinct Human Cytochromes Mediate Amitriptyline N-Demethylation In Vitro: Dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 1998; 38: 112–121, (g)
  • Venkatakrishnan K., von Moltke L.L., Obach R.S., Greenblatt D.J. Microsomal Binding of Amitriptyline: Effect on Estimation of Enzyme Kinetic Parameters In Vitro. J. Pharmacol. Exp. Ther. 2000; 293: 343–350, (h)
  • Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Application of the Relative Activity Factor Approach in Scaling from Heterologously Expressed Cytochromes p450 to Human Liver Microsomes: Studies on Amitriptyline as a Model Substrate. J. Pharmacol. Exp. Ther. Appr. 2001; 297(1)326–337, (i)
  • Schmider J., Greenblatt D.J., von Moltke L.L., Shader R.I. N-Demethylation of Amitriptyline In Vitro: Role of CYP3A Isoforms. Clin. Pharmacol. Ther. 1995; 57: 193 (OII-A-2), (a)
  • Lee Y.S., Reidenberg M.M. Grapefruit Juice Inhibits 11-beta Hydroxysteroid Dehydrogenase (11-beta OHSD). Clin. Pharmacol. Ther. 1995; 57: 173 (PII-39), (b)
  • Brannan M.D., Affrime M.B., Radwanski D.E., Cayem M.N., Banfield C. Effects of Various Cytochrome P450 Inhibitors on the Metabolism of Loratadine. Clin. Pharmacol. Ther. 1995; 57: 193 (OII-A-4), (a)
  • Yumibe N., Huie K., Chen K.-J., Snow M., Clement R.P., Cayen M.N. Identification of Human Liver Cytochromes P450 Enzymes That Metabolise the Nonsedating Antihistamine Loratadine. Biochem. Pharmacol. 1996; 51: 165–172, (b)
  • Jähnchen E., Buschmann M., Trenk D. Pharmacokinetics of the Class I Antiarhythmic Drug Diprafenone in Poor Metabolizers of Sparteine/Debrisoquine. Clin. Pharmacol. Ther. 1995; 57: 151 (PI-67)
  • Kimonen T., Juvonen R.O., Alhava E., Pasanen M. The Inhibition of CYP Enzymes in Mouse and Human Liver by Pilocarpine. Br. J. Pharmacol. 1995; 114: 832–836, (a)
  • Kimonen T., Pasanen M., Gynther J., Poso A., Järvinen T., Alhava E., Juvonen R.O. Competitive Inhibition of Coumarin 7-Hydroxylation by Pilocarpine and Its Interaction with Mouse CYP2A5 and Human CYP2A6. Br. J. Pharmacol. 1995; 116: 2625–2630, (b)
  • Richardson T.H., Jung F., Griffin K.J., Wester M., Raucy J.L., Johnson E.F. Expression and Characterization of Human Cytochrome P450 2C Enzymes in E. coli. Identification of P4502C19 as a Progesterone 21-Hydroxylase. FASEB J. 1995; 9: A1489
  • Bornheim L.M., Lasker J.M., Raucy J.L. Human Hepatic Microsomal Metabolism of delta1-Tetrahydrocannabinol. Drug Metab. Dispos. 1992; 20: 241–246
  • Jaeger W., Benet L.Z., Bornheim L.M. Inhibition of Cyclosporine and Tetrahydrocannabidiol by Cannabidiol in Mouse and Human Microsomes. Xenobiotica 1996; 26: 275–284, (b)
  • Lake B.G., Charzat C., Tredger J.M., Renwick A.B., Beamand J.A., Price R.J. Induction of Cytochrome P450 Isoenzymes in Cultured Precision-Cut Rat and Human Liver Slices. Xenobiotica 1996; 26: 297–306
  • Hakkola J., Pasanen M., Hukkanen J., Pelkonen O., Mäenpää J., Edwards R.J., Boobis A.R., Raunio H. Expression of Xenobiotic-Metabolizing Cytochrome P450 Forms in Human Full-Term Placenta. Biochem. Pharmacol. 1996; 51: 403–411
  • Strömsted M., Rozman D., Waterman M.R. The Ubiquitously Expressed Human CYP 51 Encodes Lanosterol 14alpha-Demethylasse, a Cytochrome P450 Whose Expression is Regulated by Oxysterols. Arch. Biochem. Biophys. 1996; 329: 73–81
  • Hamman M.A., Thompson G.A., Hall S.D. Regioselective and Stereoselective Metabolism of Ibuprofen by Human Cytochrome P450 2C. Biochem. Pharmacol. 1997; 54: 33–41
  • De Groene A.M., Hassing I.G.A.M., Blom M.J., Seinen W., Fink-Gremmels J., Horbach G.J. Development of Human Cytochrome P450-Expressing Cell Lines: Application in Mutagenicity Testing of Ochratoxin A. Cancer Res. 1996; 56: 299–304
  • Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-Mediated Metabolism of the HIV-1 Protease Inhibitor Ritonavir (ABT-538) in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 423–431
  • Ebner T., Meese C.O., Eichelbaum M. Mechanism of Cytochrome P450-Catalysed Sparteine Metabolism in Humans. Mol. Pharmacol. 1995; 48: 1078–1086
  • Kamataki T., Hashimoto H., Shimoji M., Itoh S., Nakayama K., Hattori K., Yokoi T., Katsuki M., Aizawa S. Expression of CYP3A7, a Human Fetus-Specific Cytochrome P450, in Cultered Cells and in the Hepatocytes of p53-Knockout Mice. Toxicol. Lett. 1995; 82/83: 879–882
  • Ahmed S., Smith J.H., Nicholls P.J., Whomsley R., Cariuk P. Synthesis and Biological Evaluation of Imidazole Based Compounds as Cytochrome P450 Inhibitors. Drug Des. Dis. 1995; 13: 27–41
  • Gross A.S., Philips A.C., Rieutord A., Shenfield G.M. The Influence of Sparteine Debrisoquine Genetic Polymorphism on Dispodition of Dexfenfluramine. Br. J. Clin. Pharmacol. 1996; 41: 311–317
  • Christians U., Schmidt G., Bader A., Lampen A., Schottman R., Linck A., Sewing K.F. Identification of Drugs Inhibiting the In Vitro Metabolism of Tacrolimus by Human Liver Microsomes. Br. J. Clin. Pharmacol. 1996; 41: 187–190, (a)
  • Shiraga T., Matsuda H., Nagase K., Iwasaki K., Noda K., Yamazaki H., Shimada T., Funae Y. Metabolism of FK506, a Potent Immunosuppressive Agent, by Cytochrome P450 3A Enzymes in Rat, Dog and Human Liver Microsomes. Biochem. Pharmacol. 1995; 47: 727–735, (b)
  • Lampen A., Christians U., Guengerich F.P., Watkins P.B., Kolars J.C., Bader A., Gonschior A.K., Dralle H., Hackbarth I., Sewing K.F. Metabolism of Immunosupressant Tacrolimus in the Small Intestine: Cytochrome P450, Drug Interactions, and Interindividual Variability. Drug Metab. Dispos. 1995; 23: 1315–1324, (c)
  • Nunoya K.I., Yokoi T., Kimura K., Kodama T., Funayama M., Inuoe K., Nagashima K., Funae Y., Shimada N., Kamataki T. (+)-cis-3,5-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a Novel Substrate for Cytochrome P4502A6 in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 768–774
  • Smith T.J., Guo Z.Y., Guengerich F.P., Yung C.S. Metabolism of 4-Methylnitrosamino-1(3-pyridyl)1-butanone (NNK) by Human Cytochrome P4501A2 and Its Inhibition by Phenethyl Isothiocyanate. Carcinogenesis 1996; 17: 809–813
  • Chiba M., Hensleigh M., Balani J.A., Lin J.H. Role of Cytochrome P4503A4 in Human Metabolism of MK-639, a Potent Human Immunodeficiency Virus Protease Inhibitor. Drug Metab. Disopos. 1996; 24: 307–314
  • Iribarne C., Berthou F., Baird S., Dreano Y., Picart D., Bail J.P., Beaune P., Menez J.F. Involvement of Cytochrome P4503A4 Enzyme in the N-Demethylation of Methadone in Human Liver Microsomes. Chem. Res. Toxicol. 1996; 9: 365–373, (a)
  • Iribarne C., Dreano Y., Bardou L.G., Menez J.F., Berthou F. Interaction of Methadone with Substrates of Human Hepatic Cytochrome P450 3A4. Toxicology 1997; 117: 13–23, (b)
  • Gram L.F., Guentert T.W., Grange S., Vistisen K., Brøsen K. Moclobemide: a Substrate of CYP2C19 and an Inhibitor of CYP2C19, CYP2D6 and CYP1A2: a Panel Study. Clin. Pharmacol. Ther. 1995; 57: 670–677, (a)
  • Ketter T., Flochart D.A., Post R.M., Denicoff K., Pazaglia P.J., Marangell L.B., George M.S., Callahan A.M. The Emerging Role of Cytochrome P450 3A in Psychopharmacology. J. Clin. Psychopharmacol. 1995; 15: 387–398, (b)
  • Li A.P., Kaminski D.L., Rasmussen A. Substrates of Human Hepatic Cytochrome P450 3A4. Toxicology 1995; 104: 1–8, (c)
  • Greene D.S., Barbhaiya R.H. Clinical Pharmacokinetics of Nefazodone. Clin. Pharmacokinet. 1997; 33: 260–275, (d)
  • Owen J.R., Nemeroff C.B. New Antidepressants and the Cytochrome P450 System: Focus on Venlafaxine, Nefazodone, and Mirtazapine. Depress. Anxiety 1998; 7(Suppl. 1)24–32, (e)
  • Schmider J., Greenblatt D.J., von Moltke L.L., Harmatz J.S., Shader R.I. Inhibition of Cytochrome P450 by Nefazodone In Vitro: Studies of Dextromethorphan O- and N-Demethylation. Br. J. Clin. Pharmacol. 1996; 41: 339–343, (f)
  • Brosen K. Are Pharmacokinetic Drug Interactions with the SSRIs an issue?. Int. Clin. Psychopharmacol. 1996; 11: 23–27, (a)
  • Nemeroff C.B., DeVane C.L., Pollock B.G. Newer Antidepressants and the Cytochrome P450 System. Am. J. Psychol. 1996; 153: 311–320, (b)
  • Pirmohamed M., Williams D., Madden S., Templeton E., Park B.K. Metabolism and Bioactivation of Clozapine by Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1995; 272: 984–990, (a)
  • Fang J., Coutts R.T., McKenna K.F., Backer G.B. Elucidation of Individual Cytochrome P450 Enzymes Involved in the Metabolism of Clozapine. Naunyn Schmiedebergs Arch. Pharmacol. 1998; 358: 592–599, (b)
  • Fischer V., Vogels B., Maurer G., Tynes R.E. The Antipsychotic Clozapine Is Metabolized by the Polymorphic Human Microsomal and Recombinant Cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 1992; 260: 1355–1360, (c)
  • Quattrochi L.C., Tukey R.H. The Human CYP1A2 Gene and Induction by 3-Methylcholantrene. J. Biol. Chem. 1994; 269: 6949–6954
  • Shou M.G., Krausz K.W., Gonzalez F.J., Gelboin H.V. Metabolic Activation of the Potent Carcinogen Dibenzo[a,h]Anthracene by cDNA-Expresed Human Cytochromes P450. Arch. Biochem. Biophys. 1996; 328: 201–207
  • Wu S., Moomaw C.R., Tomer K.B., Falck J.R., Zeldin D.C. Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxigenase Highly Expressed in Heart. J. Biol. Chem. 1996; 271: 3460–3468, (a)
  • Zeldin D.C., Foley J., Goldsworthy S.M., Cook M.E., Boyle J.E., Ma J., Moomaw C.R., Tomer K.B., Steenbergen C., Wu S. CYP2J Subfamily Cytochrome P450s in the Gastrointestinal Tract: Expression, Localization, and Potential Functional Significance. Mol. Pharmacol. 1997; 51: 931–943, (b)
  • Scarborough P.E., Ma J., Qu W., Zeldin D.C. P450 Subfamily CYP2J and Their Role in the Bioactivation of Arachidonic Acid in Extrahepatic Tissues. Drug Metab. Rev. 1999; 31: 205–234, (c)
  • Wright M.C., Maurel P., Paine A.J. Induction of Cytochrome P450 3A by Metyrapone in Human Hepatocyte Culture. Hum. Exp. Toxicol. 1996; 15: 203–204
  • Chen T.L., Ueng T.H., Chen S.H., Lee P.H., Fan S.Z., Liu C.C. Human Cytochrome P450 mono-Oxygenase System is Suppressed by Propofol. Br. J. Anaesth. 1995; 74: 558–562
  • Hargreaves J.A., Howald W.N., Racha J.K., Levy R.H. Identification of Enzymes Responsible for the Metabolism of Phenobarbital. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 259
  • von Rosentiel N.-A., Adam D. Macrolide Antibacterials, Drug Interactions of Clinical Significance. Drug Safety 1995; 13: 105–122, (a)
  • Greenblatt D.J., von Moltke L.L., Harmatz J.S., Counihan M., Graf J.A., Durol A.L., Mertzanis P., Duan S.X., Wright C.E., Shader R.I. Inhibition of Triazolam Clearance by Macrolide Antimicrobial Agents: In Vitro Correlates and Dynamic Consequences. Clin. Pharmacol. Ther. 1998; 64: 278–285, (b)
  • Barcelo S., Mace C., Pfeifer A., Chipman J.K. Inhibition of Human CYP1A2 Mediated Genotoxicity of 2-Amino-3-methylimidazo[4,5f]quinoline (IQ) by Sulforaphane as a Potential Mechanism of Cancer Chemoprevention. ISSX Proceedings, ISSX 1996 European Spring Workshop: Food Toxins and Host Mechanisms Conditioning Toxic Responses, Sitges, Spain, Jun 1–4, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 9: 40, (a)
  • Barcelo S., Mace K., Pfeifer A.M., Chipman J.K. Production of DNA Strand Breaks by N-Nitrosodimethylamine and 2-Amino-3-methylimidazo[4,5-f]quinoline in THLE Cells Expressing Human CYP Isoenzymes and Inhibition by Sulforaphane. Mutat. Res. 1998; 402: 111–120, (b)
  • Zhang Y., Guo X., Lin E.T., Benet L.Z. Overlapping Substrate Specificities of Cytochrome P450 3A and P-Glycoprotein for a Novel Cysteine Protease Inhibitor. Drug Metab. Dispos. 1998; 26: 360–366
  • Watkins P.B., Lown K.S., Fontana R. Effects of Diet and Medications on CYP3A4 and MDR1 in Human Small Bowel. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 39
  • Madan A., Kramer K.K. Evaluation of New Molecular Entities (NMEs) as Inhibitors of Human P450 Enzymes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 49
  • Liu X., Sinz M.W., Woolf T.F., Wang Y., Castagnoli N., Jr. In Vitro Metabolism of Milameline in Monkey and Human Hepatocytes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 216
  • LeCluyse E.L., Ribadeneira M.D., Diamond S., Forster J., Huang S.-M., Madan A., Caroll K., Parkinson A. Induction of CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A by Various Drugs and Prototypical Inducers in Primary Cultures of Human Hepatocytes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 196
  • Clement B., Demesmaeker M. Formation of Guanoxabenz from Guanabenz in Human Liver: a New Metabolic Marker for CYP1A2. Drug Metab. Dispos. 1997; 25: 1266–1271
  • Wong B.K., Goldstein J., Spielberg S.P., Roshmore T.H. Characterisation of an In Vitro Model for Assessing Polymorphic Metabolism by CYP2C9: Involvement in the Mechanism of Deficient Losartan Metabolism. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 236, (a)
  • Stearns R.A., Miller R.R. The Biotransformation of Losartan to Its Active Metabolite E-3174 in Human Liver Microsomes: Inhibition by HMG-CoA Reductase Inhibitors and non-Steroidal Anti-inflammatory Drugs. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 385, (b)
  • Jung F., Richardson T.H., Griffin K.J., Johnson E.F. Identification of Structural Elements Contributing to High Affinity Sulphaphenazole Binding by CYP2C9. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 237
  • He M.M., Rettie A.E., Trager W.F. Metabolism of Sulfinpyrazone by Human Liver Microsomes and cDNA-Expressed P450s. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 239
  • Peter R.M., Chen W., Darbyshire J.F., Kunze K.L., Nelson S.D. Inhibition of Human CYP2E1 and Metabolic Intermediate Complex Formation by Isoniazid. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 245, (a)
  • O'Shea D., Kim R.B., Wilkinson G.R. Modulation of CYP2E1 Activity by Isoniazid in Rapid and Slow N-Acetylators. Br. J. Clin. Pharmacol. 1997; 43: 99–103, (b)
  • Wacher V.J., Wong S., Wong H.T., Benet L.Z. Contribution of CYP3A to Selegiline Metabolism in Rat, and Human Liver Microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 351, (a)
  • Scheinin H., Anttila M., Dahl M.L., Karnani H., Nyman L., Taavitsainen P., Pelkonen O., Bertilsson L. CYP2D6 Polymorphism Is Not Crucial for the Disposition of Selegiline. Clin. Pharmacol. Ther. 1998; 64: 402–411, (b)
  • Fang J., Baker G.B., Coutts R.T., Silverstone P. Enzymatic Studies on the Metabolism of Haloperidol: Invovement of CYP3A4 and 2D6. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 357, (a)
  • Usuki E., Van Der Schyf C.J., Castagnoli N., Jr. Metabolism of Haloperidol and Tetrahydropyridine Dehydration Product HPTP. Drug Metab. Rev. 1998; 30: 809–826, (b)
  • Camille G.P., Sharkawi M., Ducharme J., Madan A., Sanzghiri U., Parkinson A., Wainer I.W. Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of Ifosfamide. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 360
  • Hein N.I., Howell S.R., Ulm E.H. Evaluation of the cytochrome P450 (P450) isozymes involved in the metabolism of TargretinTM, an RXR-selective retinoid. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 364, (a)
  • Shirley M.A., Loewen G.R., Farmer L.J., Small D.S., Ulm E.H. Human Metabolism of ALRT 1057 (9-cis-Retinoic Acid) to 4-oxo-9-cis-Retinoic Acid: Retention of Biological Activity and Identification of Cytochrome P450 Isoenzymatic Origin. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 365, (b)
  • Glue P., Banfield C.R., Perhach J.L., Mather G.G., Racha J.K., Levy R.H. Pharmacokinetic Interactions with Felbmate. In Vitro–In Vivo Correlation. Clin. Pharmacokinet. 1997; 33: 214–224
  • Wurm R.M., Dunn J.A., Silver I.S., Patel D.K. In Vitro Metabolism of Bupropion by Human Liver Microsomes and cDNA Expressed Human Cytochrome P450's. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 371, (a)
  • Ekins S., Bravi G., Ring B.J., Gillespie T.A., Gillespie J.S., Vandenbranden M., Wrighton S.A., Wikel J.H. Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6. J. Pharmacol. Exp. Ther. 1999; 288: 21–29, (b)
  • Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., Greenblatt D.J. CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants. Drug Metab. Dispos. 2000; 28: 1176–1183, (c)
  • Faucette S.R., Hawke R.L., Lecluyse E.L., Shord S.S., Yan B., Laethem R.M., Lindley C.M. Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab. Dispos. 2000; 28: 1222–1230, (d)
  • Lang D., Böcker R.H., Schmalix W., Doehmer J. Investigation into the Enzymatic Reaction Pathways Responsible for the Metabolism of Atrazine, Terbuthylazine, Ametryne, and Terbutryne on Human Liver Microsomes and Heterologously Expressed Cytochrome P450s. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 375
  • Ikeda T., Ishigami M., Komai T., Yamazoe Y., Ohno Y. Inhibition of CYP3A by 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Reductase Inhibitors. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 386
  • Grimm S.W., Stams K.R., Aaron E.J. Zafirlukast Is a Substrate for CYP2C9 and an Inhibitor of CYP2C9 and CYP3A In Vitro. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 392, (a)
  • Shader R.I., Granda B.W., von Moltke L.L., Giancarlo G.M., Greenblatt D.J. Inhibition of Human Cytochrome P450 Isoforms In Vitro by Zafirlukast. Biopharm. Drug Dispos. 1999; 20: 385–388, (b)
  • Yun C.-H., Park H.-J., Guengerich F.P. Effect of Kaempferol on Cytochrome P450 Activities in Human and Rat Liver Microsomes. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 397
  • Fitzsimmons M.E., Collins J.M. Selective Biotransformation of the HIV Protease Inhibitor Saquinavir by Human Small Intestinal Cytochrome P450 3A4: Potential Contribution to High First-Pass Metabolism. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 400, (a)
  • Fitzsimmons M.E., Collins J.M. Selective Biotransformation of the HIV Protease Inhibitor Saquinavir by Human Small Intestinal Cytochrome P450 3A4: Potential Contribution to High First-Pass Metabolism. Drug Metab. Dispos. 1997; 25: 256–266, (b)
  • Vella S., Floridia M. Clinical Pharmacology and Efficacy. Clin. Pharmacokinet. 1998; 34: 189–201, (c)
  • Ridgewell R.E., Mauch K.L., Myhre P.E. In Vitro Biotransformation of Imiquimod Catalysed Predominantly by Human Liver CYP1A2 and CYP3A4/5. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 352
  • Prakash C., Kamel A., Cui D. Identification of the Human Cytochrome P450 Responsible for the Formation of Major Metabolites of an Antipsychotic Drug Ziprasidone. ISSX Proceedings, 7th North American ISSX Meeting, San Diego, CA, USA, Oct 20–25, 1996. International Society for the Study of Xenobiotics, Bethesda, MD 1996; Vol. 10: 369, (a)
  • Prakash C., Kamel A., Cui D., Whalen R.D., Miceli J.J., Tweedie D. Identification of the Major Human Liver Cytochrome P450 Isoform(s) Responsible for the Formation of the Primary Metabolites of Ziprasidone and Prediction of Possible Drug Interactions. Br. J. Clin. Pharmacol. 2000; 49(Suppl. 1)35–42, (b)
  • Mae T., Hosoe K., Fujii K., Yamashita K., Yamane T., Hidaka T., Ohashi T. In Vitro Metabolism of a Rifamicin Derivative by Animal and Human Liver Microsomes, Whole Blood and Expressed Human CYP3A Isoforms. Xenobiotica 1996; 26: 793–802
  • Fujimaki Y., Hakusu H., Yamazoe Y. Nefiracetam Hydroxylation by Rat Liver Microsomes and Expressed Human Cytochrome P450s. Xenobiotica 1996; 26: 821–830
  • Koyama E., Chiba K., Tani M., Ishizaki T. Identification of Human Cytochrome P450 Enzymes Isoforms Involved in Stereoselective Metabolism of Mianserin Enantiomers. J. Pharmacol. Exp. Ther. 1996; 278: 21–30
  • Sahali-Sahly Y., Balani S.K., Jin J.H., Baillie T.A. In Vitro Studies on the Metabolic Activation of the Furanopyridine l-754,394, a Highly Potent and Selective Mechanism Based Inhibitor of Cytochrome P450 3A4. Chem. Res. Toxicol. 1996; 9: 1007–1012
  • Walter B.A. Cytochrome P450-Mediated Metabolism of the HIV Reverse Transcriptase Inhibitor Nevirapine. Course Book of the Presentations at the IBC's Recent Advances in Drug–Drug Interactions, Washington, DC, USA, Dec 10–11. 1996; B54710
  • Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., Sutter T.R. Activation of Chemically diverse Procarcinogens by Human Cytochrome P450 1B1. Cancer Res. 1996; 56: 2979–2984, (a)
  • Murray G.I., Taylor M.C., McFadyen C.E., McKay J.A., Greenlee W.F., Burke M.D., Melvin W.T. Tumor-Specific Expression of Cytochrome P450 CYP1B1. Cancer Res. 1997; 57: 3026–3031, (b)
  • Araya Z., Norlin M., Postlind A. Possible Role for CYP27 as a Major Renal Mitochondrial 25-Hydroxyvitamin D3 1 alpha-Hydroxylase. HFEBS Lett. 1996; 390: 10–14
  • Feierman D.E., Lasker J.M. Metabolism of Fentanyl, a Synthetic Opoid Analgesic, by Human Liver Microsomes. Drug Metab. Dispos. 1996; 24: 932–939
  • Zhao X.-J., Yokoyama H., Chiba K., Wanwimolruk S., Shizaki T. Identification of Human Cytochrome P450 Isoforms Involved in the 3-Hydroxylation of Quinine by Human Liver Microsomes and Nine Recombinant Human Cytochromes P450. J. Pharmacol. Exp. Ther. 1996; 279: 1327–1334, (a)
  • Zhang H., Coville P.F., Walker R.J., Miners J.O., Brikett D.J., Wanwimolruk S. Evidence for Involvment of Human CYP3A in the 3-Hydroxylation of Quinine. Br. J. Clin. Pharmacol. 1997; 43: 245–252, (b)
  • Poulsen K., Brosen L., Arendt-Nielsen L.F., Gram K., Elbaek S.H. Codeine and Morphine in Extensive and Poor Metabolisers of Sparteine: Pharmacokinetics, Analgesic Effect and Side Effects. Eur. J. Clin. Pharmacol. 1996; 51: 289–295
  • Laganiere S., Davies R.F., Carignan G., Foris K., Goernert L., Carrier K., Pereira C., McGilverai I. Pharmacokinetic and Pharmacodynamic Interactions Between Diltiazem and Quinidine. Clin. Pharmacol. Ther. 1996; 60: 255–264, (a)
  • Guengerich F.P., Muller-Enoch D., Blair I.A. Oxidation of Quinidine by Human Liver Cytochrome P-450. Mol. Pharmacol. 1986; 30: 287–295, (b)
  • Leo M.A., Lasker J.M., Raucy J.L., Kim C.I., Black M., Lieber C.S. Metabolism of Retinol and Retinoic Acid by Human Liver Cytochrome P450IIC8. Arch. Biochem. Biophys. 1989; 269: 305–312
  • Wilkinson G.R. Cytochrome P4503A (CYP3A) Metabolism: Prediction of In Vivo Activity in Humans. J. Pharmacokinet. Biopharm. 1998; 5: 475–490
  • Smith D.A. Pharmacokinetics and Pharmacodynamics in Toxicology. Xenobiotica 1997; 27: 513–525
  • Kim H., Wang R.S., Elovaara E., Raunio H., Pelkonen O., Aoyama T., Vainio H., Nakajima T. Cytochrome P450 Isozymes Responsible for the Metabolism of Toluene and Styrene in Human Liver Microsomes. Xenobiotica 1997; 27: 657–665, (a)
  • Nakajima T., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., Aoyama T. Styrene Metabolism by cDNA-Expressed Human Hepatic and Pulmonary Cytochromes P450. Chem. Res. Toxicol. 1994; 7: 891–896, (b)
  • Simpson A.E.C.M. The Cytochrome P450 4 (CYP4) Family. Gen. Pharmacol. 1997; 3: 351–359
  • Ling Y., Li J., Liu Y., Kato K., Klus G.T., Brodie A. 17-Imidazolyl, Pyrazolyl, and Isoxazolyl Androstene Derivatives: Novel Steroidal Inhibitors of Human Cytochrome C17, 20-Lyase (P45017alpha). J. Med. Chem. 1997; 40: 3297–3304
  • Kelloff G.J., Lubet R.A., Lieberman R., Eisenhauer K., Steele V.E., Crowell J.A., Hawk E.T., Boone C.W., Sigman C.C. Aromatase Inhibitors as Potential Cancer Chemopreventives. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 65–78, (a)
  • Ahmed S., Amanuel Y. Synthesis and Biochemical Evaluation of Novel Inhibitors of Aromatase (AR) Using an Enhanced Representation of the Active Site of AR Derived from the Consideration of the Reaction Mechanism. Biochem. Biophys. Res. Commun. 2000; 267: 356–361, (b)
  • Goss P.E., Walde D., De Coster R., Langenaeken C., Bruynseels J. Rivizor—A New Third-Generation Aromatase Inhibitor for the Treatment of Advanced Breast Cancer after Tamoxifen Failure. Oncology 1999; 56: 114–121, (c)
  • Numazawa M., Oshibe M., Yamaguchi S. 6-Alkylandrosta-4,6-diene-3, 17-Diones and their 1,4,6-Triene Analogs as Aromatase Inhibitors: Structure–Activity Relationships. Steroids 1997; 62: 595–602
  • Nguyen L.B., Shefer S., Salen G., Tint S.G., Batta A.K. Competitive Inhibition of Hepatic Sterol 27-Hydroxylase by Sitosterol: Decreased Activity in Sitosterolemia. Proc. Assoc. Am. Physicians 1998; 110: 32–39
  • Huang Z., Guengerich F.P., Kaminsky L.S. 16alpha-Hydroxylation of Estrone by Human Cytochrome P4503A4/5. Carcinogenesis 1998; 19: 867–872
  • Ohmori S., Fujiki N., Nakasa H., Nakamura H., Ishii I., Itahashi K., Kitada M. Steroid Hydroxylation by Human Fetal CYP3A7 and Human NADPH-Cytochrome P450 Reductase Coexpressed in Insect Cells Using Baculovirus. Res. Commun. Mol. Pathol. Pharmacol. 1998; 100: 15–28
  • Pikuleva I.A., Babiker A., Waterman M.R., Bjorkhem I. Activities of Recombinant Human Cytochrome P450C27 (CYP27) Which Produce Intermediates of Alternative Bile Acid Biosynthetic Pathways. J. Biol. Chem. 1998; 273: 18153–18160
  • Yamazaki H., Shaw P.M., Guengerich F.P., Shimada T. Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes. Chem. Res. Toxicol. 1998; 11: 659–665, (a)
  • Shou M., Korzekwa K.R., Brooks E.N., Krausz K.W., Gonzalez F.J., Gelboin H.V. Role of Human Hepatic Cytochrome P450 1A2 and 3A4 in the Metabolic Activation of Estrone. Carcinogenesis 1997; 18: 207–214, (b)
  • Niwa T., Yabusaki Y., Honma K., Matsuo N., Tatsuta K., Ishibashi F., Katagiri M. Contribution of Human Hepatic Cytochrome P450 Isoforms to Regioselective Hydroxylation of Steroid Hormones. Xenobiotica 1998; 6: 539–547
  • Yamazaki H., Shimada T. Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes. Arch. Biochem. Biophys. 1997; 346: 161–169, (a)
  • Schwarz D., Kisselev P., Schunck W.H., Chernogolov A., Boidol W., Cascorbi I., Roots I. Allelic Variants of Human Cytochrome P450 1A1 (CYP1A1): Effect of T461N and I462V Substitutions on Steroid Hydroxylase Specificity. Pharmacogenetics 2000; 10: 519–530, (b)
  • Tomlinson E.S., Lewis D.F.V., Maggs J.L., Kroemer H.K., Park B.K., Back D.J. In Vitro Metabolism of Dexamethasone (DEX) in Human Liver and Kidney: the Involvement of CYP3A4 and CYP17 (17,20 Lyase) and Molecular Modelling Studies. Biochem. Pharmacol. 1997; 54: 605–611, (a)
  • Gentile D.M., Tomlinson E.S., Maggs J.L., Park B.K., Back D.J. Dexamethasone Metabolism by Human Liver In Vitro. Metabolite Identification and Inhibition of 6-Hydroxylation. J. Pharmacol. Exp. Ther. 1996; 277: 105–112, (b)
  • Quattrochi L.C., Shih H., Pickwell G.V. Introduction of the Human CYP1A2 Enhancer by Phorbol Ester. Arch. Biochem. Biophys. 1998; 350: 41–48
  • Kikuta Y., Kato M., Yamashita Y., Miyauchi Y., Tanaka K., Kamada N., Kusunose M. Human Leukotriene B4 omega-Hydroxylase (CYP4F3) Gene: Molecular Cloning and Chromosomal Localization. DNA Cell. Biol. 1998; 17: 221–230, (a)
  • Kikuta Y., Kusunose E., Sumimoto H., Mikuzami Y., Takeshige K., Sakaki T., Yabusaki Y., Kusunose M. Purification and Characterization of Recombinant Human Neutrophil Leukotriene B4 omega-Hydroxylase (cytochrome P450 4F3). Arch. Biochem. Biophys. 1998; 355: 201–205, (b)
  • Kikuta Y., Miyauchi Y., Kusunose E., Kusunose M. Expression and Molecular Cloning of Human Liver Leukotriene B4 omega-Hydroxylase (CYP4F2) Gene. DNA Cell. Biol. 1999; 18: 723–730, (c)
  • Kikuta Y., Kusunose E., Kusunose M. Characterization of Human Liver Leukotriene B(4) omega-Hydroxylase P450 (CYP4F2). J. Biochem. (Tokyo) 2000; 127: 1047–1052, (d)
  • Zhang X., Chen L., ardwick J.P.H. Promoter activity and Regulation of the CYP4F2 Leukotriene B(4) omega-Hydroxylase Gene by Peroxisomal Proliferators and Retinoic Acid in HepG2 Cells. Arch. Biochem. Biophys. 2000; 378: 364–376, (e)
  • Jin R., Koop D.R., Raucy J.L., Lasker J.M. Role of Human CYP4F2 in Hepatic Catabolism of the Proinflammatory Agent Leukotriene B4. Arch. Biochem. Biophys. 1998; 359: 89–98, (f)
  • Yamane M., Abe A. omega-Hydroxylation Activity Toward Leukotriene B(4) and Polyunsaturated Fatty Acids in the Human Hepatoblastoma Cell Line, HepG2, and Human Lung Adenocarcinoma Cell Line, A549. J. Biochem. (Tokyo) 2000; 128: 827–835, (g)
  • Pikuleva I.A., Bjorkhem I., Waterman M.R. Expression, Purification and Enzymatic Properties of Recombinant Human Cytochrome P450C27 (CYP27). Arch. Biochem. Biophys. 1997; 343: 123–130
  • Sonneveld E., van den Brink C.E., van der Leede B.M., Schulkes R.K., Petkovich M., van der Burg B., van der Saag P.T. Human Retinoic Acid (RA) 4-Hydroxylase (CYP26) Is Highly Specific for all-trans-RA and Can be Inducted Through RA Receptors in Human Breast and Colon Carcinoma Cells. Cell. Growth Differ. 1998; 9: 629–637, (a)
  • Haque M., Andreola F., DeLuca L.M. The Cloning and Characterization of a Novel Cytochrome P450 Family, CYP26, with Specificity Toward Retinoic Acid. Nutr. Rev. 1998; 56: 84–85, (b)
  • Ray W.J., Bain G., Yao M., Gottlieb D.I. CYP26, a Novel Mammalian Cytochrome P450, Is Induced by Retinoic Acid and Defines a New Family. J. Biol. Chem. 1997; 272: 18702–18706, (c)
  • Wynalda M.A., Wienkers L.C. Assessment of Potential Interactions Between Dopamine Receptor Agonists and Various Human Cytochrome P450 Enzymes Using a Simple In Vitro Inhibition Screen. Drug Metab. Dispos. 1997; 25: 1211–1214
  • Powell P.K., Wolf I., Jin R., Lasker J.M. Metabolism of Arachidonic Acid to 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid by P450 Enzymes in Human Liver: Involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 1998; 285: 1327–1336, (a)
  • Kawashima H., Naganuma T., Kusunose E., Kono T., Yasumoto R., Sugimura K., Kishimoto T. Human Fatty Acid omega-Hydroxylase, CYP4A11: Determination of Complete Genomic Sequence and Characterization of Purified Recombinant Protein. Arch. Biochem. Biophys. 2000; 378: 333–339, (b)
  • Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-Hydroxyeicosatetraenoic Acid, a Vasoactive and Natriuretic Eicosanoid, in Human Kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 2000; 275: 4118–4126, (c)
  • Hiroi T., Imaoka S., Funae Y. Dopamine Formation from Tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 1998; 249: 838–843
  • Martinez C., Agundez J.A., Gervasini G., Martin R., Benitez J. Tryptamine: a Possible Endogenous Substrate for CYP2D6. Pharmacogenetics 1997; 7: 85–93, (a)
  • Martinez C., Gervasini G., Agundez J.A., Carrillo J.A., Ramos S.I., Garcia-Gamito F.J., Gallardo L., Benitez J. Modulation of Midazolam 1-Hydroxylation Activity In Vitro by Neurotransmitters and Precursors. Eur. J. Clin. Pharmacol. 2000; 56: 145–151, (b)
  • Agundez J.A., Gallardo L., Martinez C., Gervasini G., Benitez J. Modulation of CYP1A2 Enzyme Activity by Indoleamines: Inhibition by Serotonin and Tryptamine. Pharmacogenetics 1998; 8: 251–258, (c)
  • Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., Rahman A., Tummel K.E., Fisher J.M., Hollenberg P.F., Watkins P.W. Mechanisms of Enhanced Oral Availability of CYP3A4 Substrates by Grapefruit Constituents: Decreased Enterocyte CYP3A4 Concentration and Mechanism-Based Inactivation by Furanocoumarins. Drug Metab. Dispos. 1997; 25: 1228–1233, (a)
  • He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice. Chem. Res. Toxicol. 1998; 11: 252–259, (b)
  • Fukuda K., Ohta T., Yamazoe Y. Grapefruit Component Interacting with Rat and Human P450 CYP3A: Possible Involvement of non-Flavonoid Components in Drug Interaction. Biol. Pharm. Bull. 1997; 20: 560–564
  • Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., Yamazoe Y. Specific CYP3A4 Inhibitors in Grapefruit Juice: Furocoumarin Dimers as Components of Drug Interaction. Pharmacogenetics 1997; 7: 391–396
  • Chan W.K., Nguyen L.T., Miller V.P., Harris R.Z. Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Grapefruit Juice and Red Wine. Life Sci. 1998; 62: 135–142
  • Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A., Brown M.B., Guo W., Watkins P.B. Grapefruit Juice Increases Felodipine Oral Availability in Humans by Decreasing Intestinal CYP3A Protein Expression. J. Clin. Invest. 1997; 99: 2545–2553
  • Bailey D.G., Kreeft J.H., Munoz C., Freeman D.J., Bend J.R. Grapefruit–Felodipine Interaction: Effect of Naringin and 6′,7′-Dihydroxybergamottin in Humans. Clin. Pharmacol. Ther. 1998; 64: 248–256
  • Seidegard J., Dahlstrom K., Kullberg A. Effect of Grapefruit Juice on Urinary 6beta-Hydroxycortisol/Cortisol Excretion. Clin. Exp. Pharmacol. Physiol. 1998; 25: 379–381
  • Ozdemir M., Aktan Y., Boydag B.S., Cingi M.I., Musmul A. Interaction Between Grapefruit Juice and Diazepam in Humans. Eur. J. Drug Metab. Pharmacokinet. 1998; 23: 55–59
  • Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable Contribution of Cytochromes P450 2D6, 2C9 and 3A4 to the 4-Hydroxylation of Tamoxifen by Human Liver Microsomes. Biochem. Pharmacol. 1997; 53: 171–178
  • Shimada T., Gillam E.M., Sutter T.R., Strickland P.T., Guengerich F.P., Yamazaki H. Oxidation of Xenobiotics by Recombinant Human Cytochrome P450 1B1. Drug Metab. Dispos. 1997; 25: 617–622
  • Wynalda M.A., Hauer M.J., Wienkers L.C. Human Biotransformation of Bropirimine: Characterization of the Major Bropirimine Oxidative Metabolites Formed In Vitro. Drug Metab. Dispos. 1998; 26: 1048–1051
  • Yamazaki H., Shimada T. Comparative Studies of In Vitro Inhibition of Cytochrome P450 3A4-Dependent Testosterone 6beta-Hydroxylation by Roxithromycin and Its Metabolites, Troleandomycin, and Erythromycin. Drug Metab. Dispos. 1998; 26: 1053–1057
  • Eiermann B., Edlud P.O., Tjernberg A., Alen P.D., Dahl M.L., Bertilsson L. 1- and 3-Hydroxylations, in Addition to 4-Hydroxylation, of Debrisoquine Are Catalyzed by Cytochrome P450 2D6 in Humans. Drug Metab. Dispos. 1998; 26: 1096–1101
  • Lightfoot T., Ellis S.W., Mahling J., Ackland M.J., Blaney F.E., Bijloo G.J., De Groot M.J., Vermeulen N.P., Blackburn G.M., Lennard M.S., Tucker G.T. Regioselective Hydroxylation of Debrisoquine by Cytochrome P4502D6: Implications for Active Site Modelling. Xenobiotica 2000; 30: 219–233, (b)
  • Jones B.C., Hyland R., Ackland M., Tyman C.A., Smith D.A. Interaction of Terfenadine and Its Primary Metabolites with Cytochrome P450 2D6. Drug Metab. Dispos. 1998; 26: 875–882
  • Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada M., Ishizaki T., Kuroiwa Y. Human Buprenorphine N-Dealkylation Is Catalyzed by Cytochrome P450 3A4. Drug Metab. Dispos. 1998; 26: 818–821, (a)
  • Iribarne C., Picart D., Dreano Y., Bail J.P., Berthou F. Involvement of Cytochrome P450 3A4 in N-Dealkylation of Buprenorphine in Human Liver Microsomes. Life Sci. 1997; 60: 1953–1964, (b)
  • Obach R.S., Pablo J., Mash D.C. Cytochrome P450 2D6 Catalyzes the O-Demethylation of the Psychoactive Alkaloid Ibogaine to 12-Hydroxyibogaine. Drug Metab. Dispos. 1998; 26: 764–768
  • Nakamura K., Yokoi T., Inoue K., Shimada N., Ohashi N., Kume T., Kamataki T. CYP2D6 is the Principal Cytochrome P450 Responsible for Metabolism of the Histamine H1 Antagonist Promethazine in Human Liver Microsomes. Pharmacogenetics 1996; 6: 449–457
  • Hashizume T., Mise M., Terauchi Y.O.L., Fujii T., Miyazaki H., Inaba T. N-Dealkylation and Hydroxylation of Ebastine by Liver Cytochrome P450. Drug Metab. Dispos. 1998; 26: 566–571
  • Moody D.E., Alburgers M.E., Parker R.J., Colins J.M., Strong J.M. The Involvment of Cytochrome P450 3A4 in the N-Demethylation of L-Alpha-Acethylmethadol (LAAM), norLAAM, and Methadone. Drug Metab. Dispos. 1997; 25: 1347–1353
  • Lee S.H., Slattery J.T. Cytochrome P450 Isozymes Involved in Lisofylline Metabolism to Pentoxifylline in Human Liver Microsomes. Drug Metab. Dispos. 1997; 25: 1354–1358, (a)
  • Shin S.H., Slattery J.T. CYP3A4-Mediated Oxidation of Lisofylline to Lisofylline 4,5-Diol in Human Liver Microsomes. J. Pharm. Sci. 1998; 87: 390–393, (b)
  • Teramura T., Fukunaga Y., Van Hoogdalem E.J., Watanabe T., Higuchi S. Examination of Metabolic Pathways and Identification of Human Liver Cytochrome P450 Isozymes Responsible for the Metabolism of Barnidipine, a Calcium Channel Blocker. Xenobiotica 1997; 27: 885–900
  • Zhao X.J., Kawashiro T., Ishizaki T. Mutual Inhibition Between Quinine and Etoposide by Human Liver Microsomes. Evidence for Cytochrome P450 3A4 Involvement in Their Major Metabolic Pathways. Drug Metab. Dispos. 1998; 26: 188–191, (a)
  • Zhao X.J., Ishizaki T. A Further Interaction Study of Quinine with Clinically Important Drugs by Human Liver Microsomes: Determinations of Inhibition Constant (Ki) and Type of Inhibition. Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 272–278, (b)
  • Postlind H., Danielson A., Lindgren A., Andersson S.H.G. Tolterodine, a New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes. Drug Metab. Dispos. 1998; 26: 289–293, (a)
  • Brynne N., Forslund C., Hallen B., Gustafsson L.L., Bertilsson L. Ketoconazole Inhibits the Metabolism of Tolterodine in Subjects with Deficient CYP2D6 Activity. Br. J. Clin. Pharmacol. 1999; 48: 564–572, (b)
  • Surapaneni S.S., Clay M.P., Spangle L.A., Paschal J.W., Lindstrom T.D. In Vitro Biotransformation and Identification of Human Cytochrome P450 Isozyme-Dependent Metabolism of Tazofelone. Drug Metab. Dispos. 1997; 25: 1383–1388
  • Koenigs L.L., Peter R.M., Thompson S.J., Rettie A.E., Trager W.F. Mechanism-Based Inactivation of Human Liver Cytochrome P450 2A6 by 8-Methoxypsoralen. Drug Metab. Dispos. 1997; 25: 1407–1415
  • Linnet K., Olesen O.V. Metabolism of Clozapine by cDNA-Expressed Human Cytochrome P450 Enzymes. Drug Metab. Dispos. 1997; 25: 1379–1382, (a)
  • Eiermann B., Engel G., Johansson I., Zanger U.M., Bertilsson I. The Involvement of CYP1A2 and CYP3A4 in the Metabolism of Clozapine. Br. J. Clin. Pharmacol. 1997; 44: 439–446, (b)
  • Raaska K., Neuvonen P.J. Serum Concentrations of Clozapine and N-Desmetylclozapine are Unaffected by the Potent CYP3A4 Inhibitor Itraconazole. Br. J. Clin. Pharmacol. 1998; 54: 167–170, (c)
  • Kumar G.N., Dubberke E., Rodrigues A.D., Roberts E., Dennisen J.F. Identification of Cytochromes P450 Involved in the Human Liver Microsomal Metabolism of the Thromboxane A2 Inhibitor Seratrodast (ABT-001). Drug Metab. Dispos. 1997; 25: 110–115
  • Sadeque A.M.J., Fisher M.B., Korzekwa K.R., Gonzalez F.J., Rettie A.E. Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-ene-Valproic Acid. J. Pharmacol. Exp. Ther. 1997; 238: 698–703
  • Olesen V.O., Linnet K. Hydroxylation and Demethylation of the Tricyclic Antidepressant Nortriptyline by cDNA-Expressed Human Cytochrome P450 Isozymes. Drug Metab. Dispos. 1997; 25: 740–744
  • Jang G.R., Benet L.Z. Cytochrome P450 3A4-Mediated N-Demethylation of the Antiprogestin Lilopristone and Onapristone. Drug Metab. Dispos. 1997; 25: 1119–1122
  • Whitlock J.P., Chichester C.H., Bedgood R.M., Okino S.T., Ko H.P., Ma Q., Dong L., Li H., Clarke-Katzenberg R. Induction of Drug-Metabolizing Enzymes by Dioxin. Drug Metab. Dispos. 1997; 29: 1107–1127
  • McLellan R.A., Drobitch R.K., Monshouwer M., Renton K.W. Fluoroquinolone Antibiotics Inhibit Cytochrome P450-Mediated Microsomal Drug Metabolism in Rat and Human. Drug Metab. Dispos. 1996; 24: 1134–1138
  • Yamaguchi Y., Kirita S., Baba T., Aoyama J., Touchi A., Tukey R.H., Guengerich F.P., Matsubara T. Identification of Rat and Human Cytochrome P450 Forms Involved in the Metabolism of the Thromboxane A2 Receptor Antagonist (+)-S-145. Drug Metab. Dispos. 1997; 25: 75–80
  • Machinist J.M., Mayer M.D., Roberts E.M., Surber B.W., Rodrigues A.D. Identification of the Human Liver Cytochrome P450 Enzymes Involved in the In Vitro Metabolism of a Novel 5-Lipoxygenase Inhibitor. Drug Metab. Dispos. 1998; 26: 970–976
  • Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A.E. The Multidrug Resistance Modulator Valspodar (PSC 833) is Metabolized by Human Cytochrome P450 3A. Implications for Drug–Drug Interactions and Pharmacological Activity of the Main Metabolite. Drug Metab. Dispos. 1998; 26: 802–811
  • Lillibridge J.H., Liang B.H., Kerr B.M., Webber S., Quart B., Shetty B.V., Lee C.A. Characterization of the Selectivity and Mechanism of Human Cytochrome PP450 Inhibition by the Human Immunodeficiency Virus-Protease Inhibitor Nelfinavir Mesylate. Drug Metab. Dispos. 1998; 26: 609–619
  • Sutton D., Butler A.M., Nadin L., Murray M. Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites. Br. J. Clin. Pharmacol. 1997; 282: 294–300
  • Yamazaki H., Inoue K., Shaw P.M., Checovich W.J., Guengerich F.P., Shimada T. Different Contributions of Cytochrome P450 2C19 and 3A4 in the Oxidation of Omeprazole by Human Liver Microsomes: Effects of Contents of these Two Forms in Individual Human Samples. J. Pharmacol. Exp. Ther. 1997; 283: 434–442
  • Jean P., Lopez-Garcia P., Ansette P.D., Mansuy D., Goldstein J.L. Oxidation of Tienilic Acid by Human Yeast-Expressed Cytochrome P450 2C8, 2C9, 2C18 and 2C19. Evidence That This Drug is a Mechanism-Based Inhibitor Specific for Cytochrome P450 2C9. Eur. J. Biochem. 1996; 241: 797–804
  • Delaforge M., Andre F., Jaouen M., Dolgos H., Benech H., Gomis J.M., Noel J. P., Cavelir F., Verducci J., Aubagnac J.L., Liebermann B. Metabolism of Tentoxin by Hepatic Cytochrome P450 3A Isozymes. Eur. J. Biochem. 1997; 250: 150–157
  • Tanaka E., Ishikawa A., Abei M., Kobayashi S. Trimethadione as a Probe Drug to Estimate Hepatic Oxidizing Capacity in Humans. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol. 1996; 115: 211–216
  • Villikka K., Kivisto K.T., Luurila H., Neuvonen P.J. Rifampin Reduces Plasma Concentrations and Effects of Zolpidem. Clin. Pharmacol. Ther. 1997; 62: 629–634
  • Chang T.K., Yu L., Maurel P., Waxman D.J. Enhanced Cyclophosphamide and Ifosfamide Activation in Primary Human Hepatocyte Cultures: Response to Cytochrome P450 Inducers and Autoinductions by Oxazaphosphorines. Cancer Res. 1997; 57: 1946–1954
  • Haaz M.C., Rivory L., Riche C., Vernillet L., Robert J. Metabolism of Irinotecan (CPT-11) by Human Hepatic Microsomes: Participation of Cytochrome P450 3A and Drug Interactions. Cancer Res. 1998; 58: 468–472, (a)
  • Santos A., Zanetta S., Cresteil T., Deroussent A., Pein F., Raymond E., Vernillet L., Risse M.L., Boige V., Gouyette A., Vassal G. Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans. Clin. Cancer. Res. 2000; 6: 2012–2020, (b)
  • Guitton J., Buronfosse T., Desage M., Lepape A., Brazier J.L., Beaune P. Possible Involvement of Multiple Cytochrome P450s in Fentanil and Sulfentanil Metabolism as Opposed to Alfentanil. Biochem. Pharmacol. 1997; 53: 1613–1619
  • Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Shader R.I. Inhibition of CYP2C9 by Selective Serotonin Reuptake Inhibitors In Vitro: Studies of Phenytoin p-Hydroxylation. Br. J. Clin. Pharmacol. 1997; 44: 495–498
  • Kirkwood L.C., Nation R.L., Somogyi A.A. Characterization of the Human Cytochrome P450 Enzymes Involved in the Metabolism of Dihydrocodeine. Br. J. Clin. Pharmacol. 1997; 44: 549–555
  • Pan L.P., Wijnant P., De Vriendt C., Rosseel M.T., Belpaire F.M. Characterization of the Cytochrome P450 Isoenzymes Involved in the In Vitro N-Dealkylation of Haloperidol. Br. J. Clin. Pharmacol. 1997; 44: 557–564
  • Pan L., Belpaire F.M. In Vitro Study on the Involvement of CYP1A2, CYP2D6 and CYP3A4 in the Metabolism of Haloperidol and Reduced Haloperidol. Eur. J. Clin. Pharmacol. 1999; 55: 599–604, (b)
  • Wang J.S., Wang W., Xie H.G., Huang S.L., Zhou H.H. Effect of Troleandomycin on the Pharmacokinetics of Imipramine in Chinese: the Role of CYP3A. Br. J. Clin. Pharmacol. 1997; 44: 195–198
  • Otton S.V., Ball S.E., Cheung S.W., Inaba T., Rudolph R.L., Sellers E.M. Venlafaxine Oxidation In Vitro is Catalyzed by CYP2D6. Br. J. Clin. Pharmacol. 1996; 41: 149–156, (a)
  • Ball S.E., Ahern D., Scatina J., Kao J. Venlafaxine: In Vitro Inhibition of CYP2D6 Dependent Imipramine and Desimipramine Metabolism; Comparative Studies with Selected SSRIs, and Effects on Human Hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol. 1997; 43: 619–626, (b)
  • Chiba M., Hensleigh M., Lin J.H. Hepatic and Intestinal Metabolism of Indinavir, an HIV Protease Inhibitor, in Rat and Human Microsomes. Major Role of CYP3A. Biochem. Pharmacol. 1997; 53: 1187–1195
  • Kim B.R., Oh H.S., Kim D.H. Differential Inhibition of Aflatoxin B1 Oxidation by Gestodene Action on Human Liver Microsomes. Biochem. Mol. Biol. Int. 1997; 43: 839–846
  • Kurata N., Nishimura Y., Iwase M., Fisher N.E., Tang K., Inaba T., Yasuhara H. Trimethadione Metabolism by Human Liver Cytochrome P450: Evidence for the Involvement of CYP2E1. Xenobiotica 1998; 28: 1041–1047
  • Lake B.G., Tredger J.M., Renwick A.B., Barton P.T., Price J. 3,3- Diindolylmethane Induces CYP1A2 in Cultured Precision-Cut Human Liver Slices. Xenobiotica 1998; 28: 803–811
  • Pastrakuljic A., Tang B.K., Roberts E.A., Kalow W. Distinction of CYP1A1 and CYP1A2 Activity by Selective Inhibition Using Fluvoxamine and Isosafrole. Biochem. Pharmacol. 1997; 53: 531–538
  • Koley A.P., Robinson R.C., Markowitz A., Friedman F.K. Drug–Drug Interactions: Effect of Quinidine on Nifedipine Binding to Human Cytochrome P450 3A4. Biochem. Pharmacol. 1997; 54: 455–460
  • Lasker J.M., Wester M.R., Aramsombatdee E., Raucy J.L. Characterization of CYP2C19 and CYP2C9 from Human Liver: Respective Roles in Microsomal Tolbutamide, S-Mephenytoin, and Omeprazole Hydroxylation. Arch. Biochem. Biophys. 1998; 353: 16–24
  • Nakasa H., Nakamura H., Ono S., Tsutsui M., Kiuchi M., Ohmori S., Kitada M. Prediction of Drug–Drug Interactions of Zonisamide Metabolism in Humans from In Vitro Data. Eur. J. Clin. Pharmacol. 1998; 54: 177–183
  • Wandel C., Lang C.C., Cowart C.D., Girard A.F., Bramer S., Flockhart D.A., Wood A.J. Effect of CYP3A Inhibition on Vesnarinone Metabolism in Humans. Clin. Pharmacol. Ther. 1998; 63: 506–511, (a)
  • Frye R.F., Tammara B., Cowart T.D., Bramer S.L. Effect of Disulfiram-Mediated CYP2E1 Inhibition on the Disposition of Vesnarinone. J. Clin. Pharmacol. 1999; 39: 1177–1183, (b)
  • Brynne N., Dalen P., Alvan G., Bertilsson L., Gabrielsson J. Influence of CYP2D6 Polymorphism on the Pharmacokinetics and Pharmacodynamic of Tolterodine. Clin. Pharmacol. Ther. 1998; 63: 529–539, (a)
  • Brynne N., Svanstrom C., Aberg-Wistedt A., Hallen B., Bertilsson L. Fluoxetine Inhibits the Metabolism of Tolterodine-Pharmacokinetic Implications and Proposed Clinical Relevance. Br. J. Clin. Pharmacol. 1999; 48: 553–563, (b)
  • Kudo S., Odomi M. Involvement of Human Cytochrome P450 3A4 in Reduced Haloperidol Oxidation. Eur. J. Clin. Pharmacol. 1998; 54: 253–259
  • Belpaire F.M., Wijnant P., Temmerman A., Rasmussen B.B., Brosen K. The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors. Eur. J. Clin. Pharmacol. 1998; 54: 261–264, (a)
  • Ellis S.W., Rowland K., Ackland M.J., Rekka E., Simula A.P., Lennard M.S., Wolf C.R., Tucker G.T. Influence of Amino Acid Residue 374 of Cytochrome P-450 2D6 (CYP2D6) on the Regio- and Enantio-Selective Metabolism of Metoprolol. Biochem. J. 1996; 316: 647–654, (b)
  • Guitton J., Buronfosse T., Desage M., Flinois J.P., Perdrix J.P., Brazier J.L., Beaune P. Possible Involvement of Multiple Human Cytochrome P450 Isoforms in the Liver Metabolism of Propofol. Br. J. Anaesth. 1998; 80: 788–795
  • McKillop D., Wild M.J., Butters C.J., Simcock C. Effects of Propofol on Human Hepatic Microsomal Cytochrome P450 Activities. Xenobiotica 1998; 28: 845–853
  • Kashuba A.D., Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R., Rocci M.L., Kulawy R.W., Beck D.J., Bertino J.S. Effect of Fluvoxamine Therapy on the Activities of CYP1A2, CYP2D6, and CYP3A as Determined by Phenotyping. Clin. Pharmacol. Ther. 1998; 64: 257–268
  • von Moltke L.L., Greenblatt D.J., Duan S.X., Schmider J., Wright C.E., Harmatz J.S., Shader R.I. Human Cytochrome Mediating N-Demethylation of Fluoxetine In Vitro. Psychopharmacology 1997; 132: 402–407, (a)
  • Fjordside L., Jeppesen U., Eap C.B., Powell K., Baumann P., Brosen K. The Stereoselective Metabolism of Fluoxetine in Poor and Extensive Metabolizers of Sparteine. Pharmacogenetics 1999; 9: 55–60, (b)
  • Margolis J.M., O'Donnell J.P., Mankowski D.C., Ekins S., Obach R.S. (R)- (S)-, and Racemic Fluoxetine N-Demethylation by Human Cytochrome P450 Enzymes. Drug Metab. Dispos. 2000; 28: 1187–1191, (c)
  • Pan L.P., De Vriendt C., Belpaire F.M. In-Vitro Characterization of the Cytochrome P450 Isoenzymes Involved in the Back Oxidation and N-Dealkylation of Reduced Haloperidol. Pharmacogenetics 1998; 8: 383–389
  • Yasui N., Kondo T., Otani K., Furukori H., Kaneko S., Ohkubo T., Nagasaki T., Sugawara K. Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Alprazolam. Psychopharmacology 1998; 139: 269–273
  • Rotzinger S., Fang J., Backer G.B. Trazodone is Metabolized to m-Chlorophenylpiperazine by CYP3A4 from Human Sources. Drug Metab. Dispos. 1998; 26: 572–575, (a)
  • Yasui N., Otani K., Kaneko S., Ohkubo T., Osanai T., Ishida M., Mihara K., Kondo T., Sugawara K., Fukushima Y. Inhibition of Trazodone Metabolism B702by Thioridazine in Humans. Ther. Drug Monit. 1995; 17: 333–335, (b)
  • Zalma A., von Moltke L.L., Granda B.W., Harmatz J.S., Shader R.I., Greenblatt D.J. In Vitro Metabolism of Trazodone by CYP3A: Inhibition by Ketoconazole and Human Immunodeficiency Viral Protease Inhibitors. Biol. Psychiatry. 2000; 47: 655–661, (c)
  • Lampen A., Zhang Y., Hackbarth I., Benet L.Z., Sewing K.F., Christians U. Metabolism and Transport of Macrolide Immunosuppressant Sirolimus in the Small Intestine. J. Pharmacol. Exp. Ther. 1998; 258: 1104–1112
  • Chiba M., Nishime J.A., Chen I.W., Vastag K.J., Sahly Y.S., Kim B.M., Dorsey B.D., Vacca J.P., Lin J.H. Metabolite-P450 Complex Formation by Methylenedioxyphenyl HIV Protease Inhibitors in Rat and Human Liver Microsomes. Biochem. Pharmacol. 1998; 56: 223–230
  • Zhao X.J., Ishizaki T. Metabolic Interactions of Selected Antimalarial and Non-antimalarial Drugs with the Major Pathway (3-Hydroxylation) of Quinine in Human Liver Microsomes. Br. J. Clin. Pharmacol. 1997; 44: 505–511, (a)
  • Zhao X.J., Ishizaki T. The In Vitro Hepatic Metabolism of Quinine in Mice, Rats and Dogs: Comparison with Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1997; 283: 1168–1176, (b)
  • Kostrubsky V.E., Lewis L.D., Strom S.C., Wood S.G., Schuetz E.G., Schuetz J.D., Sinclair P.R., Wrighton S.A., Sinclair J.F. Introduction of Cytochrome P450 3A by Taxol in Primary Cultures of Human Hepatocytes. Arch. Biochem. Biophys. 1998; 355: 131–136
  • Nakajima M., Kobayashi K., Shimada N., Tokudome S., Yamamoto T., Kuroiwa Y. Involvement of CYP1A2 in Mexiletine Metabolism. Br. J. Clin. Pharmacol. 1998; 46: 55–62
  • Wu D., Otton S.V., Inaba T., Kalow W., Sellers E.M. Interactions of Amphetamine Analogs with Human Liver CYP2D6. Biochem. Pharmacol. 1997; 53: 1605–1612
  • Yaich M., Popon M., Medard Y., Aigrain E.J. In-Vitro Cytochrome P450 Dependent Metabolism of Oxybutynin to N-Deethyloxybutynin in Humans. Pharmacogenetics 1998; 8: 449–451
  • Lukkari E., Taavitsainen P., Juhakoski A., Pelkonen O. Cytochrome P450 Specificity of Metabolism and Interactions of Oxybutynin in Human Liver Microsomes. Pharmacol. Toxicol. 1998; 82: 161–166
  • Horikiri Y., Suzuki T., Mizobe M. Stereoselective Metabolism of Bisprolol Enantiomers in Dogs and Humans. Life Sci. 1998; 63: 1097–1108, (a)
  • Horikiri Y., Suzuki T., Mizobe M. Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans. J. Pharm. Sci. 1998; 87: 289–294, (b)
  • Chesne C., Guyomard C., Guillouzo A., Schmid J., Ludwig E., Sauter T. Metabolism of Meloxicam in Human Liver Involves Cytochromes P450 2C9 and 3A4. Xenobiotica 1998; 28: 1–13
  • Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., Birkett D.J. Tolbutamide and Phenytoin Hydroxylations by cDNA-Expressed Human Liver Cytochrome P4502C9. Biochem. Biophys. Res. Commun. 1991; 175(3)1112–1118
  • Wang R.W., Newton D.J., Scheri T.D., Lu A.Y.H. Human Cytochrome P450 3A4-Catalyzed Testosterone 6beta-Hydroxylation and Erythromycin N-Demethylation. Drug Metab. Dispos. 1997; 25: 502–507
  • Wienkers L.C., Steenwyk R.C., Hauer M.J., Fleishaker J.C., Pearson P.G. Biotransformation of Tirilazad in Human: 3. Tirilazad A-Ring Reduction by Human Liver Microsomal 5Alpha-Reductase type 1 and type 2. J. Pharmacol. Exp. Ther. 1998; 287: 583–590
  • Draper A.J., Madan A., Parkinson A. Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes. Arch. Biochem. Biophys. 1997; 341: 47–61
  • Tateishi T., Soucek P., Caraco Y., Guengerich F.P., Wood A.J. Colchicine Biotransformation by Human Liver Microsomes. Identification of CYP3A4 as the Major Isoform Responsible for Colchicine Demethylation. Biochem. Pharmacol. 1997; 53: 111–116
  • Paar W.D., Poche S., Gerloff J., Dengler H.J. Polymorphic CYP2D6 Mediates O-Demethylation of the Opioid Analgesic Tramadol. Eur. J. Clin. Pharmacol. 1997; 53: 235–239
  • Adedoyin A., Stiff D.D., Smith D.C., Romkes M., Bahnson R.C., Day R., Hofacker J., Branch R.A., Trump D.L. All-trans-Retinoic Acid Modulation of Drug-Metabolizing Enzyme Activities: Investigation with Selective Metabolic Drug Probes. Cancer Chemother. Pharmacol. 1998; 41: 133–139
  • Takahashi H., Kashima T., Nomoto S., Iwade K., Tainaka H., Shimizu T., Nomizo Y., Muramoto N., Kimura S., Echizen H. Comparisons Between In-Vitro and In-Vivo Metabolism of (S)-Warfarin: Catalytic Activities of cDNA- Expressed CYP2C9, its Leu359 Variant and Their Mixture Vs. Unbound Clearance in Patients with the Corresponding CYP2C9 Genotypes. Pharmacogenetics 1998; 8: 365–373
  • Grimm S.W., Dyroff M.C. Inhibition of Human Drug Metabolizing Cytochromes P450 by Anastrozole, a Potent and Selective Inhibitor of Aromatase. Drug Metab. Dispos. 1997; 25: 598–602
  • Bloomer J.C., Clarke S.E., Chenery R.J. In Vitro Identification of the P450 Enzymes Responsible for the Metabolism of Ropinirole. Drug Metab. Dispos. 1997; 25: 840–844
  • Senda C., Kishimoto W., Sakai K., Nagakura A., Igarashi T. Identification of Human Cytochrome P450 Isoforms Involved in the Metabolism of Brotizolam. Xenobiotica 1997; 27: 913–922
  • Jones B.C., Tyman C.A., Smith D.A. Identification of the Cytochrome P450 Isoforms Involved in the O-Demethylation of 4-Nitroanisole in Human Liver Microsomes. Xenobiotica 1997; 27: 1025–1037
  • Jang G.R., Benet L.Z. Antiprogestin-Mediated Inactivation of Cytochrome P450 3A4. Pharmacology 1998; 56: 150–157, (a)
  • He K., Woolf T.F., Hollenberg P.F. Mechanism-Based Inactivation of Cytochrome P-450-3A4 by Mifepristone. J. Pharm. Exp. Ther. 1999; 288: 791–797, (b)
  • Lessard E., Fortin A., Belanger P.M., Beaune P., Hamelin B.A., Turgeon J. Role of CYP2D6 in the N-Hydroxylation of Procainamide. Pharmacogenetics 1997; 7: 381–390
  • Nakamura K., Yokoi T., Kodama T., Inoue K., Nagashima K., Shimada N., Shimizu T., Kamataki T. Oxidation of Histamine H1 Antagonist Mequitazine is Catalyzed by Cytochrome P450 2D6 in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1998; 284: 437–442
  • Ko J.W., Sukhova N., Thacker D., Chen P., Flockhart D.A. Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms. Drug Metab. Dispos. 1997; 25: 853–862, (a)
  • Lewis D.F.V., Lake B.G. Molecular Modeling and Quantitative Structure-Activity Relationship Studies on the Interaction of Omeprazole with Cytochrome P450 Isozymes. Toxicology 1998; 125: 31–44, (b)
  • Funck-Bretano C., Becquemont L., Lenevue A., Roux A., Jallion P., Beaune P. Inhibition by Omeprazole of Proguanil Metabolism: Mechanisms of the Interaction In Vitro and Prediction of In Vivo Results from the In Vitro Experiments. J. Pharmacol. Exp. Ther. 1997; 280: 730–738, (c)
  • Wright J.D., Helsby N.A., Ward S.A. The Role of S-Mephenytoin Hydroxylase (CYP2C19) in the Metabolism of the Antimalarial Biguanides. Br. J. Clin. Pharmacol. 1995; 39: 441–444, (d)
  • Birkett D.J., Rees D., Andersson T., Gonzalez F.J., Miners J.O., Veronese M.E. In Vitro Proguanil Activation to Cycloguanil by Human Liver Microsomes is Mediated by CYP3A Isoforms as well as by S-Mephenytoin Hydroxylase. Br. J. Clin. Pharmacol. 1994; 37: 413–420, (e)
  • Meyer U.A. Metabolic Interactions of the Proton-Pump Inhibitors Lansoprazole, Omeprazole and Pantoprazole with Other Drugs. Eur. J. Gastroenterol. Hepatol. 1996; 1: 21–25, (a)
  • Meyer U.A. Interaction of Proton Pump Inhibitors with Cytochrome P450: Consequences for Drug Interactions. Yale J. Biol. Med. 1996; 69: 203–209, (b)
  • Kokufu T., Ihara N., Sugioka N., Koyama H., Ohta T., Mori S., Nakajima K. Effects of Lansoprazole on Pharmacokinetics and Metabolism of Theophylline. Eur. J. Clin. Pharmacol. 1995; 48: 391–395, (c)
  • Masubuchi N., Li A.P., Okazaki O. An Evaluation of Cytochrome P450 Induction Potential of Pantoprazole in Primary Human Hepatocytes. Chem.-Biol. Interact. 1998; 114: 1–13
  • Svensson U.S., Ashton M., Trinh N.H., Bertilsson L., Dinh X.H., Nguyen V.H., Nguyen T.N., Nguyen D.S., Lykkesfeldt J., Le D.C. Artemisinin Induces Omeprazole Metabolism in Human Beings. Clin. Pharmacol. Ther. 1998; 64: 160–167, (a)
  • Mihara K., Svensson U.S., Tybring G., Hai T.N., Bertilsson L., Ashton M. Stereospecific Analyses of Omeprazole supports Artemisinin as a Potent Inducer of CYP2C19. Fund. Clin. Pharmacol. 1999; 13: 671–675, (b)
  • Mutlib A.E., Klein J.T. Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone. J. Pharmacol. Exp. Ther. 1998; 286: 1285–1293
  • Ekins S., Vanden Branden M., Ring B.J., Gillespie J.S., Yang T.J., Gelboin H.V., Wrighton S.A. Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6. J. Pharmacol. Exp. Ther. 1998; 286: 1253–1259
  • Kawashiro T., Yamashita K., Zhao X.J., Koyama E., Tani M., Chiba K., Ishizaki T. A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1998; 286: 1294–1300
  • Madan A., Parkinson A., Faiman M.D. Identification of the Human P450 Enzymes Responsible for the Sulfoxidation and Thiono-Oxidation of Diethyldithiocarbamate Methyl Ester: Role of P450 Enzymes in Disulfiram Bioactivation. Alcohol Clin. Exp. Res. 1998; 22: 1212–1219, (a)
  • Kharasch E.D., Hankins D.C., Baxter P.J., Thummel K.E. Single-Dose Disulfiram Does Not Inhibit CYP2A6 Activity. Clin. Pharmacol. Ther. 1998; 64: 39–45, (b)
  • von Moltke L.L., Greenblatt D.J., Duan S.X., Daily J.P., Harmatz J.S., Shader R.I. Inhibition of Desipramine Hydroxylation (Cytochrome P450-2D6) In Vitro by Quinidine and by Viral Protease Inhibitors: Relation to Drug Interactions In Vivo. J. Pharm. Sci. 1998; 87: 1184–1189
  • Shou M., Martinet M., Korzekwa K.R., Krausz K.W., Gonzalez F.J., Gelboin H.V. Role of Human Cytochrome P450 3A4 and 3A5 in the Metabolism of Taxotere and its Derivates: Enzyme Specificity, Inter-individual Distribution and Metabolic Contribution in Human Liver. Pharmacogenetics 1998; 8: 391–401, (a)
  • Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. Metabolism of Docetaxel by Human Cytochromes P450: Interactions with Paclitaxel and Other Antineoplastic Drugs. Cancer. Res. 1996; 56: 58–65, (b)
  • Marre F., Sanderink G.J., de Sousa G., Gaillard C., Martinet M., Rahmani R. Hepatic Biotransformation of Docetaxel (Taxotere) In Vitro: Involvement of the CYP3A Subfamily in Humans. Cancer. Res. 1996; 56: 1296–1302, (c)
  • Haritos V.S., Ching M.S., Ghabrial H., Gross A.S., Taavitsainen P., Pelkonen O., Battaglia S.E., Smallwood R.A., Ahokas J.T. Metabolism of Dexfenfluramine in Human Liver Microsomes and by Recombinant Enzymes: Role of CYP2D6 and 1A2. Pharmacogenetics 1998; 8: 423–432
  • Gorski J.C., Jones D.R., Wrigton S.A., Hall S.D. Contribution of Human CYP3A Subfamily Members to the 6-Hydroxylation of Chlorzoxazone. Xenobiotica 1997; 3: 243–256
  • Patten C.J., Smith T.J., Friesen M.J., Tynes R.E., Yang C.S., Murphy S.E. Evidence for Cytochrome P450 2A6 and 3A4 as Major Catalysts for N′-Nitrosonornicotine Alpha-Hydroxylation by Human Liver Microsomes. Carcinogenesis 1997; 18: 1623–1630, (a)
  • Berkman C.E., Park S.B., Wrighton S.A., Cashman J.R. In Vitro–In Vivo Correlations of Human (S)-Nicotine Metabolism. Biochem. Pharmacol. 1995; 50: 565–570, (b)
  • Cashman J.R., Park S.B., Yang Z.C., Wrighton S.A., Jacob P., Benowitz N.L. Metabolism of Nicotine by Human Liver Microsomes: Stereoselective Formation of trans-Nicotine N′-Oxide. Chem. Res. Toxicol. 1992; 5: 639–646, (c)
  • Yamazaki H., Shimada T. Human Liver Cytochrome P450 Enzymes Involved in the 7-Hydroxylation of R- and S- Warfarin Enantiomers. Biochem. Pharmacol. 1997; 54: 1195–1203
  • Shet M.S., McPhaul M., Fisher C.W., Stallings N.R., Estabrook R.W. Metabolism of the Antiandrogenic Drug (Flutamide) by Human CYP1A2. Drug Metab. Dispos. 1997; 11: 1298–1303
  • Boberg M., Angerbauer R., Fey P., Kanhai W.K., Karl W., Kern A., Ploschke J., Radtke M. Metabolism of Cerivastatin by Human Liver Microsomes In Vitro: Characterization of Primary Metabolic Pathways and of Cytochrome P450 Isozymes Involved. Drug Metab. Dispos. 1997; 25: 321–331, (a)
  • Muck W., Ochmann K., Rohde G., Unger S., Kuhlmann J. Influence of Erythromycin Pre- and Co-treatment on Single-Dose Pharmacokinetics of the HMG-CoA Reductase Inhibitor Cerivastatin. Eur. J. Clin. Pharmacol. 1998; 53: 469–473, (b)
  • Kantola T., Kivisto K.T., Neuvonen P.J. Effect of Itraconazole on Cerivastatin Pharmacokinetics. Eur. J. Clin. Pharmacol. 1999; 54: 851–855, (c)
  • Ucar M., Mjorndal T., Dahlqvist R. HMG-CoA Reductase Inhibitors and Myotoxicity. Drug Saf. 2000; 22: 441–457, (d)
  • Wolfgang M. Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity of Drug Interaction. Drugs 1998; 56(Suppl. 1)15–23, (e)
  • Sachse R., Ochmann K., Rohde G., Muck W. The Effect of Omeprazole Pre- and Co-treatment on Cerivastatin Absorption and Metabolism in Man. Int. J. Clin. Pharmacol. Ther. 1998; 36: 517–520, (f)
  • Herman R. Drug Interactions and the Statins. Can. Med. Assn. J. 1999; 161: 1281–1286, (g)
  • Muck W. Clinical Pharmacokinetics of Cerivastatin. Clin. Pharmacokinet. 2000; 39: 99–116, (h)
  • Manchee G.R., Eddershaw P.J., Ranshaw L.E., Herriott D., Park G.R., Bayliss M.K., Tarbit M.H. The Aliphatic Oxidation of Salmeterol to Alpha-Hydroxysalmestreol in Human Liver Microsomes is Catalyzed by CYP3A. Drug Metab. Dispos. 1996; 24: 555–559
  • Kashiyama E., Yokoi T., Odomi M., Funae Y., Inoue K., Kamataki T. Cytochrome P450 Responsible for the Stereoselective S-Oxidation of Flosequinan in Hepatic Microsomes from Rats and Humans. Drug Metab. Dispos. 1997; 25: 716–724
  • Labroo R.B., Paine M.F., Thummel K.E., Kharasch E.D. Fentanyl Metabolism by Human Hepatic and Intestinal Cytochrome P450 3A4: Implications for Inter-individual Variability in Disposition, Efficacy, and Drug Interactions. Drug Metab. Dispos. 1997; 25: 1072–1080
  • Li A.P., Reith M.K., Rasmussen A., Gorski J.C., Hall S.D., Xu L., Kaminski D.L., Cheng L.K. Primary Human Hepatocytes as a Tool for the Evaluation of Structure-Activity Relationship in Cytochrome P450 Induction Potential of Xenobiotics: Evaluation of Rifampin, Rifapentine and Rifabutin. Chem.-Biol. Interact. 1997; 107: 17–30
  • Inaba T., Fischer N.E., Riddick D.S., Stewart D.J., Hidaka T. HIV Protease Inhibitors, Saquinavir, Indinavir and Ritonavir: Inhibition of CYP3A4-Mediated Metabolism of Testosterone and Benzoxazinorifamycin, KRM-1648, in Human Liver Microsomes. Toxicol. Lett. 1997; 93: 215–219, (a)
  • Eagling V.A., Back D.J., Barry M.G. Differential Inhibition of Cytochrome P450 Isoforms by the Protease Inhibitors, Ritonavir, Saquinavir, and Indinavir. Br. J. Clin. Pharmacol. 1997; 44: 190–194, (b)
  • Iribarne C., Berthou F., Carlhant D., Dreano Y., Picart D., Lohezic F., Riche C. Inhibition of Methadone and Buprenoprhine N-Dealkylations by Three HIV-1 Protease Inhibitors. Drug Metab. Dispos. 1998; 26: 257–260
  • Guo Z., Raeissi S., White R.B., Stevens J.C. Orphenadrine and Methimazole Inhibit Multiple Cytochrome P450 Enzymes in Human Liver Microsomes. Drug Metab. Dispos. 1997; 26: 390–393
  • Kobayashi K., Nakajima M., Chiba K., Yamamoto T., Tani M., Ishizaki T., Kuroiwa Y. Inhibitory Effects of Antiarrhythmic Drugs on Phenacetin O-Deethylation Catalyzed by Human CYP1A2. Br. J. Clin. Pharmacol. 1998; 45: 361–368
  • Nakajima M., Inoue T., Shimada N., Tokudome S., Yamamoto T., Kuroiwa Y. Cytochrome P450 2C9 Catalyzes Indomethacin O-Demethylation in Human Liver Microsomes. Drug Metab. Dispos. 1998; 26: 261–266
  • Desta Z., Kerbusch T., Soukhova N., Richard E., Ko J.-W., Flockhart D.A. Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide. J. Pharmacol. Exp. Ther. 1998; 285: 428–437, (a)
  • Desta Z., Kerbusch T., Flockhart D.A. Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy Poor and Extensive Metabolizers of Cytochrome P450 2D6. Clin. Pharmacol. Ther. 1999; 65: 10–20, (b)
  • Tassaneeyakul W., Birkett D.J., Miners J.O. Inhibition of Human Hepatic Cytochrome P450 2E1 by Azole Antifungals, CNS-Active Drugs and Non-steroidal Anti-inflammatory Agents. Xenobiotica 1998; 28: 293–301
  • Renwick A.B., Mistry H., Ball S.E., Walters D.G., Kao J., Lake B.G. Metabolism of Zaleplon by Human Hepatic Microsomal Cytochrome P450 Isoforms. Xenobiotica 1998; 28: 337–348
  • Zeng Z., Andrew N.W., Arison B.H., Luffer-Atlas D., Wang R.W. Identification of Cytochrome P450 3A4 as the Major Enzyme Responsible for the Metabolism of Ivermectin by Human Liver Microsomes. Xenobiotica 1998; 28: 313–321
  • Gilham D.E., Cairns W., Paine M.J.I., Modi S., Poulsom R., Roberts G.C.K., Wolf C.R. Metabolism of MPTP by Cytochrome P450 2D6 and the Demonstration of 2D6 mRNA in Human Fetal and Adult Brain by In Situ Hybridization. Xenobiotica 1997; 27: 111–125, (a)
  • Modi S., Gilham D.E., Sutcliffe M.J., Lian L.J., Primrose W.U., Wolf C.R., Roberts G.C. 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine as a Substrate of Cytochrome P450 2D6: Allosteric Effects of NADPH-Cytochrome P450 Reductase. Biochemistry 1997; 36: 4461–4470, (b)
  • Beresford A.P., Ellis W.J., Ayrton J., Johnson M.A., Lewis D.F.V. Cytochrome P450 1A (CYP1A) Induction in Rat and Man by the Benzodioxino Derivative, Fluparoxan. Xenobiotica 1997; 27: 159–173
  • Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., Tucker G.T., Cho A.K. Oxidation of Methamphetamine and Methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 1997; 9: 1059–1064
  • Stresser D.M., Kupfer D. Prosubstrates of CYP3A4, the Major Human Hepatic Cytochrome P450: Transformation into Substrates by Other P450 Isoforms. Biochem. Pharmacol. 1998; 55: 1861–1871, (a)
  • Dehal S.S., Kupfer D. Metabolism theof Proestrogenic Pesticide Methoxychlor by Hepatic P450 Monooxygenases in Rats and Humans. Dual Pathways Involving Novel Ortho Ring-Hydroxylation by CYP2B. Drug Metab. Dispos. 1994; 22: 937–946, (b)
  • Stresser D.M., Kupfer D. Catalytic Characteristics of CYP3A4: Requirement for a Phenolic Function in Ortho Hydroxylation of Estradiol and Mono-O-Demethylated Methoxychlor. Biochemistry 1997; 36: 2203–2210, (c)
  • Clarke S.E. In Vitro Assessment of Human Cytochrome P450. Xenobiotica 1998; 28: 1167–1202
  • Roberts E.S., Hopkins N.E., Foroozesh M., Alworth W.L., Halpert J.R., Hollenberg P.F. Inactivation of Cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by Arylalkynes. Drug Metab. Dispos. 1997; 25: 1242–1248
  • Drahushuk A.T., McGarrigle B.P., Larsen K.E., Stegman J.J., Olson J.R. Detection of CYP1A1 Protein in Human Liver and Induction by TCDD in Precision-Cut Liver Slices Incubated in Dynamic Organ Culture. Carcinogenesis 1998; 19: 1361–1368, (a)
  • Kress S., Reichert J., Schwarz M.F. Functional Analysis of the Human Cytochrome P4501A1 (CYP1A1) Gene Enhancer. Eur. J. Biochem. 1998; 258: 803–812, (b)
  • Hammons G.J., Milton D., Stepps K., Guengerich F.P., Turkey R.H., Kadlubar F.F. Metabolism of Carcinogenic Heterocyclic and Aromatic Amines by Recombinant Cytochrome P450 Enzymes. Carcinogenesis 1997; 18: 851–854
  • Mehmood Z., Kelly D.E., Kelly S.L. Cytochrome P450 3A4 Mediated Metabolism of 2,4-Dichlorophenol. Chemosphere 1997; 34: 2281–2291
  • Bellec G., Dreano Y., Bail J.P., Menez J.F., Berthou F. Cytochrome P450 Hydroxylation of Carbon Atoms of the Alkyl Chain of Symmetrical N-Nitrosodialkylamines by Human Liver Microsomes. Mutat. Res. 1997; 377: 199–209, (a)
  • Bellec G., Dreano Y., Lozach P., Menez J.F., Berthou F. Cytochrome P450 Metabolic De-Alkylation of Nine N-Nitrosodialkylamines by Human Liver Microsomes. Carcinogenesis 1996; 17: 2029–2034, (b)
  • Nieusma J.L., Claffey D.J., Koop D.R., Chen W., Peter R.M., Nelson S.D., Ruth J.A., Ross D. Oxidation of 1,3-Butadiene to (R)- and (S)-Butadiene Monoxide by Purified Recombinant Cytochrome P450 2E1 from Rabbit, Rat and Human. Toxicol. Lett. 1998; 95: 123–129
  • Adas F., Berthou F., Picart D., Lozac'h P., Beauge F., Amet Y. Involvement of Cytochrome P450 2E1 in the (Omega-1)-Hydroxylation of Oleic Acid in Human and Rat Liver Microsomes. J. Lipid. Res. 1998; 39: 1210–1219
  • Khojasteh-Bakht S.C., Koenigs L.L., Peter R.M., Trager W.F., Nelson S.D. (R)-(+)-Menthofuran is a Potent, Mechanism-Based Inactivator of Human Liver Cytochrome P450 2A6. Drug Metab. Dispos. 1998; 26: 701–704
  • Koenigs L.L., Trager W.F. Mechanism Based Inactivation of P450 2A6 by Furanocoumarins. Biochemistry 1998; 37: 10047–10061, (a)
  • Maenpaa J., Juvonen R., Raunio H., Rautio A., Pelkonen O. Metabolic Interactions of Methoxsalen and Coumarin in Humans and Mice. Biochem. Pharmacol. 1994; 48: 1363–1369, (b)
  • Kim J.H., Stansbury K.H., Walker N.J., Trush M.A., Strickland P.T., Sutter T.R. Metabolism of Benzo[a]Pyrene and Benzo[a]Pyrene-7, 8-Diol by Human Cytochrome P450 1B1. Carcinogenesis 1998; 19: 1847–1853
  • Nakajima T., Wang R.S., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., Aoyama T. Toluene Metabolism by cDNA-Expressed Human Hepatic Cytochrome P450. Biochem. Pharmacol. 1997; 53: 271–277
  • Einolf H.J., Story W.T., Marcus C.B., Larsen M.C., Jefcoate C.R., Greenlee W.F., Yagi H., Jerina D.M., Amin S., Park S.S., Gelboin H.V., Baird W.M. Role of Cytochrome P450 Enzyme Induction in the Metabolic Activation of Benzo[c]Phenentrene in Human Cell Lines and Mouse Epidermis. Chem. Res Toxicol. 1997; 10: 609–617, (a)
  • Seidel A., Soballa V.J., Raab G., Greim H., Grimmer G., Jacob J., Doehmer J. Regio- and Stereoselectivity of Metabolism of Benzo[c]Phenanthrene Mediated by Genetically Engineered V79 Chinese Hamster Cells Expressing Rat and Human Cytochromes P450. Environ. Toxicol. Pharmacol. 1998; 5: 179–196, (b)
  • Oldham H.G., Clarke S.E. In Vitro Identification of the Human Cytochrome P450 Enzymes Involved in the Metabolism of R(+)- and S(−)-Carvedilol. Drug Metab. Dispos. 1997; 25: 970–976
  • Kudo S., Uchida M., Odomi M. Metabolism of Carteolol by c-DNA-Expressed Human Cytochrome P450. Eur. J. Clin. Pharmacol. 1997; 52: 479–485
  • Helsby N.A., Chipman J.K., Gescher A., Kerr D. Inhibition of Mouse and Human CYP1A- and 2E1-Dependent Substrate Metabolism by the Isoflavonoids Genistein and Equol. Food Chem. Toxicol. 1998; 36: 375–382
  • Monostory K., Vereczkey L., Levai F., Szatmari I. Ipriflavone as an Inhibitor of Human Cytochrome P450 Enzymes. Br. J. Pharmacol. 1998; 123: 605–610
  • Zhai S., Dai R., Wei X., Friedman F.K., Vestal R.E. Inhibition of Metoxyresorufin Demethylase Activity by Flavonoids in Human Liver Microsomes. Life Sci. 1998; 63: 119–123
  • Zhai S., Dai R., Friedman F.K., Vestal R.E. Comparative Inhibition of Human Cytochrome P450 1A1 and 1A2 by Flavonoids. Drug Metab. Dispos. 1998; 26: 989–992
  • Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., Orza D., Marinina J., Gerber N. Metabolism of the Human Immunodeficiency Virus Protease Inhibitors Indinavir and Ritonavir by Human Intestinal Microsomes and Expressed Cytochrome P450 3A4/3A5: Mechanism-Based Inactivation of Cytochrome P4503A by Ritonavir. Drug Metab. Dispos. 1998; 26: 552–561, (a)
  • Hochman J.H., Chiba M., Nishime J., Yamazaki M., Lin J.H. Influence of P-Glycoprotein on the Transport and Metabolism of Indinavir in Caco-2 Cells Expressing Cytochrome P-450 3A4. J. Pharmacol. Exp. Ther. 2000; 292: 310–318, (b)
  • Laurenzana E.M., Owens S.M. Metabolism of Phencyclidine by Human Liver Microsomes. Drug Metab. Dispos. 1997; 25: 557–563
  • Forkert P.G., Lee R.P. Metabolism of Ethyl Carbamate by Pulmonary Cytochrome P450 and Carboxylesterase Isozymes: Involvement of CYP 2E1 and Hydrolase A. Toxicol. Appl. Pharmacol. 1997; 146: 245–254, (a)
  • Hubner P., Groux P.M., Weibel B., Sengstag C., Horlbeck J., Leong-Morgenthaler P.M., Luthy J. Genotoxicity of Ethyl Carbamate (Urethane) in Salmonella, Yeast and Human Lymphoblastoid Cells. Mutat Res. 1997; 390: 11–19, (b)
  • Kishimoto W., Hiroi T., Sakai K., Funae Y., Igarashi T. Metabolism of Epinastine, a Histamine H1 Receptor Antagonist, in Human Liver Microsomes in Comparison with That of Terfenadine. Res. Commun. Mol. Pathol. Pharmacol. 1997; 98: 273–292
  • Stresser D.M., Kupfer D. Human Cytochrome P450-Catalyzed Conversion of the Proestrogenic Pesticide Methoxychlor into an Estrogen. Role of CYP2C19 and CYP1A2 in O-Demethylation. Drug Metab. Dispos. 1998; 26: 868–874
  • Amet Y., Berthou F., Biard S., Dreano Y., Bail J.P., Menez J.F. Validation of the (Omega-1)-Hydroxylation of Lauric Acid as an In Vitro Substrate Probe for Liver Human CYP2E1. Biochem. Pharmacol. 1995; 50: 1775–1782, (a)
  • Amet Y., Zerilli A., Goasduff T., Dreano Y., Berthou F. Noninvolvement of CYP2E1 in the (Omega-1)-Hydroxylation of Fatty Acids in Rat Kidney Microsomes. Biochem. Pharmacol. 1997; 54: 947–952, (b)
  • Crofts F.G., Sutter T.R., Strickland P.T. Metabolism of 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine by Human Cytochrome P4501A1 and P4501B1. Carcinogenesis 1998; 19: 1969–1973
  • Fontaine F., Delescluse C., de Sousa G., Lesca P., Rahmani R. Cytochrome 1A1 Induction by Primaquine in Human Hepatocytes and HepG2 Cells: Absence of Binding to the Aryl Hydrocarbon Receptor. Biochem. Pharmacol. 1999; 57: 255–262
  • Bylund J., Ericsson J., Oliw E.H. Analysis of Cytochrome P450 Metabolites of Arachidonic and Linoleic Acids by Liquid Chromatography-Mass Spectrometry with Ion Trap MS. Anal. Biochem. 1998; 265: 55–68
  • Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol Inhibits Transcription of CYP1A1 In Vitro by Preventing Activation of the Aryl Hydrocarbon Receptor. Cancer Res. 1998; 58: 5707–5712
  • Dai R., Zhai S., Wei X., Pincus M.R., Vestal R.E., Friedman F.K. Inhibition of Human Cytochrome P450 1A2 by Flavones:a Molecular Modeling Study. J. Protein Chem. 1998; 17: 643–650
  • Lilly P.D., Thornton-Manning J.R., Gargas M.L., Clewell H.J., Andersen M.E. Kinetic Characterization of CYP2E1 Inhibition In Vivo and In Vitro by the Chloroethylenes. Arch. Toxicol. 1998; 72: 609–621
  • Desai P.B., Duan J.Z., Zhu Y.W., Kouzi S. Human Liver Microsomal Metabolism and Drug Interactions. Eur. J. Drug Metab. Pharmacokinet. 1998; 23: 417–424
  • Kamimura H., Oishi S., Matsushima H., Watanabe T., Higuchi S., Hall M., Wood S.G., Chasseaud L.F. Identification of Cytochrome P450 Isozymes Involved in Metabolism of the Alpha1-Adrenoceptor Blocker Tamsulosin in Human Liver Microsomes. Xenobiotica 1998; 28: 909–922
  • Raleigh S.M., Wanogho E., Burke M.D., McKeown S.R., Patterson L.H. Involvement of Human Cytochrome P450 (CYP) in the Reducive Metabolism of AQ4N, a Hypoxia Activated Anthraquinone Di-N-Oxide Prodrug. Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 763–767, (a)
  • Patterson L.H., McKeown S.R., Robson T., Gallagher R., Raleigh S.M., Orr S. Antitumour Prodrug Development Using Cytochrome P450 (CYP) Mediated Activation. Anticancer Drug Des. 1999; 14: 473–486, (b)
  • Rotzinger S., Fang J., Coutts R.T., Baker G.B. Human CYP 2D6 and Metabolism of m-Chlorophenylpiperazine. Biol. Psychiatry 1998; 44: 1185–1191
  • Arlander E., Ekstrom G., Alm C., Carrillo J.A., Bielenstein M., Bottiger Y., Bertilsson L., Gustafsson L.L. Metabolism of Ropivacaine in Humans is Mediated by CYP1A2 and to a Minor Extent by CYP3A4: an Interaction Study with Fluvoxamine and Ketoconazole as In Vivo Inhibitors. Clin. Pharmacol. Ther. 1998; 64: 484–491
  • Campbell D.R., Kurzer M.S. Flavonoid Inhibition of Aromatase Enzyme Activity in Human Preadipocytes. J. Steriod. Biochem. Mol. Biol. 1993; 46: 381–388
  • Welker H.A., Wiltshire H., Bullingham R. Clinical Pharmacokinetics of Mibefradil. Clin. Pharmacokinet. 1998; 35: 405–423, (a)
  • Prueksaritanont T., Ma B., Tang C., Meng Y., Assang C., Lu P., Reider P.J., Lin J.H., Baillie T.A. Metabolic Interactions Between Mibefradil and HMG-CoA Reductase Inhibitors: an In Vitro Investigation with Human Liver Preparations. Br. J. Clin. Pharmacol. 1999; 47: 291–298, (b)
  • Zeng Y.-M., Fisher M.B., Rettie A.E. Expression and Catalytic Properties of Human Holo-CYP4B1. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 25–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 35
  • Shin J.-G., Soukhova N., Desta Z., Flockhart D.A. Inhibitory Effects of Antipsychotics on Human Liver CYP Isoforms In Vitro 25. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 25–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 44
  • Koenigs L., Friedberg T., Pritchard M., Rushmore T., Shou M., Trager W. Mechanism-Based Inactivation of P450 3A4 by L-754, 394. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 47, (a)
  • Lightning L.K., Jones J.P., Friedberg T., Pritchard M.P., Shou M., Rushmore T.H., Trager W.F. Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754, 394. Biochemistry 2000; 39: 4276–4287, (b)
  • Chiba M., Nishime J.A., Lin J.H. Potent and Selective Inactivation of Human Liver Microsomal Cytochrome P-450 Isoforms by L-754, 394, an Investigational Human Immune Deficiency Virus Protease Inhibitor. J. Pharmacol. Exp. Ther. 1995; 275: 1527–1534, (c)
  • Nash A., Huges H.M., Wood S.G., Raum K., Curtis C.G. Drug–Drug interaction Studies with Ganaxolone in Human Liver Microsomes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 47
  • Fisher V., Johnson L., Heitz F., Tullman R., Graham E., Baldec J.-P., Robinson W. Multiple Cytochrome P450 Routes for Metabolism of Fluvastatin In Vitro: Reduced Potential for Drug Interactions. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 52, (a)
  • Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.B., Robinson W.T. The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions. Drug Metab. Dispos. 1999; 27: 410–416, (b)
  • Boecker R.H., Lang D., Lupu M., Wandel C. Comparison of the Metabolic Conversions of Several Triazine Compounds and Some Other Xenobiotics on Human Liver Microsomes and Heterologously Expressed Cytochrome P450 Enzymes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 52
  • Kuriya S.-I., Ohmori S., Hino M., Ishii I., Nakamura H., Senda C., Igarashi T., Kiuchi M., Kitada M. Identification of Cytochrome P450 Isoenzyme(s) Responsible for the Metabolism of Pimobendan in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 73–78
  • Anari M.R., Chang T.K.H., Abbott F.S. Role of Human CYP2B6 in Metabolic Formation of 4-ene-Valparoic Acid. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 54
  • Lillibridge J.H., Lee C.A., Pithavala Y.K., Sandoval T.M., Wu E.Y., Zhang K.E., Mazabel E.L., Zhang M., Kerr B.M. The Role of CYP2C19 in the Formation of Nelfinavir Hydroxy-t-Butylamide(M8): In Vitro/In Vivo Correlation. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 55, (a)
  • Wu E.Y., Sandoval T.M., Zhang K.E., Grettenberger H.M., Hee B.R., Lee C.A., Webber S., Shetty B.V. Cytochrome P450 Isoforms Involved in the Metobolism of Nelfinavir Mesylate, an HIV-1 Protease Inhibitor. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 55, (b)
  • Lillibridge J.H., Kerr B.M., Shetty B.V., Lee C.A. Prediction and Interpretation of P450 Isoform Selective Drug Interactions for the Hydroxy-t-Butylamide Metabolite of the HIV-Protease Inhibitor Nelfinavir Mesylate. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 56, (c)
  • Zhang K., Kerr B., Hee B., Talaat R., Moger L., Shetty B., Webber S. Biotransformation of Nelfinavir, a Potent HIV Protease Inhibitor, in Healthy Human Subjects. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 56, (d)
  • Flockhart D.A., Thacker D., Shin J.-G., Desta Z. Identification and Characterization of Human Cytchrome P450 Isoforms Interacting with Cisapride. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 57, (a)
  • Bohets H., Lavrijsen K., Hendrickx J., van Houdt J., van Genechten V., Verboven P., Meuldermans W., Heykants J. Identification of the Cytochrome P450 Enzymes Involved in the Metabolism of Cisapride: In Vitro Studies of Potential Co-medication Interactions. Br. J. Pharmacol. 2000; 129: 1655–1667, (b)
  • Desta Z., Soukhova N., Mahal S.K., Flockhart D.A. Interaction of Cisapride with the Human Cytochrome P450 System: Metabolism and Inhibition Studies. Drug Metab. Dispos. 2000; 28: 789–800, (c)
  • Gibbs M.A., Kunze K.L., Howald W.N., Thummel K.E. Effect of Inhibitor Depletion on Percent Inhibition: Tight Binding of CYP3A by Clotrimazole. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 46
  • Tassaneeyakul W., Birkett D.J., Miners J.O. The Inhibition of Human Hepatic CYP2E1 by Selected Clinically Use Drugs. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 45
  • Tassaneeyakul W., Guo L., Yamazoe Y. Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 45, (a)
  • Guo L.Q., Fukuda K., Ohta T., Yamazoe Y. Role of Furanocoumarin Derivatives on Grapefruit Juice-Mediated Inhibition of Human CYP3A Activity. Drug Metab. Dispos. 2000; 28: 766–771, (b)
  • Tassaneeyakul W., Guo L.Q., Fukuda K., Ohta T., Yamazoe Y. Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450. Arch. Biochem. Biophys. 2000; 378: 356–363, (c)
  • Miners J.O., Bhasker C.R., Birkett D.J., Ong C.-E. The Xenobitic Inhibitor Specificity of Cytochrome P450 2C8. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 43
  • Bach M.V., Coutts R.T., Baker G.B. Involment of CYP2D6 in the In Vitro Metabolism of Amphetamine, Two N-Alkylamphetamines and Their 4-Methoxylated Derivates. Xenobiotica 1999; 29: 885–898, (a)
  • Bach M.V., Coutts R.T., Baker G.B. Metabolism of N,N-Dialkylated Amphetamines, Including Deprenyl, by CYP2D6 Expressed in a Human Cell Line. Xenobiotica 2000; 30: 297–306, (b)
  • Colbourne P.D., Baker G.B., Coutts R.T. Studies on the Metabolism of the Beta-Blocker Metoprolol Using Human Liver Microsomes and Individual Cytochrome P450 Enzymes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 58
  • Duchene P.D., Giudicelli M.-D., Ramis J., Ledirac N., Rahmani R., Houin G.P. Research of the CYP Involved in 14C-Rupatadine-Fumarate In Vitro Metabolism. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 59
  • Coller J.K., Somogyi A.A., Bochner F. Identification of Cytochrome P450 Isoforms Involved in Human Drug Metabolism: Chemical Vs. Antibody Inhibition and Expressed Enzymes Studies with Flunitrazepam. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 60, (a)
  • Coller J.K., Somogyi A.A., Bochner F. Flunitrazepam Oxidative Metabolism in Human Liver Microsomes: Involvement of CYP2C19 and CYP3A4. Xenobiotica 1999; 29: 973–986, (b)
  • Hesse L.M., Venkatakrishnan K., von Moltke L.L., Shader R.I., Greenblatt D.J. CYP3A4 is the Major CYP Isoform Mediating the In Vitro Hydroxylation and Demethylation of Flunitrazepam. Drug Metab. Dispos. 2001; 29: 133–140, (c)
  • Prakash C., Johnson K., Vaidya M., Davis J., Smolarek T. Identifications of Human Cytochrome P450 (CYP) Isoform(s) Responsible for the Metabolism of CP-358, 774, a Potent and Selective EGF Receptor Tyrosine Kinase Inhibitor. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 60
  • Arai H., Noguchi S., Higuchi S. Characterization of CYP Isozymes Involved in the Metabolism of YM511, a Nonsteroidal Aromatase Inhibitor, in Human Liver. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 61
  • Rawden H.C., Kokwaro G.O., Edwards G. Sulphoxidation of Albendazole by Human Liver Microsomes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 62, (a)
  • Rawden H.C., Kokwaro G.O., Ward S.A., Edwards G. Relative Contribution of Cytochromes P-450 and Flavin-Containing Monoxygenases to the Metabolism of Albendazole by Human Liver Microsomes. Br. J. Clin. Pharmacol. 2000; 49: 313–322, (b)
  • Fukunaga Y., Miyashita A., Iwatsubo T., Noguchi K., Watanabe T., Higuchi S. Identifications of the Human Liver Cytochrome P-450 Isozymes Involed in Nicardipine Metabolism. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 62
  • Takeshita M., Miura M., Ohkubo T., Sugawara K. Asymmetric Redox Reactions in Human Liver Stereoselective Oxidation of Optically Active Dihydrohaloperidols, Dihydrobromoperidols and Stereospecific Reduction of Haloperidol and Bromoperidol. Enantiomer 2000; 5: 189–195
  • Ratanasavanh D., Riche D., Biour M., Hourmant N., Hulot T. Medifoxamine Metabolism in Human Liver Microsomes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 63
  • Nadin L., Murray M. The Participation of CYP3A and CYP2C Enzymes in All-trans-Retinoic Acid 4-Hydroxylation in Human Hepatic Microsomes. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 79, (a)
  • Chen H., Fantel A.G., Juchau M.R. Catalysis of the 4-Hydroxylation of Retinoic Acids by CYP3A7 in Human Fetal Hepatic Tissues. Drug Metab. Dispos. 2000; 28: 1051–1057, (b)
  • Marill J., Cresteil T., Lanotte M., Chabot G.G. Identification of Human Cytochrome P450s Involved in the Formation of All-trans-Retinoic Acid Principal Metabolites. Mol. Pharmacol. 2000; 58: 1341–1348, (c)
  • Bogards J.J.P., Salmon F.G.C., van Bladeren P.J. The Biotransformation of Isoprene and Two Isoprene Monoepoxides by Human Cytochrome P450 and Glutathione S Transferase, Compared to Mouse and Rat. 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 91
  • Cuttle L., Munns A.J., Ward S., Hogg N.A., Hooper W.D., Dickinson R.G., Gillam E.M.J. Bioactivation of Phenytoin by Human Cytochrome P450 3A and 2C Forms Catalyze Catehol Formation and Drug-Protein Adduct Formation. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 152, (a)
  • Cuttle L., Munns A.J., Hogg N.A., Scott J.R., Hooper W.D., Dickinson R.G., Gillam E.M. Phenytoin Metabolism by Human Cytochrome P450: Involvement of P450 3A and 2C Forms in Secondary Metabolism and Drug-Protein Adduct Formation. Drug Metab. Dispos. 2000; 28: 945–950, (b)
  • Komatsu T., Yamazaki H., Asahi S., Gillam E.M., Guengerich F.P., Nakajima M., Yokoi T. Formation of A Dihydroxy Metabolite of Phenytoin in Human Liver Microsomes/Cytosol: Roles of Cytochromes P450 2C9, 2C19, and 3A4. Drug Metab. Dispos. 2000; 28: 1361–1368, (c)
  • Testai E., Gemma S., Vittozzi L. The Role of Different Human CYPs in Chloroform Metabolism. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 155
  • Avent K.M., Gillam E.M.J. The Bioactivation of Haloperidol to Pyridium Metabolites by Cytochrome P450 3A4. ISSX Proceedings, 5th International ISSX Meeting, Cairns, Australia, Oct 27–29, 1998. International Society for the Study of Xenobiotics, Cabin John, MD 1998; Vol. 13: 167
  • Decker C.J., Laitinen L.M., Bridson G.W., Raybuck S.A., Tung R.D., Chaturvedi P.R. Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions. J. Pharm. Sci. 1998; 87: 803–807, (a)
  • Fung H.B., Kirschenbaum H.L., Hameed R. Amprenavir: a New Human Immunodeficiency Virus Type 1 Protease Inhibitor. Clin. Ther. 2000; 22: 549–572, (b)
  • Rendic S., Nolteernsting E., Schänzer W. Metabolism of Anabolic Steroids by Recombinant Human Cytochrome P450 Enzymes. Doping Analysis, W. Schaenzer, H. Geyer, A. Gotzmann, U. Mareck-Engelke. Sport and Buch Strauss, Cologne 1999; Vol. 6: 81–95, (a)
  • Rendic S., Nolteernsting E., Schänzer W. Metabolism of Anabolic Steroids by Recombinant Human Cytochrome P450 Enzymes: Gas Chromatographic-Mass Spectrometric Determination of Metabolites. J. Chromatogr. B 1999; 735: 73–83, (b)
  • Bourrie M., Meunier V., Berger Y., Fabre G. Role of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 288–296
  • Kudo S., Okumura H., Miyamoto G., Ishizaki T. Cytochrome P-450 Isoforms Involved in Carboxylic Acid Ester Cleavage of Hantzsch Pyridine Ester of Pranidipine. Drug Metab. Dispos. 1999; 27: 303–308
  • Machinist J.M., Mayer M.D., Shet M.S., Ferrero J.L., Rodrigues A.D. Identification of the Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of Zileuton (ABT-077) and its N-Dehydroxylated Metabolite, Abbott-66193. Drug Metab. Dispos. 1995; 23: 1163–1174, (a)
  • Roudrigues A.D., Wong S.L. Application of Human Liver Microsomes in Metabolism-Based Drug–Drug Interactions: In Vitro–In Vivo Correlations and the Abbott Laboratories Experience. Adv. Pharmacol. 1997; 43: 65–101, (b)
  • Rodrigues A.D. Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-Expressed Cytochromes P450 and Native Human Liver Microsomes. Biochem. Pharmacol. 1999; 57: 465–480, (c)
  • Zhang Y., Guo X., Lin E.T., Benet L.Z. In Vitro Biotransformation of a Novel Antimalarial Cysteine Protease Inhibitor in Human Liver. Pharmacology 1999; 58: 147–159
  • McLellan R.A., Drobitch R.K., McLellan H., Acott P.D., Crocker J.F., Renton K.W. Norfloxacin Interferes with Cyclosporine Disposition in Pediatric Patients Undergoing Renal Transplantation. Clin. Pharmacol. Ther. 1995; 58: 322–327
  • Spina E., Pisani F., Perucca E. Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine, An Update. Clin. Pharmacokinet. 1996; 3: 198–214
  • Kaplan B., Friedman G., Jacobs M., Viscuso R., Lyman N., DeFranco P., Bonomini L., Mulgaonkar S.P. Potential Interaction of Troglitazone and Cyclosporine. Transplantation 1998; 65: 1399–1400, (a)
  • Koup J.R., Anderson G.D., Loi C.M. Effect of Troglitazone on Urinary Excretion of 6beta-Hydroxycortisol. J. Clin. Pharmacol. 1998; 38: 815–818, (b)
  • Ramachandran V., Kostrubsky V.E., Komoroski B.J., Zhang S., Dorko K., Esplen J.E., Strom S.C., Venkataramanan R. Troglitazone Increases Cytochrome P-450 3A Protein and Activity in Primary Cultures of Human Hepatocytes. Drug Metab. Dispos. 1999; 27: 1194–1199, (c)
  • Wang R.W., Liu L., Cheng H. Identification of Human Liver Cytochrome P450 Isoforms Involved in the In Vitro Metabolism of Cyclobenzaprine. Drug Metab. Dispos. 1996; 24: 786–791
  • Carillo J.A., Dahl M.-L., Svennson J.-O., Alm C., Rodriguez I., Bertillson L. Disposition of Fluvoxamine in Humans is Determined by the Polymorphic CYP2D6 and Also by the CYP1A2 Activity. Clin. Pharmacol. Ther. 1996; 60: 183–190
  • Sanderink G.J., Bournique B., Stevens J., Petry M., Martinet M. Involvement of Human CYP1A Isoenzymes in the Metabolism and Drug Interactions of Riluzole In Vitro. J. Pharmacol. Exp. Ther. 1997; 282: 1465–1472
  • Kobayashi K., Nakajima M., Chiba K., Yamamoto T., Tani M., Ishizaki T., Kuroiwa Y. Inhibitory Effects of Antiarrhythmic Drugs on Phenacetin O-Deethylation Catalyzed by Human CYP1A2. Br. J. Clin. Pharmacol. 1998; 45: 361–368
  • Arlander E., Ekstrom G., Alm C., Carrillo J.A., Bielenstein M., Bottiger Y., Bertilsson L., Gustafsson L.L. Metabolism of Ropivacaine in Humans is Mediated by CYP1A2 and to a Minor Extent by CYP3A4: an Interaction Study with Fluvoxamine and Ketoconazole as In Vivo Inhibitors. Clin. Pharmacol. Ther. 1998; 64: 484–491
  • Hosea N.A., Guengerich P. Oxidation of Nonionic Detergents by Cytochrome P450 Enzymes. Arch. Biochem. Biophys. 1998; 353: 365–373
  • Williams J.A., Stone E.M., Millar B.C., Gusterson B.A., Grover P.L., Phillips D.H. Determination of the Enzymes Responsible for Activation of the Heterocyclic Amine 2-Amino-3-Methylimidazo (4,5) Quinoline in the Human Breast. Pharmacogenetics 1999; 8: 519–528
  • Josephy P.D., Evans D.H., Parikh A., Guengerich F.P. Metabolic Activation of Aromatic Amine Mutagens by Simultaneous Expression of Human Cytochrome P450 1A2, NADPH-Cytochrome P450 Reductase, and N-Acetyltransferase in Escherichia coli. Chem. Res. Toxicol. 1998; 11: 70–74
  • Ando Y., Shimizu T., Nakamura K., Mushiroda T., Nakagawa T., Kodama T., Kamataki T. Potent and Non-specific Inhibition of Cytochrome P450 by JM216, a New Oral Platinum Agent. Br. J. Cancer 1998; 78: 1170–1174
  • Nielsen T.L., Rasmusen B.B., Flinois J.P., Beaune P., Brosen K. In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1999; 289: 31–37
  • Michalets E.L. Update: Clinically Significant Cytochrome P-450 Drug Interactions. Pharmacotherapy 1998; 18: 84–112
  • Turesky R.J., Constable A., Richoz J., Varga N., Markovic J., Martin M.V., Guengerich F.P. Activation of Heterocyclic Aromatic Amines by Rat and Human Liver Microsomes and by Purified Rat and Human Cytochrome P450 1A2. Chem. Res. Toxicol. 1998; 11: 925–936, (a)
  • Turesky R.J., Constable A., Fay L.B., Guengerich F.P. Interspecies Differences Between Rat and Human P450 1A2 in the Metabolism of Heterocyclic Aromatic Amines. Cancer Lett. 1999; 143: 109–112, (b)
  • Guengerich F.P., Parikh A., Turesky R.J., Josephy P.D. Inter-Individual Differences in the Metabolism of Environmental Toxicants: Cytochrome P450 1A2 as a Prototype. Mutat. Res. 1999; 428: 115–124, (c)
  • Williams J.A., Martin F.L., Muir G.H., Hewer A., Grover P.L., Phillips D.H. Metabolic Activation of Carcinogens and Expression of Various Cytochromes P450 in Human Prostate Tissue. Carcinogenesis 2000; 21: 1683–1689, (d)
  • Wu D., Otton S.V., Sproule B.A., Busto U., Inaba T., Kalow W., Sellers E.M. Inhibition of Human Cytochrome P450 2D6 (CYP2D6) by Methadone. Br. J. Clin. Pharmacol. 1993; 35: 30–34
  • Tiseo P.J., Perdomo C.A., Friedhoff L.T. Concurrent Administration of Donepezil HCl and Ketoconazole: Assessment of Pharmacokinetic Changes Following Single and Multiple Doses. Br. J. Clin. Pharmacol. 1998; 46(Suppl. 1)30–34
  • Yamazaki H., Tanaka M., Shimada T. Highly Sensitive HPLC Assay for Coumarin 7-Hydroxylation and 7-Ethoxycoumarin O-Deethylation by Human Liver Cytochrome P450 Enzymes. J. Chromatogr. B 1999; 721: 13–19
  • Shimada T., Yamazaki H., Foroozesh M., Hopkins N.E., Alworth W.L., Guengerich F.P. Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 1998; 11: 1048–1056
  • Yamazaki H., Inoue K., Shimada T. Roles of Two Allelic Variants (Arg144Cys and Ile359Leu) of Cytochrome P450 2C9 in the Oxidation of Tolbutamide and Warfarin by Human Liver Microsome. Xenobiotica 1998; 28: 103–115
  • Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., Goldstein J.A., Guengerich F.P., Shimada T. Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomesr. Biochem. Pharmacol. 1998; 56: 243–251
  • Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of Human Cytochrome P450 2A6 in C-Oxidation of Nicotine. Drug Metab. Dispos. 1996; 24: 1212–1217
  • Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki K., Kuroiwa Y. Characterization of CYP2A6 Involved in 3′-Hydroxylation of Cotinine in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 1010–1015, (b)
  • Kim B.R., Oh H.S., Kim D.-H. Differential Inhibition of Aflatoxin B1 Oxidation by Gestodene Action on Human Liver Microsomes. Biochem. Mol. Biol. Int. 1997; 43: 839–846, (a)
  • Wang H., Dick R., Yin H., Licad-Coles E., Kroetz D.L., Szklarz G., Harlow G., Halpert J.R., Correia M.A. Structure–Function Relationships of Human Liver Cytochromes P450 3A: Aflatoxin B1 Metabolism As a Probe. Biochemistry 1998; 37: 12536–12545, (b)
  • Grace J.M., Aguilar A.J., Trotman K.M., Brewer T.G. Metabolism of Beta-Arteether to Dihydroqinghaosu by Human Liver Microsomes and Recombinant Cytochrome P450. Drug Metab. Dispos. 1998; 26: 313–317
  • Rodrigues A.D., Roberts E.M., Mulford D.J., Yao Y., Ouellet D. Oxidative Metabolism of Clarithromycin in the Presence of Human Liver Microsomes, Major Role for the Cytochrome P450 3A. Drug Metab. Dispos. 1997; 25: 623–630
  • Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzales F.J., Tracy T.S. Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites. Biochemistry 1998; 37: 4137–4147
  • Guengerich F.P. Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism. Ann. Rev. Pharmacol. Toxicol. 1999; 39: 1–17, (a)
  • Ball S.E., Maurer G., Zollinger M., Ladona M., Vickers A.E. Characterization of the Cytochrome P-450 Gene Family Responsible for the N-Dealkylation of the Ergot Alkaloid CQA 206-291 in Humans. Drug Metab. Dispos. 1992; 20: 56–63, (b)
  • Le Guellec C., Lacarelle B., Catalin J., Durand A. Inhibitory Effects of Anticancer Drugs on Dextromethorphan-O-Demethylase Activity in Human Liver Microsomes. Cancer Chemother. Pharmacol. 1993; 32: 491–495
  • von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M., Aily J.P.D., Harmatz J.S., Shader R.I. Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with RITONAVIR. J. Clin. Pharmacol. 1998; 38: 106–111
  • Le Bail J.C., Laroche T., Marre-Fournier F., Habrioux G. Aromatase and 17beta-Hydroxysteroid Dehydrogenase Inhibition by Flavonoids. Cancer. Lett. 1999; 133: 101–106
  • Doostzadeh J., Flinois J.P., Beaune P., Morfin R. Pregnenolone-7beta-Hydroxylating Activity of Human Cytochrome P450-1A1. J. Steroid Biochem. Mol. Biol. 1997; 60: 147–152
  • Gautier J.C., Leceour S., Cosme J., Perret A., Urban P., Beaune P., Pompon D. Contribution of Human Cytochrome P450 to Benzo[a]Pyrene and Benzo[a]pyrene-7, 8-Dihydrodiol Metabolism, as Predicted from Heterologous Expression in Yeast. Pharmacogenetics 1996; 6: 489–499, (a)
  • Shou M., Korzekwa K.R., Crespi C.L., Gonzalez F.J., Gelboin H.V. The Role of 12 cDNA-Expressed Human, Rodent, and Rabbit Cytochromes P450 in the Metabolism of Benzo[a]Pyrene and Benzo[a]Pyrene trans-7, 8-Dihydrodiol. Mol. Carcinogen. 1994; 10: 159–168, (b)
  • Yun C.H., Shimada T., Guengerich F.P. Roles of Human Liver Cytochrome P4502C and 3A Enzymes in the 3-Hydroxylation of BenzoPyrene. Cancer Res. 1992; 52: 1868–1874, (a)
  • Schwarz D., Kisselev P., Cascorbi I., Schunck W.H., Roots I. Differential Metabolism of Benzo[a]Pyrene and Benzo[a]Pyrene-7,8-Dihydrodiol by Human CYP1A1 Variants. Carcinogenesis 2001; 22: 453–459, (d)
  • Wormhoudt L.W., Ploemen J.H., de Waziers I., Commandeur J.N., Beaune P.H., van Bladeren P.J., Vermeulen N.P. Inter-individual Variability in the Oxidation of 1,2-Dibromoethane: Use of Heterologously Expressed Human Cytochrome P450 and Human Liver Microsomes. Chem.-Biol. Interact. 1996; 101: 175–192
  • Horsmans Y., Lannes D., Larrey D., Tinel M., Letteron P., Loeper J., Pessayre D. Nilutamide Inhibits Mephenytoin 4-Hydroxylation in Untreated Male Rats and in Human Liver Microsomes. Xenobiotica 1991; 21: 1559–1570
  • Mancy A., Broto P., Dijols S., Dansette P.M., Mansuy D. The Substrate Binding Site of Human Liver Cytochrome P450 2C9: an Approach Using Designed Tienilic Acid Derivatives and Molecular Modeling. Biochemistry 1995; 34: 10365–10375
  • Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. Pharmacokinetics of the Novel Antipsychotic Agent Risperidone and the Prolactin Response in Healthy Subjects. Clin. Pharmacol. Ther. 1993; 54: 257–268, (a)
  • Fang J., Bourin M., Baker G.B. Metabolism of Risperidone To 9-Hydroxyrisperidone by Human Cytochromes P450 2D6 and 3A4, Naunyn Schmiedebergs. Arch. Pharmacol. 1999; 359: 147–151, (b)
  • Tyndale R.F., Sunahara R.K., Inaba T., Kalow W., Gonzalez F.J., Niznik H.B. Neuronal Cytochrome P450IID1 (Debrisoquine/Sparteine-Type): Potent Inhibition of Activity by (−)-Cocaine and Nucleotide Sequence Identity to Human Hepatic P450 Gene CYP2D6. Mol. Pharmacol. 1991; 40: 63–68
  • Guengerich F.P., Shimada T. Activation of Procarcinogens by Human Cytochrome P450 Enzymes. Mutat. Res. 1998; 400: 201–213, (a)
  • Shou M., Korzekwa K.R., Krausz K.W., Buters J.T., Grogan J., Goldfarb I., Ardwick J.P.H., Gonzalez F.J., Gelboin H.V. Specificity of cDNA-Expressed Human and Rodent Cytochrome P450s in the Oxidative Metabolism of the Potent Carcinogen 7,12-Dimethylbenz[a]anthracene. Mol. Carcinog. 1996; 17: 241–249, (b)
  • Yamazaki H., Inui Y., Yun C.H., Guengerich F.P., Shimada T. Cytochrome P450 2E1 and 2A6 Enzymes as Major Catalysts for Metabolic Activation of N-Nitrosodialkylamines and Tobacco-Related Nitrosamines in Human Liver Microsomes. Carcinogenesis 1992; Vol. 13: 1789–1794, (c)
  • Yun C.H., Shimada T., Guengerich F.P. Contributions of Human Liver Cytochrome P450 Enzymes to the N-Oxidation of 4,4′-Methylene-bis(2-Chloroaniline). Carcinogenesis 1992; 13: 217–222, (d)
  • Wei X., Dai R., Zhai S., Thummel K.E., Friedman F.K., Vestal R.E. Inhibition of Human Liver CYP 1A2 by the Class IB Antiarrhythmics Mexiletine, Lidocaine, and Tocainide. J. Pharmacol. Exp. Ther. 1999; 289: 853–858
  • Chae Y.H., Yun C.H., Guengerich F.P., Kadlubar F.F., El-Bayoumy K. Roles of Human Hepatic and Pulmonary Cytochrome P450 Enzymes in the Metabolism of the Environmental Carcinogen 6-Nitrochrysene. Cancer Res. 1993; 53: 2028–2034, (a)
  • Chae Y.-H., Thomas T., Guengerich F.P., Fu P.P., El-Bayoumy K. Comparative Metabolism of 1-, 2-, and 4-Nitropyrene by Human Hepatic and Pulmonary Microsomes. Cancer. Res. 1999; 59: 1473–1480, (b)
  • Malaty L.I., Kuper J.J. Drug Interactions of HIV Protease Inhibitors. Drug Saf. 1999; 20: 147–169
  • Kivisto K.T., Lamberg T.S., Kantola T., Neuvonen P.J. Plasma Buspirone Concentrations are Greatly Increased by Erythromycin and Itraconazole. Clin. Pharmacol. Ther. 1997; 62: 348–354, (a)
  • Lilja J.J., Kivisto K.T., Backman J.T., Lamberg T.S., Neuvonen P.J. GrapeFruit Juice Substantially Increases Plasma Concentrations of Buspirone. Clin. Pharmacol. Ther. 1998; 64: 655–660, (b)
  • Lamberg T.S., Kivisto K.T., Laitila J., Martensson K., Neuvonen P.J. The Effect of Fluoxamine on the Pharmacokinetics and Pharmacodynamics of Buspirone. Eur. J. Clin. Pharmacol. 1998; 54: 761–766, (c)
  • Lamberg T.S., Kivisto K.T., Neuvonen P.J. Concentations and Effects of Buspirone are Considerably Reduced by Rifampicin. Br. J. Clin. Pharmacol. 1998; 45: 381–385, (d)
  • Kivisto K.T., Lamberg T.S., Neuvonen P.J. Interactions of Buspirone with Itraconazole and Rifampicin Effects on the Pharmacokinetics of the Active 1-(2-Pyrimidinyl)-Piperazine metabolite of Buspirone. Pharmacol. Toxicol. 1999; 84: 94–97, (e)
  • Jacobsen W., Kirchner G., Hallensleben K., Mancinelli L., Deters M., Hackbarth I., Benet L.Z., Sewing K.F., Christians U. Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver. Drug Metab. Dispos. 1999; 27: 173–179, (a)
  • Hatanaka T. Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events. Clin. Pharmacokinet. 2000; 39: 397–412, (b)
  • Shen S., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic Activation of diclofenac by Human Cytochrome P450 3A4: Role of 5-Hydroxydiclofenac. Chem. Res. Toxicol. 1999; 12: 214–222, (a)
  • Tang W., Stearns R.A., Wang R.W., Chiu S.H., Baillie T.A. Roles of Human Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac. Chem. Res. Toxicol. 1999; 12: 192–199, (b)
  • Ngui J.S., Tang W., Stearns R.A., Shou M., Miller R.R., Zhang Y., Lin J.H., Baillie T.A. Cytochrome P450 3A4-Mediated Interaction of Diclofenac and Quinidine. Drug Metab. Dispos. 2000; 28: 1043–1050, (c)
  • Hemeryck A., De Vriendt C., Belpaire F.M. Inhibition of CYP2C9 by Selective Serotonin Reuptake Inhibitors: In Vitro Studies with Tolbutamide and (S)-Warfarin Using Human Liver Microsomes. Eur. J. Clin. Pharmacol. 1999; 54: 947–951
  • Furster C., Wikvall K. Identification of CYP3A4 as the Major Enzyme Responsible for 25-Hydroxylation of 5beta-Cholestane-3alpha, 7alpha, 12alpha-Triol in Human Liver Microsomes. Biochim. Biophys. Acta 1999; 1437: 46–52
  • Elkahwaji J., Robin M.A., Berson A., Tinel M., Letteron P., Labbe G., Beaune P., Elias D., Rougier P., Escudier B., Uvillard P.D., Pessayre D. Decrease in Hepatic Cytochrome P450 After Interleukin-2 Immunotherapy. Biochem. Pharmacol. 1999; 57: 951–954
  • He K., Woolf T.F., Hollenberg P.F. Mechanism-Based Inactivation of Cytochrome P-450-3A4 by Mifepristone (RU486). J. Pharmacol. Exp. Ther. 1999; 288: 791–797
  • Kinzig-Schippers M., Fuhr U., Zaigler M., Dammeyer J., Rusing G., Labedzki A., Bulitta J., Sorgel F. Interaction of Pefloxacin and Enoxacin with the Human Cytochrome P450 Enzyme CYP1A2. Clin. Pharmacol. Ther. 1999; 65: 262–274
  • Zusman R.M., Morales A., Glasser D.B., Osterloh I.H. Overall Cardiovascular Profile of Sildenafil Citrate. Am. J. Cardiol. 1999; 83: 35C–44C
  • Hall S.D., Guengerich F.P., Branch R.A., Wilkinson G.R. Characterization and Inhibition of Mephenytoin 4-Hydroxylase Activity in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1987; 240: 216–222
  • Kerry N.L., Somogyi A.A., Bochner F., Mikus G. The Role of CYP2D6 in Primary and Secondary Oxidative Metabolism of Dextromethorphan: In Vitro Studies Using Human Liver Microsomes. Br. J. Clin. Pharmacol. 1994; 38: 243–248
  • Schmider J., Greenblatt D.J., Fogelman S.M., von Moltke L.L., Shader R.I. Metabolism of Dextromethorphan In Vitro: Involvement of Cytochromes P450 2D6 and 3A3/4, with a Possible Role of 2E1. Biopharm. Drug Dispos. 1997; 18: 227–240, (a)
  • von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Schmider J., Harmatz J.S., Shader R.I. Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-Vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3and. J. Pharm. Pharmacol. 1998; 50: 997–1004, (b)
  • Min D.I., Ku Y.M., Vichiendilokkul A., Fleckenstein L.L. A Urine Metabolic Ratio of Dextromethorphan and 3-Methoxymorphinan as a Probe for CYP3A Activity and Prediction of Cyclosporine Clearance in Healthy Volunteers. Pharmacotherapy 1999; 19: 753–759, (c)
  • Halliday R.C., Jones B.C., Smith D.A., Kitteringham N.R., Park B.K. An Investigation of The Interaction Between Halofantrine, CYP2D6 and CYP3A4: Studies with Human Liver Microsomes and Heterologous Enzyme Expression Systems. Br. J. Clin. Pharmacol. 1995; 40: 369–378, (a)
  • Khoo S.M., Porter J.H., Edwards G.A., Charman W.N. Metabolism of Halofantrine to Its Equipotent Metabolite, Desbutylhalofantrine, is Decreased When Orally Administered with Ketoconazole. J. Pharm. Sci. 1998; 87: 1538–1541, (b)
  • Gardner I., Wakazono H., Bergin P., de Waziers I., Beaune P., Kenna J.G., Caldwell J. Cytochrome P450 Mediated Bioactivation of Methyleugenol to 1′-Hydroxymethyleugenol in Fischer 344 Rat and Human Liver Microsomes. Carcinogenesis 1997; 18: 1775–1783
  • Donahue S.R., Flockhart D.A., Abernethy D.R., Ko J.W. Ticlopidine Inhibition of Phenytoin Metabolism Mediated by Potent Inhibition of CYP2C19. Clin. Pharmacol. Ther. 1997; 62: 572–577, (a)
  • Tateishi T., Kumai T., Watanabe M., Nakura H., Tanaka M., Kobayashi S. Ticlopidine Decreases the In Vivo Activity of CYP2C19 as Measured by Omeprazole Metabolism. Br. J. Clin. Pharmacol. 1999; 47: 454–457, (b)
  • Ko J.W., Desta Z., Soukhova N.V., Tracy T., Flockhart D.A. In Vitro Inhibition of the Cytochrome P450 (CYP450) System by the Antiplatelet Drug Ticlopidine: Potent Effect on CYP2C19 and CYP2D6. Br. J. Clin. Pharmacol. 2000; 49: 343–351, (c)
  • Zweers-Zeilmaker W.M., Horbach G.J., Witkamp R.F. Differential Inhibitory Effects of Phenytoin, Diclofenac, Phenylbutazone and a Series of Sulfonamides on Hepatic Cytochrome P4502C Activity In Vitro, and Correlation with Some Molecular Descriptors in the Dwarf Goat (Caprus hircus aegagrus). Xenobiotica 1997; 27: 769–780
  • Ozdemir V., Naranjo C.A., Shulman R.W., Herrmann N., Sellers E.M., Reed K., Kalow W. Determinants of Interindividual Variability and Extent of CYP2D6 and CYP1A2 Inhibition by Paroxetine and Fluvoxamine In Vivo. J. Clin. Psychopharmacol. 1998; 18: 198–207
  • Brosen K. Differences in Interactions of SSRIs. Int. Clin. Psychopharmacol. 1998; 5: 45–47
  • Villikka K., Kivisto K.T., Lamberg T.S., Kantola T., Neuvonen P.J. Concentrations and Effects of Zopiclone are Greatly Reduced by Rifampicin. Br. J. Clin. Pharmacol. 1997; 43: 471–474
  • Lipscomb J.C., Garrett C.M., Snawder J.E. Cytochrome P450-Dependent Metabolism of Trichloroethylene: Interindividual Differences in Humans. Toxicol. Appl. Pharmacol. 1997; 142: 311–318
  • Miners J.O., Coulter S., Tukey R.H., Veronese M-E., Birkett D.J. Cytochrome P450, 1A2, and 2C9 are responsible for the human hepatic O-Demethylation of R- and S-Naproxen. Biochem. Pharmacol. 1996; 51: 1003–1008, (a)
  • Rodrigues A.D., Kukulka M.J., Roberts E.M., Ouellet D., Rodgers T.R. (O-Methyl 14C) naproxen O-Demethylase Activity in Human Liver Microsomes, Evidence for the involvement of cytochrome P450 1A2 and P450 2C9/10. Drug Metab. Disopos. 1996; 24: 126–136, (b)
  • Tracy T.S., Marra C., Wrighton S.A., Gonzalez F.J., Korzekwa R. Involvement of Multiple Cytochrome P450 Isoforms in Naproxen O-Demethylation. Eur. J. Clin. Pharmacol. 1997; 52: 293–298, (c)
  • Zerilli A., Ratanasavanh D., Lucas D., Goasduff T., Dreano Y., Menard C., Picart D., Berthou F. Both Cytochromes P450 2E1 and 3A are Involved in the O-Hydroxylation of p-Nitrophenol, A Catalytic Activity Known to be Specific for P450 2E1. Chem. Res. Toxicol. 1997; 10: 1205–1212
  • Prueksaritanont T., Gorham L.M., Ma B., Liu L., Yu X., Zhao J.J., Slaughter D.E., Arison B.H., Vyas K.P. In Vitro Metabolism of Simvastatin in Humans [SBT]Identification of Metabolizing Enzymes and Effect of the Drug on Hepatic P450s. Drug Metab. Dispos. 1997; 25: 1191–1199
  • Venkatakrishnan K., von Moltke L.L., Duan S.X., Fleishaker J.C., Shader R.I., Greenblatt D.J. Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N-Desmethyladinazolam in Man. J. Pharm. Pharmacol. 1998; 50: 265–274
  • von Moltke L.L., Greenblatt D.J., Ciraulo D.A., Grassi J.M., Granda B.W., Duan S.X., Harmatz J.S., Shader R.I. Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450: In Vitro Inhibition of P450-2D6 by d- and l-Fenfluramine, But Not Phentermine. J. Clin. Psychopharmacol. 1998; 18: 338–341, (a)
  • von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Fogelman S.M., Harmatz J.S., Kramer S.J., Fabre L.F., Shader R.I. Gepirone and 1-(2-Pyrimidinyl)-Piperazine In Vitro: Human Cytochromes Mediating Transformation and Cytochrome Inhibitory Effects. Psychopharmacology (Berl) 1998; 140: 293–299, (b)
  • Jeppesen U., Rasmussen B.B., Brosen K. Fluvoxamine Inhibits the CYP2C19-Catalyzed Bioactivation of Chloroguanide. Clin. Pharmacol. Ther. 1997; 62: 279–286, (a)
  • Rasmussen B.B., Nielsen T.L., Brosen K. Fluvoxamine Inhibits the CYP2C19-Catalysed Metabolism of Proguanil In Vitro. Eur. J. Clin. Pharmacol. 1998; 54: 735–740, (b)
  • Chauret N., Gauthier A., Nicoll-Griffith D.A. Effect of Common Organic Solvents on In Vitro Cytochrome P450-Mediated Metabolic Activities in Human Liver Microsomes. Drug Metab. Dispos. 1998; 26: 1–4, (a)
  • Easterbrook J., Lu C., Sakai Y., Li A.P. Effects of Organic Solvents on The Activities of Cytochrome P450 Isoforms, UDP-Dependent Glucuronyl Transferase, and Phenol Sulfotransferase in Human Hepatocytes. Drug Metab. Dispos. 2001; 29: 141–144, (b)
  • Easterbrook J., Lu C., Fackett A., Li A.P. Effects of Organic Solvents on P450 Oxidation and Phase ii Conjugation Activites in Human Hepatocytes. Drug Metab. Rev 2000; 32(Suppl. 2)241, (c)
  • Luer M.S., Rhoney D.H. Tiagabine: A Novel Antiepileptic Drug. Ann. Pharmacother. 1998; 32: 1173–1180
  • Cato A., III, Cavanaugh J., III, Shi H., III, Hsu A., III, Leonard J., III, Granneman R., III. The Effect of Multiple Doses of Ritonavir on the Pharmacokinetics of Rifabutin. Clin. Pharmacol. Ther. 1998; 63: 414–421, (a)
  • Trapnell C.B., Jamis-Dow C., Klecker R.W., Collins J.M. Metabolism of Rifabutin and Its 25-Desacetyl Metabolite, LM565, by Human Liver Microsomes and Recombinant Human Cytochrome P-450 3A4: Relevance to Clinical Interaction with Fluconazole. Antimicrob Agents Chemother. 1997; 41: 924–926, (b)
  • Hsu A., Granneman G.R., Bertz R.J. Ritonavir. Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents. Clin. Pharmacokinet. 1998; 35: 275–291
  • Numazawa M., Yamaguchi S. 6-Phenylaliphatic-Substituted Androst-4-ene-3, 17-Diones as Aromatase Inhibitors: Structure–Activity Relationships. J. Steroid Biochem. Mol. Biol. 1998; 67: 41–48, (a)
  • Numazawa M., Yoshimura A., Oshibe M. Enzymic Aromatization of 6-Alkyl-Substituted Androgens, Potent Competitive and Mechanism-Based Inhibitors of Aromatase. Biochem. J. 1998; 329: 151–156, (b)
  • Rasmussen E., Eriksson B., Oberg K., Bondesson U., Rane A. Selective Effects of Somatostatin Analogs on Human Drug-Metabolizing Enzymes. Clin. Pharmacol. Ther. 1998; 64: 150–159
  • Varis T., Kaukonen K.M., Kivisto K.T., Neuvonen P.J. Plasma Concentrations and Effects of Oral Methylprednisolone are Considerably Increased by Itraconazole. Clin. Pharmacol. Ther. 1998; 64: 363–368
  • Gentile D.M., Verhoeven C.H., Shimada T., Back D.J. The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel. J. Pharmacol. Exp. Ther. 1998; 287: 975–982
  • Salmela K.S., Kessova I.G., Tsyrlov I.B., Lieber C.S. Respective Roles of Human Cytochrome P-4502E1, 1A2, and 3A4 in the Hepatic Microsomal Ethanol Oxidizing System. Alcohol Clin. Exp. Res. 1998; 22: 2125–2132
  • Kantola T., Kivisto K.T., Neuvonen P.J. Effect of Itraconazole on the Pharmacokinetics of Atorvastatin. Clin. Pharmacol. Ther. 1998; 64: 58–65
  • Voorman R.L., Maio S.M., Hauer M.J., Sanders P.E., Payne N.A., Ackland M.J. Metabolism of Delavirdine, A Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A. Drug Metab. Dispos. 1998; 26: 631–639, (a)
  • Voorman R.L., Payne N.A., Wienkers L.C., Hauer M.J., Sanders P.E. Interaction of Delavirdine with Human Liver Microsomal Cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab. Dispos. 2001; 29: 41–47, (b)
  • Voorman R.L., Maio S.M., Payne N.A., Zhao Z., Koeplinger K.A., Wang X. Microsomal Metabolism of Delavirdine: Evidence for Mechanism-Based Inactivation of Human Cytochrome P450 3A. J. Pharmacol. Exp. Ther. 1998; 287: 381–388, (c)
  • Miller D.B., Spence J.D. Clinical Pharmacokinetics of Fibric Acid Derivatives (fibrates). Clin. Pharmacokinet. 1998; 34: 155–162
  • Caccia S. Metabolism of the Newer Antidepressants. An Overview of the Pharmacological and Pharmacokinetic Implications. Clin. Pharmacokinet. 1998; 34: 281–302
  • Yang T.J., Krausz K.W., Shou M., Yang S.K., Buters J.T., Gonzalez F.J., Gelboin H.V. Inhibitory Monoclonal Antibody to Human Cytochrome P450 2B6. Biochem. Pharmacol. 1998; 55: 1633–1640
  • Chabot G.G., Robert J., Lokiec F., Canal P. Irinotecan Pharmacokinetics. Bull. Cancer 1998; Spec. No, 11–20
  • Sonnet P., Guillon J., Enguehard C., Allemagne P.D., Bureau R., Rault P., Auvray S., Moslemi S., Sourdiane P., Galopin S., Seralini G.E. Design and Synthesis of A New Type of Non Steroidal Human Aromatase Inhibitors. Bioorg. Med. Chem. Lett. 1998; 8: 1041–1044, (a)
  • Auvray P., Sourdaine P., Moslemi S., Seralini G.E., Sonnet P., Enguehard C., Guillon J., Dallemagne P., Bureau R., Rault S. MR 20492 and MR 20494: Two Indolizinone Derivatives That Strongly Inhibit Human Aromatase. J. Steroid Biochem. Mol. Biol. 1999; 70: 59–71, (b)
  • Sonnet P., Allemagne P.D., Guillon J., Enguehard C., Stiebing S., Tanguy J., Bureau R., Rault S., Auvray P., Moslemi S., Sourdaine P., Seralini G.E. New Aromatase Inhibitors. Synthesis and Biological Activity of Aryl-Substituted Pyrrolizine and Indolizine Derivatives. Bioorg. Med. Chem. 2000; 8: 945–955, (c)
  • Jarman M., Barrie S.E., Llera J.M. The 16, 17-Double Bond is Needed for Irreversible Inhibition of Human Cytochrome p45017alpha by Abiraterone (17-(3-Pyridyl)androsta-5, 16-dien-3beta-ol) and Related Steroidal Inhibitors. J. Med. Chem. 1998; 41: 5375–5381
  • Jensen K.G., Dalgaard L. In Vitro Metabolism of the M1-Muscarinic Agonist 5-(2-Ethyl-2H-Tetrazol-5-yl)-1-Methyl-1,2,3,6-Tetrahydropyridine by Human Hepatic Cytochromes P-450 Determined at pH 7.4 and 8.5. Drug Metab. Dispos. 1999; 27: 125–132
  • Yang T.J., Krausz K.W., Sai Y., Gonzalez F.J., Gelboin H.V. Eight Inhibitory Monoclonal Antibodies Define the Role of Individual P-450s in Human Liver Microsomal Diazepam, 7-Ethoxycoumarin, and Imipramine Metabolism. Drug Metab. Dispos. 1999; 27: 102–109, (a)
  • Yang T.J., Shou M., Korzekwa K.R., Gonzalez F.J., Gelboin H.V., Yang S.K. Role of cDNA-Expressed Human Cytochromes P450 in the Metabolism of Diazepam. Biochem. Pharmacol. 1998; 55: 889–896, (b)
  • Koyama E., Chiba K., Tani M., Ishizaki T. Reappraisal of Human CYP Isoforms Involved in Imipramine N-Demethylation and 2-Hydroxylation: A Study Using Microsomes Obtained from Putative Extensive and Poor Metabolizers of S-Mephenytoin and Eleven Recombinant Human CYPs. J. Pharmacol. Exp. Ther. 1997; 281: 1199–1210, (c)
  • Yang T.J., Sai Y., Krausz K.W., Gonzalez F.J., Gelboin H.V. Inhibitory Monoclonal Antibodies to Human Cytochrome P450 1A2: Analysis of Phenacetin O-Deethylation in Human Liver. Pharmacogenetics 1998; 8: 375–382, (a)
  • Shou M., Korzekwa K.R., Krausz K.W., Crespi C.L., Gonzalez F.J., Gelboin H.V. Regio- and Stereo-Selective Metabolism of Phenanthrene by Twelve cDNA-Expressed Human, Rodent, And Rabbit Cytochromes P-450. Cancer Lett. 1994; 83: 305–313, (b)
  • Long B.J., Tilghman S.L., Yue W., Thiantanawat A., Grigoryev D.N., Brodie A.M. The Steroidal Antiestrogen ICI 182, 780 is An Inhibitor Of Cellular Aromatase Activity. J. Steroid Biochem. Mol. Biol. 1998; 67: 293–304
  • Iatsimirskaia E., Tulebaev S., Storozhuk E., Utkin I., Smith D., Gerber N., Koudriakova T. Metabolism of Rifabutin in Human Enterocyte and Liver Microsomes: Kinetic Parameters, Identification of Enzyme Systems, and Drug Interactions with Macrolides and Antifungal Agents. Clin. Pharmacol. Ther. 1997; 61: 554–562
  • Dupont I., Berthou F., Bodenez P., Bardou L., Guirriec C., Stephan N., Dreano Y., Lucas D. Involvement of Cytochromes P-450 2E1 and 3A4 in the 5-Hydroxylation of Salicylate in Humans. Drug Metab. Dispos. 1999; 27: 322–326
  • Hamelin B.A., Bouayad A., Drolet B., Gravel A., Turgeon J. In Vitro Characterization of Cytochrome P450 2D6 Inhibition by Classic Histamine H1 Receptor Antagonists. Drug Metab. Dispos. 1998; 26: 536–539, (a)
  • Hamelin B.A., Bouayad A., Methot J., Jobin J., Esgagnes P.D., Poirier P., Allaire J., Dumesnil J., Turgeon J. Significant Interaction Between the Nonprescription Antihistamine Diphenhydramine and the CYP2D6 Substrate Metoprolol in Healthy Men with High or Low CYP2D6 Activity. Clin. Pharmacol. Ther. 2000; 67: 466–477, (b)
  • Kariya S., Isozaki S., Uchino K., Suzuki T., Narimatsu S. Oxidative Metabolism of Flunarizine and Cinnarizine by Microsomes from B-Lymphoblastoid Cell Lines Expressing Human Cytochrome P450 Enzymes. Biol. Pharm. Bull. 1996; 19: 1511–1514
  • Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J. O- and N-Demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants. Neuropsychopharmacology 1999; 20: 480–490
  • Ciolino H.P., Yeh G.C. The Flavonoid Galangin is An Inhibitor of CYP1A1 Activity and An Agonist/Antagonist of the Aryl Hydrocarbon Receptor. Br. J. Cancer 1999; 79: 1340–1346
  • Rauschenbach R., Gieschen H., Husemann M., Salomon B., Hildebrand M. Stable Expression of Human Cytochrome P450 3A4 in V79 Cells and Its Application for Metabolic Profiling of Ergot Derivatives. Eur. J. Pharmacol. 1995; 293: 183–190, (a)
  • Gieschen H., Hildebrand M., Salomon B. Metabolism of Two Dopaminergic Ergot Derivatives in Genetically Enigineered V79-Cells Expressing CYP450-Enzymes. Cytochrome P450. 8th International Conference, M.C. Lochner. John Libbey Eurotext, Paris 1994; 467–470, (b)
  • Rauschenbach R., Gieschen H., Salomon B., Kraus C., Kühne G., Hildebrand M. Development of V79 Cell Lines Expressing Human Cytochrome P450 2D6 and its Application as A Metabolic Screening Tool. Environ. Toxicol. Pharmacol. 1997; 3: 31–39, (c)
  • Tran A., Rey E., Pons G., Rousseau M., ‘Athis P.D., Olive G., Mather G.G., Bishop F.E., Wurden C.J., Labroo R., Trager W.F., Kunze K.L., Thummel K.E., Vincent J.C., Gillardin J.M., Lepage F., Levy R. Influence of Stiripentol on Cytochrome P450-Mediated Metabolic Pathways in Humans: In Vitro and In Vivo Comparison and Calculation of In Vivo Inhibition Constants. Clin. Pharmacol. Ther. 1997; 62: 490–504
  • Rodgers E.H., Grant M.H. The Effect of the Flavonoids, Quercetin, Myricetin and Epicatechin on the Growth and Enzyme Activities of MCF7 Human Breast Cancer Cells. Chem.–Biol. Interact. 1998; 116: 213–228
  • Narimatsu S., Kato R., Horie T., Ono S., Tsutsui M., Yabusaki Y., Ohmori S., Kitada M., Ichioka T., Shimada N., Kato R., Ishikawa T. Enantioselectivity of Bunitrolol 4-Hydroxylation is Reversed by the Change of An Amino Acid Residue from Valine to Methionine at Position 374 of Cytochrome P450-2D6. Chirality 1999; 11: 1–9
  • Lee H., Yeom H., Kim Y.G., Yoon C.N., Jin C., Choi J.S., Kim B.R., Kim D.H. Structure-Related Inhibition of Human Hepatic Caffeine N3-Demethylation by Naturally Occurring Flavonoids. Biochem. Pharmacol. 1998; 55: 1369–1375
  • Nedelcheva V., Gut I., Soucek P., Tichavska B., Tynkova L., Mraz J., Guengerich F.P., Ingelman-Sundberg M. Metabolism of Benezene in Human Liver Microsomes: Individual Variations in Relation to CYP2E1 Expression. Arch. Toxicol. 1999; 73: 33–40
  • Hickman D., Wang J.P., Wang Y., Unadkat J.D. Evaluation of The Selectivity of In Vitro Probes and Suitability of Organic Solvents for the Measurement of Human Cytochrome P450 Monooxygenase Activities. Drug Metab. Dispos. 1998; 26: 207–215, (a)
  • Busby W.F., Jr., Ackermann J.M., Jr., Crespi C.L., Jr. Effect of Methanol, Ethanol, Dimethyl Sulfoxide, and Acetonitrile on In Vitro Activities of cDNA-Expressed Human Cytochromes P-450. Drug Metab. Dispos. 1999; 27: 246–249, (b)
  • Palamanda J., Feng W.W., Lin C.C., Nomeir A.A. Stimulation of Tolbutamide Hydroxylation by Acetone and Acetonitrile in Human Liver Microsomes and in A Cytochrome P-450 2C9-Reconstituted System. Drug Metab. Dispos. 2000; 28: 38–43, (c)
  • Jacobsen W., Hallensleben K., Sewing K.F., Benet L.Z., Christians U. Comparison of the Hepatic CYP-Dependent Metabolism of the HMG-CoA Reductase Inhibitor Atorvastatin and Its Lactone. ISSX Proceedings, 7th European ISSX Meeting, Budapest, Hungary, August 22–26; Abstr., 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 14: 32, (a)
  • Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., Benet L.Z., Christians U. Lactonization is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin. Drug Metab. Dispos. 2000; 28: 1369–1378, (b)
  • Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M., Kamataki T. A new Deleted Allele in the Human Cytochrome P450 2A6 (CYP2A6) Gene Found in Individuals Showing Poor Metabolic Capacity to Coumarin and (+)-cis-3,5-Dimethyl-2-(3-Pyridyl)thiazolidin-4-one Hydrochloride (SM-12502). Pharmacogenetics 1998; 8: 239–249, (a)
  • Nunoya K.I., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A New CYP2A6 Gene Deletion Responsible for the In Vivo Polymorphic Metabolism of (+)-cis-3,5-Dimethyl-2-(3-Pyridyl)thiazolidin-4-one Hydrochloride in humans. J. Pharmacol. Exp. Ther. 1999; 289: 437–442, (b)
  • Araya Z., Wikvall K. 6alpha-Hydroxylation of Taurochenodeoxycholic Acid and Lithocholic Acid by CYP3A4 in Human Liver Microsomes. Biochim. Biophys. Acta 1999; 1438: 47–54
  • Gates S., Miners J.O. Cytochrome P450 Isoform Selectivity in Human Hepatic Theobromine Metabolism. Br. J. Clin. Pharmacol. 1999; 47: 299–305
  • Luch A., Schober W., Soballa V.J., Raab G., Greim H., Jacob J., Doehmer J., Seidel A. Metabolic Activation of Dibenzo[a,l]pyrene by Human Cytochrome P450 1A1 and P450 1B1 Expressed in V79 Chinese Hamster Cells. Chem. Res. Toxicol. 1999; 12: 353–364, (a)
  • Luch A., Kishiyama S., Seidel A., Doehmer J., Greim H., Baird W.M. The K-region trans-8,9-diol Does Not Significantly Contribute as An Intermediate in the Metabolic Activation of Dibenzo[a,l]Pyrene to DNA-Binding Metabolites by Human Cytochrome P450 1A1 or 1B1. Cancer Res. 1999; 59(18)4603–4609, (b)
  • Luch A., Coffing S.L., Tang Y.M., Schneider A., Soballa V., Greim H., Jefcoate C.R., Seidel A., Greenlee W.F., Baird W.M., Doehmer J. Stable Expression of Human Cytochrome P450 1B1 in V79 Chinese Hamster Cells and Metabolically Catalyzed DNA Adduct Formation of Dibenzo[a,l]pyrene. Chem. Res. Toxicol. 1998; 11(6)686–695, (c)
  • Granvil C.P., Madan A., Sharkawi M., Parkinson A., Wainer I.W. Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 533–541
  • Yamazaki H., Shimada T. Effects of Arachidonic Acid, Prostaglandins, Retinol, Retinoic Acid and Cholecalciferol on Xenobiotic Oxidations Catalysed by Human Cytochrome P450 Enzymes. Xenobiotica 1999; 29: 231–241
  • Denner K., Vogel R., Schmalix W., Doehmer J., Bernhardt R. Cloning and Stable Expression of the Human Mitochondrial Cytochrome P45011B1 cDNA in V79 Chinese Hamster Cells and Their Application for Testing of Potential Inhibitors. Pharmacogenetics 1995; 5: 89–96
  • Yasumori T., Chen L.S., Li Q.H., Ueda M., Tsuzuki T., Goldstein J.A., Kato R., Yamazoe Y. Human CYP2C-Mediated Stereoselective Phenytoin Hydroxylation in Japanese: Difference in Chiral Preference of CYP2C9 and CYP2C19. Biochem. Pharmacol. 1999; 57: 1297–1303
  • Yanev S., Kent U.M., Pandova B., Hollenberg P. Selective Mechanism-Based Inactivation of Cytochromes P-450 2B1 and P-450 2B6 by a Series of Xanthates. Drug Metab. Dispos. 1999; 27: 600–604
  • Thornton-Manning J., Appleton J.L., Gonzalez F.J., Yost G.S. Metabolism of 3-Methylindole by Vaccinia-Expressed P450 Enzymes: Correlation of 3-Methyleneindolenine Formation and Protein-, Binding. J. Pharmacol. Exp. Ther. 1999; 276: 21–29
  • Lanza D.L., Code E., Crespi C.L., Gonzalez F.J., Yost G.S. Specific Dehydrogenation of 3-Methylindole and Epoxidation of Naphthalene by Recombinant Human CYP2F1 Expressed in Lymphoblastoid Cells. Drug Metab. Dispos. 1999; 27: 798–803
  • Zheng Y.M., Fisher M.B., Yokotani N., Fujii-Kuriyama Y., Rettie A.E. Identification of a Meander Region Proline Residue Critical for Heme Binding to Cytochrome P450: Implications for the Catalytic Function of Human CYP4B1. Biochemistry 1998; 37: 12847–12851
  • Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Nortriptyline E-10-Hydroxylation In Vitro is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme-Inducing Drugs. J. Clin. Pharmacol. 1999; 39: 567–577
  • Mastyugin V., Aversa E., Bonazzi A., Vafaes C., Mieyal P., Schwartzman M.L. Hypoxia-Induced Production of 12-Hydroxyeicosanoids in the Corneal Epithelium: Involvement of a Cytochrome P-4504B1 Isoform. J. Pharmacol. Exp. Ther. 1999; 289: 1611–1619
  • Yamazaki H., Inoue K., Hashimoto M., Shimada T. Roles of CYP2A6 and CYP2B6 in Nicotine C-Oxidation by Human Liver Microsomes. Arch. Toxicol. 1999; 73: 65–70
  • Kharasch E.D., Hankins D.C., Jubert C., Thummel K.E., Taraday J.K. Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1. Drug Metab. Dispos. 1999; 27: 717–723
  • Roy P., Yu L.J., Crespi C.L., Waxman D.J. Development of a Substrate-Activity Based Approach to Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles. Drug Metab. Dispos. 1999; 27: 655–666, (a)
  • Zhou D., Lu Y., Steiner M.S., Dalton J.T. Cytochrome P-450 2C9 Sensitizes Human Prostate Tumor Cells to Cyclophosphamide Via A Bystander Effect. Antimicrob. Agents Chemother. 2000; 44: 2659–2663, (b)
  • Ludwig E., Schmid J., Beschke K., Ebner T. Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5′-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro. J. Pharmacol. Exp. Ther. 1999; 290: 1–8
  • Kobayashi K., Ishizuka T., Shimada N., Yoshimura Y., Kamijima K., Chiba K. Sertraline N-Demethylation is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro. Drug Metab. Dispos. 1999; 27: 763–766, (a)
  • Greenblatt D.J., von Moltke L.L., Harmatz J.S., Shader R.I. Human Cytochromes Mediating Sertraline Biotransformation: Seeking Attribution. J. Clin. Psychopharmacol. 1999; 19: 489–493, (b)
  • Abdel-Rahman S.M., Marcucci K., Boge T., Gotschall R.R., Kearns G.L., Leeder J.S. Potent Inhibition of Cytochrome P-450 2D6-Mediated Dextromethorphan O-Demethylation by Terbinafine. Drug Metab. Dispos. 1999; 27: 770–775
  • Zhao X.J., Koyama E., Ishizaki T. An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 776–785
  • Nakajima M., Ohyama K., Nakamura S., Shimada N., Yamazaki H., Yokoi T. Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes. Drug Metab. Dispos. 1999; 27: 792–797
  • Lund E.G., Guileyardo J.M., Russell D.W. cDNA Cloning of Cholesterol 24-Hydroxylase, A Mediator of Cholesterol Homeostasis in the Brain. Proc. Natl Acad. Sci. USA 1999; 96: 7238–7243
  • Yun C.H., Ahn T., Guengerich F.P., Yamazaki H., Shimada T. Phospholipase D Activity of Cytochrome P450 in Human Liver Endoplasmic Reticulum. Arch. Biochem. Biophys. 1999; 367: 81–88
  • Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., Wrighton S.A. Selectivity of the Multidrug Resistance Modulator, LY335979, for p-Glycoprotein and Effect on Cytochrome P-450 Activities. J. Pharmacol. Exp. Ther. 1999; 290: 854–862
  • Stevens J.C., Domanski T.L., Harlow G.R., White R.B., Orton E., Halpert J.R. Use of the Steroid Derivative RPR 106541 in Combination with Site-Directed Mutagenesis for Enhanced Cytochrome P-450 3A4 Structure/Function analysis. J. Pharmacol. Exp. Ther. 1999; 290: 594–602
  • May-Manke A., Kroemer H., Hempel G., Bohnenstengel F., Hohenlochter B., Blaschke G., Boos J. Investigation of The Major Human Hepatic Cytochrome P450 Involved in 4-Hydroxylation and N-Dechloroethylation of Trofosfamide. Cancer Chemother. Pharmacol. 1999; 44: 327–334
  • Mankowski D.C. The Role of CYP2C19 in the Metabolism of (+/−) bufuralol, the prototypic substrate of CYP2D6. Drug Metab. Dispos. 1999; 27: 1024–1028, (a)
  • Gelboin H.V., Krausz K.W., Shou M., Gonzalez F.J., Yang T.J. A Monoclonal Antibody Inhibitory to Human P450 2D6: A Paradigm for Use in Combinatorial Determination of Individual P450 Role in Specific Drug Tissue Metabolism. Pharmacogenetics 1997; 7: 469–477, (b)
  • Foster D.J., Somogyi A.A., Bochner F. Methadone N-Demethylation in Human Liver Microsomes: Lack of Stereoselectivity and Involvement of CYP3A4. Br. J. Clin. Pharmacol. 1999; 47: 403–412
  • Gieschen H., Salomon B., Hildebrand M. Metabolism of Three Different Sex Steroids in Genetically Enigineered V79-Cells Expressing Human CYP450-3A4. 9th International Conference on Cytochrome P450, Book of Abstracts, 23–27 July, 1995 Zurich, Switzerland. 1995; 237
  • Gieschen H., Hildebrand M., Salomon B. Metabolism of Two Beta-Carboline Derivatives in Genetically Enigineered V79-Cells Expressing Human CYP450-Enzymes. 9th International Conference on Cytochrome P450, Abstracts, 18–21 July 1994, Toronto, Canada. 1995; 249
  • Hashimoto K., Shirafuji T., Sekino H., Matsuoka O., Sekino H., Onnagawa O., Okamoto T., Kudo S., Azuma J. Interaction of Citrus Juices with Pranidipine, a New 1,4-Dihydropyridine Calcium Antagonist, in Healthy Subjects. Eur. J. Clin. Pharmacol. 1998; 54: 753–760, (a)
  • Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit Juice–Drug Interactions. Br. J. Clin. Pharmacol. 1998; 46: 101–110, (b)
  • Coller J.K., Somogyi A.A., Bochner F. Comparison of (S)-Mephenytoin and Proguanil Oxidation In Vitro: Contribution of Several CYP Isoforms. Br. J. Clin. Pharmacol. 1999; 48: 158–167
  • Hakkola J., Pelkonen O., Pasanen M., Raunio H. Xenobiotic-Metabolizing Cytochrome P450 Enzymes in the Human Feto-Placental Unit: Role in Intrauterine Toxicity. Crit. Rev. Toxicol. 1998; 28: 35–72
  • Zeldin D.C., Moomaw C.R., Jesse N., Tomer K.B., Beetham J., Hammock B.D., Wu S. Biochemical Characterization of The Human Liver Cytochrome P450 Arachidonic Acid Epoxygenase Pathway. Arch. Biochem. Biophys. 1996; 330: 87–96, (a)
  • Zeldin D.C., DuBois R.N., Falck J.R., Capdevila J.H. Molecular Cloning, Expression and Characterization of An Endogenous Human Cytochrome P450 Arachidonic Acid Epoxygenase Isoform. Arch. Biochem. Biophys. 1995; 322: 76–86, (b)
  • Rifkind A.B., Lee C., Chang T.K., Waxman D.J. Arachidonic Acid Metabolism by Human Cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective Oxygenation and Evidence for a Role for CYP2C Enzymes in Arachidonic Acid Epoxygenation in Human Liver Microsomes. Arch. Biochem. Biophys. 1995; 320: 380–389, (c)
  • Hakkola J., Pasanen M., Pelkonen O., Hukkanen J., Evisalmi S., Anttila S., Rane A., Mantyla M., Purkunen R., Saarikoski S., Tooming M., Raunio H. Expression of CYP1B1 in Human Adult and Fetal Tissues and Differential Inducibility of CYP1B1 and CYP1A1 by Ah Receptor Ligands in Human Placenta and Cultured Cells. Carcinogenesis 1997; 18: 391–397, (a)
  • Osawa Y., Higashiyama T., Toma Y., Yarborough C. Diverse Function of Aromatase and the N-Terminal Sequence Deleted Form. J. Steroid Biochem. Mol. Biol. 1997; 61: 117–126, (b)
  • Osawa Y., Higashiyama T., Shimizu Y., Yarborough C. Multiple Functions of Aromatase and the Active Site Structure. Aromatase is the Placental Estrogen 2-Hydroxylase. J. Steroid Biochem. Mol. Biol. 1993; 44: 469–480, (c)
  • Okubo K., Jinbo M., Toma Y., Shimizu Y., Yanaihara T. Aromatase and Estrogen 2-Hydroxylase Activities of Human Placental Microsomes in Pregnancy-Induced Hypertension. Endocr. J. 1996; 43: 363–368, (d)
  • McKillop D., Back D.J., McCormick A.D., Evans J.A., Tjia J. Preclinical and In Vitro Assessment of the Potential of D0870, An Antifungal Agent, For Producing Clinical Drug Interactions. Xanobiotica 1999; 29: 395–408
  • Liehr J.G., Ricci M.J., Jefcoate C.R., Hannigan E.V., Hokanson J.A., Zhu B.T. 4-Hydroxylation of Estradiol by Human Uterine Myometrium and Myoma Microsomes: Implications for the Mechanism of Uterine Tumorigenesis. Proc. Natl Acad. Sci. USA 1995; 92: 9220–9224
  • Tugnait M., Hawes E.M., McKay G., Eichelbaum M., Midha K.K. Characterization of the Human Hepatic Cytochromes P450 Involved in the In Vitro Oxidation of Clozapine. Chem. Biol. Interact. 1999; 118: 171–189, (a)
  • Buur-Rasmussen B., Brosen K. Cytochrome P450 and Therapeutic Drug Monitoring with Respect to Clozapine. Eur. Neuropsychopharmacol. 1999; 9: 453–459, (b)
  • Langouet S., Furge L.L., Kerriguy N., Nakamura K., Guillouzo A., Guengerich F.P. Inhibition of Human Cytochrome P450 Enzymes by 1,2-Dithiole-3-thione, Oltipraz and Its Derivatives, and Sulforaphane. Chem. Res. Toxicol. 2000; 13: 245–252
  • Baune B., Flinois J.P., Furlan V., Gimenez F., Taburet A.M., Becquemont L., Farinotti R. Halofantrine Metabolism in Microsomes in Man: Major Role of CYP 3A4 and CYP 3A5. J. Pharm. Pharmacol. 1999; 51: 419–426
  • Prior T.I., Chue P.S., Tibbo P., Baker G.B. Drug Metabolism and Atypical Antipsychotics. Eur. Neuropsychopharmacol. 1999; 9: 301–309
  • Minamiyama Y., Takemura S., Akiyama T., Imaoka S., Inoue M., Funae Y., Okada S. Isoforms of Cytochrome P450 on Organic Nitrate-Derived Nitric Oxide Release in Human Heart Vessels. FEBS Lett. 1999; 452: 165–169
  • Minoletti C., Dijols S., Dansette P.M., Mansuy D. Comparison of the Substrate Specificities of Human Liver Cytochrome P450s 2C9 and 2C18: Application to the Design of a Specific Substrate of CYP 2C18. Biochemistry 1999; 38: 7828–7836
  • Teyssier C., Guenot L., Suschetet M., Siess M.H. Metabolism of Diallyl Disulfide by Human Liver Microsomal Cytochromes P-450 and Flavin-Containing Monooxygenases. Drug Metab. Dispos. 1999; 27: 835–841
  • von Moltke L.L., Greenblatt D.J., Granda B.W., Grassi J.M., Schmider J., Harmatz J.S., Shader R.I. Nefazodone, Meta-Chlorophenylpiperazine, and Their Metabolites In Vitro: Cytochromes Mediating Transformation, and P450-3A4 Inhibitory Actions. Psychopharmacology (Berl) 1999; 145: 113–122
  • Christmas P., Ursino S.R., Fox J.W., Soberman R.J. Expression of the CYP4F3 Gene. Tissue-Specific Splicing and Alternative Promoters Generate High And Low k(m) Forms of Leukotriene b(4) Omega-Hydroxylase. J. Biol. Chem. 1999; 274: 21191–21199
  • Murphy S.E., Johnson L.M., Pullo D.A. Characterization of Multiple Products of Cytochrome P450 2A6-Catalyzed Cotinine Metabolism. Chem. Res. Toxicol. 1999; 12: 639–645
  • Shimada T., Gillam E.M., Oda Y., Tsumura F., Sutter T.R., Guengerich F.P., Inoue K. Metabolism of Benzo[a]pyrene to trans-7,8-Dihydroxy-7,8-Dihydrobenzo[a]pyrene by Recombinant Human Cytochrome P450 1B1 and Purified Liver Epoxide Hydrolase. Chem. Res. Toxicol. 1999; 12: 623–629
  • Roberts-Kirchhoff E.S., Crowley J.R., Hollenberg P.F., Kim H. Metabolism of Genistein by Rat and Human Cytochrome P450s. Chem. Res. Toxicol. 1999; 12: 610–616
  • Moreno R.L., Kent U.M., Hodge K., Hollenberg P.F. Inactivation of Cytochrome P450 2E1 by Benzyl Isothiocyanate. Chem. Res. Toxicol. 1999; 12: 582–587
  • Onderwater R.C., Venhorst J., Commandeur J.N., Vermeulen N.P. Design, Synthesis, and Characterization of 7-methoxy-4-(aminomethyl)coumarin as a Novel and Selective Cytochrome P450 2D6 Substrate Suitable for High-Throughput Screening. Chem. Res. Toxicol. 1999; 12: 555–559, (a)
  • Venhorst J., Onderwater R.C., Meerman J.H., Vermeulen N.P., Commandeur J.N. Evaluation of a Novel High-Throughput Assay for Cytochrome P450 2D6 Using 7-Methoxy-4-(aminomethyl)-Coumarin. Eur. J. Pharm. Sci. 2000; 12: 151–158, (b)
  • Venhorst J., Onderwater R.C., Meerman J.H., Commandeur J.N., Vermeulen N.P. Influence of N-Substitution of 7-Methoxy-4-(aminomethyl)-Coumarin on Cytochrome P450 Metabolism and Selectivity. Drug Metab. Dispos. 2000; 28: 1524–1532, (c)
  • Weber C., Schmitt R., Birnboeck H., Hopfgartner G., Eggers H., Meyer J., van Marle S., Viischer H.W., Jonkman J.H. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers. J. Clin. Pharmacol. 1999; 39: 703–714
  • Jones G., Ramshaw H., Zhang A., Cook R., Byford V., White J., Petkovich M. Expression and Activity of Vitamin D-Metabolizing Cytochrome P450s (CYP1alpha and CYP24) in Human Nonsmall Cell Lung Carcinomas. Endocrinology 1999; 140: 3303–3310, (a)
  • Fu G.K., Portale A.A., Miller W.L. Complete Structure of the Human Gene for the Vitamin D 1alpha-Hydroxylase, P450c1alpha. DNA Cell. Biol. 1997; 16: 1499–1507, (b)
  • Beckman M.J., Tadikonda P., Werner E., Prahl J., Yamada S., DeLuca H.F. Human 25-Hydroxyvitamin D3-24-Hydroxylase, A Multicatalytic Enzyme. Biochemistry 1996; 35: 8465–8472, (c)
  • Hewison M., Zehnder D., Bland R., Stewart P.M. 1alpha-Hydroxylase and the Action of Vitamin D. J. Mol. Endocrinol. 2000; 25: 141–148, (d)
  • Kobayashi K., Nakajima M., Oshima K., Shimada N., Yokoi T., Chiba K. Involvement of CYP2E1 as a Low-Affinity Enzyme in Phenacetin O-Deethylation in Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 860–865
  • Kostrubsky V.E., Ramachandran V., Venkataramanan R., Dorko K., Esplen J.E., Zhang S., Sinclair J.F., Wrighton S.A., Strom S.C. The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450. Drug Metab. Dispos. 1999; 27: 887–894, (a)
  • Kostrubsky V.E., Lewis L.D., Strom S.C., Wood S.G., Schuetz E.G., Schuetz J.D., Sinclair P.R., Wrighton S.A., Sinclair J.F. Induction of Cytochrome P4503A by Taxol in Primary Cultures of Human Hepatocytes. Arch. Biochem. Biophys. 1998; 355: 131–136, (b)
  • De Groene E.M., Salmon F.G.C., Verhoeckx K.C.M., Bogaards J.J.P., Van de Sant H.J.M. Cytochrome P450 Induction in Rat and Human Slices. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 230, (c)
  • Kumar G.N., Dykstra J., Roberts E.M., Jayanti V.K., Hickman D., Uchic J., Yao Y., Surber B., Thomas S., Granneman G.R. Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug–Drug Interaction. Drug Metab. Dispos. 1999; 27: 902–908
  • Imai T., Taketani M., Suzu T., Kusube K., Otagiri M. In Vitro Identification of the Human Cytochrome P-450 Enzymes Involved in the N-demethylation of Azelastine. Drug Metab. Dispos. 1999; 27: 942–946, (a)
  • Nakajima M., Nakamura S., Tokudome S., Shimada N., Yamazaki H., Yokoi T. Azelastine N-Demethylation by Cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in Human Liver Microsomes: Evaluation of Approach to Predict the Contribution of Multiple CYPs. Drug Metab. Dispos. 1999; 27: 1381–1391, (b)
  • Shimada T., Watanabe J., Kawajiri K., Sutter T.R., Guengerich F.P., Gillam E.M., Inoue K. Catalytic Properties of Polymorphic Human Cytochrome P450 1B1 Variants. Carcinogenesis 1999; 20: 1607–1614, (a)
  • Yun C.H., Shimada T., Guengerich F.P. Purification and Characterization of Human Liver Microsomal Cytochrome P-450 2A6. Mol. Pharmacol. 1991; 40: 679–685, (b)
  • Kostrubsky V.E., Strom S.C., Wood S.G., Wrighton S.A., Sinclair P.R., Sinclair J.F. Ethanol and Isopentanol Increase CYP3A and CYP2E in Primary Cultures of Human Hepatocytes. Arch Biochem. Biophys. 1995; 322: 516–520
  • Sawada M., Kitamura R., Norose T., Kitada M., Itahashi K., Kamataki T. Metabolic Activation of Aflatoxin B1 by Human Placental Microsomes. J. Toxicol. Sci. 1993; 18: 129–132
  • Agren J., Terelius Y. In Vitro Metabolism of Clomethiazole (ZendraR) by Microsomes From Insect Cells and East Cells Expressing Human P450 Isozymes. ISSX Proceedings, 7th European ISSX Meeting, Budapest, Hungary, Aug 22–26, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 14: 49
  • Lamb D.C., Kelly D.E., Waterman M.R., Stromstedt M., Rozman D., Kelly S.L. Characteristics of the Heterologously Expressed Human Lanosterol 14alpha-Demethylase (Other Names: P45014DM, CYP51, P45051) and Inhibition of the Purified Human and Candida Albicans CYP51 with Azole Antifungal Agents. Yeast 1999; Vol. 15: 755–763, (a)
  • Lamb D.C., Kelly D.E., Baldwin B.C., Kelly S.L. Differential Inhibition of Human CYP3A4 and Candida Albicans CYP51 with Azole Antifungal Agents. Chem. Biol. Interact. 2000; 125: 165–175, (b)
  • Pang S., Cao J.Q., Katz B.H., Hayes C.L., Sutter T.R., Spink D.C. Inductive and Inhibitory Effects of Non-Ortho-Substituted Polychlorinated Biphenyls on Estrogen Metabolism and Human Cytochromes P450 1A1 and 1B1. Biochem. Pharmacol. 1999; 58: 29–38
  • Bort R., Mace K., Boobis A., Gomez-Lechon M.J., Pfeifer A., Castell J. Hepatic Metabolism of Diclofenac: Role of Human CYP in the Minor Oxidative Pathways. Biochem. Pharmacol. 1999; 58: 787–796
  • Ciolino H.P., Yeh G.C. Inhibition of Aryl Hydrocarbon-Induced Cytochrome P-450 1A1 Enzyme Activity and CYP1A1 Expression by Resveratrol. Mol. Pharmacol. 1999; 56: 760–767, (a)
  • Chun Y.J., Kim M.Y., Guengerich F.P. Resveratrol is A Selective Human Cytochrome P450 1A1 Inhibitor. Biochem. Biophys. Res. Commun. 1999; 262: 20–24, (b)
  • Jones D.R., Gorski J.C., Hamman M.A., Mayhew B.S., Rider S., Hall S.D. Inhibition of Cytochrome P-450 3A Activity is Due to Metabolite Intermediate Complex Formation. J. Pharmacol. Exp. Ther. 1999; 290: 1116–1125
  • Azuma R., Komuro M., Korsch B.H., Andre J.C., Onnagawa O., Black S.R., Mathews J.M. Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease. Xenobiotica 1999; 29: 747–762
  • Hamaoka N., Oda Y., Hase I., Mizutani K., Nakamoto T., Ishizaki T., Asada A. Propofol Decreases the Clearance of Midazolam by Inhibiting CYP3A4: an In Vivo and In Vitro Study. Clin. Pharmacol. Ther. 1999; 66: 110–117
  • Maenpaa J., Hall S.D., Ring B.J., Strom S.C., Wrighton S.A. Human Cytochrome P450 3A (CYP3A) Mediated Midazolam Metabolism: The Effect of Assay Conditions and Regioselective Stimulation by alpha-Naphthoflavone, Terfenadine and Testosterone. Pharmacogenetics 1998; 8: 137–155
  • Engst W., Landsiedel R., Hermersdorfer H., Doehmer J., Glatt H. Benzylic Hydroxylation of 1-Methylpyrene and 1-Ethylpyrene by Human and Rat Cytochromes P450 Individually Expressed in V79 Chinese Hamster Cells. Carcinogenesis 1998; 20: 1777–1785
  • Coleman S., Liu S., Linderman R., Hodgson E., Rose R.L. In Vitro Metabolism of Alachlor by Human Liver Microsomes and Human Cytochrome P450 Isoforms. Chem. Biol. Interact. 1999; 122: 27–39
  • Sonneveld E., van den Brink C.E., Tertoolen L.G., van der Burg B., van der Saag P.T. Retinoic Acid Hydroxylase (CYP26) is A Key Enzyme in Neuronal Differentiation of Embryonal Carcinoma Cells. Dev. Biol. 1999; 213: 390–404
  • Nadin L., Murray M. Participation of CYP2C8 in Retinoic Acid 4-Hydroxylation in Human Hepatic Microsomes. Biochem. Pharmacol. 1999; 58: 1201–1208
  • Domanski T.L., Schultz K.M., Roussel F., Stevens J.C., Halpert J.R. Structure-Function Analysis of Human Cytochrome P-450 2B6 Using a Novel Substrate, Site-Directed Mutagenesis, and Molecular Modeling. J. Pharmacol. Exp. Ther. 1999; 290: 1141–1147, (a)
  • Stevens J.C., White R.B., Hsu S.H., Martinet M. Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401. J. Pharmacol. Exp. Ther. 1997; 282: 1389–1395, (b)
  • Ishizaki T., Horai Y. Review Article: Cytochrome P450 and the Metabolism of Proton Pump Inhibitors—Emphasis on Rabeprazole. Aliment Pharmacol. Ther. 1999; 3: 27–36, (a)
  • Lew E.A. Review Article: Pharmacokinetic Concerns in the Selection of Anti-Ulcer Therapy. Aliment Pharmacol Ther. 1999; 5: 11–16, (b)
  • VandenBranden M., Ring B.J., Binkley S.N., Wrighton S.A. Interaction of Human Liver Cytochromes P450 In Vitro with LY307640, A Gastric Proton Pump Inhibitor. Pharmacogenetics 1996; 6: 81–91, (c)
  • Lucas D., Ferrara R., Gonzalez E., Bodenez P., Albores A., Manno M., Berthou F. Chlorzoxazone, A Selective Probe for Phenotyping CYP2E1 in Humans. Pharmacogenetics 1999; 9: 377–388
  • Shin J.G., Soukhova N., Flockhart D.A. Effect of Antipsychotic Drugs on Human Liver Cytochrome P-450 (CYP) Isoforms In Vitro: Preferential Inhibition of CYP2D6. Drug Metab. Dispos. 1999; 27: 1078–1084
  • Becquemont L., Mouajjah S., Escaffre O., Beaune P., Funck-Brentano C., Jaillon P. Cytochrome P-450 3A4 and 2C8 are Involved in Zopiclone Metabolism. Drug Metab. Dispos. 1999; 27: 1068–1073
  • Vickers A.E., Sinclair J.R., Zollinger M., Heitz F., Glanzel U., Johanson L., Fischer V. Multiple Cytochrome P-450s Involved in the Metabolism of Terbinafine Suggest a Limited Potential for Drug–Drug Interactions. Drug Metab. Dispos. 1999; 27: 1029–1038
  • Grace J.M., Skanchy D.J., Aguilar A.J. Metabolism of Artelinic Acid to Dihydroqinqhaosu by Human Liver Cytochrome P4503A. Xenobiotica 1999; 29: 703–717
  • Wild M.J., McKillop D., Butters C.J. Determination of the Human Cytochrome P450 Isoforms Involved in the Metabolism of Zolmitriptan. Xenobiotica 1999; 29: 847–857
  • Taguchi K., Konishi T., Nishikawa H., Kitamura S. Identification of Human Cytochrome P450 Isoforms Involved in the Metabolism of S-2-[4-(3-Methyl-2-thienyl)phenyl]propionic Acid. Xenobiotica 1999; 29: 899–907
  • Shiraga T., Kaneko H., Iwasaki K., Tozuka Z., Suzuki A., Hata T. Identification of Cytochrome P450 Enzymes Involved in the Metabolism of Zotepine, an Antipsychotic Drug, in Human Liver Microsomes. Xenobiotica 1999; 29: 217–229
  • Teiber J.F., Hollenberg P.F. Metabolism of N-Nitrosodi-n-Propylamine by Human Cytocrome P450s. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 59, (a)
  • Teiber J.F., Hollenberg P.F. Identification of the Human Liver Microsomal Cytochrome P450s Involved in the Metabolism of N-Nitrosodi-n-propylamine. Carcinogenesis 2000; 21: 1559–1566, (b)
  • Sai Y., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V. An Inhibitory Monoclonal Antibody to Human Cytochrome P450 2A6 Defines Its Role in the Metabolism of Coumarin, 7-ethoxycoumarin and 4-nitroanisole in Human Liver. Pharmacogenetics 1999; 9: 229–237, (a)
  • Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: A Human Coumarin 7-Hydroxylase. Toxicology 2000; 144: 139–147, (b)
  • Reed J.R., Hollenberg P.F. Effects of Cytochrome B5 on the Metabolism of Expressed Human P450 2B6: A Comparison with Rat P450 2B1 and Rabbit P450 2B4. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24-28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 61
  • Nakamura K., Yoshihara S., Shimada T., Guengerich F.P. Selection and Characterization of Human Cytochrome P450 1B1 Mutants by Random Mutagenesis. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 62
  • Moreno R.L., Hollenberg P.F. Differential Effects of Naturally Occuring Isothiocyanates on the Activity of Cytochrome P450 2E1 and the Mutant P450 2E1 T303A. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 62
  • Chun J., Kent U.M., Moss R.M., Sayre L.M., Hollenberg P.F. Mechanism-Based Inactivation of Cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. Drug Metab. Dispos. 2000; 28: 905–911
  • Soohoo D., Natta K.L.V., Carlson T.J. Potent and Selective Mechanism-Based Inhibition of CYP2D6 by RO115-1954. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct. 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 66
  • Kensler T.W., Groopman J.D., Sutter T.R., Curphey T.J., Roebuck B.D. Development of Cancer Chemopreventive Agents: Oltipraz as a Paradigm. Chem. Res. Toxicol. 1999; 12: 113–126
  • Ozarowski J., Zhang J., Augustin B., Testino T., Myers T., Arrendale R., Hui J., Thurston A. The Inhibitory Interactions of Fluvoxamine Maleate with Cytochrome P450 Isozymes in Human Livers. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 96, (a)
  • Olesen O.V., Linnet K. Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism. J. Clin. Psychopharmacol. 2000; 20: 35–42, (b)
  • Mills D., Kent U.M. Hollenberg Mechanism-BasediInactivation of Cytochrome P450 2B6 by 17alpha-EthynylestradioleI. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 97
  • Morris C.R., Mirvish S.S. Diallyl Sulfide Inhibition of Methylamylnitrosamine Metabolism by Individual P450s. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 98, (a)
  • Chen S.C., Wang X., Xu G., Zhou L., Vennerstrom J.L., Gonzalez F., Gelboin H.V., Mirvish S.S. Depentylation of [3H-pentyl]Methyl-n-amylnitrosamine by Rat Esophageal and Liver Microsomes and by Rat and Human Cytochrome P450 Isoforms. Cancer Res. 1999; 59: 91–98, (b)
  • Sridar C., Kent U.M., Hollenberg P.F. Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome P450 2B6. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 99
  • Jushchyshyn M.I., Kent U.M. Hollenberg Mechanism-Based Inactivation of Human P450 2B6 by Phencyclidine. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 100
  • Grubb M.F., Diamond S., Christ D.D. Inhibition of Human CYP Isozymes by Efavirenz and Its Metabolite 8-Hydroxyefavirenz. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 100
  • Diamond S., Christ D.D. Mechanism-Based Inhibition of Rhesus Monkey and Human CYP3A by DMP777. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 101
  • Desta Z., Soukhova N.V., Flockhart D.A. In Vitro Inhibition of Cytochrome P450s by Isoniazid: Potent Effect on CYP2C19 and CYP3A. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 102, (a)
  • Desta Z., Soukhova N.V., Flockhart D.A. Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 2001; 45(2)382–392, (b)
  • Dehal S.S., Kupfer D. CYP2D6 Catalyzes Tamoxifen 4-Hydroxylation in Human Liver. Cancer Res. 1997; 57(16)3402–3406, (a)
  • Dehal S.S., Rodriguez-Velenzuela C.S., Brodie A.M.H., Kupfer D. 4-Hydroxyandrostenedione (4-OH-A), The Aromatase Inactivator, Inhibits Tamoxifen Metabolism by Human Hepatic Cytochrome P450 3A4 and 2D6: Potential for Interaction of Tamoxifen and 4-OH-A Incombinedanti-Breast Cancer Therapy. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 103, (b)
  • Farina P., Tajana A., Barchielli M., Russell A.L., Coutts J. Effect of Lercanidipine on CYP2D6 and CYP3A4 Activities: In Vitro/In Vivo Correlation. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 104
  • He K., Woolf T.F., Kindt E.K., Fielder A., Talaat R.E. Troglitazone Quinone Formation Catalyzed by Human and Rat CYP3A4: An Atypical P450 Oxidation Reaction15. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 104, (a)
  • Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., Yokoi T. Oxidation of Troglitazone to a Quinone-Type Metabolite Catalyzed by Cytochrome P-450 2C8 and P-450 3A4 in Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 1260–1266, (b)
  • Kharasch E.D., Hankins D.C., Taraday J.K. Single-Dose Methoxsalen Effects on Human Cytochrome P-450 2A6 Humans. Drug Metab. Dispos. 2000; 28: 28–33, (a)
  • Maenpaa J., Sigusch H., Raunio H., Syngelma T., Vuorela P., Vuorela H., Pelkonen O. Differential Inhibition of Coumarin 7-Hydroxylase Activity in Mouse and Human Liver Microsomes. Biochem. Pharmacol. 1993; 45: 1035–1042, (b)
  • Zhao G., Pegram R.A., Harrison R., Allis J.W. Recombinant Human CYP2E1 Metabolizes Bromodichloromethane In Vitro. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 108
  • Zhang J., Ozarowski J., Augustin B., Testino T., Myers T., Arrendale R., Hui J., Thurston A. In Vitro Biotransformation of Fluvoxamine Maleate: Identification of Cytochrome P450 2D6 as the Catalyzing Isozyme in Human Hepatic Microsomes. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 108
  • Yu E., Heyn H., Godin C.S., Chovan J.P. In Vitro Metabolism of Modafinil by Human Liver Microsomes. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 109
  • VandenBranden M., Nallani S.C., Wrighton S.A., Jensen C.B. The Effect of Macrolide LY274301 on Drug Metabolizing Enzymes in Primary Monolayer Cultures of Human Hepatocytes. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 111
  • Thompson T.N., Burmaster S.D., Emmons G.T., Geary J.L., Gross G., Weihl R., Shen D.D. In Vitro Characterization of the Cytochrome P450 Isoenzymes Involved in the Metabolism of M100907, A Novel Anti-Psychotic Agent. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 113
  • Sai Y., Rettie A.E., Thompson S.J., Hankins D., Kharasch E.D. Anaerobic and Aerobic Metabolism of Halothane by Purified CYP2A6 In Vitro. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 13, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 113, (a)
  • Kharasch E.D., Hankins D.C., Fenstamaker K., Cox K. Human Halothane Metabolism, Lipid Peroxidation, and Cytochromes P(450)2A6 and P(450)3A4. Eur. J. Clin. Pharmacol. 2000; 55: 853–859, (b)
  • Rossulek M.I., O-Donnell J.P., Khojasteh S.C. Characterization of Human Cytochrome P450 Involved in Oxidation of CP-195543, A Leukotriene B4 Receptor Antagonis. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 114
  • Madden S., Gentile D., Simpson A., Best S., Oxford J. In Vitro Metabolism Studies with Bupivicaine and Its S-Enantiomer Levobupivacain. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 116, (a)
  • Gantenbein M., Attolini L., Bruguerolle B., Villard P.H., Puyoou F., Durand A., Lacarelle B., Hardwigsen J., Le-Treut Y.P. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab. Dispos. 2000; 28: 383–385, (b)
  • Jacobsen W., Serkova N., Hallensleben K., Sewing K., Benet L.Z., Christians U. In Vitro Metabolism of The Novel Immunsuppressant SDZ-RAD and Comparison with Rapamycin. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 117
  • Huang Z., Roy P., Waxman D.J. Role of Human Liver Microsomal CYP3A4 and CYP2B6 in Catalyzing N-Dechloroethylation of Cyclophosphamide and Ifosfamide. Biochem. Pharmacol. 2000; 59: 961–972
  • Grubb M.F., Rao G.P., Gan L.L. Role of CYP2B6 and CYP3A4 In Vitro Human Metabolism of Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 120
  • Grimm S.W., Stams K., Bui K. In Vitro Prediction of Metabolic Drug Interactions for Seroquel (Quetiapine). ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 121
  • Dong H., Haining R.L., Thummel K.E., Rettie A.E., Nelson S.D. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 122, (a)
  • Chen W., Koenigs L.L., Thompson S.J., Peter R.M., Rettie A.E., Trager W.F., Nelson S.D. Oxidation of Acetaminophen to its Toxic Quinone Imine and Nontoxic Catechol Metabolites by Baculovirus-Expressed and Purified Human Cytochromes P450 2E1 and 2A6. Chem. Res. Toxicol. 1998; 11: 295–301, (b)
  • Dong H., Haining R.L., Thummel K.E., Rettie A.E., Nelson S.D. InVolvement of Human Cytochrome P450 2D6 in the Bioactivation of Acetaminophen. Drug Metab. Dispos. 2000; 28: 1397–1400, (c)
  • Richards L.E., Du Y.A., Liang L., Ribadeneira M., Hu H., Emm T.A., Mulvana D., Gan L. Identification of Trace DMP 543 Urinary Metabolites in Humans Through the Use of In Vitro Human Metabolism Systems and LC/MS/MS/ Techniques. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 123
  • Tracy T.S., Rettie A.E., Haining R.L., Goldstein J.A. Metabolism of Flurbiprofen, Naproxen and Piroxicam by Cytochrome P450 2C Isoforms: CYP2C9 Selectivity, Atypical Kinetics and Effect of Allelic Variants on the Kinetic Profile. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 131
  • Harr J.E.V., Liang B., Shetty B.V., Lee C.A. Metabolism and Pharmacokinetics of AG7088, A Rhinovirus Protease Inhibitor, in Various Animal Species. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 164
  • Kharasch E.D., Russell M., Jubert C., Thummel K., Langdale L., Eubank W., Senn T., Joseph T. Validation of Alfentanil as a Noninvasive CYP3A4 Probe. Applications of In Vitro-In Vivo Modeling. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 178, (a)
  • Labroo R.B., Thummel K.E., Kunze K.L., Podoll T., Trager W.F., Kharasch E.D. Catalytic Role of Cytochrome P4503A4 in Multiple Pathways of Alfentanil Metabolism. Drug Metab. Dispos. 1995; 23: 490–496, (b)
  • Murphy S.E., Johnson L.A., Hochalter J.B., Hecht S.S. Multiple Products of P450 2A6 Catalyzed Nicotine and Cotinine Metabolism. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 197, (a)
  • Hecht S.S., Hochalter J.B., Villalta P.W. Murphy SE2′-Hydroxylation of Nicotine by Cytochrome P450 2A6 and Human Liver Microsomes: Formation of a Lung Carcinogen Precursor. Proc. Natl Acad. Sci. USA 2000; 97: 12493–12497, (b)
  • Schrag M.L., Wienkers L.C. Interactions with CYP3A4 are Substrate Dependent. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct. 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 198
  • Jayyosi Z., Muc M., Gallagher M., Toutain H., Stevens J., Kelley M. Covalent Binding of Troglitazone and Other Members of the Thiazolidinedione Family to Human Liver Microsomes, Implications for Case of Idiosyncratic Hepatotoxicity. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 200
  • Silva J.M., Day S., Chauret N., Nicoll-Griffith D. Fluorescent Probe for CYP3A Activity in Human Hepatocytes Cultured on a 96-well Plate. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 204
  • Rendic S., Nolteernsting E., Schanzer W. Biotransformation of 5alpha- and 5beta-androstane-3alpha, 17beta-diol by Human CYP3A4 and 2C19 Enzymes. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Oct 24–28, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 15: 236
  • Nakajima M., Kobayashi K., Oshima K., Shimada N., Tokudome S., Chiba K., Yokoi T. Activation of Phenacetin O-Deethylase Activity by Alpha-Naphthoflavone in Human Liver Microsomes. Xenobiotica 1999; 29: 885–898
  • Nakamura A., Hirota T., Morino A., Imaoka S., Funae Y., Yamamoto Y., Tasaki T., Masuda M., Kazusaka A., Fujita S. Cytochrome P450 Isoforms Responsible for the N-Deethylation and Cyclohexane-Hydroxylation of NS-21. Xenobiotica 1999; 29: 243–252
  • Iwatsubo T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C.E., Tyson C.A., Yokoi T., Kamataki T., Sugiyama Y. Prediction of In Vivo Hepatic Metabolic Clearance of YM796 from In Vitro Data by Use of Human Liver Microsomes and Recombinant P-450 Isozymes. J. Pharmacol. Exp. Ther. 1997; 282: 909–919
  • King L.C., Adams L., Allison J., Kohan M.J., Nelson G., Desai D., Amin S., Ross J.A. A Quantitative Comparison of Dibenzo[a,l]pyrene-DNA Adduct Formation by Recombinant Human Cytochrome P450 Microsomes. Mol. Carcinog. 1999; 26: 74–82, (a)
  • Shou M., Krausz K.W., Gonzalez F.J., Gelboin H.V. Metabolic Activation of the Potent Carcinogen Dibenzo[a,l]pyrene by Human Recombinant Cytochromes P450, Lung and Liver Microsomes. Carcinogenesis 1996; 17: 2429–2433, (b)
  • Hong J.W., Wang Y.Y., Bondoc F.Y., Lee M., Yang C.S., Hu W.Y., Pan J. Metabolism of Methyl tert-butyl ether and Other Gasoline Ethers by Human Liver Microsomes and Heterologously Expressed Human Cytochromes P450: Identification of CYP2A6 as A Major Catalyst. Toxicol. Appl. Pharmacol. 1999; 160: 43–48
  • Tuvesson H., Gunnarsson P.O., Seidegard J. Metabolism of Tauromustine in Liver and Lung Microsomes from Various Species. Xenobiotica 1999; 29: 783–792
  • Furukori H., Kondo T., Yasui N., Otani K., Tokinaga N., Nagashima U., Kaneko S., Inoue Y. Effects of Itraconazole on the Steady-State Plasma Concentrations of Bromperidol and Reduced Bromperidol in Schizophrenic Patients. Psychopharmacology (Berl) 1999; 145: 189–192
  • Roy P., Tretyakov O., Wright J., Waxman D.J. Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6, Favorable metabolic properties of R-Enantiomer. Drug Metab. Dispos. 1999; 27: 1309–1318
  • Masubuchi Y., Horie T. Mechanism-Based Inactivation of Cytochrome P450s 1A2 and 3A4 by Dihydralazine in Human Liver Microsomes. Chem. Res. Toxicol. 1999; 12: 1028–1032
  • Sasaki J.C., Arey J., Eastmond D.A., Parks K.K., Phousongphouang P.T., Grosovsky A.J. Evidence for Oxidative Metabolism in the Genotoxicity of the Atmospheric Reaction Product 2-Nitronaphthalene in Human Lymphoblastoid Cell Lines. Mutat. Res. 1999; 445: 113–125
  • Xu Z.H., Wang W., Zhao X.J., Huang S.L., Zhu B., He N., Shu Y., Liu Z.Q., Zhou H.H. Evidence for Involvement of Polymorphic CYP2C19 and 2C9 in the N-Demethylation of Sertraline in Human Liver Microsomes. Br. J. Clin. Pharmacol. 1999; 48: 416–423
  • Sinclair P.R., Gorman N., Tsyrlov I.B., Fuhr U., Walton H.S., Sinclair J.F. Uroporphyrinogen Oxidation Catalyzed by Human Cytochromes P450. Drug Metab. Dispos. 1998; 26: 1019–1025
  • Baldwin S.J., Clarke S.E., Chenery R.J. Characterization of the Cytochrome P450 Enzymes Involved in the In Vitro Metabolism of Rosiglitazone. Br. J. Clin. Pharmacol. 1999; 48: 424–432
  • Emery M.G., Jubert C., Thummel K.E., Kharasch E.D. Duration of Cytochrome P-450 2E1 (CYP2E1) Inhibition and Estimation of Functional CYP2E1 Enzyme Half-Life After Single-Dose Disulfiram Administration in Humans. J. Pharmacol. Exp. Ther. 1999; 291: 213–219
  • Wienkers L.C., Allievi C., Hauer M.J., Wynalda M.A. Cytochrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes. Drug Metab. Dispos. 1999; 27: 1334–1340
  • Shimada T., Tsumura F., Yamazaki H. Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone With Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes. Drug Metab. Dispos. 1999; 27: 1274–1280
  • Suzuki A., Iida I., Tanaka F., Akimoto M., Fukushima K., Tani M., Ishizaki T., Chiba K. Identification of Human Cytochrome P-450 Isoforms Involved in Metabolism of R(+)- and S(−)-Gallopamil: Utility of In Vitro Disappearance Rate. Drug Metab. Dispos. 1999; 27: 1254–1259
  • Adas F. Requirement for Omega and (Omega-1)-Hydroxylations of Fatty Acids by Human Cytochromes P450 2E1 and 4A11. J. Lipid Res. 1999; 40: 1990–1997, (a)
  • Adas F., Berthou F., Salaun J.P., Dreano Y., Amet Y. Interspecies Variations in Fatty Acid Hydroxylations Involving Cytochromes P450 2E1 and 4A. Toxicol. Lett. 1999; 110: 43–55, (b)
  • Olesen O.V., Linnet K. Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes. Pharmacology 1999; 59: 298–309, (a)
  • von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Duan S.X., Fogelman S.M., Harmatz J.S., Shader R.I. Citalopram and Desmethylcitalopram In Vitro: Human Cytochromes Mediating Transformation, and Cytochrome Inhibitory Effects. Biol. Psychiatry 1999; 46: 839–849, (b)
  • Gillam E.M., Aguinaldo A.M., Notley L.M., Kim D., Mundkowski R.G., Volkov A.A., Arnold F.H., Soucek P., DeVoss J.J., Guengerich F.P. Formation of Indigo by Recombinant Mammalian Cytochrome P450. Biochem. Biophys. Res. Commun. 1999; 265: 469–472
  • Martinez C., Albet C., Agundez J.A., Herrero E., Carrillo J.A., Marquez M., Benitez J., Ortiz J.A. Comparative In Vitro and In Vivo Inhibition of Cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-Receptor Antagonists. Clin. Pharmacol. Ther. 1999; 65: 369–376
  • Peyronneau M.A., Delaforge M., Riviere R., Renaud J.P., Mansuy D. High Affinity of Ergopeptides for Cytochromes P450 3A. Importance of Their peptide moiety for P450 Recognition and Hydroxylation of Bromocriptine. Eur. J. Biochem. 1994; 223: 947–956
  • Ball S.E., Maurer G., Zollinger M., Ladona M., Vickers A.E. Characterization of the Cytochrome P-450 Gene Family Responsible for the N-Dealkylation of the Ergot Alkaloid CQA 206–291 in Humans. Drug Metab. Dispos. 1992; 20: 56–63
  • Muralidharan G., Cooper J.K., Hawes E.M., Korchinski E.D., Midha K.K. Quinidine Inhibits the 7-Hydroxylation of Chlorpromazine in Extensive Metabolisers of Debrisoquine. Eur. J. Clin. Pharmacol. 1996; 50: 121–128, (a)
  • Yoshii K., Kobayashi K., Tsumuji M., Tani M., Shimada N., Chiba K. Identification of Human Cytochrome P450 Isoforms Involved in the 7-Hydroxylation of Chlorpromazine by Human Liver Microsomes. Life Sci. 2000; 67: 175–184, (b)
  • Tracy T.S., Korzekwa K.R., Gonzalez F.J., Wainer I.W. Cytochrome P450 Isoforms Involved in Metabolism of the Enantiomers of Verapamil and Norverapamil. Br. J. Clin. Pharmacol. 1999; 47: 545–552, (a)
  • Busse D., Cosme J., Beaune P., Kroemer H.K., Eichelbaum M. Cytochromes of the P450 2C Subfamily Are the Major Enzymes Involved in the O-Demethylation of Verapamil in Humans. Naunyn Schmiedebergs Arch. Pharmacol. 1995; 353: 116–121, (b)
  • Kroemer K., Gautier J.C., Beaune P., Henderson C., Wolf C.R., Eichelbaum M. Identification of P450 Enzymes Involved in Metabolism of Verapamil in Humans. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 348: 332–337, (c)
  • Fuhr U., Woodcock B.G., Siewert M. Verapamil and Drug Metabolism by the Cytochrome P450 Isoform CYP1A2. Eur. J. Clin. Pharmacol. 1992; 42: 463–464, (d)
  • Zhang L., Fitzloff J.F., Cook C.S. Comparative In Vitro Stereoselectivity of Verapamil N-Delakylation With CYP3A4 and CYP3A12. Drug Metab. Rev. 2000; 32(Suppl. 2)249, (e)
  • Crespi C.L., Penman B.W., Steimel D.T., Smith T., Yang C.S., Sutter T.R. Development of a Human Lymphoblastoid Cell Line Constitutively Expressing Human CYP1B1 cDNA: Substrate Specificity With Model Substrates and Promutagens. Mutagenesis 1997; 12(2)83–89, (a)
  • Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., Waxman D.J. Human Cytochrome P4502B6: Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation. Drug Metab. Dispos. 1997; 25: 985–993, (b)
  • Smith T.J., Guo Z., Gonzalez F.J., Guengerich F.P., Stoner G.D., Yang C.S. Metabolism of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Human Lung and Liver Microsomes and Cytochromes P-450 Expressed in Hepatoma Cells. Cancer Res. 1992; 52: 1757–1763, (c)
  • Abdel-Rahman S.Z., Salama S.A., Au W.W., Hamada F.A. Role of Polymorphic CYP2E1 and CYP2D6 Genes in NNK-Induced Chromosome Aberrations in Cultured Human Lymphocytes. Pharmacogenetics 2000; 10: 239–249, (d)
  • Ciolino H.P., Yeh G.C. The Steroid Hormone Dehydroepiandrosterone Inhibits CYP1A1 Expression In Vitro by a Post-Transcriptional Mechanism. J. Biol. Chem. 1999; 274: 35186–35190
  • Mancy A., Antignac M., Minoletti C., Dijols S., Mouries V., Ha Duong N.T., Battioni P., Dansette P.M., Mansuy D. Diclofenac and Its Derivatives as Tools for Studying Human Cytochromes P450 Active Sites: Particular Efficiency and Regioselectivity of P450 2Cs. Biochemistry 1999; 38: 14264–14270
  • Oda Y., Mizutani K., Hase I., Nakamoto T., Hamaoka N., Asada A. Fentanyl Inhibits Metabolism of Midazolam: Competitive Inhibition of CYP3A4 In Vitro. Br. J. Anaesth. 1999; 82: 900–903
  • Backman J.T., Wang J.S., Wen X., Kivisto K.T., Neuvonen P.J. Mibefradil But Not Isradipine Substantially Elevates the Plasma Concentrations of the CYP3A4 Substrate Triazolam. Clin. Pharmacol. Ther. 1999; 66: 401–407
  • Rowland K., Ellis S.W., Lennard M.S., Tucker G.T. Variable Contribution of CYP2D6 to the N-Dealkylation of S-(−)-Propranolol by Human Liver Microsomes. Br. J. Clin. Pharmacol. 1996; 42: 390–393
  • Reid J.M., Kuffel M.J., Miller J.K., Rios R., Ames M.M. Metabolic Activation of Dacarbazine by Human Cytochromes P450: the Role of CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res. 1999; 5: 2192–2197
  • Ciolino H.P., Wang T.T., Yeh G.C. Diosmin and Diosmetin Are Agonists of the Aryl Hydrocarbon Receptor That Differentially Affect Cytochrome P450 1A1 Activity. Cancer Res. 1998; 58: 2754–2760
  • Ciolino H.P., Daschner P.J., Yeh G.C. Dietary Flavonols Quercetin and Kaempferol Are Ligands of the Aryl Hydrocarbon Receptor That Affect CYP1A1 Transcription Differentially. Biochem. J. 1999; 340: 715–722
  • Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., Yokoi T. Inhibitory Effects of Amiodarone and Its N-Deethylated Metabolite on Human Cytochrome P450 Activities: Prediction of In Vivo Drug Interactions. Br. J. Clin. Pharmacol. 2000; 49: 244–253
  • Katoh M., Nakajima M., Shimada N., Yamazaki H., Yokoi T. Inhibition of Human Cytochrome P450 Enzymes by 1,4-Dihydropyridine Calcium Antagonists: Prediction of In Vivo drug–drug Interactions. Eur. J. Clin. Pharmacol. 2000; 55: 843–852
  • Nakajima M., Suzuki R., Yamaji R., Takashima H., Shimada N., Yamazaki H., Yokoi T. Isoform Selective Inhibition and Inactivation of Human Cytochrome P450s by Methylenedioxyphenyl Compounds. Xenobiotica 1999; 29: 1191–1202
  • Kobayashi K., Abe S., Nakajima M., Shimada N., Tani M., Chiba K., Yamamoto T. Role of Human CYP2B6 in S-Mephobarbital N-Demethylation. Drug Metab. Dispos. 1999; 27: 1429–1433
  • Lu Y.F., Santostefano M., Cunningham B.D., Threadgill M.D., Safe S. Substituted Flavones as Aryl Hydrocarbon (Ah) Receptor Agonists and Antagonists. Biochem. Pharmacol. 1996; 51: 1077–1087
  • Lu Y.F., Santostefano M., Cunningham B.D., Threadgill M.D., Safe S. Identification of 3′-methoxy-4′-Nitroflavone as a Pure Aryl Hydrocarbon (Ah) Receptor Antagonist and Evidence for More Than One Form of The Nuclear Ah Receptor in MCF-7 Human Breast Cancer Cells. Arch. Biochem. Biophys. 1995; 316: 470–477
  • Reiners J.J., Jr, Lee J.W., Jr, Clift R.E., Jr, Dudley D.T., Jr, Myrand S.P., Jr. PD98059 is an Equipotent Antagonist of the Aryl Hydrocarbon Receptor and Inhibitor of Mitogen-Activated Protein Kinase Kinase. Mol. Pharmacol. 1998; 53: 438–445
  • Denison M.S., Phelan D., Winter G.M., Ziccardi M.H. Carbaryl, a Carbamate Insecticide, Is a Ligand for the Hepatic Ah (Dioxin) Receptor. Toxicol. Appl. Pharmacol. 1998; 152: 406–414, (a)
  • Delescluse C., Ledirac N., de Sousa G., Pralavorio M., Lesca P., Rahmani R. Cytotoxic Effects and Induction of Cytochromes P450 1A1/2 by Insecticides, in Hepatic or Epidermal Cells: Binding Capability to the Ah Receptor. Toxicol. Lett. 1998; 96,97: 33–39, (b)
  • Ledirac N., Delescluse C., de Sousa G., Pralavorio M., Lesca P., Amichot M., Berge J.B., Rahmani R. Carbaryl Induces CYP1A1 Gene Expression in HepG2 and HaCaT Cells but Is Not a Ligand of the Human Hepatic Ah Receptor. Toxicol. Appl. Pharmacol. 1997; 144: 177–182, (c)
  • Heath-Pagliuso S., Rogers W.J., Tullis K., Seidel S.D., Cenijn P.H., Brouwer A., Denison M.S. Activation of the Ah Receptor by Tryptophan and Tryptophan Metabolites. Biochemistry 1998; 37: 11508–11515
  • Ciolino H.P., Daschner P.J., Wang T.T., Yeh G.C. Effect of Curcumin on the Aryl Hydrocarbon Receptor and Cytochrome P450 1A1 in MCF-7 Human Breast Carcinoma Cells. Biochem. Pharmacol. 1998; 56: 197–206
  • Henderson G.L., Harkey M.R., Gershwin M.E., Hackman R.M., Stern J.S., Stresser D.M. Effects of Ginseng Components on c-DNA-Expressed Cytochrome P450 Enzyme Catalytic Activity. Life Sci. 1999; 65: 209–214
  • Rendic S., Nolteernsting E., Schänzer W. Biotransformation of testostereone and epitestosterone by human CYP3A4, ISSX Proceedings, 7th European ISSX Meeting, Budapest, Hungary, Aug 22–26, 1999. International Society for the Study of Xenobiotics, Cabin John, MD 1999; Vol. 14: 57
  • Rendic S. Drug Interactions of H2 Receptor Antagonists Involving Cytochrome P450 Enzymes (CYPs): from Laboratory to the Clinic. Croat. Med. J. 1999; 40: 357–367
  • Yamazaki H., Suzuki M., Tane K., Shimada N., Nakajima M., Yokoi T. In Vitro Inhibitory Effects of Troglitazone and Its Metabolites on Drug Oxidation Activities of Human Cytochrome P450 Enzymes: Comparison With Pioglitazone and Rosiglitazone. Xenobiotica 2000; 30: 61–70, (a)
  • Mu Y.M., Yanase T., Nishi Y., Waseda N., Oda T., Tanaka A., Takayanagi R., Nawata H. Insulin Sensitizer, Troglitazone, Directly Inhibits Aromatase Activity in Human Ovarian Granulosa Cells. Biochem, Biophys. Res. Commun. 2000; 271: 710–713, (b)
  • Fontana R.J., Lown K.S., Paine M.F., Fortlage L., Santella R.M., Felton J.S., Knize M.G., Greenberg A., Watkins P.B. Effects of a Chargrilled Meat Diet on Expression of CYP3A, CYP1A, and P-Glycoprotein Levels in Healthy Volunteers. Gastroenterology 1999; 117: 89–98
  • Merry C., Barry M.G., Ryan M., Tjia J.F., Hennessy M., Eagling V.A., Mulcahy F., Back D.J. Interaction of Sildenafil and Indinavir When Co-Administered to HIV-Positive Patients. AIDS 1999; Vol. 13: F101–F107
  • Erickson D.A., Mather G., Trager W.F., Levy R.H., Keirns J.J. Characterization of the In Vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450. Drug Metab. Dispos. 1999; 27: 1488–1495
  • Kudo S., Ishizaki T. Pharmacokinetics of Haloperidol: an Update. Clin. Pharmacokinet. 1999; 37: 435–456, (a)
  • Shin J.G., Kane K., Flockhart D.A. Potent Inhibition of CYP2D6 by Haloperidol Metabolites: Stereoselective Inhibition by Reduced Haloperidol. Br. J. Clin. Pharmacol. 2001; 51(1)81–86, (b)
  • Walker D.K., Ackland M.J., James G.C., Muirhead G.J., Rance D.J., Wastall P., Wright P.A. Pharmacokinetics and Metabolism of Sildenafil in Mouse, Rat, Rabbit, Dog and Man. Xenobiotica 1999; 29: 297–310
  • Damkier P., Hansen L.L., Brosen K. Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Quinidine. Pharmacol. Toxicol. 1999; 85: 257–262
  • Loi C.M., Young M., Randinitis E., Vassos A., Koup J.R. Clinical Pharmacokinetics of Troglitazone. Clin. Pharmacokinet. 1999; 37: 91–104
  • Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine, Pharmacokinetic and Pharmacodynamic Profile. Clin. Pharmacokinet. 1999; 37: 177–193
  • Fujimaki Y., Arai N., Inaba T. Identification of Cytochromes P450 Involved in Human Liver Microsomal Metabolism of Ecabapide, a Prokinetic Agent. Xenobiotica 1999; 29: 1273–1282
  • Glossmann H., Petrischor G., Bartsch G. Molecular Mechanisms of the Effects of Sildenafil (VIAGRA). Exp. Gerontol. 1999; 34: 305–318
  • Greenblatt D.J., von Moltke L.L., Harmatz J.S., Shader R.I. Human Cytochromes and Some Newer Antidepressants: Kinetics, Metabolism, and Drug Interactions. J. Clin. Psychopharmacol. 1999; 19(Suppl. 1)23S–35S, (a)
  • Schmider J., von Moltke L.L., Shader R.I., Harmatz J.S., Greenblatt D.J. Extrapolating In Vitro Data on Drug Metabolism to In Vivo Pharmacokinetics: Evaluation of the Pharmacokinetic Interaction Between Amitriptyline and Fluoxetine. Drug Metab. Rev. 1999; 31: 545–560, (b)
  • Timmer C.J., Sitsen J.M., Delbressine L.P. Clinical Pharmacokinetics of Mirtazapine. Clin. Pharmacokinet. 2000; 38: 461–474, (c)
  • Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L. CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations. J. Clin. Pharmacol. 2000; 40: 58–66, (d)
  • Stormer E., von Moltke L.L., Shader R.I., Greenblatt D.J. Metabolism of the Antidepressant Mirtazapine In Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab. Dispos. 2000; 28: 1168–1175, (e)
  • Ishiguro N., Senda C., Kishimoto W., Sakai K., Funae Y., Igarashi T. Identification of CYP3A4 as the Predominant Isoform Responsible for the Metabolism of Ambroxol in Human Liver Microsomes. Xenobiotica 2000; 30: 71–80
  • Joanna L., Harvey L., Alan J., Paine J., Maurel P., Wright M.C. Effect of the Adrenal 11-Beta-Hydroxylase Inhibitor Metyrapone on Human Hepatic Cytochrome P-450 Expression: Induction of Cytochrome P-450 3A4. Drug Metab. Dispos. 2000; 28: 96–101
  • Zhang Q.-Y., Dunbar D., Kaminsky L. Human Cytochrome P-450 Metabolism of Retinals to Retinoic Acids. Drug Metab. Dispos. 2000; 28: 292–297
  • Wester M.R., Lasker J.M., Johnson E.F., Raucy J.L. CYP2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 354–359, (a)
  • Komatsu K., Ito K., Nakajima Y., Kanamitsu S.I., Imaoka S., Funae Y., Green C.E., Tyson C.A., Shimada N., Sugiyama Y. Prediction of In Vivo Drug–Drug Interactions Between Tolbutamide and Various Sulfonamides in Humans Based on In Vitro Experiments. Drug Metab. Dispos. 2000; 28: 475–481, (b)
  • Chen H., Howald W.N., Juchau M.R. Biosynthesis of All-Trans-Retinoic Acid from All-trans-Retinol: Catalysis of All-trans-Retinol Oxidation by Human P-450 Cytochromes. Drug Metab. Dispos. 2000; 28: 315–322
  • Ma B., Prueksaritanont T., Lin J.H. Drug Interactions With Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation With CYP3A. Drug Metab. Dispos. 2000; 28: 125–130
  • Bonnabry P., Leemann T., Dayer P. Role of Human Liver Cytochrome P450TB (2C9) in the Biotransformation of Lornoxicam. Clin. Pharmacol. Ther. 1995; 57: 152(PI-70), (a)
  • Kohl Christopher, Steinkellner Michael. Prediction of Pharmacokinetic Drug/Drug Interactions from In Vitro Data: Interactions of the Nonsteroidal Anti-Inflammatory Drug Lornoxicam With Oral Anticoagulants. Drug Metab. Dispos. 2000; 28: 161–168, (b)
  • Ohe Tomoyuki, Hirobe Masaaki, Mashino Tadahiko. Novel Metabolic Pathway of Estrone and 17-Estradiol Catalyzed by Cytochrome P-450. Drug Metab. Dispos. 2000; 28: 110–112
  • Äbelö Angela, Andersson Tommy B., Bredberg Ulf, Skanberg Inger, Weidolf Lars. Stereoselective Metabolism by Human Liver CYP Enzymes of a Substituted Benzimidazole. Drug Metab. Dispos. 2000; 28: 58–64
  • Abel S.M., Back D.J. Cortisol Metabolism In Vitro—III. Inhibition of Microsomal 6 Beta-Hydroxylase and Cytosolic 4-ene-Reductase. J. Steroid Biochem. Mol. Biol. 1993; 46: 827–832
  • Prueksaritanont T., Lu P., Gorham L., Sternfeld F., Vyas K.P. Interspecies Comparison and Role of Human Cytochrome P450 and Flavin-Containing Monooxygenase in Hepatic Metabolism of L-775, 606, a Potent 5-HT(1D) Receptor Agonist. Xenobiotica 2000; 30: 47–59
  • Bachus R., Bickel U., Thomsen T., Roots I., Kewitz H. The O-Demethylation of the Antidementia Drug Galanthamine Is Catalysed by Cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661–668
  • Lessard E., Hamelin B.A., Labbe L., O'Hara G., Belanger P.M., Turgeon J. Involvement of CYP2D6 Activity in the N-Oxidation of Procainamide in Man. Pharmacogenetics 1999; 9: 683–696
  • Rodrigues A.D., Roberts E.M. The In Vitro Interaction of Dexmedetomidine With Human Liver Microsomal Cytochrome P4502D6 (CYP2D6). Drug Metab. Dispos. 1997; 25: 651–655, (a)
  • Kharasch E.D., Hill H.F., Eddy A.C. Influence of Dexmedetomidine and Clonidine on Human Liver Microsomal Alfentanil Metabolism. Anesthesiology 1991; 75: 520–524, (b)
  • Morse M.A., Lu J., Stoner G.D., Murphy S.E., Peterson L.A. Metabolism of N-Nitrosobenzylmethylamine by Human Cytochrome P-450 Enzymes. J. Toxicol. Environ. Health 1999; 58: 397–411
  • Khan K.K., Halpert J.R. Structure-Function Analysis of Human Cytochrome P450 3A4 Using 7-Alkoxycoumarins as Active-Site Probes. Arch. Biochem. Biophys. 2000; 373: 335–345
  • Numazawa M., Yoshimura A. Biological Aromatization of Delta4,6- and Delta1,4,6-Androgens and Their 6-Alkyl Analogs, Potent Inhibitors of Aromatase. J. Steroid Biochem. Mol. Biol. 1999; 70: 189–196
  • Perloff M.D., von Moltke L.L., Court M.H., Kotegawa T., Shader R.I., Greenblatt D.J. Midazolam and Triazolam Biotransformation in Mouse and Human Liver Microsomes: Relative Contribution of CYP3A and CYP2C Isoforms. J. Pharmacol. Exp. Ther. 2000; 292: 618–628
  • Cohen J.C. Contribution of Cholesterol 7alpha-Hydroxylase to the Regulation of Lipoprotein Metabolism. Curr. Opin. Lipidol. 1999; 10: 303–307
  • Bylund J., Finnstrom N., Oliw E.H. Gene Expression of a Novel Cytochrome P450 of the CYP4F Subfamily in Human Seminal Vesicles. Biochem. Biophys. Res. Commun. 1999; 261: 169–174, (a)
  • Bylund J., Hidestrand M., Ingelman-Sundberg M., Oliw E.H. Identification of CYP4F8 in Human Seminal Vesicles as a Prominent 19-Hydroxylase of Prostaglandin Endoperoxides. J. Biol. Chem. 2000; 175: 21844–21849, (b)
  • Durant J.L., Lafleur A.L., Busby W.F., Jr, Donhoffner L.L., Jr, Penman B.W., Jr, Crespi C.L., Jr. Mutagenicity of C24H14 PAH in Human Cells Expressing CYP1A1. Mutat. Res. 1999; 446: 1–14
  • Sonneveld E., van den Brink C.E., van der Leede B.M., Schulkes R.K., Petkovich M., van der Burg B., van der Saag P.T. Human Retinoic Acid (RA) 4-Hydroxylase (CYP26) Is Highly Specific for All-trans-RA and Can Be Induced Through RA Receptors in Human Breast and Colon Carcinoma Cells. Cell Growth Differ. 1998; 9: 629–637
  • Yoshida N., Yoshida T., Nakamura A., Monkawa T., Hayashi M., Saruta T. Calcitonin Induces 25-Hydroxyvitamin D3 1Alpha-Hydroxylase mRNA Expression via Protein Kinase C Pathway in LLC-PK1 Cells. J. Am. Soc. Nephrol. 1999; 10: 2474–2479
  • Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., de Waziers I. Human CYP2B6: Expression, Inducibility and Catalytic Activities. Pharmacogenetics 1999; 9: 295–306
  • Gorski J.C., Hall S.D., Becker P., Affrime M.B., Cutler D.L., Haehner-Daniels B. In Vivo Effects of Interleukin-10 on Human Cytochrome P450 Activity. Clin. Pharmacol. Ther. 2000; 67: 32–43
  • Suri A., Forbes W.P., Bramer S.L. Effects of CYP3A Inhibition on the Metabolism of Cilostazol. Clin. Pharmacokinet. 1999; 37(Suppl 2)61–68, (a)
  • Abbas R., Chow C.P. Browder In vitro Metabolism and Interaction of Cilostazol With Human Hepatic Cytochrome P450 Isoforms. Hum. Exp. Toxicol. 2000; 19: 178–184, (b)
  • Burton P.M., Swinney D.C., Heller R., Dunlap B., Chiou M., Malonzo E., Haller J., Walker K.A., Salari A., Murakami S., , et al. Azalanstat (RS-21607), a Lanosterol 14 Alpha-Demethylase Inhibitor With Cholesterol-Lowering Activity. Biochem. Pharmacol. 1995; 50: 529–544, (a)
  • Swinney D.C., So O.Y., Watson D.M., Berry P.W., Webb A.S., Kertesz D.J., Shelton E.J., Burton P.M., Walker K.A. Selective Inhibition of Mammalian Lanosterol 14 Alpha-Demethylase by RS-21607 In Vitro and In Vivo. Biochemistry 1994; 33: 4702–4713, (b)
  • Schmider J., Brockmoller J., Arold G., Bauer S., Roots I. Simultaneous Assessment of CYP3A4 and CYP1A2 Activity In Vivo With Alprazolam and Caffeine. Pharmacogenetics 1999; 9: 725–734
  • Lewis D.F., Bird M.G., Dickins M., Lake B.G., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular Modelling of Human CYP2E1 by Homology With the CYP102 Haemoprotein Domain: Investigation of the Interactions of Substrates and Inhibitors Within the Putative Active Site of the Human CYP2E1 Isoform. Xenobiotica 2000; 30: 1–25
  • Lewis D.F., Lake B.G., Dickins M., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular Modelling of CYP2B6, the Human CYP2B Isoform, by Homology With the Substrate-Bound CYP102 Crystal Structure: Evaluation of CYP2B6 Substrate Characteristics, the Cytochrome b5 Binding Site and Comparisons With CYP2B1 and CYP2B4. Xenobiotica 1999; 29: 361–393
  • Lewis D.F., Bird M.G., Dickins M., Lake B.G., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular Modelling of the Human Cytochrome P450 Isoform CYP2A6 and Investigations of CYP2A Substrate Selectivity. Toxicology 1999; 133: 1–33, (a)
  • Nunoya K., Yokoi Y., Kimura K., Kodama T., Funayama M., Inoue K., Nagashima K., Funae Y., Shimada N., Green C., Kamataki T. (+)-cis-35-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a Novel Substrate for Cytochrome P450 2A6 in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 768–774, (b)
  • Dehal S.S., Kupfer D. Cytochrome P-450 3A and 2D6 Catalyze Ortho Hydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins. Drug Metab. Dispos. 1999; 27: 681–688, (a)
  • Styles J.A., Davies A., Lim C.K., De Matteis F., Stanley L.A., White I.N., Yuan Z.X., Smith L.L. Genotoxicity of Tamoxifen, Tamoxifen Epoxide and Toremifene in Human Lymphoblastoid Cells Containing Human Cytochrome P450s. Carcinogenesis 1994; 15: 5–9, (b)
  • Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J. Stereoselective Metabolism of a New Anticonvulsant Drug Candidate, Losigamone, by Human Liver Microsomes. Drug Metab. Dispos. 1996; 24: 1002–1008
  • Liu C., Zhuo X., Gonzalez F.J., Ding X. Baculovirus-Mediated Expression and Characterization of Rat CYP2A3 and Human CYP2A6: Role in Metabolic Activation of Nasal Toxicants. Mol. Pharmacol. 1996; 50: 781–788, (a)
  • Ding X., Spink D.C., Bhama J.K., Sheng J.J., Vaz A.D., Coon M.J. Metabolic Activation of 2,6-Dichlorobenzonitrile, an Olfactory-Specific Toxicant, by Rat, Rabbit, and Human Cytochromes P450. Mol. Pharmacol. 1996; 49: 1113–1121, (b)
  • Ching M.S., Blake C.L., Ghabrial H., Ellis S.W., Lennard M.S., Tucker G.T., Smallwood R.A. Potent Inhibition of Yeast-Expressed CYP2D6 by Dihydroquinidine, Quinidine, and Its Metabolites. Biochem. Pharmacol. 1995; 50: 833–837
  • Numazawa M., Nagaoka M., Morio M., Kamiyama T. 19-Oxygenations of 3-Deoxy Androgens, Potent Competitive Inhibitors of Estrogen Biosynthesis, With Human Placental Aromatase. J. Steroid Biochem. Mol. Biol. 1999; 71: 173–179
  • Fiorelli G., Picariello L., Martineti V., Tonelli F., Brandi M.L. Estrogen Synthesis in Human Colon Cancer Epithelial Cells. J. Steroid Biochem. Mol. Biol. 1999; 71: 223–230
  • Adlouni E.I., Pinelli C.E., Azemar B., Zaoui D., Beaune P., Pfohl-Leszkowicz A. Phenobarbital Increases DNA Adduct and Metabolites Formed by Ochratoxin A: Role of CYP 2C9 and Microsomal Glutathione-S-Transferase. Environ. Mol. Mutagen. 2000; 35: 123–131
  • Kang Z.C., Tsai S.J., Lee H. Quercetin Inhibits Benzo[a]pyrene-Induced DNA Adducts in Human Hep G2 Cells by Altering Cytochrome P-450 1A1 Gene Expression. Nutr. Cancer 1999; 35: 175–179
  • Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance. Clin. Pharmacokinet. 2000; 38: 111–180, (a)
  • Benedetti M.S., Bani M. Metabolism-Based Drug Interactions Involving Oral Azole Antifungals in Humans. Drug Metab. Rev. 1999; 31: 665–717, (b)
  • Boxenbaum H. Cytochrome P450 3A4 In Vivo Ketoconazole Competitive Inhibition: Determination of Ki and Dangers Associated With High Clearance Drugs in General. J. Pharm. Sci. 1999; 2: 47–52, (c)
  • Hiemke C., Hartter S. Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Pharmacol. Ther. 2000; 85: 11–28
  • Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., Peters F.T. Toxicokinetics and Analytical Toxicology of Amphetamine-Derived Designer Drugs (“Ecstasy”). Toxicol. Lett. 2000; 112–113: 133–142, (a)
  • Kreth K., Kovar K., Schwab M., Zanger U.M. Identification of the Human Cytochromes P450 Involved in the Oxidative Metabolism of “Ecstasy”-Related Designer Drugs. Biochem. Pharmacol. 2000; 59: 1563–1571, (b)
  • Bort R., Ponsoda X., Carrasco E., Gomez-Lechon M.J., Castell J.V. Metabolism of Aceclofenac in Humans. Drug Metab. Dispos. 1996; 24: 834–841
  • Kasahara M., Suzuki H., Komiya I. Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic Intermediate Complex Formation With CYP, and Identification of the Human CYP Isoforms. Drug Metab. Dispos. 2000; 28: 409–417
  • Hanna I.H., Reed J.R., Guengerich F.P., Hollenberg P.F. Expression of Human Cytochrome P450 2B6 in Escherichia coli: Characterization of Catalytic Activity and Expression Levels in Human Liver. Arch. Biochem. Biophys. 2000; 376: 206–216
  • Baker M.T., Olson M.J., Wang Y., Ronnenberg W.C., Johnson J.T., Brady A.N. Isoflurane-Chlorodifluoroethene Interaction in Human Liver Microsomes Role of Cytochrome P4502B6 in Potentiation of Haloethene Metabolism. Drug Metab. Dispos. 1995; 23: 60–64
  • Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Vena R., Friedman H.L., Shader R.I. Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: the Role of Cytochrome P-450 2C9 and Metabolic Inhibitors. J. Clin. Pharmacol. 1997; 37: 193–200
  • Eberhart D.C., Gemzik B., Halvorson M.R., Parkinson A. Species Differences in the Toxicity and Cytochrome P450 IIIA-Dependent Metabolism of Digitoxin. Mol. Pharmacol. 1991; 40: 859–867
  • Rodvold K.A. Clinical Pharmacokinetics of Clarithromycin. Clin. Pharmacokinet. 1999; 37: 385–398
  • Prueksaritanont T., Ma B., Tang C., Meng Y., Assang C., Lu P., Reider P.J., Lin J.H., Baillie T.A. Metabolic Interactions Between Mibefradil and HMG-CoA Reductase Inhibitors: an In Vitro Investigation With Human Liver Preparations. Br. J. Clin. Pharmacol. 1999; 47: 291–298
  • Ekins S., Wrighton S.A. The Role of CYP2B6 in Human Xenobiotic Metabolism. Drug Metab. Rev. 1999; 31: 719–754
  • Roy S.K., Korzekwa K.R., Gonzalez F.J., Moschel R.C., Dolan M.E. Human Liver Oxidative Metabolism of O6-Benzylguanine. Biochem. Pharmacol. 1995; 50: 1385–1389
  • Ariyoshi N., Oguri K., Koga N., Yoshimura H., Funae Y. Metabolism of Highly Persistent PCB Congener, 2,4,5,2′,4′,5′-Hexachlorobiphenyl, by Human CYP2B6. Biochem. Biophys. Res. Commun. 1995; 212: 455–460
  • Crosbie S.J., Blain P.G., Williams F.M. Metabolism of n-Hexane by Rat Liver and Extrahepatic Tissues and the Effect of Cytochrome P-450 Inducers. Hum. Exp. Toxicol. 1997; 16: 131–137
  • Doostdar H., Burke M.D., Mayer R.T. Bioflavonoids: Selective Substrates and Inhibitors for Cytochrome P450 CYP1A and CYP1B1. Toxicology 2000; 144: 31–38
  • Warrington J.S., Shader R.I., von Moltke L.L., Greenblatt D.J. In Vitro Biotransformation of Sildenafil (Viagra): Identification of Human Cytochromes and Potential Drug Interactions. Drug Metab. Dispos. 2000; 28: 392–397
  • Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J.C., Corcos L., Turlin B., Beaune P., Guillouzo A. Cytokines Down-Regulate Expression of Major Cytochrome P-450 Enzymes in Adult Human Hepatocytes in Primary Culture. Mol. Pharmacol. 1993; 44: 707–715, (a)
  • Abdel-Razzak Z., Corcos L., Fautrel A., Campion J.P., Guillouzo A. Transforming Growth Factor-Beta 1 Down-Regulates Basal and Polycyclic Aromatic Hydrocarbon-Induced Cytochromes P-450 1A1 and 1A2 in Adult Human Hepatocytes in Primary Culture. Mol. Pharmacol. 1994; 46: 1100–1110, (b)
  • Muntane-Relat J., Ourlin J.C., Domergue J., Maurel P. Differential Effects of Cytokines on the Inducible Expression of CYP1A1, CYP1A2, and CYP3A4 in Human Hepatocytes in Primary Culture. Hepatology 1995; 22: 1143–1153, (c)
  • Bleau A.M., Levitchi M.C., Maurice H., du Souich P. Cytochrome P450 Inactivation by Serum from Humans With a Viral Infection and Serum from Rabbits With a Turpentine-Induced Inflammation: the Role of Cytokines. Br. J. Pharmacol. 2000; 130: 1777–1784, (d)
  • Katiyar S.K., Matsui M.S., Mukhtar H. Ultraviolet-B Exposure of Human Skin Induces Cytochromes P450 1A1 and 1B1. J. Invest. Dermatol. 2000; 114: 328–333
  • Tassaneeyakul W., Vannaprasaht S., Yamazoe Y. Formation of Omeprazole Sulphone But Not 5-Hydroxyomeprazole Is Inhibited by Grapefruit Juice. Br. J. Clin. Pharmacol. 2000; 49: 139–144
  • Uchida T., Watanabe T., Van Hoogdalem E.J., Higuchi S. In-Vitro Metabolism of YM17E, an Inhibitor of Acyl Coenzyme A: Cholesterol Acyltransferase, by Liver Microsomes in Man. J. Pharm. Pharmacol. 1996; 48: 1049–1056
  • Bangchang K.N., Karbwang J., Back D.J. Mefloquine Metabolism by Human Liver Microsomes. Effect of Other Antimalarial Drugs. Biochem. Pharmacol. 1992; 43: 1957–1961, (a)
  • Fontaine F., de Sousa G., Burcham P.C., Duchene P., Rahmani R. Role of Cytochrome P450 3A in the Metabolism of Mefloquine in Human and Animal Hepatocytes. Life Sci. 2000; 66: 2193–2212, (b)
  • Bangchang K.N., Karbwang J., Back D.J. Primaquine Metabolism by Human Liver Microsomes: Effect of Other Antimalarial Drugs. Biochem. Pharmacol. 1992; 44: 587–590
  • Sanderson J.T., Seinen W., Giesy J.P., van den Berg M. 2-Chloro-s-triazine Herbicides Induce Aromatase (CYP19) Activity in H295R Human Adrenocortical Carcinoma Cells: a Novel Mechanism for Estrogenicity?. Toxicol. Sci. 2000; 54: 121–127
  • Reigh G., McMahon H., Ishizaki M., Ohara T., Shimane K., Esumi Y., Green C., Tyson C., Ninomiya S. Cytochrome P450 Species Involved in the Metabolism of Quinoline. Carcinogenesis 1996; 17: 1989–1996
  • Madan A., Parkinson A., Faiman M.D. Identification of the Human and Rat P450 Enzymes Responsible for the Sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The Terminal Step in the Bioactivation of Disulfiram. Drug Metab. Dispos. 1995; 23: 1153–1162
  • Gelboin H.V., Goldfarb I., Krausz K.W., Grogan J., Korzekwa K.R., Gonzalez F.J., Shou M. Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 2E1. Chem. Res. Toxicol. 1996; 9: 1023–1030
  • Li-Hawkins J., Lund E.G., Bronson A.D., Russell D.W. Expression Cloning of an Oxysterol 7alpha-Hydroxylase Selective for 24-Hydroxycholesterol. J. Biol. Chem. 2000; 275: 16543–16549
  • Manyike P.T., Kharasch E.D., Kalhorn T.F., Slattery J.T. Contribution of CYP2E1 and CYP3A to Acetaminophen Reactive Metabolite Formation. Clin. Pharmacol. Ther. 2000; 67: 275–282, (a)
  • Thummel K.E., Slattery J.T., Ro H., Chien J.Y., Nelson S.D., Lown K.E., Watkins P.B. Ethanol and Production of the Hepatotoxic Metabolite of Acetaminophen in Healthy Adults. Clin. Pharmacol. Ther. 2000; 67: 591–599, (b)
  • Sinclair J., Jeffery E., Wrighton S., Kostrubsky V., Szakacs J., Wood S., Sinclair P. Alcohol-Mediated Increases in Acetaminophen Hepatotoxicity: Role of CYP2E and CYP3A. Biochem. Pharmacol. 1998; 55: 1557–1565, (c)
  • Sarich T., Kalhorn T., Magee S., al-Sayegh F., Adams S., Slattery J., Goldstein J., Nelson S., Wreight J. The Effect of Omeprazole Pretreatment on Acetaminophen Metabolism in Rapid and Slow Metabolizers of S-Mephenytoin. Clin. Pharmacol. Ther. 1997; 62: 21–28, (d)
  • Sato S., Someya T., Shioiri O., Koitabashi T., Inoue Y. Involvement of CYP3A4 in the Metabolism of Bromperidol In Vitro. Pharmacol. Toxicol. 2000; 86: 145–148
  • Henderson M.C., Miranda C.L., Stevens J.F., Deinzer M.L., Buhler D.R. In Vitro Inhibition of Human P450 Enzymes by Prenylated Flavonoids from Hops, Humulus lupulus. Xenobiotica 2000; 30: 235–251
  • Brandes L.J., Queen G.M., LaBella N. N, N-Diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a Chemopotentiating and Cytoprotective Agent in Clinical Trials: Interaction With Histamine at Cytochrome P450 3A4 and Other Isozymes That Metabolize Antineoplastic Drugs. Cancer Chemother. Pharmacol. 2000; 45: 298–304
  • Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., Korzekwa K.R. Activation of CYP3A4: Evidence for the Simultaneous Binding of Two Substrates in a Cytochrome P450 Active Site. Biochemistry 1994; 33: 6450–6455
  • Xu L., Li A.P., Kaminski D.L., Ruh M.F. 2,3,7,8 Tetrachlorodibenzo-p-dioxin Induction of Cytochrome P4501A in Cultured Rat and Human Hepatocytes. Chem. Biol. Interact. 2000; 124: 173–189, (a)
  • Hukkanen J., Lassila A., Paivarinta K., Valanne S., Sarpo S., Hakkola J., Pelkonen O., Raunio H. Induction and Regulation of Xenobiotic-Metabolizing Cytochrome P450s in the Human A549 Lung Adenocarcinoma Cell Line. Am. J. Respir. Cell Mol. Biol. 2000; 22: 360–366, (b)
  • Wang Y., Unadkat J.D. Enzymes in Addition to CYP3A4 and 3A5 Mediate N-Demethylation of Dextromethorphan in Human Liver Microsomes. Biopharm. Drug Dispos. 1999; 20: 341–346
  • Zangar R.C., Benson J.M., Burnett V.L., Springer D.L. Cytochrome P450 2E1 is the Primary Enzyme Responsible for Low-Dose Carbon Tetrachloride Metabolism in Human Liver Microsomes. Chem. Biol. Interact. 2000; 125: 233–243
  • Draper A.J., Hammock B.D. Identification of CYP2C9 as a Human Liver Microsomal Linoleic Acid Epoxygenase. Arch. Biochem. Biophys. 2000; 376: 199–205
  • Butler A.M., Murray M. Biotransformation of Parathion in Human Liver: Participation of CYP3A4 and Its Inactivation During Microsomal Parathion Oxidation. J. Pharmacol. Exp. Ther. 1997; 280: 966–973, (a)
  • Sams C., Mason H.J., Rawbone R. Evidence for the Activation of Organophosphate Pesticides by Cytochromes P450 3A4 and 2D6 in Human Liver Microsomes. Toxicol. Lett. 2000; 116: 217–221, (b)
  • Plastaras J.P., Guengerich F.P., Nebert D.W., Marnett L.J. Xenobiotic Metabolizing Cytochromes P450 Convert Prostaglandin Endoperoxide to Hydroxyheptadecatrienoic Acid and Mutagen, Malondialdehyde. J. Biol. Chem. 2000; 275: 11784–11790
  • Hosea N.A., Miller G.P., Guengerich F.P. Elucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4. Biochemistry 2000; 39: 5929–5939
  • Ibrahim R.B., Wilson J.G., Thorsby M.E., Edwards D.J. Effect of Buprenorphine on CYP3A Activity in Rat and Human Liver Microsomes. Life Sci. 2000; 66: 1293–1298
  • Niwa T., Tsutsui M., Kishimoto K., Yabusaki Y., Ishibashi F., Katagiri M. Inhibition of Drug-Metabolizing Enzyme Activity in Human Hepatic Cytochrome P450s by Bisphenol A. Biol. Pharm. Bull. 2000; 23: 498–501
  • Tang C., Shou M., Mei Q., Rushmore T.H., Rodrigues A.D. Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor. J. Pharmacol. Exp. Ther. 2000; 293: 453–459, (a)
  • Davies N.M., McLachlan A.J., Day R.O., Williams K.M. Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: a Selective Cyclo-Oxygenase-2 Inhibitor. Clin. Pharmacokinet. 2000; 38: 225–242, (b)
  • Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., Busse R. Cytochrome P450 2C is an EDHF Synthase in Coronary Arteries. Nature 1999; 401: 493–497
  • Song J.C., White C.M. Pharmacologic, Pharmacokinetic, and Therapeutic Differences Among Angiotensin II Receptor Antagonists. Pharmacotherapy 2000; 20: 130–139, (a)
  • Taavitsainen P., Kiukaanniemi K., Pelkonen O. In Vitro Inhibition Screening of Human Hepatic P450 Enzymes by Five Angiotensin-II Receptor Antagonists. Eur. J. Clin. Pharmacol. 2000; 56: 135–140, (b)
  • Taavitsainen P., Anttila M., Nyman L., Karnani H., Salonen J.S., Pelkonen O. Selegiline Metabolism and Cytochrome P450 Enzymes: In Vitro Study in Human Microsomes. Pharmacol. Toxicol. 2000; 86: 215–221, (a)
  • Jurima-Romet M., Smith I.L., Brule C., Tran P., Lahaie M., Chun D., Ryan P., Reimer M., Goodhead M., Azzaro A. In Vitro Metabolism Studies of Selegiline Using Human Liver Microsomes: CYP Enzyme Identification and Inhibition. Drug Metab. Rev. 2000; 32(Suppl. 2)229, (b)
  • Jorga K.M., Fotteler B., Gasser R., Banken L., Birnboeck H. Lack of Interaction Between Tolcapone and Tolbutamide in Healthy Volunteers. J. Clin. Pharmacol. 2000; 40: 544–551
  • Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., Shou M. Assessment of Specificity of Eight Chemical Inhibitors Using cDNA-Expressed Cytochromes P450. Xenobiotica 2000; 30: 327–343
  • Shou M., Lu T., Krausz K.W., Sai Y., Yang T., Korzekwa K.R., Gonzalez F.J., Gelboin H.V. Use of Inhibitory Monoclonal Antibodies to Assess the Contribution of Cytochromes P450 to Human Drug Metabolism. Eur. J. Pharmacol. 2000; 394: 199–209
  • Jacobs C., Frotscher M., Dannhardt G., Hartmann R.W. 1-Imidazolyl(alkyl)-Substituted Di- and Tetrahydroquinolines and Analogues: Syntheses and Evaluation of Dual Inhibitors of Thromboxane A(2) Synthase and Aromatase. J. Med. Chem. 2000; 43: 1841–1851, (a)
  • Hartmann R.W., Frotscher M. 1-Imidazolylcarbonyloxy-Substituted Tetrahydroquinolines and Pyridines: Synthesis and Evaluation of P450 TxA2 Inhibition. Arch. Pharm. (Weinheim) 1999; 332: 358–362, (b)
  • Ackerley N., Brewster A.G., Brown G.R., Clarke D.S., Foubister A.J., Griffin S.J., Hudson J.A., Smithers M.J., Whittamore P.R. A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors. J. Med. Chem. 1995; 38: 1608–1628, (c)
  • Robertson P., DeCory H.H., Madan A., Parkinson A. In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil. Drug Metab. Dispos. 2000; 28: 664–671
  • White J.A., Ramshaw H., Taimi M., Stangle W., Zhang A., Everingham S., Creighton S., Tam S.P., Jones G., Petkovich M. Identification of the Human Cytochrome P450 P450RAI-2, Which is Predominantly Expressed in the Adult Cerebellum and Is Responsible for All-trans-Retinoic Acid Metabolism. Proc. Natl Acad. Sci. USA 2000; 97: 6403–6408, (a)
  • Loudig O., Babichuk C., White J., Abu-Abed S., Mueller C., Petkovich M. Cytochrome P450RAI(CYP26) Promoter: a Distinct Composite Retinoic Acid Response Element Underlies the Complex Regulation of Retinoic Acid Metabolism. Mol. Endocrinol. 2000; 14: 1483–1497, (b)
  • Backman J.T., Maenpaa J., Belle D.J., Wrighton S.A., Kivisto K.T., Neuvonen P.J. Lack of Correlation Between In Vitro and In Vivo Studies on the Effects of Tangeretin and Tangerine Juice on Midazolam Hydroxylation. Clin. Pharmacol. Ther. 2000; 67: 382–390
  • Lampe J.W., King I.B., Li S., Grate M.T., Barale K.V., Chen C., Feng Z., Potter J.D. Brassica Vegetables Increase and Apiaceous Vegetables Decrease Cytochrome P450 1A2 Activity in Humans: Changes in Caffeine Metabolite Ratios in Response to Controlled Vegetable Diets. Carcinogenesis 2000; 21: 1157–1162
  • Hukannen J., Lassila A., Hakkola J., Pelkonen O., Raunio H. Induction of Cytochrome P450 3A5 (CYP3A5) in Human A549 Lung Adenocarcinoma Cell Line by Antiasthmatic Glucocorticoids. Drug Metab. Rev. 2000; 32(Suppl. 1)63
  • Kanmacher I., Millet P., Moachon G. Buflomedil Elimination: Relationship With CYP2D6 Activity. Drug Metab. Rev. 2000; 32(Suppl. 1)67, (a)
  • Kanmacher I., Oreal N., Andre N., Millet P., Cambois A., Moachon G. Buflomedil Metabolism in Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 1)68, (b)
  • MacKay C., Cameron G.A., Chenery R.J., Hawksworth G.M. Identification of Isoforms Involved in Cytochrome P450-Dependent Formation of Fluorescent Metabolites in Isolated Rat Hepatocytes. Drug Metab. Rev. 2000; 32(Suppl. 1)77
  • Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton A., Krueger L., Czerwinski M., Forster J., Ribadeneira M.D., Gan L., LeCluyse E.L., Zech K., Robertson P., Koch P., Antonian L., Wagner G., Yu L., Parkinson A. Effects of β-Naphthoflavone, Phenobarbital and Rifampin on CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4 in Human Hepatocytes. Drug Metab. Rev. 2000; 32(Suppl. 1)77
  • Mathews J.M., Etheridge A.S., Black S.L., de Costa K.S. Cannabidiol Inhibits Multiple Cytochrome P450 Isozymes In Vivo in Rat and In Vitro in Human Microsomes: Unexpected Inhibition of CYP2D Isoforms. Drug Metab. Rev. 2000; 32(Suppl. 1)79
  • McFadyen M.C.E., McLeod H.L., Melvin W.T., Doehmer J., Murray G.I. CYP1B1 Metabolism: a Novel Mechanism of Anti-Cancer Drug Resistance. Drug Metab. Rev. 2000; 32(Suppl. 1)80
  • Olesen O.V., Linnet K. Relative Contribution of Five CYP Isoforms Involved in the Demethylation of the Antipsychotic Drug Clozapine. Drug Metab. Rev. 2000; 32(Suppl. 1)87
  • Paxton J.W., Zhou S., Kestell P., Tingle M. Hydroxylation of 56-dimethylxanthenone-4-acetic acid (DMXAA) by Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 1)90
  • Striborova M., Bieler C.A., Wiessler M., Frei E. Evidence for Cytochrome P450-Dependent Covalent Binding of Antitumor Drug Ellipticine to DNA. Drug Metab. Rev. 2000; 32(Suppl. 1)106
  • Taavitsainen P., Juvonen R., Pelkonen O. Selective Inhibition of CYP2A6 by t-2-Phenylcyclopropylamine (Tranylcypromine), But Not by Cyclopropylbenzene. Drug Metab. Rev. 2000; 32(Suppl. 1)111, (a)
  • Taavitsainen P., Juvonen R., Pelkonen O. In Vitro Inhibition of Cytochrome P450 Enzymes in Human Liver Microsomes by a Potent CYP2A6 Inhibitor, trans-2-Phenylcyclopropylamine (Tranylcypromine), and Its Nonamine Analog, Cyclopropylbenzene. Drug Metab. Dispos. 2001; 29: 217–222, (b)
  • Bicknell H.A., Worboys P.D., Houston J.B. Regioselective and Stereoselective Hydroxylations of Warfarin in Human Liver Microsomes and c-DNA Expressed Cytochrome P450. Drug Metab. Rev. 2000; 32(Suppl. 1)35
  • Belghazi M., Jean P., Poli S., Schmitter J.-M., Mansuy D., Dansette P.M. Use of Isotopes and LC-MS-ESI-TOF for Mechanistic Studies of Tienilic Acid and Tienilic Acid Isomer Metabolic Activation. Drug Metab. Rev. 2000; 32(Suppl. 1)42
  • EL-Sankary W.M., Plant N.J., Gibson G.G. Involvement of the Human Pregnane X Receptor and the Human Glucocorticoid Receptor in the Regulation of the CYP3A4 Gene. Drug Metab. Rev. 2000; 32(Suppl. 1)50
  • Ioannides C. Effect of Diet and Nutrition on the Expression of Cytochromes P450. Xenobiotica 1999; 29: 109–154
  • von Bahr C., Ursing C., Yasui N., Tybring G., Bertilsson L., Rojdmark S. Fluvoxamine But Not Citalopram Increases Serum Melatonin in Healthy Subjects—an Indication That Cytochrome P450 CYP1A2 and CYP2C19 Hydroxylate Melatonin. Eur. J. Clin. Pharmacol. 2000; 56: 123–127
  • Ueng T.H., Hu S.H., Chen R.M., Wang H.W., Kuo M.L. Induction of Cytochrome P-450 1A1 in Human Hepatoma HepG2 and Lung Carcinoma NCI-H322 Cells by Motorcycle Exhaust Particulate. J. Toxicol. Environ. Health 2000; 60: 101–119
  • Ledirac N., Delescluse C., Lesca P., Piechocki M.P., Hines R.N., de Sousa G., Pralavorio M., Rahmani R. Diflubenzuron, a Benzoyl-Urea Insecticide, is a Potent Inhibitor of TCDD-Induced CYP1A1 Expression in HepG2 Cells. Toxicol. Appl. Pharmacol. 2000; 164: 273–279
  • Caccia S. Biotransformation of Post-Clozapine Antipsychotics: Pharmacological Implications. Clin. Pharmacokinet. 2000; 38: 393–414
  • Soucy P. Conversion of Pregnenolone to DHEA by Human 17Alpha-Hydroxylase/1720-lyase (P450c17) Evidence That DHEA is Produced from the Released Intermediate, 17alpha-Hydroxypregnenolone. Eur. J. Biochem. 2000; 267: 3243–3247
  • Brown A.J., Watts G.F., Burnett J.R., Dean R.T., Jessup W. Sterol 27-Hydroxylase Acts on 7-Ketocholesterol in Human Atherosclerotic Lesions and Macrophages in Culture. J. Biol. Chem. 2000; 275: 27627–27633
  • Guo L.Q., Taniguchi M., Xiao Y.Q., Baba K., Ohta T., Yamazoe Y. Inhibitory Effect of Natural Furanocoumarins on Human Microsomal Cytochrome P450 3A Activity. Jpn. J. Pharmacol. 2000; 82: 122–129
  • Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St John's Wort Induces Hepatic Drug Metabolism Through Activation of the Pregnane X Receptor. Proc. Natl Acad. Sci. USA 2000; 97: 7500–7502
  • Noguchi K., Mera A., Watanabe T., Higuchi S., Chiba K. Identification of Cytochrome P450 Isoform Involved in the Metabolism of YM992, a Novel Selective Serotonin Re-Uptake Inhibitor, in Human Liver Microsomes. Xenobiotica 2000; 30: 503–513
  • Li D.N., Seidel A., Pritchard M.P., Wolf C.R., Friedberg T. Polymorphisms in P450 CYP1B1 Affect the Conversion of Estradiol to the Potentially Carcinogenic Metabolite 4-Hydroxyestradiol. Pharmacogenetics 2000; 10: 343–353, (a)
  • Jefcoate C.R., Liehr J.G., Santen R.J., Sutter T.R., Yager J.D., Yue W., Santner S.J., Tekmal R., Demers L., Pauley R., Naftolin F., Mor G., Berstein L. Tissue-Specific Synthesis and Oxidative Metabolism of Estrogens. J. Natl Cancer Inst. Monogr. 2000; 27: 95–112, (b)
  • Spink D.C., Spink B.C., Zhuo X., Hussain M.M., Gierthy J.F., Ding X. NADPH- and Hydroperoxide-Supported 17beta-Estradiol Hydroxylation Catalyzed by a Variant Form (432L, 453S) of Human Cytochrome P450 1B1. J. Steroid Biochem. Mol. Biol. 2000; 74: 11–18, (c)
  • Josephy P.D., Bibeau K.L., Evans D.H. Activation of MeIQ (2-Amino-3,4-dimethylimidazo- [4,5-f]quinoline) by Sequence Variants of Recombinant Human Cytochrome P450 1A2. Environ. Mol. Mutagen 2000; 35: 328–335
  • Kushida H., Fujita K.I., Suzuki A., Yamada M., Endo T., Nohmi T., Kamataki T. Metabolic Activation of N-Alkylnitrosamines in Genetically Engineered Salmonella typhimurium Expressing CYP2E1 or CYP2A6 Together With Human NADPH-Cytochrome P450 Reductase. Carcinogenesis 2000; 21: 1227–1232
  • Eaton D.L. Biotransformation Enzyme Polymorphism and Pesticide Susceptibility. Neurotoxicology 2000; 21: 101–111
  • Abelo A., Andersson T.B., Antonsson M., Naudot A.K., Skanberg I., Weidolf L. Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes. Drug Metab. Dispos. 2000; 28: 966–972
  • Quintieri L., Rosato A., Napoli E., Sola F., Geroni C., Floreani M., Zanovello P. In Vivo Antitumor Activity and Host Toxicity of Methoxymorpholinyl Doxorubicin: Role of Cytochrome P450 3A. Cancer Res. 2000; 60: 3232–3238, (a)
  • Lau D.H., Duran G.E., Lewis A.D., Sikic B.I. Metabolic Conversion of Methoxymorpholinyl Doxorubicin: from a DNA Strand Breaker to a DNA Cross-Linker. Br. J. Cancer 1994; 70: 79–84, (b)
  • Lewis A.D., Lau D.H., Duran G.E., Wolf C.R., Sikic B.I. Role of Cytochrome P-450 from the Human CYP3A Gene Family in the Potentiation of Morpholino Doxorubicin by Human Liver Microsomes. Cancer Res. 1992; 52: 4379–4384, (c)
  • Mae T., Inaba T., Konishi E., Hosoe K., Hidaka T. Identification of Enzymes Responsible for Rifalazil Metabolism in Human Liver Microsomes. Xenobiotica 2000; 30: 565–574
  • Wandel C., Kim R.B., Guengerich F.P., Wood A.J. Mibefradil is a P-Glycoprotein Substrate and a Potent Inhibitor of Both P-Glycoprotein and CYP3A In Vitro. Drug Metab. Dispos. 2000; 28: 895–898
  • Coulet M., Eeckhoutte C., Larrieu G., Sutra J., Alvinerie M., Mace K., Pfeifer A., Zucco F., Stammati L., De Angelis I., Vignoli A.L., Galtier P. Evidence for Cytochrome P4501A2-Mediated Protein Covalent Binding of Thiabendazole and for Its Passive Intestinal Transport: Use of Human and Rabbit Derived Cells. Chem–Biol. Interact. 2000; 127: 109–124, (a)
  • Coulet M., Dacasto M., Eeckhoutte C., Larrieu G., Sutra J.F., Alvinerie M., Mace K., Pfeifer A.M., Galtier P. Identification of Human and Rabbit Cytochromes P450 1A2 as Major Isoforms Involved in Thiabendazole 5-Hydroxylation. Fundam. Clin. Pharmacol. 1998; 12: 225–235, (b)
  • Labbe L., O'Hara G., Lefebvre M., Lessard E., Gilbert M., Adedoyin A., Champagne J., Hamelin B., Turgeon J. Pharmacokinetic and Pharmacodynamic Interaction Between Mexiletine and Propafenone in Human Beings. Clin. Pharmacol. Ther. 2000; 68: 44–57
  • Tsukada M., Schroder M., Roos T.C., Chandraratna R.A., Reichert U., Merk H.F., Orfanos C.E. Zouboulis CC13-cis Retinoic Acid Exerts Its Specific Activity on Human Sebocytes Through Selective Intracellular Isomerization to all-trans Retinoic Acid and Binding to Retinoid Acid Receptors. J. Invest. Dermatol. 2000; 115: 321–327
  • Obach R.S. Metabolism of Ezlopitant, a Nonpeptidic Substance P Receptor Antagonist, in Liver Microsomes: Enzyme Kinetics, Cytochrome P450 Isoform Identity, and In Vitro–In Vivo Correlation. Dispos. Drug Metab. 2000; 28: 1069–1076
  • Sueyasu M., Fujito K., Shuto H., Mizokoshi T., Kataoka Y., Oishi R. Protein Binding and the Metabolism of Thiamylal Enantiomers In Vitro. Anesth. Analg. 2000; 91: 736–740
  • Ekins S., Ring B.J., Binkley S.N., Hall S.D., Wrighton S.A. Autoactivation and Activation of the Cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 1998; 36: 642–651
  • Kim S.Y., Adachi H., Koo J.S., Jetten A.M. Induction of the Cytochrome P450 Gene CYP26 During Mucous Cell Differentiation of Normal Human Tracheobronchial Epithelial Cells. Mol. Pharmacol. 2000; 58: 483–490
  • Kobayashi K., Mimura N., Fujii H., Minami H., Sasaki Y., Shimada N., Chiba K. Role of Human Cytochrome P450 3A4 in Metabolism of Medroxyprogesterone Acetate. Clin. Cancer Res. 2000; 6: 3297–3303
  • Kelly P.A., Wang H., Napoli K.L., Kahan B.D., Strobel H.W. Metabolism of Cyclosporine by Cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 321–328
  • Sawada N., Sakaki T., Ohta M., Inouye K. Metabolism of Vitamin D(3) by Human CYP27A1. Biochem. Biophys. Res. Commun. 2000; 273: 977–984
  • Winter H.R., Wang Y., Unadkat J.D. CYP2C8/9 Mediate Dapsone n-Hydroxylation at Clinical Concentrations of Dapsone. Drug Metab. Dispos. 2000; 28: 865–868
  • Kajita J., Kuwabara T., Kobayashi H., Kobayashi S. CYP3A4 is Mainly Responsibile for the Metabolism of a New Vinca Alkaloid, Vinorelbine, in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 1121–1127
  • von Moltke L.L., Durol A.L., Duan S.X., Greenblatt D.J. Potent Mechanism-Based Inhibition of Human CYP3A In Vitro by Amprenavir and Ritonavir: Comparison With Ketoconazole. Eur. J. Clin. Pharmacol. 2000; 56: 259–261
  • Echizen H., Tanizaki M., Tatsuno J., Chiba K., Berwick T., Tani M., Gonzalez F.J., Ishizaki T. Identification of CYP3A4 as the Enzyme Involved in the Mono-N-Dealkylation of Disopyramide Enantiomers in Humans. Drug Metab. Dispos. 2000; 28: 937–944
  • Budzinski J.W., Foster B.C., Vandenhoek S., Arnason J.T. An In Vitro Evaluation of Human Cytochrome P450 3A4 Inhibition by Selected Commercial Herbal Extracts and Tinctures. Phytomedicine 2000; 7: 273–282
  • Barone G.W., Gurley B.J., Ketel B.L., Lightfoot M.L., Abul-Ezz S.R. Drug Interaction Between St John's Wort and Cyclosporine. Ann. Pharmacother. 2000; 34: 1013–1016, (a)
  • Barone G.W., Gurley B.J., Ketel B.L., Abul-Ezz S.R. Herbal Supplements: a Potential for Drug Interactions in Transplant Recipients. Transplantation 2001; 71: 239–241, (b)
  • Mushiroda T., Douya R., Takahara E., Nagata O. The Involvement of Flavin-Containing Monooxygenase But Not CYP3A4 in Metabolism of Itopride Hydrochloride, a Gastroprokinetic Agent: Comparison With Cisapride and Mosapride Citrate. Drug Metab. Dispos. 2000; 28: 1231–1237
  • Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human Cytochrome P450 CYP2A13: Predominant Expression in the Respiratory Tract and Its High Efficiency Metabolic Activation of a Tobacco-Specific Carcinogen4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000; 60: 5074–5079
  • Gabelova A., Bacova G., Ruzekova L., Farkasova T. Role of Cytochrome P4501A1 in Biotransformation of a Tissue Specific Sarcomagen N-Methyldibenzo[c,g]Carbazole. Mutat. Res. 2000; 469: 259–269
  • Stormer E., Brockmoller J., Roots I., Schmider J. Cytochrome P-450 Enzymes and FMO3 Contribute to the Disposition of the Antipsychotic Drug Perazine In Vitro. Psychopharmacology (Berl) 2000; 151: 312–320
  • Jacobsen W., Christians U., Benet L.Z. In Vitro Evaluation of the Disposition of a Novel Cysteine Protease Inhibitor. Drug Metab. Dispos. 2000; 28: 1343–1351
  • Benedetti M.S. Enzyme Induction and Inhibition by New Antiepileptic Drugs: a Review of Human Studies. Fundam. Clin. Pharmacol. 2000; 14: 301–319
  • Hara H., Mitani N., Adachi T. Inhibitory Effect of Nitric Oxide on the Induction of Cytochrome P450 3A4 mRNA by 1,25-Dihydroxyvitamin D3 in Caco-2 Cells. Free Radical Res. 2000; 33: 279–285
  • Thijssen H.H., Flinois J.P., Beaune P.H. Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 1284–1290
  • Haritos V.S., Ghabrial H., Ahokas J.T., Ching M.S. Role of Cytochrome P450 2D6 (CYP2D6) in the Stereospecific Metabolism of E- and Z-Doxepin. Pharmacogenetics 2000; 10: 591–603
  • Shimada T., Tsumura F., Gillam E.M., Guengerich F.P., Inoue K. Roles of NADPH-P450 Reductase in the O-Deethylation of 7-Ethoxycoumarin by Recombinant Human Cytochrome P450 1B1 Variants in Escherichia coli. Protein Expr. Purif. 2000; 20: 73–80
  • Chen R., Chou M.W., Ueng T. Induction of Cytochrome P450 1A1 in Human Hepatoma HepG2 Cells by 6-Nitrochrysene. Toxicol. Lett. 2000; 117: 69–77
  • Chua M.S., Kashiyama E., Bradshaw T.D., Stinson S.F., Brantley E., Sausville E.A., Stevens M.F. Role of Cyp1A1 in Modulation of Antitumor Properties of the Novel Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203 NSC 674495) in Human Breast Cancer Cells. Cancer Res. 2000; 60: 5196–5203
  • Schwarz D., Kisselev P., Schunck W.H., Chernogolov A., Boidol W., Cascorbi I., Roots I. Allelic Variants of Human Cytochrome P450 1A1 (CYP1A1): Effect of T461N and I462V Substitutions on Steroid Hydroxylase Specificity. Pharmacogenetics 2000; 10: 519–530
  • Matsunaga T., Kishi N., Higuchi S., Watanabe K., Ohshima T., Yamamoto I. CYP3A4 is a Major Isoform Responsible for Oxidation of 7-Hydroxy-Delta(8)-Tetrahydrocannabinol to 7-Oxo-Delta(8)-Tetrahydrocannabinol in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 1291–1296
  • Mayhew B.S., Jones D.R., Hall S.D. An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation. Drug Metab. Dispos. 2000; 28: 1031–1037
  • Kawahara I., Kato Y., Suzuki H., Achira M., Ito K., Crespi C.L., Sugiyama Y. Selective Inhibition of Human Cytochrome P450 3A4 by N-[2(R)-Hydroxy-1(S)-Indanyl]-5-[2(S)-(11-Dimethylethylaminocarbonyl)-4-[(Furo[2,3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-Hydroxy-2(R)-phenylmethylpentanamide and P-Glycoprotein by Valspodar in Gene Transfectant Systems. Drug Metab. Dispos. 2000; 28: 1238–1243
  • Lang D.H., Rettie A.E. In Vitro Evaluation of Potential In Vivo Probes for Human Flavin-Containing Monooxygenase (FMO): Metabolism of Benzydamine and Caffeine by FMO and P450 Isoforms. Br. J. Clin. Pharmacol. 2000; 50: 311–314
  • Tang C., Shou M., Rodrigues A.D. Substrate-Dependent Effect of Acetonitrile on Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) Activity. Drug Metab. Dispos. 2000; 28: 567–572
  • Mankowski D.C., Lawton M.P., Ekins S. Characterization of Transgenic Mouse Strains Using Six Human Hepatic Cytochrome P450 Probe Substrates. Xenobiotica 2000; 30: 745–754
  • LeCluyse E., Madan A., Hamilton G., Carroll K., DeHaan R., Parkinson A. Expression and Regulation of Cytochrome P450 Enzymes in Primary Cultures of Human Hepatocytes. J. Biochem. Mol. Toxicol. 2000; 14: 177–188, (a)
  • McCune J.S., Hawke R.L., LeCluyse E.L., Gillenwater H.H., Hamilton G., Ritchie J., Lindley C. In Vivo and In Vitro Induction of Human Cytochrome P4503A4 by Dexamethasone. Clin. Pharmacol. Ther. 2000; 68: 356–366, (b)
  • Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Pichard-Garcia L., Vilarem M.J., Manuel P. Regulation of CYP3A4, CYP2As and PXR in Cultured Human Hepatocytes. Drug Metab. Rev. 2000; 32: 164, (a)
  • Pascussi J.M., Gerbal-Chaloin S., Fabre J.M., Maurel P., Vilarem M.J. Dexamethasone Enhances Constitutive Androstane Receptor Expression in Human Hepatocytes: Consequences on Cytochrome P450 Gene Regulation. Mol. Pharmacol. 2000; 58: 1441–1450, (b)
  • Kazmi Y., Marengo J., Zhang J., Testino S., Thurston A. Detection of Lauric Acid Metabolites With LC/MS: Selectivity and Specificity of the 11 and 12-Hydroxylations as Probes for CYP2E1 and 4A11 Isozymes. Drug Metab. Rev. 2000; 32(Suppl. 2)174
  • Cheng Z., Chilton A.S., Yanni S.B. High Troughpt Screening of P450 Isozymes' Inhibitors Using Fluorescent and Probe Substrates. Drug Metab. Rev. 2000; 32: 184
  • Geelen J.A., Deckers G.H., van der Wardt J.T., Loozen H.J., Tax L.J., Kloosterboer H.J. Selection of 19-(Ethyldithio)-androst-4-ene-317-dione (ORG 30958): a Potent Aromatase Inhibitor In Vivo. J. Steroid Biochem. Mol. Biol. 1991; 38: 181–188, (a)
  • Streser D.M., Blanchard A.P., Miller V.P., Crespi C.L. Fluorometric High-Throughput Screening for Inhibitors of Cytochrome P450: Substrate Dependent IC50 Values With CYP3A4. Drug Metab. Rev. 2000; 32(Suppl. 2)184, (b)
  • Stresser D.M., Turner S.D., McNamara J., Miller V.P., Crespi C.L., Patten C.J. A High Throughput Screen to Identify Inhibitors of CYP19. Drug Metab. Rev. 2000; 32(Suppl. 2)185, (a)
  • Geelen J.A., Deckers G.H., van der Wardt J.T., Loozen H.J., Tax L.J., Kloosterboer H.J. Selection of 19-(Ethyldithio)-androst-4-ene-317-dione (ORG 30958): a Potent Aromatase Inhibitor In Vivo. J. Steroid Biochem. Mol. Biol. 1991; 38: 181–188, (b)
  • Yanni S.B., Yang T.J., Chilton A.S., Gan L.L. Evaluation of BFC as a Probe for CYP 3A4 Drug Interactions. Drug Metab. Rev. 2000; 32(Suppl. 2)186
  • Du A.-Y., Mutlib A., Gan L. A High Throughput Quantitative LC/MS Assay for a Marker Metabolite of Specific Probe Substrate (Efavirenz) of Human Cytochrome P450 2B6. Drug Metab. Rev. 2000; 32(Suppl. 2)186
  • Ghosal A., Hapangama N., Yuan Y., Favreau L.V., Palamanda J.R., Patrick J.E., Cayen M.N., Zbaida S. Microtiter Plate-Based Assay for Rapid Determination of Enzyme Activites of 13 P450 Supersomes and Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)188
  • Cummins C.L., Jacobsen W., Christians U., Benet L.Z. The Role of CYP3A4 in the In Vitro Transport of Rapamicyn: Studies in CYP3A4-Expressing Caco-2 Cells. Drug Metab. Rev. 2000; 188(Suppl. 2)188
  • Lakshman M.K., Kole P., Chaturvedi S., Saugier J.H., Yeh H.J.C., Glusker J.P., Carrell H.L., Katz A.K., Afshar C.E., Doehmer J., Dashwood W., Baird W.M. Metabolic activation of 14-Dimethylbenzo[c]phenanthrene by Human Cytochrome P450 1B1 Expressed in V79 cells. Drug Metab. Rev. 2000; 32(Suppl. 2)200
  • Zha G., Allis J.W. Estimation of Kinetic Constants for BDCM Metabolism by Recombinant Human and Rat Cytochrome P450 Isoenzymes. Drug Metab. Rev. 2000; 32(Suppl. 2)208, (a)
  • Allis J.W., Zhao G. CYP2E1 is the Low Km Metabolizing Enzyme for Bromodichloromethane in Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)219, (b)
  • Chauret N., Dobbs B., Lackman R., Bateman K., Nicoll-Griffith D., Stresser D.M., Miller V.P., Crespi C. The Use of 3-[2-(N N-Diethyl-N-methylammonium)ethyl]-7-metoxy-4-methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)211
  • Yu A., Lang D., Dong H., Haining R.L. Dextromethorphan N-Demethylation Catalyzed by Highly Purified Recombinant CYP2D6. Drug Metab. Rev. 2000; 212(Suppl. 2)212, (a)
  • RussellGotschall R., Pearce R.C., Sharpe D., Leeder J.S. CYP3A4-Mediated N-Demethylation of Dextromethorphan is the Initial Stop for 3-Hydroxymorphinan Formation. Drug Metab. Rev. 2000; 32(Suppl. 2)213, (b)
  • Pearce R.E., Gotschall R.R., Kearns G.L., Steven J. Leeder Role of CYP4A4 in Cisapride and Norcisapride Metabolism. Drug Metab. Rev. 2000; 32(Suppl. 2)214
  • Scharg M.L., Wienkers L.C. Diferential In Vitro Inhibition Profiles of CYP3A4 Marker Substrates, Testosteron and Triazolam. Drug Metab. Rev. 2000; 32(Suppl. 2)215
  • Zhou D., Grimm S.W., Adedoyin A. Comparison of Tolbutamide and Diclofenac as In Vitro Probes of CYP2C9 Activity. Drug Metab. Rev. 2000; 159(Suppl. 2)216
  • Evanchik M., Dawson M.W., Korzekwa K.R., Carlson T.J. The Observation of Substrate-Dependent Inhibition of CYP2C9. Drug Metab. Rev. 2000; 32(Suppl. 2)216
  • Hutzler J.M., Retie A.E., Haining R.L., Tracy T.S. Dapsone Activation of CYP2C9 Allelic Variants. Drug Metab. Rev. 2000; 32(Suppl. 2)217, (a)
  • Matthew J., Hutzler J.M. Activation of CYP2C9 by Dapsone and Analogs. Drug Metab. Rev. 2000; 32(Suppl. 2)217, (b)
  • Suzuki H., Kneller B., Rao S., Jones J.P., Trager W.F., Rettie A.E. Hydantoin and Barbiturate Inhibitors of CYP2C19 and CYP2C9. Drug Metab. Rev. 2000; 32(Suppl. 2)218
  • Stevens J., Hauer M., Beck J., Voorman R. Further Characterization of Human Liver CYP2B6 Expression and Catalytic Function. Drug Metab. Rev. 2000; 32(Suppl. 2)218
  • Jones D.R., Zhao X.-Y., Grimm S.W., Haii S.D. The inhibition of CYP3A metabolism by Tamoxifen and Metabolites. Drug Metab. Rev. 2000; 32(Suppl. 2)229
  • Oglivie B.W., Otradovec S.M., Paris B.L., Scheinkoenig J.A., Carrott P.W., Loecker S.P., Hanzlik R.P., Parkinson A., Madan A. 10-(Imidazoly)-decanoic acid (10-IDA) is a Selective and Potent Inhibitor of CYP4A9/11. Drug Metab. Rev. 2000; 32(Suppl. 2)230
  • Kim D.H., Beak M., Kim J.Y., Kim B.R. Inhibition of Microsomal Testosterone 6β-Hydroxylase Activity by Dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxy phenyl-2,2′-dicarboxylate. Drug Metab. Rev. 2000; 32(Suppl. 2)232
  • Kaminsky L.S., Vakharia D.D., Zhang Q., Liu N. Pah Induction of CYP1A1/1A2 in Human Hepatocytes:Effects of Toxic Metals. Drug Metab. Rev. 2000; 32(Suppl. 2)242
  • Mather G.G., Bartlett B., Kellough J., Podoll T.P., Black C.B. Use of Primary Human Hepatocyte Cultures to Evaluate the Potential for Enzyme Induction Using a GLP Format. Drug Metab. Rev. 2000; 32(Suppl. 2)244
  • McKown L.A., Wu W.-N., Streeter A.J., Takacs A.R. Identification of CYP3A4 as the Cytochrome P450 Isform Responsible for Hydroxylation of the Novel Anxiolytic Agent RWJ-51204, in Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)253
  • Tang J., Cao J., Coleman S., Rose R.L., Goldstein J.A., Hodgson E. In Vitro Metabolism of Chlorpyrifos by Human Liver Microsomes and Human Cytochrome P450 Isoforms. Drug Metab. Rev. 2000; 32(Suppl. 2)255
  • Melendez V., Del Valle P.L., Jennings B., Skanchy D.J. Metabolism of Artelinic Acid Using Human Liver Microsomes and Expressed CP450 Isoenzymes. Drug Metab. Rev. 2000; 32(Suppl. 2)257
  • Otake Y., Walle T. Metabolism of the Flavonols Galangin and Kaempferide by the Human Cell Lines hep G2 and Caco-2. Drug Metab. Rev. 2000; 32(Suppl. 2)258
  • Liu X., Vlasak S.L., McQuinn R.L. Resiquimod Metabolism in Human Liver Microsomes: Enzyme Characterization and the Influence of NADPH Regenerating Systems. Drug Metab. Rev. 2000; 32(Suppl. 2)258
  • Adedoyin A., Richards A.L., Grimm S.W. Characterization of CYP Enzyme Metabolizing ZD6021 and ZD2249. Drug Metab. Rev. 2000; 32(Suppl. 2)259
  • Hoover R.K., Bilyeu T.A., Vant'Land C.W., Sanders M.E., Cole K.C., Velagaleti P.R. Characterization of CYP450 Isoenzymes Involved in the In Vitro Metabolism of Brinzolamide by Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)259
  • Desager J.P., De Buck C., Horsmans Y. In Human Volunteers Watercress Delays Ethanol Absorption Without Modifying Its Metabolism. Drug Metab. Rev. 2000; 32(Suppl. 2)277
  • Wang Z., Maya J.F., Hall S.D., Gorski J.C. Increased Chlorzoxazone Clearance in Type II Diabetics. Drug Metab. Rev. 2000; 32(Suppl. 2)280
  • Ngui J.S., Tang W., Wang R., Stearns R.A. Stimulation of the Cytochrome P450 3A4-Catalyzed 10-Hydroxylation of Warfarin by Quinidne. Drug Metab. Rev. 2000; 32(Suppl. 2)288
  • van der Aar E.M., Zuijderduijn F.J., Burger A., Yanagihara T., Higuchi S., Swart P.J. Evaluation of the Potential of Cytochrome P450-Mediated Drug Interactions With YM905. Drug Metab. Rev. 2000; 32(Suppl. 2)289
  • Brian W., Brandl J. Investigating Potential Drug Interactions With SR46559A in Human Liver Microsomes. Drug Metab. Rev. 2000; 32(Suppl. 2)289
  • Kajita J., Kuwabara T., Kobayashi H., Kobayashi S. Metabolic Interaction of Vinorelbine With Anti-Cancer Drugs. Drug Metab. Rev. 2000; 32(Suppl. 2)291
  • Tracy T.S., Hamman M.A., Hall S.D. Dapsone Activation of CYP2C9 Mediated Ibuprofen Metabolism: Regio and Stereoselective Effects. Drug Metab. Rev. 2000; 32(Suppl. 2)294
  • Gillam E.M., Notley L.M., Cai H., De Voss J.J., Guengerich F.P. Oxidation of Indole by Cytochrome P450 Enzymes. Biochemistry 2000; 39: 13817–13824
  • Nwankwo J.O., Tahnteng J.G., Emerole G.O. Inhibition of Aflatoxin B1 Genotoxicity in Human Liver-Derived HepG2 Cells by Kolaviron Biflavonoids and Molecular Mechanisms of Action. Eur. J. Cancer Prev. 2000; 9: 351–361
  • Hartmann R.W., Hector M., Haidar S., Ehmer P.B., Reichert W., Jose J. Synthesis and Evaluation of Novel Oxime Inhibitors of P450 17 (17Alpha-hydroxylase/C17-20-lyase) and 5Alpha-reductase Types 1 and 2. J. Med. Chem. 2000; 43: 4266–4277
  • Satoh T., KiH H.F., Munakata H., Itoh S., Nakamura K., Kamataki T., Itoh S., Yoshizawa I. Studies on the Interactions Between Drugs and Estrogen: Analytical Method for Prediction System of Gynecomastia Induced by Drugs on the Inhibitory Metabolism of Estradiol Using Escherichia coli Coexpressing Human CYP3A4 With Human NADPH-Cytochrome P450 Reductase. Anal. Biochem. 2000; 286: 179–186
  • Hartmann R.W., Hector M., Wachall B.G., Palusczak A., Palzer M., Huch V., Veith M. Synthesis and Evaluation of 17-Aliphatic Heterocycle-Substituted Steroidal Inhibitors of 17Alpha-hydroxylase/C17-20-lyase (P450 17). J. Med. Chem. 2000; 43: 4437–4445
  • Nagahori H., Yoshino H., Tomigahara Y., Isobe N., Kaneko H., Nakatsuka I. Metabolism of Furametpyr1. Identification of Metabolites and In Vitro Biotransformation in Rats and Humans. J. Agric. Food Chem. 2000; 48: 5754–5759
  • Powley M.W., Carlson G.P. Cytochromes P450 Involved With Benzene Metabolism in Hepatic and Pulmonary Microsomes. J. Biochem. Mol. Toxicol. 2000; 14: 303–309
  • Lampen A., Meyer S., Arnhold T., Nau H.J. Metabolism of Vitamin A and Its Active Metabolite All-trans-Retinoic Acid in Small Intestinal Enterocytes. Pharmacol. Exp. Ther. 2000; 295: 979–985
  • Kushida H., Fujita K., Suzuki A., Yamada M., Nohmi T., Kamataki T. Development of a Salmonella tester Strain Sensitive to Promutagenic N-Nitrosamines: Expression of Recombinant CYP2A6 and Human NADPH-Cytochrome P450 Reductase in S. typhimurium YG7108. Mutat. Res. 2000; 471: 135–143
  • Lilja J.J., Kivisto K.T., Neuvonen P.J. Duration of Effect of Grapefruit Juice on the Pharmacokinetics of the CYP3A4 Substrate Simvastatin. Clin. Pharmacol. Ther. 2000; 68: 384–390, (a)
  • Varis T., Kivisto K.T., Neuvonen P.J. Grapefruit Juice Can Increase the Plasma Concentrations of Oral Methylprednisolone. Eur. J. Clin. Pharmacol. 2000; 56: 489–493, (b)
  • Lilja J.J., Kivisto K.T., Backman J.T., Neuvonen P.J. Effect of Grapefruit Juice Dose on Grapefruit Juice-Triazolam Interaction: Repeated Consumption Prolongs Triazolam Half-Life. Eur. J. Clin. Pharmacol. 2000; 56: 411–415, (c)
  • Palovaara S., Kivisto K.T., Tapanainen P., Manninen P., Neuvonen P.J., Laine K. Effect of an Oral Contraceptive Preparation Containing Ethinylestradiol and Gestodene on CYP3A4 Activity as Measured by Midazolam 1-Hydroxylation. Br. J. Clin. Pharmacol. 2000; 50: 333–337
  • Vecchini F., Mace K., Magdalou J., Mahe Y., Bernard B.A., Shroot B. Constitutive and Inducible Expression of Drug Metabolizing Enzymes in Cultured Human Keratinocytes. Br. J. Dermatol. 1995; 132: 14–21
  • Moran J.H., Mitchell L.A., Bradbury J.A., Qu W., Zeldin D.C., Schnellmann R.G., Grant D.F. Analysis of the Cytotoxic Properties of Linoleic Acid Metabolites Produced by Renal and Hepatic P450s. Toxicol. Appl. Pharmacol. 2000; 168: 268–279
  • Zhou S., Paxton J.W., Tingle M.D., Kestell P. Identification of the Human Liver Cytochrome P450 Isoenzyme Responsible for the 6-6Ethylhydroxylation of the Novel Anticancer Drug 5,6-Dimethylxanthenone-4-acetic acid. Drug Metab. Dispos. 2000; 28: 1449–1456
  • Komatsu T., Yamazaki H., Shimada N., Nakajima M., Yokoi T. Roles of Cytochromes P450 1A22A6, and 2C8 in 5-Fluorouracil Formation from Tegafur, an Anticancer Prodrug, in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 1457–1463, (a)
  • Ikeda K., Yoshisue K., Matsushima E., Nagayama S., Kobayashi K., Tyson C.A., Chiba K., Kawaguchi Y. Bioactivation of Tegafur to 5-Fluorouracil is Catalyzed by Cytochrome P-450 2A6 in Human Liver Microsomes In Vitro. Clin. Cancer Res. 2000; 6: 4409–4415, (b)
  • Renwick A.B., Surry D., Price R.J., Lake B.G., Evans D.C. Metabolism of 7-Benzyloxy-4-trifluoromethylcoumarin by Human Hepatic Cytochrome P450 Isoforms. Xenobiotica 2000; 30: 955–969
  • Ozawa S., Ohta K., Miyajima A., Kurebayashi H., Sunouchi M., Shimizu M., Murayama N., Matsumoto Y., Fukuoka M., Ohno Y. Metabolic Activation of o-Phenylphenol to a Major Cytotoxic Metabolite, Phenylhydroquinone: Role of Human CYP1A2 and Rat CYP2C11/CYP2E1. Xenobiotica 2000; 30: 1005–1017
  • Chan W.K., Delucchi A.B. Resveratrol, a Red Wine Constituent, is a Mechanism-Based Inactivator of Cytochrome P450 3A4. Life Sci. 2000; 67: 3103–3112
  • Chang T.K., Lee W.B., Ko H.H. Trans-Resveratrol Modulates the Catalytic Activity and mRNA Expression of the Procarcinogen-Activating Human Cytochrome P450 1B1. Can. J. Physiol. Pharmacol. 2000; 78: 874–881
  • Kanamitsu S., Ito K., Green C.E., Tyson C.A., Shimada N., Sugiyama Y. Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4. Pharm. Res. 2000; 17: 419–426
  • Goosen T.C., Mills D.E., Hollenberg P.F. Effects of Benzyl Isothiocyanate on Rat and Human Cytochromes P450: Identification of Metabolites Formed by P450 2B1. J. Pharmacol. Exp. Ther. 2001; 296: 198–206
  • Miller V.P., Stresser D.M., Blanchard A.P., Turner S., Crespi C.L. Fluorometric High-Throughput Screening for Inhibitors of Cytochrome P450. Ann. NY. Acad. Sci. 2000; 919: 26–32
  • Court M.H., Duan S.X., Hesse L.M., Venkatakrishnan K., Greenblatt D.J. Cytochrome P-450 2B6 Is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes. Anesthesiology 2001; 94: 110–119
  • Olesen O.V., Linnet K. Identification of the Human Cytochrome P450 Isoforms Mediating In Vitro N-Dealkylation of Perphenazine. Br. J. Clin. Pharmacol. 2000; 50: 563–571
  • Chung W.G., Park C.S., Roh H.K., Lee W.K., Cha Y.N. Oxidation of Ranitidine by Isozymes of Flavin-Containing Monooxygenase and Cytochrome P450. Jpn. J. Pharmacol. 2000; 84: 213–220
  • Yamazaki H., Hatanaka N., Kizu R., Hayakawa K., Shimada N., Guengerich F.P., Nakajima M., Yokoi T. Bioactivation of Diesel Exhaust Particle Extracts and Their Major Nitrated Polycyclic Aromatic Hydrocarbon Components 1-Nitropyrene and Dinitropyrenes, by Human Cytochromes P450 1A1, 1A2, and 1B1. Mutat. Res. 2000; 472: 129–138
  • Coleman S., Linderman R., Hodgson E., Rose R.L. Comparative Metabolism of Chloroacetamide Herbicides and Selected Metabolites in Human and Rat Liver Microsomes. Environ. Health Perspect. 2000; 108: 1151–1157
  • Ong C.E., Coulter S., Birkett D.J., Bhasker C.R., Miners J.O. The Xenobiotic Inhibitor Profile of Cytochrome P4502C8. Br. J. Clin. Pharmacol. 2000; 50: 573–580
  • McGinnity D.F., Parker A.J., Soars M., Riley R.J. Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s. Drug Metab. Dispos. 2000; 28: 1327–1334
  • Shin K.J., Bae S.S., Hwang Y.A., Seo J.K., Ryu S.H., Suh P.G. 2,2′,4,6,6′-Pentachlorobiphenyl Induces Apoptosis in Human Monocytic Cells. Toxicol. Appl. Pharmacol. 2000; 169: 1–7
  • Yun C.H., Miller G.P., Guengerich F.P. Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 2000; 39: 11319–11329
  • Cherng S.H., Lin P., Yang J.L., Hsu S.L., Lee H. Benzo[g,h,i]perylene Synergistically Transactivates Benzo[a]pyrene-Induced CYP1A1 Gene Expression by Aryl Hydrocarbon Receptor Pathway. Toxicol. Appl. Pharmacol. 2001; 170: 63–68
  • Dvorak Z., Ulrichova J., Modriansky M., Maurel P. Effect of Colchicine and Its Derivatives on the Expression of Selected Isoforms of Cytochrome P450 in Primary Cultures of Human Hepatocytes. Acta Univ. Palacki. Olomuc. Fac. Med. 2000; 143: 47–50
  • Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory Potencies of 1,4-Dihydropyridine Calcium Antagonists to P-Glycoprotein-Mediated Transport: Comparison With the Effects on CYP3A4. Pharm. Res. 2000; 17: 1189–1197
  • Becquemon L., Camu M., Eschwege V., Barbu V., Re E., Funck-Brentano C., Jaillon P. Lymphocyte P-Glycoprotein Expression and Activity Before and After Rifampicin in Man. Fundam. Clin. Pharmacol. 2000; 14: 519–525
  • Rieder C.R.M., Parsons R.B., Fitch N.J., Williams A.C., Ramsden D.B. Human Brain Cytochrome P450 1B1: Immunohistochemical Localization in Human Temporal Lobe and Induction by Dimethylbenz(a)anthracene in Astrocytoma Cell Line (MOG-G-CCM). Neurosci. Lett. 2000; 278: 177–180
  • Molden E., Asberg A., Christensen H. CYP2D6 is Involved in O-Demethylation of Diltiazem. An in vitro study with transfected human liver cells. Eur. J. Clin. Pharmacol. 2000; 56: 575–579
  • Lash L.H., Fisher J.W., Lipscomb J.C., Parker J.C. Metabolism of Trichloroethylene. Environ. Health Perspect. 2000; 108(Suppl 2)177–200
  • McNamee J.P., Jurima-Romet M., Kobus S.M., Marks G.S. cDNA-Expressed Human Cytochrome P450 Isozymes Inactivation by Porphyrinogenic Xenobiotics. Drug Metab. Dispos. 1997; 25: 437–441
  • Guengerich F.P., Parikh A., Yun C.H., Kim D., Nakamura K., Notley L.M., Gillam E.M. What makes P450s Work? Searches for Answers With Known and New P450s. Drug Metab. Rev. 2000; 32: 267–281
  • Sahi J., Hamilton G., Sinz M., Barros S., Huang S.M., Lesko L.J., LeCluyse E.L. Effect of Troglitazone on Cytochrome P450 Enzymes in Primary Cultures of Human and Rat Hepatocytes. Xenobiotica 2000; 30: 273–284
  • Tuvesson H., Wienkers L.C., Gunnarsson P.O., Seidegard J., Persson R. Identification of Cytochrome P4503A as the Major Subfamily Responsible for the Metabolism of Roquinimex in Man. Xenobiotica 2000; 30: 905–914
  • Nadin L., Murray M. Arachidonic Acid-Mediated Cooxidation of All-trans-retinoic acid in Microsomal Fractions from Human Liver. Br. J. Pharmacol. 2000; 131: 851–857
  • von Moltke L.L., Greenblatt D.J., Granda B.W., Giancarlo G.M., Duan S.X., Daily J.P., Harmatz J.S., Shader R.I. Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors. J. Clin. Pharmacol. 2001; 41: 85–91
  • Miners J.O., Coulter S., Birkett D.J., Goldstein J.A. Torsemide Metabolism by CYP2C9 Variants and Other Human CYP2C Subfamily Enzymes. Pharmacogenetics 2000; 10: 267–270
  • Nebert D.W., Nelson D.R. Cytochrome P450 (CYP) Gene Superfamily. Encyclopedia of Human Genome, D.N. Cooper. Macmillan. 2002
  • Gafvels M., Olin M., Chowdhary B.P., Raudsepp T., Andersson U., Persson B., Jansson M., Bjorkhem I., Eggertsen G. Structure and Chromosomal Assignment of the Sterol 12Alpha-hydroxylase Gene (CYP8B1) in Human and Mouse: Eukaryotic Cytochrome P-450 Gene Devoid of Introns. Genomics 1999; 56: 184–196
  • Norlin M., Andersson U., Bjorkhem I., Wikvall K. Oxysterol 7Alpha -hydroxylase Activity by Cholesterol 7Alpha-hydroxylase (CYP7A). J. Biol. Chem. 2000; 275: 34046–34053
  • Niwa T., Shiraga T., Mitani Y., Terakawa M., Tokuma Y., Kagayama A. Stereoselective Metabolism of Cibenzoline, an Antiarrhythmic Drug, by Human and Rat Liver Microsomes: Possible Involvement of CYP2D and CYP3A. Drug Metab. Dispos. 2000; 28: 1128–1134
  • Yamakoshi Y., Kishimoto T., Sugimura K., Kawashima H. Human Prostate CYP3A5: Identification of a Unique 5′-Untranslated Sequence and Characterization of Purified Recombinant Protein. Biochem. Biophys. Res. Commun. 1999; 260: 676–681
  • Mackman R., Guo Z., De Montelano P.R.O., Guengerich F.P. Active Site Topology of Human Cytochrome P450 2E1. Chem. Res. Toxicol. 1993; 6: 197–207
  • Hesse L.M., von Moltke L.L., Shader R.I., Greenblatt D.J. Ritonavir, Efavirenz, and Nelfinavir Inhibit CYP2B6 Activity In Vitro: Potential Drug Interactions with Bupropion. Drug Metab. Dispos. 2001; 29: 100–102
  • Althaus M., Retzow A., Castell J.V., Gomez-Lechon M.J., Amalou Z., Rose T., Appel K. In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of alpha-Dihydroergocryptine. Xenobiotica 2000; 30: 1033–1045
  • Domanski T.L., Finta C., Halpert J.R., Zaphiropoulos P.G. cDNA Cloning and Initial Characterization of CYP3A43, a Novel Human Cytochrome P450. Mol. Pharmacol. 2001; 59: 386–392
  • Parikh A., Josephy P.D., Guengerich F.P. Selection and Characterization of Human Cytochrome P450 1A2 Mutants with Altered Catalytic Properties. Biochemistry 1999; 38: 5283–5289
  • Ishigami M., Honda T., Takasaki W., Ikeda T., Komai T., Ito K., Sugiyama Y. A Comparison of the Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam In Vitro. Drug Metab. Dispos. 2001; 29: 282–288
  • Forkert P.G., Lee R.P., Reid K. Involvement of CYP2E1 and Carboxylesterase Enzymes in Vinyl Arbamate Metabolism in Human Lung Microsomes. Drug Metab. Dispos. 2001; 29: 258–263
  • Seree E.J., Pisano P.J., Placidi M., Rahmani R., Barra Y.A. Identification of the Human and Animal Hepatic Cytochromes P450 Involved in Clonazepam Metabolism. Fundam. Clin. Pharmacol. 1993; 7: 69–75
  • Hyland R., Gescher A., Thummel K., Schiller C., Jheeta P., Mynett K., Smith A.W., Mraz J. Metabolic Oxidation and Toxification of N-Methylformamide Catalyzed by the Cytochrome P450 Isoenzyme CYP2E1. Mol. Pharmacol. 1992; 41: 259–266, (a)
  • Mraz J., Jheeta P., Gescher A., Hyland R., Thummel K., Threadgill M.D. Investigation of the Mechanistic Basis of N,N-Dimethylformamide Toxicity, Metabolism of N,N-Dimethylformamide and Its Deuterated Isotopomers by Cytochrome P450 2E1. Chem. Res. Toxicol. 1993; 6: 197–207, (b)
  • Zhang X., Hardwick J.P. Regulation of CYP4F2 Leukotriene B(4) omega-Hydroxylase by Retinoic Acids in HepG2 Cells. Biochem. Biophys. Res. Commun. 2000; 279: 864–871
  • Miyazawa M., Shindo M., Shimada T. Oxidation of 1,8-Cineole, the Monoterpene Cyclic Ether Originated from Eucalyptus Polybractea, by Cytochrome P450 3A Enzymes in Rat and Human Liver Microsomes. Drug Metab. Dispos. 2001; 29: 200–205
  • Fontaine S.M., Mash E.A., Hoyer P.B., Sipes I.G. Stereochemical Aspects of Vinylcyclohexene Bioactivation in Rodent Hepatic Microsomes and Purified Human Cytochrome P450 Enzyme Systems. Drug Metab. Dispos. 2001; 29: 179–184
  • Gervasini G., Martinez C., Agujndez J.A., Garcia-Gamito F.J., Benitez J. Inhibition of Cytochrome P450 2C9 Activity In Vitro by 5-Hydroxytryptamine and Adrenaline. Pharmacogenetics 2001; 11: 29–37
  • Ladona M.G., Gonzalez M.L., Rane A., Peter R.M., de la Torre R. Cocaine Metabolism in Human Fetal and Adult Liver Microsomes Is Related to Cytochrome P450 3A Expression. Life Sci. 2000; 68: 431–443
  • Hashizume T., Imaoka S., Hiroi T., Terauchi Y., Fujii T., Miyazaki H., Kamataki T., Funae Y. cDNA Cloning and Expression of a Novel Cytochrome P450 (CYP4F12) from Human Small Intestine. Biochem. Biophys. Res. Commun. 2001; 280: 1135–1141
  • Beckmann-Knopp S., Rietbrock S., Weyhenmeyer R., Bocker R.H., Beckurts K.T., Lang W., Fuhr U. Inhibitory Effects of Trospium Chloride on Cytochrome P450 Enzymes in Human Liver Microsomes. Pharmacol. Toxicol. 1999; 85: 299–304
  • Jang G.R., Benet L.Z. Antiprogestin Pharmacodynamics, Pharmacokinetics, and Metabolism: Implications for Their Long-Term Use. J. Pharmacokinet. Biopharm. 1997; 25: 647–672
  • Wang M.H., Wade D., Chen L., White S., Yang C.S. Probing the Active Sites of Rat and Human Cytochrome P450 2E1 with Alcohols and Carboxylic Acids. Arch. Biochem. Biophys. 1995; 317: 299–304
  • Gautier J.C., Richoz J., Welti D.H., Markovic J., Gremaud E., Guengerich F.P., Turesky R.J. Metabolism of Ochratoxin A: Absence of Formation of Genotoxic Derivatives by Human and Rat Enzymes. Chem. Res. Toxicol. 2001; 14: 34–45
  • Miyahara T., Gomyo S., Ueda Y., Ohyama Y., Sigeno C., Kozakai A., Takamura T., Yamazaki R., Higuchi S., Yamamoto M., Sakuma T., Nemoto N. Metabolism of 26,27-Hexafluoro-1alpha,25-dihydroxy Vitamin D3 and 26,27-Hexafluoro-1alpha,23(S)25-trihydroxy Vitamin D3 in ROS17/2.8 Cells Transfected with a Plasmid Expressing CYP24. Xenobiotica 2000; 30: 1055–1062
  • Bylund J., Bylund M., Oliw E.H. cDNA Cloning and Expression of CYP4F12, a Novel Human Cytochrome P450. Biochem. Biophys. Res. Commun. 2001; 280: 892–897
  • Schuster I., Egger H., Bikle D., Herzig G., Reddy G.S., Stuetz A., Stuetz P., Vorisek G. Selective Inhibition of Vitamin D Hydroxylases in Human Keratinocytes(1). Steroids 2001; 66: 409–422
  • Wikvall K. Cytochrome P450 Enzymes in the Bioactivation of Vitamin D to Its Hormonal Form (Review). Int. J. Mol. Med. 2001; 7: 201–209
  • Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T.A. Studies on the Metabolism of Troglitazone to Reactive Intermediates In Vitro and In Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission. Chem. Res. Toxicol. 2001; 14: 62–70
  • Donato M.T., Viitala P., Rodriguez-Antona C., Lindfors A., Castell J.V., Raunio H., Gomez-Lechon M.J., Pelkonen O. CYP2A5/CYP2A6 Expression in Mouse and Human Hepatocytes Treated with Various In Vivo Inducers. Drug Metab. Dispos. 2000; 28: 1321–1326
  • Karjalainen A., Kalapudas A., Sodervall M., Pelkonen O., Lammintausta R. Synthesis of New Potent and Selective Aromatase Inhibitors Based on Long-Chained Diarylalkylimidazole and Diarylalkyltriazole Molecule Skeletons. Eur. J. Pharm. Sci. 2000; 109–131
  • Rochat B., Morsman J.M., Murray G.I., Figg W.D., McLeod H.L. Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?. J. Pharmacol. Exp. Ther. 2001; 296: 537–541
  • Chiang J.Y., Kimmel R., Weinberger C., Stroup D. Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7alpha-Hydroxylase Gene (CYP7A1) Transcription. J. Biol. Chem. 2000; 275: 10918–11024
  • Yang C.S., Chhabra S.K., Hong J.Y., Smith T.J. Mechanisms of Inhibition of Chemical Toxicity and Carcinogenesis by Diallyl Sulfide (DAS) and Related Compounds from GARLIC. J. Nutr. 2001; 131: 1041S–1045S
  • Teiber J.F., Mace K., Hollenberg P.F. Metabolism of the beta-Oxidized Intermediates of N-Nitrosodi-n-propylamine: N-Nitroso-beta-hydroxypropylpropylamine and N-Nitroso-beta-oxopropylpropylamine. Carcinogenesis 2001; 22: 499–506
  • Delescluse C., Ledirac N., Li R., Piechocki M.P., Hines R.N., Gidrol X., Rahmani R. Induction of Cytochrome P450 1A1 Gene Expression, Oxidative Stress, and Genotoxicity by Carbaryl and Thiabendazole in Transfected Human HepG2 and Lymphoblastoid Cells(2). Biochem. Pharmacol. 2001; 61: 399–407
  • Chiba M., Jin L., Neway W., Vacca J.P., Tata J.R., Chapman K., Lin J.H. P450 Interaction with HIV Protease Inhibitors: Relationship Between Metabolic Stability, Inhibitory Potency, and P450 Binding Spectra. Drug Metab. Dispos. 2001; 29: 1–3
  • Ehmer P.B., Jose J., Hartmann R.W. Development of a Simple and Rapid Assay for the Evaluation of Inhibitors of Human 17alpha-Hydroxylase-C(17,20)-lyase (P450cl7) by Coexpression of P450cl7 with NADPH-Cytochrome-P450-Reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 2000; 75: 57–63
  • Morfin R., Lafaye P., Cotillon A.C., Nato F., Chmielewski V., Pompon D. 7 alpha-Hydroxy-dehydroepiandrosterone and Immune Response. J. Pharm. Pharmacol. 2001; 53: 403–408

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.